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Foreword
This is the fifth Annual Epidemiological Report that ECDC 
has published since becoming operational. As in 2007, 
when ECDC published the first of these reports, the over-
all picture is of a European Union (EU) in which citizens 
are well protected against infectious diseases. Public 
health systems in EU Member States continue to provide 
a high level of protection, most notably via their various 
vaccination programmes and operation of their surveil-
lance systems.
In 2009 Europe, and indeed the world, experienced 
the first influenza pandemic since 1968. In November 
and December of 2009, intensive care units in several 
Member States came under severe pressure. However, 
the pandemic passed without the society-wide crisis that 
had been predicted by some experts. This was partly 
due to the pandemic influenza A(H1N1) virus being sig-
nificantly less pathogenic than the worst case scenario 
for a pandemic virus. But the pandemic preparedness 
planning undertaken in the EU during 2005–08 should 
also be given some credit for this benign outcome.
In 2009, like each of the previous years, the quality and 
comparability of the surveillance data gathered in the 
EU continues to improve. ECDC can take some of the 
credit for this, but the biggest thanks need to go to our 
partners in the national public health institutes.
But despite all these positive developments, as I look 
through this report I see some worrying signals. 
There were several significant outbreaks of measles in 
EU countries during 2009. This was a clear marker that 
Europe was on track to miss its target of eliminating 
measles by 2010. Though incidence of tuberculosis con-
tinued to decline, progress was slow. Progress towards 
achieving bacteriological confirmation of and completed 
treatment courses for all tuberculosis cases in the EU 
appeared to be limited. Moreover, there were signs of 
the emergence of new diseases in parts of Europe. We 
had indications that the West Nile virus might have 
established itself in parts of south-eastern Europe, and 
we even saw a few cases of locally transmitted malaria 
in one Member State. Less exotic, but even more wor-
rying, we continued to see growing resistance of patho-
gens against the most widely used antibiotics. 
The biggest threat we face is complacency about infec-
tious diseases. The attitude that the battle against 
infectious diseases has been won must be continuously 
challenged. This report provides plenty of evidence that 
microbes are still formidable enemies. The surveillance 
data it contains give us a basis to gauge the extent of 
the threat different microbes pose, and track progress 
in addressing those threats. It is only by continuing to 
invest in, and further improve, surveillance systems 
across the EU that we will really know if we are making 
progress.
Marc Sprenger
Director
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the pandemic strain required intensive care, putting 
the health systems of several countries under pressure, 
despite a relatively mild influenza season overall. Half of 
the investigated influenza strains during the 2010/2011 
influenza surveillance season were due to the pandemic 
strain. 
A monovalent vaccine recommended by WHO was 
deployed by Member States, with varying definitions 
of target groups. The vaccines used were a good match 
with the pandemic virus resulting in high observed vac-
cine effectiveness; however, their impact was limited by 
deployment after most virus transmission had occurred. 
In August 2010, Finland, followed by Sweden, reported 
an increase of narcolepsy cases in adolescents vac-
cinated with a specific brand of a pandemic vaccine. A 
number of studies were initiated to investigate whether 
there is a causal relationship between this vaccine and 
narcolepsy. 
Lessons for surveillance and response derived from this 
pandemic experience include the need for European 
countries to strengthen their individual and collective 
surveillance of ‘normal’ seasonal influenza, as systems 
in pandemic situations are developed from this founda-
tion. The pandemic also showed a need for countries to 
strengthen their ability to conduct the necessary applied 
research into the pandemic strain epidemiology in a 
timely manner, both during the pandemic and the period 
immediately thereafter.  
Several outbreaks of avian influenza were recognised 
in birds during 2009, including two due to highly patho-
genic strains – Germany, A(H5N1); and Spain, A(H7N7). 
No human cases associated with avian influenza out-
breaks were reported.
Legionnaires’ disease (legionellosis) remains an uncom-
mon infection in EU and EEA/EFTA countries. There 
has also been a significant decrease since 2007 in 
the number of travel-associated cases – 88 clusters 
of travel-associated cases of infection were identified 
in 2009. This decrease in travel-associated cases may 
be related to better implementation of guidelines for 
Legionella control and the downturn in international 
travel during the global economic recession. Further 
review of this situation is needed.
Tuberculosis (TB) remains a common infection and an 
important disease burden, with nearly 80 000 cases still 
notified annually across the EU. The number of cases of 
TB reported continued to decline; there has been a small 
but sustained decrease in notification rates in the EU/
EEA overall since 2005 of about 4 % per annum. Most 
Member States reported a decrease in rates over this 
period. Some countries with relatively low rates of infec-
tion (e.g. the Nordic countries, Cyprus, Malta, United 
Kingdom) reported increasing rates at least partly asso-
ciated with increasing numbers of cases born outside 
the reporting country. Tuberculosis is more prevalent 
among disadvantaged and marginalised groups, includ-
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This report presents the analysis of surveillance data 
reported for 2009 by the 27 EU Member States and three 
EEA/EFTA countries, as well as an analysis of threats 
detected in 2010. It is targeted towards policymakers, 
epidemiologists and the wider public and aims to pro-
vide an overview of the key aspects of communicable 
diseases in the European Union. The report describes 
areas where a more concerted public health response is 
required in order to decrease the present and future bur-
den of communicable disease on society and healthcare 
systems. The data presented here further contributes to 
ECDC’s task of providing the evidence-base for public 
health action. 
Although the quality and comparability of reported data 
has improved considerably since the establishment of 
ECDC, the reader is still cautioned against making direct 
comparisons of the presented data between countries. 
Surveillance systems differ widely, and the relationship 
between reported confirmed case rates and actual inci-
dence varies from country to country for many diseases. 
Respiratory tract infections
A pandemic influenza A(H1N1) virus emerged in North 
America in April 2009, and cases were soon recognised in 
the United Kingdom and other Member States. Following 
an initial spring and summer peak, most virus transmis-
sion occurred in the autumn and early winter, declining 
to low levels by the beginning of 2010. ECDC monitored 
the pandemic through extension of the normal European 
surveillance systems, including sentinel surveillance of 
general practice consultations, influenza-positive speci-
mens from sentinel practices and surveillance of severe 
acute respiratory infection in sentinel hospitals. 
Almost all influenza cases were caused by the new 
A(H1N1)2009 virus and only a very few percentage of 
cases were due to a B virus (Victoria lineage). The pre-
vious seasonal A(H1N1) was eclipsed, and with it the 
associated resistance to oseltamivir, widely used for 
prophylaxis and treatment during the pandemic. The 
highest primary care consultation rates were seen in the 
0–14 years age group, but severe disease predominated 
in adults under 65 years. 
Monitoring of hospitalised severe acute respiratory 
cases was implemented in varying forms by 11 Member 
States. From week 40/2009, 9 469 cases were reported 
with 569 related fatalities. The rate of reported cases 
decreased with age, and a severe outcome was related 
to increased age, male gender and the presence of at 
least one underlying medical condition. Unusually, 20 % 
of confirmed influenza deaths occurred in previously 
healthy adults and children, often in association with an 
acute respiratory distress syndrome. 
In August 2010, the pandemic was officially declared 
to have entered the post-pandemic phase. In the win-
ter of 2010, a large number of patients infected with 
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ing migrants, the homeless, poor people in inner cities, 
prisoners, people infected with HIV, and drug users. 
The proportion of combined multidrug-resistant tuber-
culosis (MDR TB) cases was down slightly from 2008 
(5.3 %), but the proportion of these cases characterised 
as extensively drug-resistant TB (7 %) is a concern, and 
related primarily to incomplete or ill-designed treatment 
regimes. The overall treatment outcome success rate 
for the 2008 cohort was 78 %; six countries reported 
achieving the 85 % treatment success target for the 2007 
cohort.
HIV, sexually transmitted 
infections, hepatitis B and C
HIV infection remains one of the major public health prob-
lems in Europe. The total number of confirmed cases 
reported annually in EU and EEA/EFTA countries has sta-
bilised at around 28 000 cases annually. Men who have 
sex with men comprised the largest group of cases (35 %), 
followed by those who acquired the virus through hetero-
sexual contact in Europe (24 %), and injecting drug users 
(5 %). Mother-to-child transmission, nosocomial infection, 
transfusion or other blood products accounted for only 1 % 
of cases.
Significant trends in patterns of disease transmission con-
tinue to be seen. Between 2004 and 2009, cases in men 
who have sex with men increased by 24 %, cases acquired 
by heterosexual transmission reported in European 
Member States remained relatively stable with some signs 
of increase in 2009; cases of heterosexual transmission 
originating from countries with a generalised HIV epidemic 
decreased by nearly 50 %. The number of cases in injecting 
drug users also declined substantially. 
Reflecting improvements in access to and effectiveness 
of treatment, the number of AIDS diagnoses in the EU has 
decreased by more than half between 2004 and 2009. The 
Baltic States were an exception to this, with increases in 
case numbers of between 8 % and 76 %.
Chlamydia is the most frequently reported sexually trans-
mitted infection (STI) in the EU, with nearly 350 000 cases 
reported in 2009. Reported rates have more than doubled 
over the past 10 years. This increase to a large extent 
reflects measures taken by Member States to improve 
diagnosis and reporting of the infection, including devel-
opment of screening and surveillance programmes. Over 
three quarters of cases are diagnosed in young adults 
under the age of 25 years. However, cases are likely to be 
underreported due to the asymptomatic nature of infection. 
Chlamydia presents a significant and increasing burden of 
infection to both individuals (predominantly young adults) 
and health services, given both the number of infections 
and the occurrence of reduced fertility as an outcome for 
some women. 
Reported rates for gonorrhoea and syphilis are much lower, 
and trends appear to be relatively stable, with a small 
decrease (9 %) overall in reported cases for both infections 
over 2006–09. However, reported rates vary greatly by 
country, and some countries do not report these infec-
tions. Rates of gonorrhoea decreased significantly in sev-
eral Member States over 2006–09; higher and stable rates 
were reported from the United Kingdom, the Netherlands 
and the Baltic States. Increasing resistance to the princi-
pal antibiotics used for treatment of gonorrhoea in the EU 
is an emerging public health issue. Both reported rates 
and trends for syphilis cases also varied greatly between 
Member States over 2006–09. Large increases in cases 
were reported from several countries, mostly associated 
with increases in reports of infection among men who have 
sex with men. 
The numbers of reported hepatitis B cases declined stead-
ily across the EU during 2006–09, with decreases seen 
in most Member States. Within this overall decline, the 
epidemiology reflects a complex mix of sexual, blood-
borne and perinatal transmission, which varies in different 
Member States. The overall trend in reported hepatitis C 
cases appears to be increasing over time, and hepatitis C 
is thought to be the most common form of viral hepatitis 
in the EU. However, this observation remains tentative, as 
many Member States’ surveillance systems do not distin-
guish between acute and chronic infection. In addition, the 
differences between diagnostic practices and surveillance 
systems in Member States, for both infections, increase 
the variations in rates reported between countries, and 
make the comparability of information for these diseases 
at country level particularly difficult. 
The coordination of the surveillance networks for HIV/AIDS 
and sexually transmitted infections was integrated into 
ECDC in 2008 and 2009, respectively, and in 2011, ECDC 
established a new network for the hepatitis surveillance. 
ECDC is working with these networks to further standard-
ise surveillance for these diseases and to work toward 
greater comparability of information on their epidemiology. 
Food- and waterborne diseases
Salmonella and Campylobacter infections remain the 
most commonly reported gastrointestinal diseases 
across the EU. The reported incidence of Salmonella 
infection has been declining steadily since 2004, asso-
ciated, at least in part, with successful infection control 
programmes in the poultry industry; rates of S. Enteriditis 
infection declined 24 % compared with 2008. Case rates 
are highest in the Czech Republic, Slovakia, Hungary 
and Lithuania, although they have also decreased sub-
stantially in these countries in recent years. Salmonella 
infection continues to be reported most frequently in 
children under 5 years of age. It also continues to be 
the source of many outbreaks; 324 outbreaks includ-
ing 4 500 identified cases were verified from Member 
States during 2009. Some outbreaks were multinational, 
including an outbreak of S. Goldcoast (six EU countries) 
and S. Typhimurium type (FDT) 191a (affecting the United 
Kingdom and the USA). 
Campylobacter infections are the most frequently 
reported gastrointestinal infection in Europe, being 
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ubiquitous across all Member States. Reported rates are 
stable, most cases are sporadic, and outbreaks infre-
quent. However, the frequency of infection constitutes a 
significant disease burden, and a minority of people with 
this infection experience significant disability, includ-
ing arthritis. Again, reported infection rates are highest 
in very young children. While the source of infection is 
unknown in many cases, poultry meat is considered the 
most important food-borne source of this infection, and 
current and likely future control measures continue to 
focus on this.
Parasitic diseases, particularly cryptosporidiosis and 
giardiasis, remain significant causes of gastrointestinal 
infection in Europe, and are particularly subject to going 
undiagnosed and underreported. The burden of these 
diseases remains poorly characterised, together with 
pertinent information for interventions to reduce their 
occurrence.
Many diseases in this group remain rarely or infre-
quently reported. Some have serious outcomes for some 
of the individuals infected (e.g. anthrax, botulism, lis-
teriosis, toxoplasmosis). Generally, these diseases are 
reported from throughout the EU, and confirmed case 
rates appear relatively stable with little or no discern-
able trend over the 2006–09 period.
There were some important exceptions in 2009. Anthrax 
cases were more frequent, due primarily to an outbreak 
among intravenous drug users in the United Kingdom; 
anthrax should be considered an emerging disease in 
relation to this route of transmission. Cases of haemo-
lytic uraemic syndrome (HUS), a potentially fatal clinical 
manifestation of STEC/VTEC infection, were reported 
more frequently in 2009 than previously. This may be 
related to the characteristics of the E. coli types respon-
sible for two large outbreaks in the United Kingdom and 
the Netherlands; however, this possible trend toward 
more severe infection needs review. Deaths due to vari-
ant CJD infection continued to decline.
Some rare or uncommon gastrointestinal infections are 
more frequent in particular sub-regions and countries. 
Brucellosis is reported primarily from Portugal, Spain 
and Greece, associated primarily with goat farming 
activities; most trichinellosis cases were reported from 
Bulgaria, Romania and Lithuania, which may be asso-
ciated with consumption of domestically reared pork 
and wild boar; most confirmed echinococcosis cases 
were reported from Bulgaria. Yersiniosis case reports 
are declining overall but reported case rates remain 
increased in Nordic states, Germany, Czech Republic 
and Slovakia; infection is often associated with pork 
consumption. Confirmed case rates for listeriosis were 
highest in Denmark, and have increased in recent years, 
for reasons that remain uncertain. Hepatitis A cases 
were reported relatively infrequently overall, but con-
firmed case rates remain relatively high in Latvia, Czech 
Republic, Slovakia, Romania and Bulgaria. 
Typhoid and paratyphoid fever and cholera are consid-
ered rare diseases in EU and EEA/EFTA countries, but 
cases occur mostly as sporadic importations from out-
side the Union, and their distribution reflects travel pat-
terns of EU citizens to countries where these diseases 
are endemic. 
Emerging and vector borne 
diseases
The reported rate of malaria cases remains stable, with 
almost all cases imported from countries outside the 
Union. The distribution of cases across Member States 
primarily reflects travel patterns of citizens to countries 
where malaria is endemic. A small number of indigenous 
cases of Plasmodium vivax were reported from Greece in 
2009. In 2010, Spain reported its first indigenous case 
of Plasmodium vivax since 1961. 
Sporadic cases of West Nile fever (WNV infection) con-
tinued to be reported during 2009 from Italy, Hungary 
and Romania. The features of the Italian cases suggest 
continuation of the 2008 outbreak in northern Italy. In 
2010, an upsurge of mosquito-borne disease including 
WNV infection was observed in several EU countries. 
The number of human WNV cases in 2010 was the high-
est reported in Europe in the last decade, with Greece 
accounting for the majority of the 340 confirmed EU 
cases. Outside Greece, WNV cases were also reported 
from Spain, Hungary, Romania and Italy, as well as from 
a large outbreak in southern Russia.
Two indigenous cases of dengue were reported from 
southern France and 15 indigenous cases of dengue 
from Croatia, both areas where the mosquito vec-
tor Aedes albopictus is known to be well established. 
Chikungunya case numbers significantly increased in 
2009 in returning travellers from countries where trans-
mission is occurring. In 2010, indigenous transmission 
was reported for the second time in Europe (after the 
Italian outbreak of 2007), with two cases identified in 
southern France. Continued close surveillance (human, 
veterinary, entomological) is needed to keep this situa-
tion under review.
High rates of Q fever cases continued to be reported, 
primarily due to an outbreak in the Netherlands stretch-
ing over several years. This is now the largest commu-
nity outbreak of Q fever ever reported. Cases and some 
small outbreaks were also reported from a number of 
other countries including Belgium, Germany, Ireland 
and Bulgaria. Q fever is an underdiagnosed disease 
due to its non-specific clinical features, and is also not 
reported by some countries.
Hantavirus infections remain the most commonly 
reported of the viral haemorrhagic fevers, with most 
cases reported from Finland in 2009. Substantial 
numbers of dengue fever cases were also reported 
by Member States; as for malaria, the epidemiology 
reflects travel of citizens to countries where dengue is 
endemic. Other forms of viral haemorrhagic fever were 
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reported rarely (as sporadic imported cases), or not at 
all, in 2009.
No cases of plague, smallpox or SARS were reported by 
Member States in 2009, but there was one case of yel-
low fever (in a traveller to Ghana).
Vector borne diseases remain a significant burden for 
Member States, both in the form of infected travel-
lers returning from countries where these diseases are 
endemic and in relation to the risk of disease transmis-
sion becoming established in EU countries. West Nile 
fever is now endemic in Europe; given the presence 
of competent vectors, and with the occurrence of out-
breaks in other world regions there is a risk that indig-
enous transmission of other diseases, such as dengue 
fever and chikungunya, could become established in 
European countries in coming years.
Vaccine-preventable diseases
Most vaccine preventable diseases continued to show 
either a declining or stable trend in reported incidence 
of confirmed cases in 2009, although a substantial 
increase in measles activity recurred in 2010. Among 
the primary vaccine schedule diseases, diphtheria 
cases were rare and continued to decline, confined to a 
few cases across five countries. Isolated tetanus cases 
were reported from a few countries; Italy was an excep-
tion with 58 cases reported. No cases of polio were 
reported in 2009, but a large polio outbreak in 2010, 
mainly affecting Tajikistan and neighbouring countries, 
with nearly 500 confirmed cases due to wild poliovirus 
serotype 1 (WPV1), was a significant challenge to the 
European Region’s certified polio-free status. 
Invasive Haemophilus influenzae disease remained 
uncommon, and stable in trend, reflecting the gains from 
previous vaccine introduction; cases were dominated by 
non-capsulated and non-b serotypes. Invasive menin-
gococcal disease also remains relatively uncommon, 
following the introduction of C group vaccine, although 
case fatality and disability rates continue to be substan-
tial. Invasive pneumococcal disease is more frequently 
reported, but surveillance systems for this disease are 
heterogeneous and not universal across Europe, and the 
effects of introduction of pneumococcal vaccination dif-
ficult to assess. 
For other diseases, the epidemiological picture is more 
varied and of concern. Despite being a primary vac-
cination in all countries, pertussis remains a relatively 
common and underdiagnosed infection, with stable or 
increasing reported rates. Increasing numbers of cases 
are reported among older children and adolescents, and 
adults. These represent a large reservoir and important 
source of infection for vulnerable younger children. 
Thousands of measles, mumps and rubella cases con-
tinue to be reported across Europe. The commitment 
for elimination of indigenous measles and rubella 
was renewed in 2010, but elimination by 2015 will not 
be reached unless effective interventions to increase 
vaccine coverage are achieved by all Member States. 
Communities with limited access to routine health serv-
ices are a particular challenge. Only three countries 
(Slovenia, Slovakia and Iceland) have maintained zero 
case reporting since 2006.  
The number of measles cases in the EU overall declined 
in 2009 compared with previous peak years (2006, 
2008) and outbreaks or increases in case numbers 
were reported in 2009 from France, Germany, Italy, 
Austria, Bulgaria, United Kingdom and Ireland. But inci-
dence increased again markedly in 2010, with Bulgaria 
accounting for the majority of the over 30 000 reported 
cases in Europe, including 21 deaths. 
Mumps cases increased significantly in 2009, mainly 
due to a national outbreak in the United Kingdom, 
related to unvaccinated cohorts reaching university age. 
Confirmed rubella cases decreased in 2009, reflecting 
partly the resolution of an outbreak in Italy in 2008, but 
also reflecting variations in surveillance systems and 
reporting, including very low rates of laboratory confir-
mation, and changes in case definitions used for report-
ing by some countries. 
Antimicrobial resistance and 
healthcare-associated 
infections
Based on the antimicrobial resistance data reported to 
EARS-Net by 28 countries in 2009, and on the results 
of trend analyses, including EARSS data from previous 
years, the situation in Europe displays large variations 
depending on the microorganism, the antimicrobial con-
cerned and the geographic region. 
In 2009, the trends of greatest concern were the rapidly 
decreasing susceptibility of Escherichia coli isolated 
from invasive infections to essentially all antimicrobial 
agents included in the EARS-Net surveillance with the 
exception of carbapenems, and the high percentages 
of resistance to third-generation cephalosporins, fluo-
roquinolone and aminoglycosides in Klebsiella pneu-
moniae from invasive infections. In half of the reporting 
countries, the percentage of K. pneumoniae isolates 
that were multidrug-resistant (combined resistance to 
third-generation cephalosporins, fluoroquinolones and 
aminoglycosides) was above 10 %, and a few coun-
tries also reported high percentages of resistance to 
carbapenems. 
These antibiotics have been widely used in many 
countries due to the increasing prevalence of 
extended-spectrum beta-lactamase (ESBL)-producing 
Enterobacteriaceae and this resulted in the emergence 
of carbapenemase (VIM, KPC and NDM-1) production, 
especially in K. pneumoniae. Resistance to third-genera-
tion cephalosporins in E. coli also increased significantly 
during the last four years in more than half of the report-
ing countries. 
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Even though the percentage of meticillin-resistant 
Staphylococcus aureus (MRSA) among Staphylococcus 
aureus isolates seems to stabilise, or even decreases in 
some European countries, MRSA remains a public health 
priority, since the proportion of MRSA is still above 25 % 
in more than one third of the reporting countries. 
Antimicrobial consumption data reported to ESAC con-
tinued to show a nearly fourfold variation between coun-
tries in outpatient antibiotic use expressed in defined 
daily doses per population. There were also large inter-
country variations in the relative use of various antimi-
crobial classes. Penicillins remained the most frequently 
used antimicrobial group, ranging from 29 % to 66 % of 
all antimicrobials used in outpatients. Other antimicro-
bial classes (e.g., cephalosporins, macrolides, quinolo-
nes) made up widely varying proportions of outpatient 
antimicrobial use depending on the country.
For the first time since the transition of the coordination 
of the surveillance of healthcare-associated infections 
to ECDC in 2008, data were collected through ECDC’s 
TESSy system. Seventeen countries submitted data for 
at least one of the HAI surveillance components. The 
number of surgical interventions included in the surveil-
lance for 2009 increased by 9.6 %, and the number of 
participating ICUs by 22.7 %, compared to 2008. 
Decreasing trends in the prevalence of surgical site 
infections following hip prosthesis continued in 2009. 
The distribution of microorganisms associated with 
infections acquired in intensive care units showed a 
high proportion of third-generation cephalosporin-
resistant Enterobacteriaceae (in particular, Klebsiella 
spp. and Enterobacter spp.) isolates. Colistin resistance 
in Pseudomonas aeruginosa, Acinetobacter baumannii 
and Stenotrophomonas maltophilia was more frequently 
reported in 2009. 
Conclusions
The pandemic of 2009 and 2010, its aftermath and 
evaluations of the response raised a number of issues 
for preparedness and response to new influenza virus 
strains with essentially unknown characteristics. One 
consistent lesson from reviews of the European experi-
ence is the need to strengthen routine seasonal influ-
enza surveillance in hospitals and especially Intensive 
Care Units in many Member States, and its coordina-
tion at European level. Systems for surveillance that 
are working well can be adapted for pandemic situa-
tions; they cannot readily be developed de novo during 
a public health emergency. While the nature of the asso-
ciation between one of the pandemic influenza vaccines 
and narcolepsy in children and young adults is still to 
be established, efficient monitoring of vaccine cover-
age, effectiveness and safety must be an integral part of 
influenza surveillance.  The next priority will be to deter-
mine the characteristics of the new seasonal influenza 
in Europe, including assessing the possible transmis-
sion of already resistant strains. 
A number of European targets appear likely to be missed 
unless more effective interventions can be implemented 
by Member States. Outbreaks and epidemics of measles 
are more frequent and widespread than previously, and 
the epidemic in Bulgaria in 2009 offered a reminder 
of how widespread and intensive such epidemics can 
be, with many avoidable cases of infection and death. 
Measles and rubella epidemiology is deteriorating rather 
than improving, with several Member States struggling 
to achieve or maintain adequate immunisation levels. 
Although the reported overall occurrence of tuberculo-
sis continues to decline, progress towards targets for 
achieving bacteriological confirmation and success-
ful treatment of all tuberculosis cases remains limited. 
The re-emergence of polio in the form of an outbreak 
in Tajikistan underlines that maintaining the European 
Region’s polio-free status requires continued vigilance.
HIV remains a major public health concern with ongoing 
transmission in all countries, although the epidemiology 
in population risk groups continues to differ from coun-
try to country. Men who have sex with men still consti-
tute the largest risk group in the EU/EEA overall, with no 
evidence of a decrease in the rate of new infections. The 
diversity of affected population groups across different 
countries also applies to certain sexually transmitted 
infections (e.g. syphilis, gonorrhoea) and Hepatitis B and 
C. The high and increasing rates of Chlamydia infection 
among young people reported from many EU countries 
is a particular concern. Countries need to complement 
classical disease prevention strategies with approaches 
that support comprehensive and coordinated interven-
tions for these risk groups.
The ability to recognise, investigate and identify the 
likely source of an outbreak remains critically important 
for food- and waterborne diseases. This report provides 
information on national and international outbreaks of 
disease from cryptosporidium and norovirus, to listerio-
sis and VTEC, affecting countries across the European 
Union. Multinational salmonella outbreaks underline 
the need to better coordinate investigation and control 
measures across Member States, at European level, and 
between human, veterinary and food safety organisa-
tions and networks. This has been further exemplified 
by the recent outbreak of enterohaemorrhagic E.coli cen-
tred in Lower Saxony.
Development of microbial resistance continues to be a 
major public health problem, as illustrated by the emer-
gence of New Delhi metallo-beta-lactamase-1 (NDM-1) 
producing Enterobacteriaceae, from the Indian subcon-
tinent, and its spread in the European Union. Countries 
need to intensify their programmes for infection control 
and prudent use of antibiotics to prevent and control 
the spread of multi-drug resistant strains of bacteria in 
Europe. The progress made in reducing the prevalence 
of meticillin-resistant Staphyloccocus aureus (MRSA) 
infections in several EU countries is encouraging, and 
represents an example of what may be achieved through 
implementation of coordinated prevention and control 
strategies.  
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Emergent diseases in the European context continue to 
pose a public health risk. West Nile virus must now be 
considered endemic in the south east of Europe, and 
there have been reports of locally acquired cases of dis-
eases previously only considered to be imported – e.g. 
malaria, dengue fever and chikungunya. Coordinated 
and enhanced human, veterinary and environmental sur-
veillance is needed in all Member States at risk of these 
diseases, together with development of effective coun-
termeasures. Other diseases are considered ‘emergent’ 
through changes in the groups affected and the means 
of transmission. Anthrax has emerged as a potential epi-
demic disease among intravenous drug users.  
i In 2009, reported rate increased overall and in 0–14 year age groups 
due to A(H1N1) pandemic.
A number of diseases remain particularly liable to under-
diagnosis and reporting, complicating efforts to under-
stand their burden, and develop appropriate public 
health interventions. These include parasitic diarrhoeal 
diseases, such as giardiasis and cryptosporidiosis, for 
which laboratory diagnostic services are not routinely 
available in a number of Member States. Meanwhile, 
some diseases are still not under surveillance or being 
routinely reported by some Member States. These 
include several that are responsible for a considerable 
burden of infection, ranging from campylobacteriosis 
and pertussis, to gonorrhoea and malaria. Countries 
affected may want to review this situation. For other dis-
eases, reporting cases according to EU case definitions 
remains a significant challenge for some Member States.
Table A.  Overview of overall recent trend, EU notification rate and main age groups affected, for communicable 
diseases reported to ECDC, 2009
Disease General trend 2006–2009 EU rate of confirmed cases for 
2009 (per 100 000)
Main age groups affected 
(2009)
Respiratory tract infections
Influenza  i N/A 0–14i
Animal influenza Insufficient data 0.0 Insufficient data
Legionnaires’ disease 
(legionellosis)
1.0 45+
Tuberculosis ↓ 9.1 25+
HIV, sexually transmitted infections and blood-borne viral infections
Chlamydia infection ↑ 185.1 15–24
Gonorrhoea infection 9.7 15–34
Hepatitis B ↓ 1.2 15–64
Hepatitis C Insufficient data 8.2 25–64
HIV 5.7 25+
AIDS ↓ 1.0 40–49
Syphilis 4.5 20–44
Food- and waterborne diseases and zoonoses
Anthrax N/A <0.01 Insufficient data
Botulism 0.03 0–4, 25–64
Brucellosis ↓ 0.08 15+
Campylobacteriosis 53.1 0–4
Cholera N/A <0.01 Insufficient data
Cryptosporidiosis 2.7 0–4
Echinocccosis ↓ 0.2 25+
Vero/Shiga toxin-producing 
Escherichia coli (VTEC/STEC)
0.9 0–4
Giardiasis 5.6 0–4
Hepatitis A 3.4 0–24
Leptospirosis ↓ 0.1 15+
Listeriosis 0.35 65+
Salmonellosis ↓ 23.6 0–4
Shigellosis 1.6 0–44
Congenital toxoplasmosis N/A 0.01 <1
Trichinellosis 0.15 5–64
Tularaemia 0.18 45+
Typhoid/paratyphoid fever 0.3 0–44
Variant Creutzfeldt–Jakob 
Disease (vCJD)
N/A <0.01 Insufficient data
Yersiniosis ↓ 2.0 0–14
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Disease General trend 2006–2009 EU rate of confirmed cases for 
2009 (per 100 000)
Main age groups affected 
(2009)
Emerging and vector-borne diseases
Malaria 0.9 25–44
Plague N/A 0.0 N/A
Q fever ↑ 0.6 45–64
Severe acute respiratory 
syndrome (SARS)
N/A 0.0 N/A
Smallpox N/A 0.0 N/A
Hantavirus infection Insufficient data 0.7 25+
Dengue fever Insufficient data 0.1 15–64
Chikungunya fever ↑ 0.02 25–64
West-Nile virus infection ↑ <0.01 45+
Yellow fever N/A <0.01 N/A
Vaccine-preventable diseases
Diphtheria ↓ <0.01 45+
Invasive Haemophilus 
influenzae disease
0.4 0–4, ≥65
Invasive meningococcal disease 0.9 0–4, 15-24
Invasive pneumococcal disease ↓ 4.4 0–4, ≥65
Measles 0.8 0–24
Mumps ↓ 3.2 15–24
Pertussis 4.9 0–24
Poliomyelitis N/A 0.0 N/A
Rabies N/A <0.01 Insufficient data
Rubella 0.1 0–4, 15–24
Tetanus ↓ 0.02 65+
Antimicrobial resistance and healthcare-associated infections
Antimicrobial resistance ↑ N/A N/A
Healthcare-associated 
infections
N/A N/A
N/A: not applicable. 
Insuﬃ  cient data – relating to uncommon diseases where trend not discernable with precision.
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1.1 Background 
This report aims to give an overview of the epidemiology 
of communicable diseases of public health significance 
in Europe, drawn from surveillance information on the 
47 communicable diseases and two health issues for 
which surveillance is mandatory in the European Union 
(EU) and three European Economic Area (EEA)/European 
Free Trade Association (EFTA) countries i,ii.
This report is produced annually and is intended for poli-
cymakers and their key advisors, epidemiologists, scien-
tists and the wider public. It is hoped that readers will 
find this overall compilation a useful one volume over-
view and reference, to better understand the present 
situation regarding communicable diseases in Europe. 
It should also usefully support policymakers, planners 
and their advisors in making evidence-based decisions 
to plan and improve programmes, services and inter-
ventions for preventing, managing and treating these 
diseases.
This report is based on data collected for 2009 from the 
surveillance systems of the Member States and uploaded 
into the European Surveillance System (TESSy), from 
data and reports produced by Dedicated Surveillance 
Networks (DSNs) not yet integrated into ECDC, and from 
various ECDC technical and scientific reports and pub-
lications related to the epidemiological situation for 
specific communicable diseases and disease groups in 
2009. The emphasis is on the outline descriptive epide-
miology of each disease in recent years, usually 2006–
2009. Some of the disease-specific sections in Chapter 
2 also include short notes of relevant epidemiological 
updates for 2010.
This document also describes emerging threats in 2010 
(Chapter 3) that were either directly reported to ECDC 
through Member State notifications on the Early Warning 
and Response System (EWRS), according to defined cri-
teriaiii, or found through active screening of various 
sources, including national epidemiological bulletins 
and international networks (e.g. Program for Monitoring 
Emerging Diseases – ProMED, Global Public Health 
Intelligence Network – GPHIN, media, and various addi-
tional sources, both formal and informal).
The reader will also find related information regarding 
these diseases and public health problems elsewhere in 
the ECDC publications and website (www.ecdc.europa.
eu). In-depth reviews of the epidemiology of particular 
diseases (e.g. tuberculosis, HIV) or disease groups (e.g. 
food- and waterborne diseases) are published sepa-
rately, sometimes in collaboration with other European 
i Commission Decisions 2000/96/EC, 2003/534/EC and 2007/875/EC.
ii Commission Decision 2119/98/EC of the Parliament and of the Council 
of 24 September 1998 setting up a network for the epidemiological 
surveillance and control of communicable diseases in the Community. 
1998, Official Journal of the European Union. p. L 268.
iii Commission Decision of 10 July 2009 amending Decision No 2000/57/
EC on the early warning and response system for the prevention and 
control of communicable diseases under the Decision No 2119/98/EC 
of the European parliament and of the Council, in Official Journal of 
the European Union. 2009. p. L 181: 57-9.
agencies or the World Health Organization’s Regional 
Office for Europe. These are referenced, for convenience, 
with the description of each disease, as appropriate. 
Finally, information relating to most diseases reported 
here, including their causes, characteristics as public 
health problems and methods for prevention and control 
are available on the ECDC website health topics pages 
(at: http://ecdc.europa.eu/en/healthtopics/).
1.2 Structure of the report
This report is set out as follows:
• The Summary and conclusions gives a brief overview of 
the main findings from the disease-specific chapters;
• Chapter 1 outlines the methods used for receiving, 
validating and analysing surveillance data from the 
27 EU Member States and three EEA/EFTA countries, 
including discussion of the value and limitations of 
the present surveillance information;
• Chapter 2 gives an overview of the epidemiological 
situation in 2009 for each of the 47 communicable 
diseases and two health issues under mandatory 
surveillance within the EU;
• Chapter 3 gives an overview of the threats monitored 
through epidemic intelligence activities during 2010, 
with emphasis on some threats of particular interest 
either because of their public health importance or 
unusual or new epidemiological patterns.
1.3 Description of methods
Data source
All EU Member States and three EEA/EFTA countries 
(Iceland, Liechtenstein and Norway) send information at 
least annually from their surveillance systems to ECDC 
relating to occurrence of cases of the 47 communica-
ble diseases and two health issues under mandatory 
EU-wide surveillancei. Reports are sent according to 
case definitions established by the EUiv.
Data upload by Member States occurs continually 
throughout the year. In conjunction with annual ECDC 
reports for particular diseases or disease groups, and 
this overall annual report, ECDC issues ‘data calls’ with 
specified end dates to facilitate accurate and up-to-date 
submission of data for the previous calendar year.
The information submitted by Member States to ECDC is 
defined through a ‘metadataset’ for each disease under 
surveillance. The metadataset includes the case clas-
sification for the disease (particularly whether the case 
is confirmed or probable) according to case definitions 
for the diseases as determined by the Commissioniv. 
The metadataset also defines the information items to 
be included with each case report. Most data is sub-
mitted as anonymised case data, but aggregated data 
is reported by some Member States for some diseases. 
iv Commission Decision 2002/253/EC.
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Countries actively report zero cases for particular dis-
eases as applicable. 
Data are uploaded and validated by the Member States 
using ECDC’s online system for the collection of surveil-
lance data, the European Surveillance System (TESSy). 
Member States’ information specialists transform the 
data in their surveillance systems into TESSy format 
before uploading. Overview reports generated by TESSy 
allow Member States to review uploaded data and to 
make modifications where necessary. Automatic valida-
tion by the TESSy system and additional data validation 
are conducted by ECDC staff, in liaison with designated 
disease experts and epidemiologists in Member States. 
Additional validation is performed by ECDC experts 
and data managers following the end of the data call. 
Member States receive summary overview tables to ver-
ify the data to be included in this annual report. Member 
States’ information staff upload any corrections required 
to TESSy. Once the draft report is produced, it is sent to 
Member States’ National Surveillance Coordinators for 
final validation. Any final corrections are uploaded to 
TESSy.
For each disease under surveillance, TESSy also holds 
a description of the key attributes of the surveillance 
systems for that disease in each Member State. This 
information is included in the report to aid the interpre-
tation of surveillance data for each reported disease. 
Member States are asked to verify and update this infor-
mation as part of the Annual Epidemiological Report 
data call.
For the present report, data was drawn from the follow-
ing sources:
• data submitted in response to data calls by ECDC 
Disease Programmes for annual reports on the 
enhanced surveillance of specific diseases/disease 
groups; 
• data from European Disease Networks not integrated 
into ECDC in 2009: this included data relating 
to: variant Creutzfeldt–Jakob disease (EuroCJD), 
diphtheria (DIPNET), measles, mumps, pertussis and 
rubella (EUVAC.NET), and data on antimicrobial use in 
the EU (ESAC). 
• for all other diseases, a data call was issued 
specifically for this report. During this data call, 
Member States could also upload updated data for 
diseases that had been previously reported to either 
ECDC or EUVAC.NET.
Table 1.1. Sources of data analysed in the Annual epidemiological report 2011
Disease Section Source of Data
Antimicrobial resistance Antimicrobial resistance and healthcare-
associated infections
TESSy (Disease-specific call)
Healthcare-associated infections Antimicrobial resistance and healthcare-
associated infections
TESSy (Disease-specific call)
Malaria Emerging and vector-borne diseases TESSy (Annual Report data call)
Plague Emerging and vector-borne diseases TESSy (Annual Report data call)
Q fever Emerging and vector-borne diseases TESSy (Disease-specific call)
SARS Emerging and vector-borne diseases TESSy (Annual Report data call)
Smallpox Emerging and vector-borne diseases TESSy (Annual Report data call)
Viral haemorrhagic fevers Emerging and vector-borne diseases TESSy (Annual Report data call)
West Nile virus infection Emerging and vector-borne diseases TESSy (Annual Report data call)
Yellow fever Emerging and vector-borne diseases TESSy (Annual Report data call)
Anthrax Food- and waterborne diseases TESSy (Annual Report data call)
Botulism Food- and waterborne diseases TESSy (Annual Report data call)
Brucellosis Food- and waterborne diseases TESSy (Disease-specific call)
Campylobacteriosis Food- and waterborne diseases TESSy (Disease-specific call)
Cholera Food- and waterborne diseases TESSy (Annual Report data call)
Cryptosporidiosis Food- and waterborne diseases TESSy (Annual Report data call)
Echinococcosis Food- and waterborne diseases TESSy (Disease-specific call)
Giardiasis Food- and waterborne diseases TESSy (Annual Report data call)
Hepatitis A Food- and waterborne diseases TESSy (Annual Report data call)
Leptospirosis Food- and waterborne diseases TESSy (Annual Report data call)
Listeriosis Food- and waterborne diseases TESSy (Disease-specific call)
Salmonellosis Food- and waterborne diseases TESSy (Disease-specific call)
Shigellosis Food- and waterborne diseases TESSy (Annual Report data call)
Toxoplasmosis Food- and waterborne diseases TESSy (Disease-specific call)
Trichinellosis Food- and waterborne diseases TESSy (Disease-specific call)
Tularaemia Food- and waterborne diseases TESSy (Annual Report data call)
Typhoid/paratyphoid fever Food- and waterborne diseases TESSy (Disease-specific call)
Variant Creutzfeldt-Jakob disease (vCJD) Food- and waterborne diseases DSN
VTEC infection Food- and waterborne diseases TESSy (Disease-specific call)
Yersiniosis Food- and waterborne diseases TESSy (Disease-specific call)
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The source of the data for each disease and disease 
group is given in Table 1.1. 
The source of the data for Chapter 3 are health threats 
identified through epidemic intelligence activities from 
formal and validated informal sources. These threats 
are documented and monitored by using a dedicated 
database, called the Threat Tracking Tool (TTT). Data 
analysed in this report are extracted from this tool and 
from the EWRS database. The analysis of monitored 
threats covers the periods from the activation of TTT in 
June 2005, and for the EWRS since January 2005, until 
the end of 2010.
The expression ‘opening a threat’ refers to the way ECDC 
assesses threats during its daily threat review meetings, 
internally known as ‘roundtable meetings’. The roundta-
ble meeting is attended by ECDC experts who evaluate 
potential threats and validate events that require further 
attention or action from ECDC due to their relevance for 
public health or the safety of EU citizens. The following 
criteria are used to open a threat and further monitor an 
event:
• more than one Member State is affected;
• a disease is new or unknown, even if there are no 
cases in the EU;
• there is a request from a Member State or from a third 
party for ECDC to deploy a response team;
• there is a request for ECDC to prepare a threat 
assessment of the situation;
• there is a documented failure in an effective control 
measure (vaccination, treatment or diagnosis);
• there is a documented change in the clinical/
epidemiological pattern of the disease, including 
changes in disease severity, the way of transmission, 
etc.;
• the event matches any of the criteria under the 
International Health Regulations (IHR) or EWRS.
Following Decision No. 2000/57/EC of the European 
Parliament and of the Council, events are considered rel-
evant to be reported to the EWRS if one or more of the 
criteria below are metv. After the revised International 
Health Regulations (IHR) entered into force on 15 June 
2007, the decision has been amended, and criteria now 
include both IHR notifications and the need to exchange 
details following contact tracingv.
The criteria for reporting to the EWRS are the following:
• outbreaks of communicable diseases extending to 
more than one EU Member State;
• spatial or temporal clustering of cases of a disease 
of a similar type if pathogenic agents are a possible 
cause and there is a risk of propagation between 
Member States within the Union;
• spatial or temporal clustering of cases of disease of a 
similar type outside the EU if pathogenic agents are 
a possible cause and there is a risk of propagation to 
the Union;
• the appearance or resurgence of a communicable 
disease or an infectious agent which may require 
timely coordinated EU action to contain it;
• any IHR notification has to be reported also through 
EWRS;
v Commission Decision of 10 July 2009 amending Decision No 
2000/57/EC on the early warning and response system for the 
prevention and control of communicable diseases under the Decision 
No 2119/98/EC of the European parliament and of the Council, in 
Official Journal of the European Union. 2009. p. L 181: 57-9.
Disease Section Source of Data
Chlamydia infection HIV/AIDS, STI and hepatitis TESSy (Disease-specific call)
Gonorrhoea HIV/AIDS, STI and hepatitis TESSy (Disease-specific call)
Hepatitis B HIV/AIDS, STI and hepatitis TESSy (Annual Report data call)
Hepatitis C HIV/AIDS, STI and hepatitis TESSy (Annual Report data call)
HIV/AIDS HIV/AIDS, STI and hepatitis TESSy (Disease-specific call)
Syphilis HIV/AIDS, STI and hepatitis TESSy (Disease-specific call)
Avian influenza in humans Influenza TESSy (Annual Report data call)
Influenza Influenza TESSy (Disease-specific call)
Legionnnaires’ disease Legionellosis TESSy (Disease-specific call)
Tuberculosis Tuberculosis TESSy (Disease-specific call)
Diphtheria Vaccine-preventable diseases DSN
Invasive Haemophilus influenzae disease Vaccine-preventable diseases TESSy (Disease-specific call)
Invasive meningococcal disease Vaccine-preventable diseases TESSy (Disease-specific call)
Invasive pneumococcal disease Vaccine-preventable diseases TESSy (Annual Report data call)
Measles Vaccine-preventable diseases DSN
Mumps Vaccine-preventable diseases DSN
Pertussis Vaccine-preventable diseases DSN
Poliomyelitis Vaccine-preventable diseases TESSy (Annual Report data call)
Rabies Vaccine-preventable diseases TESSy (Disease-specific call)
Rubella Vaccine-preventable diseases DSN
Tetanus Vaccine-preventable diseases TESSy (Annual Report data call)
TESSy: the European Surveillance System; DSN: Dedicated Surveillance Network.
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• any event related to communicable diseases with a 
potential EU dimension necessitating contact tracing 
to identify infected persons or persons potentially in 
danger may involve the exchange of sensitive personal 
data of confirmed or suspected cases between 
concerned Member States.
Data analysis
General principles
All analyses are based on confirmed cases where pos-
sible. For some diseases, some Member States do not 
distinguish confirmed from other cases – in these situa-
tions, total case reports from these countries are used in 
the analyses and the country concerned identified as a 
footnote to the summary table for each disease descrip-
tion. For some diseases (e.g. tuberculosis, Legionnaires’ 
disease), confirmed cases are defined on a specific 
basis, described in the relevant sections. 
The ‘month’ variable used in the seasonality analyses is 
based on the date that the country chooses as its pre-
ferred date for reporting. This could be either date of 
onset of disease, date of diagnosis, date of notification, 
or some other date at the country’s discretion. 
Population data
Population data for the calculation of rates is obtained 
from Eurostatvi. Data for overall calculations are 
extracted from the Eurostat database ‘Demographic bal-
ance and crude rates’ (DEMO_GIND). The population as 
of 1 January of each year is used. Totals per year and per 
country are available for all countries for 2009. For cal-
culation of age- and gender-specific rates, the data are 
aggregated into the following age groups for the analy-
ses: 0–4, 5–14, 15–24, 25–44, 45–64 and ≥ 65 years. 
Presentation of analyses
The descriptive epidemiology for each disease is set 
out as a summary table by country and supplementary 
figures describing overall epidemiology at EU and EEA/
EFTA level. These include the trend for reported con-
firmed cases over 2006–09, age- and gender-specific 
rates, and occurrence by month (‘seasonality’), if rel-
evant. Additional graphs, figures and maps are used 
where necessary to illustrate other important aspects of 
the disease epidemiology in the EU and EEA/EFTA area.
Summary table
This table, given for each disease, presents an overview 
of the number and rates of confirmed cases reported by 
the Member States surveillance systems for the period 
2006–09. The total number of reported cases (inde-
pendent of case classification) for 2009 is also shown. 
Confirmed case rates are given per 100 000 persons (the 
number of reported confirmed cases divided by the offi-
cial estimate of the population for that year multiplied by 
vi Eurostat (http://epp.eurostat.ec.europa.eu) is the statistical office of 
the European Union. 
100 000). Countries that made no report for a disease are 
excluded from the calculation for overall European rates 
for that disease. Country reports from systems with less 
than national coverage (e.g. where only some regions 
of the country report nationally) are also excluded from 
calculation of overall EU case rates. 
The summary table indicates whether the country data 
was reported from a surveillance system with national 
or lesser geographical area of coverage. The table also 
indicates what type of data the country submitted: case 
based (‘C’), aggregated (‘A’) data or data submitted to a 
Disease Specific Network (‘D’). 
Aspects of descriptive epidemiology at EU/EEA level
The descriptive epidemiology for each disease for the EU 
and EEA/EFTA region overall is described as follows: 
• Trends in reported number of confirmed cases. The 
number of confirmed cases by month, 2006–09, for 
the EU and EEA/EFTA area is presented as a figure. 
The figure also shows a centred 12-month moving 
average to show the overall trend without the effect of 
seasonal fluctuations.
• Age- and gender-specific rates for confirmed cases. 
Age- and gender-specific rates for the EU and EEA/
EFTA area are presented (as the rates ‘per 100 000’). It 
should be noted that these analyses are based only on 
cases for which both age and gender were reported. 
For some diseases this can result in exclusion of a 
significant proportion of cases, and the overall EU 
and EEA/EFTA rate will be an underestimate. The 
denominator includes the sum of the populations 
within the respective age–gender groups, including 
countries which actively reported zero cases.
• Seasonal distribution of cases. For diseases where 
reported occurrence varies by month, a figure showing 
the seasonality is presented. This shows the total 
number of confirmed cases reported for each month 
in 2009, compared with the maximum and minimum 
case numbers observed for each month for the period 
2006–08. These analyses include only cases for 
which the month of reporting is given (again for some 
diseases this can result in exclusion of significant 
numbers of cases).
It will be noted that for some diseases reported numbers 
are too small for some or all of the above analyses to be 
presented.
Data protection
The data received in TESSy from Member States is sub-
ject to Regulation (EC) No 45/2001 of the European 
Parliament and of the Council of 18 December 2000, pro-
viding for ‘the protection of individuals with regard to 
the processing of personal data by the Community insti-
tutions and bodies, and on the free movement of such 
data.’ High standards of data protection consistent with 
these requirements are applied, supervised by the ECDC 
Data Protection Officer (DPO). ECDC data protection 
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arrangements are also under the review of the European 
Data Protection Supervisor.
Data is made available on request to other European 
Agencies, Institutions and approved researchers, under 
procedures in accordance with the above requirements, 
approved by the ECDC Management Board.
1.4 A note to the reader
The reader will appreciate that most surveillance sys-
tems capture only a proportion of the cases occurring in 
their countries. Some cases of disease remain undiag-
nosed (‘under-ascertainment’), and some are diagnosed 
but not reported to public health authorities (‘underre-
porting’). The pattern of this under-ascertainment and 
underreporting varies by disease and country, being a 
complex mix of healthcare-seeking behaviour, access to 
health services, availability of diagnostic tests, report-
ing practices by doctors and others, and the operation 
of the surveillance system itself. 
The direct comparison of disease rates between coun-
tries should therefore be undertaken with caution. The 
reader should be aware that in most cases, differences 
in case rates reflect not only differences in the occur-
rence of the disease, but also in systematic differences 
in health and surveillance systems as described here. 
Each Annual Report continues to evidence the improve-
ments in the harmonisation of systems, definitions, 
protocols and data at Member State and EU levels. 
Nevertheless, data provided by the Member States con-
tinue to show a number of inconsistencies. In several 
situations, the quality and comparability of the data 
are not ideal, and more work is planned, in conjunction 
with Member States, to see how best to improve this 
situation. 
This report aims to be consistent with previously pub-
lished ECDC surveillance reports for 2009 relating to 
specific diseases and disease groups. However, Member 
States update their data continually and a number have 
made specific corrections for this report, including cor-
rections to data reported for previous years (2006–08). 
Accordingly, some minor differences will be seen when 
comparing the data in this report to previous Annual 
Epidemiological and disease-specific reports. ECDC is 
working with Member States to harmonise surveillance 
processes in order to minimise these differences in 
future.
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2 Epidemiology of communicable 
diseases in Europe, 2009
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This Chapter is sub-divided into the following main dis-
ease groups:
2.1 Respiratory tract infections
Seasonal/pandemic influenza and human infection 
with animal influenza viruses, Legionnaires’ disease, 
tuberculosis.
2.2 STI, including HIV and blood-borne viruses
Chlamydia trachomatis infection, gonorrhoea, hepatitis 
B, hepatitis C, HIV and syphilis.
2.3 Food- and waterborne diseases and zoonoses
Anthrax, botulism, brucellosis, campylobacteriosis, 
cholera, cryptosporidiosis, echinococcosis, infection 
with VTEC/STEC, giardiasis, hepatitis A, leptospirosis, 
listeriosis, salmonellosis, shigellosis, toxoplasmosis, 
trichinellosis, tularaemia, typhoid/paratyphoid, variant 
Creutzfeldt–Jakob disease and yersiniosis.
2.4 Emerging and vector-borne diseases
Malaria, plague, Q fever, SARS, smallpox, viral haem-
orrhagic fevers (including hantavirus, Crimean–Congo 
haemorrhagic fever, dengue fever, Rift Valley fever, 
Marburg and Ebola virus, Lassa fever and chikungunya), 
West Nile fever and yellow fever.
2.5 Vaccine-preventable diseases
Diphtheria, invasive haemophilus influenzae disease, 
invasive meningococcal disease, invasive pneumococ-
cal disease, measles, mumps, pertussis, poliomyelitis, 
rabies, rubella and tetanus. 
2.6 Antimicrobial resistant pathogens and healthcare-
associated infections
Antimicrobial resistance, antimicrobial use and health-
care-associated infections.
For more general information about each communicable 
disease please refer to Health Topics A–Z on the ECDC 
website (www.ecdc.europa.eu). 
An alphabetical list of diseases and special health 
issues is given overleaf, for ease of reference.
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Alphabetical list of diseases and special 
health issues
AIDS ............................................................................55
Anthrax  ......................................................................43
Antimicrobial use  .....................................................189
Antimicrobial resistance  ...........................................183
Animal influenza  ....................................................... 28
Avian influenza  ......................................................... 28
Botulism  .....................................................................65
Brucellosis  ................................................................ 68
Campylobacteriosis  .................................................... 71
Chikungunya fever.....................................................142
Chlamydia trachomatis infection  ............................... 39
Cholera  .......................................................................74
Crimean-Congo haemorrhagic fever  ......................... 138
Cryptosporidiosis  .......................................................77
Dengue fever  ............................................................ 138
Diphtheria  ................................................................149
Ebola virus infection  ................................................ 141
Echinococcosis  .......................................................... 80
Escherichia coli infection  ....................................83, 183
Giardiasis  .................................................................. 87
Gonorrhoea  ................................................................43
Hantaviruses  ............................................................ 136
Healthcare-associated infections  ............................. 192
Hepatitis A  ................................................................ 90
Hepatitis B  .................................................................47
Hepatitis C  ................................................................. 51
HIV  .............................................................................55
Influenza  ....................................................................23
Invasive Haemophilus influenzae disease  ................ 152
Invasive meningococcal disease  .............................. 155
Invasive pneumococcal disease  ............................... 158
Klebsiella pneumoniae  .............................................184
Lassa fever ................................................................142
Legionnaires’ disease ................................................ 30
Leptospirosis  ............................................................. 94
Listeriosis  ...................................................................97
Malaria  ..................................................................... 125
Marburg virus infection  ............................................ 141
Measles  .................................................................... 161
MRSA  .......................................................................183
Mumps  ..................................................................... 165
Pandemic influenza  ....................................................23
Pertussis  ..................................................................169
Plague  ......................................................................129
Poliomyelitis  ............................................................ 172
Pseudomonas aeruginosa  ........................................184
Q fever  ..................................................................... 130
Rabies  ...................................................................... 174
Rift Valley fever  ........................................................ 141
Rubella  ..................................................................... 176
Salmonellosis  ........................................................... 101
SARS  ........................................................................ 134
Seasonal influenza ......................................................23
Shigellosis ................................................................ 105
Smallpox  .................................................................. 135
Staphylococcus aureus  .............................................183
STEC/VTEC, infection with  ......................................... 83
Syphilis  ......................................................................59
Tetanus  .................................................................... 179
Toxoplasmosis  ..........................................................108
Trichinellosis  ............................................................ 110
Tuberculosis  ...............................................................33
Tularaemia  ................................................................113
Typhoid/paratyphoid fever  ....................................... 116
Variant Creutzfeldt–Jakob disease  ...........................120
Viral haemorrhagic fevers  ........................................ 136
VTEC/STEC, infection with  ......................................... 83
West Nile fever  ......................................................... 145
Yellow fever  .............................................................. 147
Yersiniosis  ................................................................ 121
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Inﬂ uenza
• The 2009/10 influenza pandemic caused by the 
A(H1N1)2009 virus that emerged in the Americas 
in April 2009 spread quickly to Europe where, 
following a modest spring/summer wave of 
infection in 2009, most transmission and cases 
took place in the autumn and early winter with a 
moderate intensity.
• Almost all influenza cases in 2009 after the 
2008/09 season were caused by the 2009 
pandemic A(H1N1) virus. Only a few percentages 
of cases were due to a B virus (Victoria lineage). 
The previous seasonal A(H1N1) was eclipsed and 
with it most oseltamivir resistance. 
• Among primary care consultations, the most 
affected age group was children under 14 years.
• Unusually severe disease and deaths due to 
influenza were more frequent in younger adults 
(under 65 years) than older people.
• Surveillance of severe (hospitalised) acute 
respiratory cases was implemented in varying 
forms by 10 EU countries during the pandemic. 
Concerning those with laboratory-confirmed 
influenza infections from week 40/2009, 9 469 
cases were reported with 569 related fatalities. 
The rate of cases reported decreased with age but 
a severe outcome was associated with increased 
age, male gender and the presence of at least one 
underlying medical condition. Nevertheless, one 
quarter of severe influenza cases had no prior 
underlying medical condition.
• Most severe disease and deaths occurred in 
people with underlying medical conditions. 
However, 20 % of confirmed influenza deaths 
occurred in previously healthy adults and children, 
often in association with a difficult to treat acute 
respiratory distress syndrome. If sustained, these 
changes in risk patterns for severe influenza may 
result in a change in thinking about who should 
be offered immunisation. 
2.1 Respiratory tract infections
• The match of the pandemic virus with the new 
pandemic vaccines was good, resulting in high 
field vaccine effectiveness. However, the impact 
of these vaccines was limited by their availability 
after most transmission had occurred in the 
2009/10 waves.
• A number of significant weaknesses in routine 
and enhanced influenza surveillance systems 
were identified, notably in severe disease and 
mortality surveillance and sero-epidemiology. 
Most require to be remedied for seasonal 
influenza both for their own sake, and if they 
are to work effectively in future pandemics. An 
additional weakness was in rapid implementation 
of essential research and development during the 
pandemic. 
Influenza is an acute respiratory disease caused by 
influenza viruses. While most illnesses cases are short 
and without consequence, regular seasonal epidemics 
of influenza include significant rates of severe illness 
and death, particularly among elderly persons and those 
with underlying chronic medical conditions. Type A virus 
causes the most severe disease and is associated with 
epidemics and pandemics. Continuing changes in the 
genetic makeup of influenza viruses lead to develop-
ment of new strains that are more effective in causing 
epidemics. Occasionally, strains develop, many humans 
have little or no immunity to the new strain and world-
wide pandemics occur, as in 2009. 
24
Epidemiological situation: 
May 2009 to May 2010 
(week 20/2009–20/2010)
Sentinel surveillance of inﬂ uenza-like illness 
and acute respiratory infection and laboratory 
reports
The 2009 pandemic A(H1N1) virus that emerged in North 
America in the spring of 2009 was brought by travellers 
to many European countries in the spring and early sum-
mer of that year. Transmission rapidly established itself 
in a number of countries. Initially, the greatest number 
of cases appeared in the United Kingdom, where a peak 
was observed in July (around week 30/2009), although 
laboratory reports indicated transmission in a number of 
European countries1. Transmission then subsided again 
in all countries in parallel with the summer closure of 
schools, but accelerated in the autumn, following school 
reopening (Figure 2.1.1).
By week 40/2009 (early October), five European coun-
tries (Belgium, Ireland, Malta, Spain and the United 
Kingdom (Northern Ireland)) already reported influenza 
activity above the baseline and 11 countries reported 
increasing intensity activity. Weekly consultations in 
sentinel practices for influenza-like illness (ILI, 14 coun-
tries) acute respiratory infections (ARI, four countries), 
or both (10 countries) had already shown increases by 
week 40/2009, and peaked around week 46/2009 (mid-
November), returning to a low level by week 53/2009 
(probably also due to low reporting during the holi-
days). The autumn/winter wave of the pandemic lasted 
on average 11 weeks in each country, and there was the 
often observed west-to-east progression of influenza 
infection in Europe2. These data were in line with the 
percentage of influenza-positive specimens reported 
among samples from sentinel medical practices sending 
specimens to supporting laboratories. This is usually the 
best surrogate indicator of the influenza activity, which 
increased from 21.8 % during week 40/2009, peaked at 
49.4 % in week 44/2009, decreased under 10 % in week 
04/2010 and did not come back over this level for the 
rest of the season. The highest rate of infection was 
reported in the 0–14 years age group1.
The intensity of the pandemic as measured by consul-
tations in primary care was lower in comparison with 
the two previous seasons in some countries. However, 
as in other parts of the world, such paradoxical find-
ings could be explained with the change in healthcare 
seeking pattern as people were advised to avoid their 
general practitioners (GPs) in some countries at certain 
periods while in other places and periods there was 
more care seeking than usual1,3. Serological studies in 
some countries found that transmission was at least as 
intense in younger people as during seasonal epidem-
ics and in some localities higher4–6. It is also noteworthy 
that cases of respiratory syncytial viruses (RSV) peaked 
concomitantly around week 53/2009, but with a lower 
intensity compared with the two previous seasons.
From the 48 317 specimens collected by sentinel GPs 
during the 2009/10 season, 17 089 influenza viruses 
were detected. Of these, 16 924 (99.0 %) were type A 
and 165 (1.0 %) type B influenza viruses. Of 16 242 sub-
typed influenza virus, 16 198 (99.7 %) were A(H1N1)2009 
virus, 36 (0.2 %) were A(H1)seasonal virus and 8 (< 0.1 %) 
were A(H3) virus.
From week 40/2009 to week 20/2010, 3 305 influenza 
viruses from sentinel and non-sentinel specimens were 
characterised antigenically and 1 251 were characterised 
genetically. Of the former, 3 248 (98.3 %) were antigeni-
cally pandemic A/California/7/2009(H1N1)-like, and of 
the latter, 1 229 (98.2 %) belonged to the phylogenetic 
cluster represented by A/California/7/2009. Fifteen 
(75 %) of the 20 influenza type B viruses antigeni-
cally characterised up to week 20/2010 were of the B/
Victoria/2/87 lineage, while the remaining five (25 %) 
were of the B/Yamagata/16/88 lineage. One mutation 
Figure 2.1.1. Number of sentinel swabs and percentage of influenza-positive sentinel samples in the EU and EEA/EFTA 
countries, by type, subtype and week of reporting, weeks 40/2009–20/2010
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in the haemagglutinin gene HA1 (known as D222G) 
was for the first time observed in Europe in association 
with severe influenza. However, no conclusion could be 
reached as to whether this was due to any increased 
pathogenicity of the virus or because it reproduced more 
successfully than other variants in certain deep tissue 
environments7.
In Europe the pandemic virus continued to circulate dur-
ing the following winter season (2010/11), and was the 
most prevalent strain along with B viruses12. By the end 
of 2010, intensive care departments had come under 
serious pressure from cases of severe influenza cases in 
a number of EU countries.
Antiviral resistance
All pandemic viruses tested were resistant to M2 inhibi-
tors. Of the 1 453 viruses tested from nine countries, 
only 37 (2.5%) were resistant to oseltamivir, and of 
1 447 viruses tested, none were resistant to zanamivir. 
All of those found to be resistant to oseltamivir had the 
well-established A(H1N1)H275Y mutation and most were 
associated with prior use of the drug, usually in immune-
deficient individuals. There were only a few reports of 
oseltamivir resistant A(H1N1)2009 viruses being found 
in well individuals with no history of previous use. This 
was a marked contrast with previous seasonal influenza 
A(H1N1) viruses, where oseltamivir resistant strains pre-
dominated after 20078. 
Surveillance of severe-end laboratory-
conﬁ rmed A(H1N1)2009 cases in sentinel 
hospitals and related fatalities
When the influenza pandemic was declared, Member 
States were asked to report severe acute respiratory 
cases. The clinical case definition used for the report-
ing of these cases included all of following symptoms: 
sudden onset of fever over 38°C, cough or sore throat in 
the absence of any other diagnosis, shortness of breath 
or difficulty breathing and requiring hospital admission.
In addition, any death in a person with severe acute res-
piratory infection (SARI) or any unexplained deaths in 
hospital were also recorded. In this report, only labora-
tory-confirmed A(H1N1)2009 cases are considered, i.e. 
82.7 % of reported cases. Five countries (Ireland, Malta, 
Netherlands, Romania and Slovakia) distinguished 
the type of hospitalisation (ICU versus hospital ward) 
while France reported only cases admitted to ICU from 
week 45/2000. This is one of the main limitations of the 
pooled analysis of reported severe A(H1N1)2009 hospi-
talised cases.
From week 40/2009 to week 20/2010, 10 countries 
reported 9 469 laboratory-confirmed cases and 569 
related fatalities. The peak period of severe A(H1N1)2009 
varied in reporting countries from week 43/2009 to week 
01/2010. The median age of all cases was 24 years old, 
44 years in patients admitted to ICU and 50 years in SARI 
patients who died. The gender ratio (male/female) was 
1.1 and the age-specific notification rate decreased from 
22/105 in children aged < 1 year to 2/105 in the elderly 
aged 75 and more. In patients with available informa-
tion, 28.2 % had no underlying condition. The crude case 
fatality ratio was 6.2 % and 77.2 % of deaths occurred in 
patients less than 65 years old. This picture was mir-
rored in national studies9,10.
The number of cases decreased logarithmically with age 
with a strong statistical association high R2 (0.83), sug-
gesting that much of the decrease was associated with 
increasing to age; on the other hand, the case-fatality 
rate increased with age exponentially, also with a very 
high R2 (0.76). Considered together, this suggested that 
though decreasing numbers of people were infected as 
age increased the individual risk of an infected individ-
ual dying increased with age (Figure 2.1.2). 
Deaths 
For the first 12 months of the pandemic (to the end of 
March 2010), ECDC actively monitored deaths officially 
Figure 2.1.2. Number of cases of influenza and case fatality ratio in the EU and EEA/EFTA countries, by age, weeks 
40/2009–20/2010
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announced by Member States as being attributed to 
the pandemic (on national websites), as well as more 
detailed reports of case-based deaths to ECDC. The 
former method using epidemic intelligence found 2 900 
confirmed announced deaths, while a considerably 
smaller number was reported to ECDC. As for all forms 
of human influenza, these totals are likely to represent 
a considerable underestimate of the true picture of mor-
tality during the pandemic1.
Case reports to ECDC indicated a considerable difference 
from the picture in previous seasonal influenza, where 
most deaths occurred in older people. During the pan-
demic, most deaths were in younger adults (under age 
65 years), and especially in those with chronic underly-
ing conditions. This was confirmed in country studies 
where it was noted that around 20 % of deaths were in 
young previously healthy adults and children and the 
only age group that showed a rise in mortality during 
the pandemic was older children11. One of the reasons 
for the low numbers of deaths in older people was pre-
existing immunity in adults born before the mid-1950s, 
apparently due to circulation of an antigenically similar 
virus before that time1,5,6.
Impact of countermeasures 
Influenza antivirals (neuraminidase inhibitors) were 
applied to variable extents. Initially, there were 
unsuccessful efforts made to use them in combina-
tion with intensive case-finding to contain the virus1. 
Observational data indicated that, in accordance with 
the findings of previous trials, their early use was associ-
ated with less risk of development of severe disease10,12. 
Following a planned prevention measure, monovalent 
vaccines were rapidly developed and authorised by the 
European Commission following scientific advice from 
the European Medicines Agency and its advisory com-
mittees13. The almost exclusive circulation of the pan-
demic strain made for a good match with the vaccines, 
which were mostly augmented with adjuvants. This 
was associated with particularly good effectiveness 
of the vaccine when this was measured in the field14. 
However, generally the vaccines arrived too late to have 
any population impact15. Pharmacovigilance for the anti-
virals revealed few adverse effects and one significant 
instance of adverse events following immunisation is 
described in Chapter 313.
Discussion 
The 2009 pandemic dominated the respiratory infec-
tions in 2009. Not only were most of the infections it 
caused mild but in other ways the pandemic was less 
severe in Europe than in parts of the world affected ear-
lier16. Equally, it was much less severe than the ‘reason-
able worse case scenario’ for which many countries had 
prepared17. However, the pressures on some hospital 
services, notably paediatric services and intensive care, 
were considerable. Cases of acute respiratory distress 
syndrome in adults proved especially difficult to treat 
and resulted in higher levels of severe disease than 
might be expected from the generally benign picture of 
the pandemic in the community18. The change in the risk 
profile of those developing severe disease, if sustained, 
may have to result in different thinking on who to offer 
immunisation to in Europe. 
Surveillance and response system weaknesses were 
exposed by the pandemic and have been identified in a 
number of evaluation reports19,20. Surveillance for severe 
disease due to influenza was already known to be not 
well developed in Europe as elsewhere, and attempts to 
establish new systems during the pandemic were only 
of limited success. Surveillance for severe acute respira-
tory infection due to any cause (a system developed for 
moderate and poorly resourced settings) was generally 
less successful in European countries than surveillance 
for confirmed influenza in hospitalised patients9,10. Too 
much time was spent producing numbers of cases and 
deaths of uncertain validity leaving little time or energy 
to answer important questions, monitor trends and 
Figure 2.1.3. Officially announced deaths and deaths reported to ECDC due to 2009 pandemic influenza A(H1N1) in EU 
and EEA/EFTA countries, by week of report, weeks 40/2009–20/2010
Epidemic intelligence (n=2,900)
Reported to ECDC (n=1,860)
Nu
m
be
r o
f d
ea
th
s 
ca
us
ed
 b
y 
in
ﬂu
en
za
 A
(H
1N
1)
20
09
0
50
100
150
200
250
300
350
17141185252494643403734312825
27
Inﬂ uenzaSURVEILLANCE REPORT
ascertain risk factors16,17. Although sero-epidemiological 
data were generated in Europe, results were available 
well after they could have advised policy4–6. 
A major test of European countries’ individual and col-
lective ability to strengthen infection surveillance will be 
the extent to which the many ‘lessons learnt’ are imple-
mented16,19,20. Most of the needed enhancements will 
need to be integrated into routine surveillance arrange-
ments for seasonal influenza. This is both because of the 
information provided each season, but also because the 
experience that systems implemented for the first time 
during the pandemic under public health emergency 
conditions generally did not work well20. Equally, there 
was a general inability to undertake essential research 
and development work in a timely manner during the 
pandemic and the immediate period thereafter4,6,10,16,21. 
However, success with rapid estimated vaccine effec-
tiveness and investigation of adverse effects associated 
with vaccination shows that this deficiency was not inev-
itable15 (see also Chapter 3). 
In the summer of 2010, Sweden, and later Finland, 
reported an unusual number of narcolepsy cases among 
children and adolescents vaccinated with one of the 
pandemic vaccines. Following these reports, several 
national and international studies to investigate a possi-
ble link between pandemic vaccine and narcolepsy have 
been initiated. Further information is given in Chapter 3.
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Animal inﬂ uenzas, including avian inﬂ uenza
• No human infections were reported in the EU 
and EEA/EFTA countries with highly pathogenic 
A(H5N1) in 2009 and there were no reports of 
human infections with other avian influenzas. 
• One human infection with a true A(H1N1) swine 
influenza was reported. This was not related to 
the later A(H1N1)2009 pandemic which was of 
swine origin. 
• It is considered that highly pathogenic A(H5N1) 
viruses remain a significant public health threat 
for Europe.
Introduction
Wild birds, along with some other animals such as pigs, 
are reservoirs of animal influenza viruses. Wild aquatic 
birds are considered to be the original natural reservoir 
for most influenza viruses. These viruses are constantly 
changing through mutation and viral recombination. 
Occasionally the viruses infect humans and very occa-
sionally they are the source of pandemic viruses1. Since 
1996, strains of highly pathogenici influenza viruses 
type A(H5N1) have become established in bird popula-
tions, which, unusually among animal influenzas, have 
led to some sporadic cases and a few clusters of human 
infection and deaths2. This particular group of influenza 
A viruses only occasionally infect humans and person-
to-person transmission is even less common. However, 
the infections that have been reported indicate high 
pathogenicity. Highly pathogenic A(H5N1) viruses remain 
a concern for human health in Europe because of four 
characteristics3:
• they are still highly pathogenic for humans; 
• they are a persistent zoonotic infection among birds 
with which humans are in close contact; 
• they are continuing to evolve; 
• there is a risk of genetic recombination with influenza 
viruses that are better adapted to, and transmissible 
among, humans.
In 2009, only two outbreaks caused by highly patho-
genic avian influenza were reported in domestic poultry 
– one in Germany, of type A(H5N1); and another in Spain, 
of type A(H7N7)4. No human cases associated with these 
two outbreaks were reported, though it cannot be deter-
mined whether public health measures implemented by 
the national authorities of these two countries contrib-
uted to this positive outcome. 
i The term ‘highly pathogenic’ refers to the pathogenicity (case fatality 
rate) in poultry, not humans.
The World Health Organization (WHO) closely monitors 
reports of avian influenza A(H5N1) infections in humans 
worldwide and in January 2010 it published a review of 
the clusters of A(H5N1) across the world spanning the 
period 2003–092. Extensive information regarding avian 
influenza A(H5N1) cases and outbreaks in humans and 
its public health implications has also been published 
by ECDC, though in the Centre’s view there is now a 
need to look for clusters of human cases and sporadic 
cases in countries where A(H5N1) is not known to be 
entrenched in poultry. Single cases of human infec-
tion in Cambodia, China, Egypt, Indonesia and Vietnam 
should no longer be remarkable though they still need 
to be monitored to detect changes in their epidemiology 
and clinical picture5,6.
Low pathogenic avian inﬂ uenza in birds
In 2009, a number of outbreaks of low pathogenic 
avian influenza occurred in the EU and were reported 
to the World Organisation for Animal Health (OIE). The 
reporting countries were Spain (one outbreak, H5 type), 
France (two outbreaks, H5N3 subtype), the Netherlands 
(two outbreaks, H5N2 subtype), Germany (multiple 
H5 type outbreaks, mostly H5N3 subtype), the Czech 
Republic (two outbreaks, one of them H5N3 subtype) 
and Romania (one outbreak, H5N3 subtype). Though 
low pathogenic avian and other animal influenzas have 
infected humans, they only rarely cause disease and 
that is almost always mild7.
Other animal inﬂ uenzas
One genuine human case of swine influenza was 
reported from Spain in early 2009, but the infection was 
probably acquired in 2008 from direct contact with a 
pig8. The result was a mild illness that did not require 
hospital care and the patient recovered fully. In fact the 
infection was only detected by chance8,9. True swine 
influenzas (influenza adapted to pigs) of the Eurasian 
types are endemic in domestic pigs in many parts of 
Europe but it is not reportable and so the epidemiology 
reporting relies on research findings9,10. Surveillance for 
swine influenzas in human seems to be considerably 
stronger in the United States than in Europe, though the 
viruses in North America are quite different and argu-
ably more dangerous than those in Europe9,10. The nam-
ing of the A(H1N1)2009 pandemic virus as ‘swine flu’ in 
some countries was unfortunate as it caused confusion, 
especially with communication to the public. The pan-
demic virus is in fact a human A(H1N1) influenza that 
originated as a recombined virus that includes swine 
influenza components.
Discussion
Worldwide, 48 cases of human influenza A(H5N1) infec-
tion were reported to WHO in 2010. But none of these 
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was from Europe11. This was the second lowest number 
of cases identified since 2005. In most instances, 
reports of avian influenza in birds are a result of passive 
surveillance activities so these infections are likely to be 
under-reported. Further, they reveal only a small propor-
tion of the pool of avian influenza viruses co-existing 
with other influenza viruses in different animal species 
and in humans. Preventing the entry of these pathogens 
into Europe is not possible as they are carried over long 
distances by asymptomatic wild (aquatic) birds, both 
during migration and through trade (legal and illicit). 
Future considerations, at least in EU countries and 
through initiatives sponsored by the European 
Commission (DG Research), could be to convert the cur-
rent passive surveillance into an active system of rou-
tine monitoring of animal influenza, including influenza 
in animals like pigs9,10. 
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Legionnaires’ disease (legionellosis)
• Legionnaires’ disease remains an uncommon 
infection in the EU and EEA/EFTA countries.
• The rate of confirmed cases remains low and 
relatively stable at 1.0 per 100 000 population.
• The peak of reported cases, in July in previous 
years, has changed in 2009 to a more prolonged 
period, from June to September.
• The number of reported cases and clusters 
of travel-associated Legionnaires’ disease 
decreased compared with 2008.
Legionnaires’ disease is an uncommon respiratory infec-
tion caused by bacteria belonging to the Legionella 
genus. The infection can be fatal and outbreaks from a 
common environmental source can occur. The bacteria 
survive well in watery environments, and transmission 
to humans is most commonly through inhalation of con-
taminated aerosols.
Epidemiological situation in 2009
Of the 5 530 cases of Legionnaires’ disease reported 
across 26 EU and EEA/EFTA countries in 2009, 5 133 
cases were confirmed. Three countries reported zero 
cases (Cyprus, Czech Republic and Lithuania). Data were 
not available from Liechtenstein.
The overall confirmed case rate was 1.0 per 100 000 
population (Table 2.1.1). The individual country rates 
varied between < 0.1 and 2.0 cases per 100 000 popula-
tion; only two countries (Slovenia and Spain) reported a 
rate over 2.5 per 100 000.
Table 2.1.1. Number and rate of reported cases of Legionnaires’ disease in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type*
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 92 83 0.99 95 1.14 96 1.16 64 0.78
Belgium Y C 80 64 0.60 0 0.00 77 0.73 131 1.25
Bulgaria Y C 4 3 0.04 0 0.00 1 0.01 2 0.03
Cyprus Y C 3 3 0.38 9 1.14 1 0.13 1 0.13
Czech Republic Y C 20 10 0.10 9 0.09 14 0.14 12 0.12
Denmark Y C 123 99 1.80 130 2.37 126 2.31 90 1.66
Estonia Y C 6 6 0.45 7 0.52 3 0.22 4 0.30
Finland Y C 22 8 0.15 30 0.57 46 0.87 0 0.00
France Y C 1 206 1 181 1.83 1 205 1.88 1 336 2.10 1 386 2.20
Germany Y C 503 378 0.46 406 0.49 392 0.48 363 0.44
Greece Y C 15 15 0.13 26 0.23 22 0.20 30 0.27
Hungary Y C 65 14 0.14 20 0.20 11 0.11 6 0.06
Ireland Y C 7 7 0.16 8 0.18 14 0.32 11 0.26
Italy Y C 1 207 1 159 1.93 2 194 3.68 1 842 3.12 1 717 2.92
Latvia Y C 3 3 0.13 10 0.44 4 0.18 2 0.09
Lithuania Y A 0 0 0.00 2 0.06 2 0.06 0 0.00
Luxembourg Y C 5 5 1.01 4 0.83 5 1.05 9 1.92
Malta Y C 4 4 0.97 2 0.49 14 3.43 2 0.49
Netherlands Y C 251 214 1.30 313 1.91 300 1.83 418 2.56
Poland Y C 10 4 0.01 6 0.02 5 0.01 18 0.05
Portugal Y C 96 93 0.88 91 0.86 78 0.74 89 0.84
Romania Y C 3 1 0.00 0 0.00 0 0.00 - -
Slovakia Y C 2 1 0.02 6 0.11 2 0.04 2 0.04
Slovenia Y C 66 61 3.00 44 2.19 32 1.59 - -
Spain Y C 1 231 1 205 2.63 1 220 2.69 1 123 2.53 1 328 3.03
Sweden Y C 126 126 1.36 153 1.67 127 1.39 105 1.16
United Kingdom Y C 376 372 0.61 394 0.64 486 0.80 581 0.96
EU total - - 5 526 5 119 1.03 6 384 1.28 6 159 1.24 6 371 1.36
Iceland Y C 7 6 1.88 2 0.63 4 1.30 1 0.33
Liechtenstein - - - - - - - - - - -
Norway Y C 34 32 0.67 35 0.74 33 0.70 26 0.56
Total - - 5 567 5 157 1.02 6 421 1.28 6 196 1.24 6 398 1.35
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
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Age and gender distribution
Cases of Legionnaires’ disease are mainly reported in 
persons in older age groups: in 2009, 4 438 (86 %) were 
at least 45 years old. The male-to-female ratio is 2.9:1. 
The confirmed case rates increased with age, from < 0.1 
per 100 000 in the under 25 years old to 2.6 per 100 000 
in persons aged 65 years and above (4.2 per 100 000 in 
males and 1.5 per 100 000 in females) (Figure 2.1.5). 
Seasonality
A clear trend in the monthly reports can be observed 
across all countries, with cases increasing in May, 
peaking during July to September and then decreasing 
gradually throughout the winter months. In 2009, July to 
September accounted for 2 547 cases which represent 
almost 50 % of the reported cases in 2009 with a known 
month of report (Figure 2.1.6).
Enhanced surveillance in 2009
EWGLINET was the EU’s dedicated surveillance network 
collecting data on cases of Legionnaires’ disease in the 
EU and travel-associated Legionnaires’ disease (TALD) 
in 2009. The network is since 1 April 2010 coordinated 
by ECDC and renamed ELDSNet (European Legionnaires’ 
Disease Surveillance Network). In 2009, the countries 
collaborating in the EWGLINET scheme reported 824 
confirmed individual TALD cases resulting in 88 new 
TALD clusters being identified1. The number of reported 
individual cases has decreased compared with 2007 
(947 cases) and 2008 (871 cases). The number of TALD 
clusters of cases detected in 2009 also decreased com-
pared with 2007 and 2008 (113 and 108, respectively).
Discussion
The confirmed case rate of reported Legionnaires’ dis-
ease across the EU and EEA/EFTA remained stable in 
2009 (allowing for delays in case reporting). Seasonality 
and age and gender distributions of cases were similar 
to those observed in previous years. The slight decrease 
in occurrence of TALD cases and clusters in 2009 com-
pared to previous years may reflect the implementation 
of EWGLI guidelines and country legislation for the con-
trol of Legionnaires’ disease in the EU and EEA/EFTA. 
However, the decrease in global travel, associated with 
the worldwide recession, is also likely to have influenced 
the occurrence of travel-associated Legionnaires’ dis-
ease. There was in 2010 a small increase in international 
Figure 2.1.5. Rates of reported confirmed Legionnaires’ disease cases, by age and gender, in EU and EEA/EFTA 
countries, 2009
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Figure 2.1.4.  Trend and number of reported confirmed Legionnaires’ disease cases by month in EU and EEA/EFTA 
countries, 2006–09
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traveller numbers, associated with a small increase in 
the number of TALD cases reported (from 824 to 863). 
More information on TALD cases and clusters in 2010 
can be found in Chapter 3.
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Surveillance systems overview
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Figure 2.1.6.  Seasonal distribution of reported confirmed cases of Legionnaires’ disease, in EU and EEA/EFTA 
countries, 2006–09
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Tuberculosis
• The overall case notification rate for tuberculosis 
(TB) in the EU and EEA/EFTA countries continues 
to decline: in 2009 it was 4.5 % lower than that 
for 2008, reflecting a net downward trend in 20 
countries.
• In 2009, 29 EU and EEA/EFTA countries reported 
79 665 tuberculosis cases with an overall 
notification rate of 15.8 per 100 000 (range: 2.8 in 
Iceland to 108.2 cases per 100 000 in Romania); 
46 046 (57.8 %) of these cases were confirmed by 
culture (9.1 per 100 000).
• The highest culture-confirmed case rates were 
reported from Romania (57.5 per 100 000), 
Lithuania (44.1), Latvia (34.2), Estonia (23.1), 
Portugal (17.8) and Bulgaria (16.8).
• In 2009, 23.6 % of TB cases were of foreign origin, 
34.2 % of these cases were from Asia (outside of 
WHO European Region); 28.6 % from Africa; 9.5 % 
from other countries of the EU and EEA/EFTA, 
10.4 % from non-EU and EEA/EFTA European 
countries and 17.3 % from other or unknown 
countries. 
• Multidrug resistance (MDR) remained most 
frequent in the Baltic States (17.4 %–28.0 %) and 
Romania (11.2 %). Other countries reported lower 
levels of MDR (0 %–8 %), where it was generally 
more common in cases of foreign origin. 
• Overall, for the 15 countries reporting drug 
susceptibility testing results for second-line 
anti-TB drugs, 7.1 % of MDR TB cases were also 
extensively drug resistant (XDR). 
• Twenty-four countries reported treatment 
outcome monitoring (TOM) data for culture-
confirmed pulmonary TB cases reported in 2008. 
Among previously untreated, culture-confirmed 
pulmonary TB cases, 78.1 % had a successful 
outcome. Successful outcomes among previously 
treated pulmonary TB cases (53.2 %) and among 
all culture-confirmed MDR TB cases at 24 months 
(32.0 %) were much lower.
Tuberculosis (TB) is a disease caused by the infection 
with bacteria of the Mycobacterium tuberculosis com-
plex (primarily M. tuberculosis, M. africanum, M. bovis). 
TB continues to be a major cause of disability and death 
in the EU and in many parts of the world. Humans are the 
primary reservoir, and the infection is usually acquired 
by inhalation of aerosol droplets from another person. 
Case fatality rates remain significant, even with treat-
ment. Compliance with treatment, developing drug 
resistance, early diagnosis and prevention of spread 
to others remain major clinical and public health 
challenges. 
Epidemiological situation in 2009
In 2009, 79 655 TB cases were reported by 27 European 
Union (EU) countries and two European Economic Area 
(EEA) countries (Iceland and Norway) (Table 2.1.2), 
showing a decrease of 3 635 cases compared with 2008i. 
Over 75 % of cases occurred in the seven countries that 
reported 3 000 cases or more each (France, Germany, 
Italy, Poland, Romania, Spain and United Kingdom). 
The overall TB notification rate in 2009 was 15.8 per 
100 000 population. Rates lower than 20 per 100 000 
were reported by 22 countries and rates higher than 
20 per 100 000 by Romania (108.2), the Baltic States — 
Lithuania (62.1), Latvia (43.2), Estonia (30.7) — Bulgaria 
(38.3), Portugal (27.0) and Poland (21.6).
The overall notification rate was 4.5% lower than that 
for 2008 (for the 29 reporting countries), reflecting a net 
downward trend in 20 countries, as compared to 2008. 
The overall average annual decrease in rates between 
2005 and 2009 was 3.8%.
Age and gender distribution
The rates of males were predominant in the notified TB 
cases in nearly all countries, this feature being more 
marked among nationals than among cases of foreign 
origin (overall male-to-female ratio was 2:1 for nationals 
compared with 1.4:1 for foreign cases).
Among previously untreated cases (Figure 2.1.7), the age 
groups 25–44 and 45–64 together accounted for more 
than 60 % of all new cases (31.1 % and 29.1 %, respec-
tively). The middle-aged (45–64 years old) and the eld-
erly (> 64 years old) together represented more than half 
of the cases (all cases) of national origin but only 28.4 % 
of foreign cases. Most cases of foreign origin were 
reported among younger adults, especially in the 15–24 
and 25–44 years age group (68.4%).
Cases in children (< 15 years old) accounted for 4.2 % of 
all notified cases. Nearly all countries experienced a 
decline or stabilisation at low levels in paediatric notifi-
cation rates since 2005, suggesting low levels of trans-
mission in the general population. In Bulgaria, Latvia, 
i A notified TB case is reported according to the EU case definition: 
cases are divided into ‘possible’ (based on clinical criteria only 
– all notifiable TB cases should classified as ‘clinical criteria 
met’), ‘probable’ (having in addition positive acid-fast bacilli 
(AFB) detected or detection of M. tuberculosis in nucleic acid or 
granulomata in histology) and ‘confirmed’ (by culture or by detection 
of both positive AFB and M. tuberculosis nucleic acid).
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Table 2.1.2. Number and notification rate of tuberculosis reported in EU and EEA/EFTA countries, 2007–09
Country National Coverage
Report 
type*
All cases 2009 Confirmed cases
(a) 
2009 2008 2007
Total number and 
notification rate per 
100 000 population 
Total number and 
notification rate per 
100 000 population 
Total number and 
notification rate per 
100 000 population 
(all reported cases)
Total number and 
notification rate per 
100 000 population 
(all reported cases)
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 707 8.5 446 5.3 822 9.9 874 10.5
Belgium Y C 1 020 9.6 815 7.6 990 9.3 1 020 9.6
Bulgaria Y C 2 911 38.3 1 280 16.8 3 150 41.3 3 038 39.7
Cyprus Y C 55 6.9 41 5.1 50 6.3 42 5.4
Czech Republic Y C 702 6.7 477 4.6 868 8.3 846 8.2
Denmark Y C 329 6.0 242 4.4 376 6.8 391 7.2
Estonia Y C 411 30.7 309 23.1 445 33.2 490 36.5
Finland Y C 419 7.9 307 5.8 344 6.5 348 6.6
France Y C 5 308 8.2 2 432 3.8 5 812 9.1 5 588 8.8
Germany Y C 4 432 5.4 3 011 3.7 4 536 5.5 4 998 6.1
Greece Y C 586 5.2 306 2.7 669 6.0 659 5.9
Hungary Y C 1 448 14.4 711 7.1 1 620 16.1 1 686 16.8
Ireland Y C 472 10.6 242 5.4 468 10.6 480 11.0
Italy Y C 3 877 6.5 2 511 4.2 4 418 7.4 4 525 7.6
Latvia Y C 977 43.2 773 34.2 1 070 47.2 1 255 55.1
Lithuania Y C 2 081 62.1 1 478 44.1 2 250 67.0 2 408 71.3
Luxembourg Y C 27 5.5 27 5.5 28 5.7 39 8.1
Malta Y C 44 10.6 20 4.8 53 12.9 38 9.3
Netherlands Y C 1 160 7.0 760 4.6 1 021 6.2 1 004 6.1
Poland Y C 8 236 21.6 5 223 13.7 8 080 21.2 8 614 22.6
Portugal Y C 2 871 27.0 1 892 17.8 3 002 28.3 3 139 29.6
Romania Y C 23 267 108.2 12 351 57.5 24 680 114.7 24 837 115.3
Slovakia Y C 506 9.3 235 4.3 633 11.7 682 12.6
Slovenia Y C 188 9.3 179 8.8 213 10.5 218 10.8
Spain Y C 7 592 16.6 4 095 8.9 8 216 18.0 7 768 17.3
Sweden Y C 627 6.8 515 5.6 546 5.9 482 5.3
United Kingdom Y C 9 040 14.8 5 075 8.3 8 621 14.1 8 314 13.6
EU total 79 293 15.9 45 753 9.2 82 981 16.7 83 783 16.9
Iceland Y C 9 2.8 8 2.5 6 1.9 14 4.5
Liechtenstein Y C - - - - - - 5 14.2
Norway Y C 363 7.6 285 5.9 313 6.6 302 6.4
Total C 79 665 15.8 46 046 9.1 83 300 16.5 84 104 16.8
Source: Country reports. A: Aggregated data report; C: Case-based report; –: No report, U: Unspeciﬁ ed. (a) A conﬁ rmed TB case for this report is deﬁ ned as a patient 
with culture-conﬁ rmation for M. tuberculosis complex.
Figure 2.1.7. Rates of tuberculosis cases, by age and gender, in EU and EEA/EFTA countries, 2009 (n = 79 402)
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Lithuania and Romania, however, rates among children 
remained high (12.9–29.6 per 100 000 child popula-
tion) in 2009 and have increased in Bulgaria since 2000 
(from 11.8 to 20.6 per 100 000). Although rates are low in 
Belgium, Finland, Germany, the Netherlands, Slovenia, 
Sweden and the United Kingdom (< 10 per 100 000), 
some increases in paediatric notified cases have been 
recorded in these countries.
Enhanced surveillance in 2009
In 2009, 79 % of the reported cases were previously 
untreated, with a wide variation between countries 
(range: 54.4–96.7 %). This proportion has not changed 
markedly in the past years, but the total number of new 
cases has decreased progressively and is probably the 
main reason for the decline observed in notification 
rates of TB in the EU and EEA/EFTA countries.
Pulmonary TB accounted for 78 % of all TB cases and 
43.5 % of these cases were sputum smear positive. 
Among paediatric cases (< 15 years), 58.2 % were pulmo-
nary cases (14.4 % sputum smear positive), and 40.7 % 
extra pulmonary.
Of the cases reported in 2009, 57.8 % were culture-
confirmed, but the level differed widely across coun-
tries (range: 44–100 %, Figure 2.1.8) and data were not 
complete for five countries (i.e. < 50 % of culture-con-
firmed cases). The latter is an improvement from 2008, 
at which point data were not complete for seven coun-
tries. The overall proportion has remained stable since 
2005. Species identification showed M. tuberculosis in 
83 % of culture-positive cases in 2009 in the 29 report-
ing countries, M. bovis (0.3 %) was reported by 10 coun-
tries and M. africanum (0.2 %) by eight countries. Data 
on the other members of M. tuberculosis complex were 
not analysed for 2009.
TB cases of foreign origin
In 2009, 23.6 % of reported TB cases were in individu-
als of foreign originii, the proportion ranging from 30.1 % 
to 89 % in 18 countries. The overall proportion was 
substantially higher (35 %) when excluding data from 
Bulgaria and Romania. Overall, all 29 reporting countries 
reported area of origin of TB cases: 10.4 % from non-
EU and EEA/EFTA European countries; 34.2 % of cases 
of foreign origin were from non-European Asia; 9.5 % 
from other countries of the EU and EEA/EFTA; 28.6 % 
from Africa and 17.3 % from other regions (Americas and 
Western Pacific countries), or of unknown origin.
ii Geographical origin of TB cases is classified according to place of 
birth (born in the country/foreign-born) or, if unavailable, citizenship 
(citizen/non-citizen). In Denmark, the place of birth of the parents is 
also used in classifying origin.
Figure 2.1.8. Proportion of culture-positive cases among all notified tuberculosis cases in the EU and EEA/EFTA 
countries, 2009
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Tuberculosis and HIV infection
Aggregated data on HIV serostatus of TB cases reported 
between 2007 and 2009 were available for 20 countries. 
Overall, for the EU and EEA/EFTA, the proportion of 
reported HIV-seropositive TB cases was 2.3 % in 2009; 
similar to the proportion in 2007 (2.4 %) and a small 
decrease compared to 2008 (3.1 %). 
The completeness of data varied, with only eight coun-
tries reporting completeIII data in 2009. This is mainly 
due to differences in testing policies and in data collec-
tion. Among these eight countries, the proportion of TB/
HIV co-infected cases in 2009 was highest in Portugal 
(12.2 %), Estonia (9.5 %), Latvia (7.5 %) and Malta (9.1 %, 
representing only four cases), and ranged between 0 % 
and 4.2 % in Belgium, Iceland, Slovakia, and Slovenia. 
iii Data considered complete when known HIV status is 50% or more of 
all reported TB cases at the latest year with data.
Multidrug-resistant tuberculosis
Data on anti-TB drug-resistance surveillance (DRS) in 
2009 were made available by 28 countries, all of which 
have national coverage. Data from 19 of the 28 countries 
reporting culture and DST data, or providing DST results 
as part of a national case-linked dataset, were consid-
ered completeiv for 2009. Nationwide aggregated data 
were reported from France, Italy and Spainv.
Cases resistant to one or more first-line anti-TB drug 
were reported by all 28 reporting countries. Overall, the 
proportion of cases with combined multidrug-resistant 
iv 100 % national coverage or culturing available for 90 % of all cases, 
and 50 % of all cases were culture-positive, 75 % of them had 
reported DST results, and EQA results have 95 % match.
v Aggregated data as submitted to WHO/CISID and thus not case-
based data (DST results provided to ECDC/TESSy as part of a 
case-based individual dataset). Spain links the two databases, 
however, Italy does not, and therefore the numbers listed in table on 
resistance may differ from other tables.
Table 2.1.3. Number and percentage of multidrug-resistant and extensively drug-resistant tuberculosis cases reported 
in EU and EEA/EFTA countries, 2009
Country
Culture-
confirmed 
cases notified
Cases with drug-resistance 
surveillance results 
Multidrug-resistant TB among 
tested culture-confirmed cases
Extensively drug-resistant TB 
among all multidrug-resistant 
TB cases
N (%) N (%) N (%)
Austria 446 439 (98.4) 22 (5.0) 2 (9.1)
Belgium 815 774 (95.0) 10 (1.3) 3 (30.0)
Bulgaria 1 280 844 (65.9) 43 (5.1) - -
Cyprus 41 31 (75.6) 4 (12.9) 0 (0.0)
Czech Republic* 477 452 (94.8) 8 (1.8) 1 (12.5)
Denmark 242 242 (100.0) 2 (0.8) - -
Estonia 309 307 (99.4) 86 (28.0) 10 (11.6)
Finland 307 302 (98.4) 6 (2.0) - -
France* 2 432 1 564 (64.3) 30 (1.9) - -
Germany 3 011 2 702 (89.7) 56 (2.1) - -
Greece 306 174 (56.9) 14 (8.0) 4 (28.6)
Hungary* 711 542 (76.2) 20 (3.7) - -
Ireland 242 206 (85.1) 0 (0.0) - -
Italy 2 511 2 511 (100.0) 82 (3.3) 1 (1.2)
Latvia 773 752 (97.3) 131 (17.4) 16 (12.2)
Lithuania 1 478 1 478 (100.0) 322 (21.8) - -
Luxembourg 27 27 (100.0) 0 (0.0) - -
Malta* 20 17 (85.0) 0 (0.0) - -
Netherlands 760 760 (100.0) 20 (2.6) - -
Poland - - - - - - -
Portugal 1 892 1 539 (81.3) 22 (1.4) 3 (13.6)
Romania* 12 351 3 867 (31.3) 435 (11.2) 22 (5.1)
Slovakia* 235 235 (100.0) 1 (0.4) 0 (0.0)
Slovenia 179 175 (97.8) 1 (0.6) - -
Spain* 4 095 1 750 (42.7) 56 (3.2) 5 (8.9)
Sweden* 515 515 (100.0) 13 (2.5) 0 (0.0)
United Kingdom 5 075 4 991 (98.3) 58 (1.2) 2 (3.4)
EU total 40 530 27 196 67.1 1 442 5.3 69 4.8
Norway 8 8 (100.0) 0 (0.0) 0 (0.0)
Liechtenstein - - - - - - -
Iceland 285 283 (99.3) 8 (2.8) 0 (0.0)
Total 40 823 27 487 67.3 1 450 (5.3) 69 (4.8)
*Countries known to have incomplete data.
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TB (MDR TB) was 5.3 %, a 0.7 percentage point decrease 
from 2008, with the Baltic States and Romania report-
ing the highest proportions (17.4–28.0 % and 11.2 %, 
respectively) (Table 2.1.3). Of the 15 countries report-
ing data on extensively drug-resistant TB (XDR TB) for 
2009, 66 XDR TB cases were reported, with the propor-
tion of XDR TB cases increasing from 6.9 % of MDR cases 
in 2008 to 7.1 % in 2009. Estonia, Latvia and Romania 
had the highest numbers of XDR cases in 2009 (10, 16 
and 22 cases, respectively), though Romania reported a 
decrease in the total number of these cases (from 54 in 
2008 to 22 in 2009). 
Treatment outcome
Although the overall treatment success rate for new pul-
monary TB cases has shown a marginal decrease (from 
79.5 % to 78.1 %) between the 2007 and 2008 cohorts, 
the number of countries achieving the 85 % treatment 
success target has doubled, with six countries report-
ing success rates of 85 % or more for the 2008 cohort. 
This achievement is further accompanied by an increase 
of countries reporting treatment outcome monitoring 
(TOM) data. 
Concerns remain, however, in the TOM of the MDR TB 
cohort. The 24-month success rate in this cohort (i.e. all 
MDR TB cases) remains extremely low, at 32.0 % for the 
2007 cohort. This poses a serious threat to patient sur-
vival and development of XDR TB, particularly in view of 
the elevated treatment failure rates.
Among previously treated cases, the overall success rate 
(53.2 %) was lower than among new cases.
Discussion
Most countries of the EU and EEA/EFTA have continued 
to experience a steady decline in the overall case notifi-
cation rates. 
As for previous years, in the EU and EEA/EFTA the data 
reflect the heterogeneity of the TB situation with two 
distinct epidemiological groups of countries:
• Low-incidence countriesvi with cases increasingly 
reported from the foreign-born population;
• Countries with relatively high notification rates and 
with a high proportion of MDR TB cases, but with 
declining overall TB rates. 
vi The current approach of subdividing countries in low versus 
intermittent/high incidence is based on the published Monitoring 
Framework that uses 20 per 100 000 as a threshold between the two 
groups.
In addition the following issues should be highlighted:
• The assessment of TB surveillance systems’ quality 
and sensitivity (i.e. ability to capture all cases) should 
become a priority and standardised approaches, 
adaptable by countries, be developed. This should 
include the implementation and optimisation of 
linkages between laboratory and epidemiological 
registers at the reporting level through case-based 
reporting.
• As successful treatment contributes to reducing 
disease transmission and preventing emergence of 
resistant strains, the treatment success rate of new, 
pulmonary TB cases is one of the core indicators in 
the Follow-up to the Framework Action Plan to fight 
TB in the EU (with a target of 85 % treatment success 
rate defined). A treatment success rate target for new 
pulmonary culture-positive MDR cases of 70 % at 24 
months is also defined. Prioritisation of improving 
treatment outcome monitoring as well as treatment 
success rates should be continued in light of the low 
proportion still measured. Urgent attention should 
be paid to the high failure rates among the cohort of 
MDR TB patients at EU/EEA level for which 24 months 
treatment outcome is reported. 
On the basis of the fundamental need to maximise 
detection of infectious cases and early identification 
of drug-resistant cases, improvement in the proportion 
of cases with bacteriological confirmation is needed. 
Culture confirmation of specimens and identification of 
M. tuberculosis is the most accurate method of confirm-
ing active tuberculosis, and defines a confirmed case of 
TB as per EU case definitions. From a programme per-
spective, the achievement of a target for bacteriological 
confirmation among new pulmonary TB cases (80 %) is 
of key importance for ensuring rapid detection and treat-
ment (following DST) for MDR/XDR TB cases. Member 
States should evaluate the extent to which the undera-
chievement of culture-confirmation targets reflects sub-
optimal practice in testing by culture, or in the reporting 
of bacteriological results. 
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Surveillance systems overview
Country Data Source
Co
m
pu
ls
or
y 
(C
p)
 /
 
Vo
lu
nt
ar
y 
(V
) /
 O
th
er
(O
)
Co
m
pr
eh
en
si
ve
 (C
o)
 /
 
Se
nt
in
el
 (S
e)
 /
 O
th
er
(O
)
Ac
ti
ve
 (A
) /
 
Pa
ss
iv
e 
(P
)
Ca
se
-B
as
ed
 (C
)/
Ag
gr
eg
at
ed
 (A
)
Data reported by
Na
tio
na
l C
ov
er
ag
e
La
bo
ra
to
ri
es
Ph
ys
ic
ia
ns
Ho
sp
it
al
s
O
th
er
s
Austria AT-TUBERKULOSEGESETZ Cp Co A C Y Y Y Y Y
Belgium BE-TUBERCULOSIS Cp Co A C Y Y N N -
Bulgaria BG-MOH Cp Co A C Y N Y N -
Cyprus CY-NOTIFIED_DISEASES Cp Co P C N Y N N Y
Czech Republic CZ-TUBERCULOSIS Cp Co P C Y Y Y Y Y
Denmark DK-MIS Cp Co P C N Y N N Y
Estonia EE-TBC Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y Y N N Y
France FR-MANDATORY_INFECTIOUS_DISEASES Cp Co P C Y Y Y Y Y
Germany DE-SURVNET@RKI-7.1/6 Cp Co P C Y Y Y Y Y
Greece GR-NOTIFIABLE_DISEASES Cp Co P C Y Y Y N Y
Hungary HU-TUBERCULOSIS Cp Co P C Y Y N N Y
Iceland IS-TUBERCULOSIS Cp Co A C Y Y Y N Y
Ireland IE-TB Cp Co P C Y Y Y N Y
Italy IT-NRS Cp Co P C Y Y Y N Y
Latvia LV-TB Cp Co P C Y Y Y N Y
Lithuania LT-TB_REGISTER - - - - - - - - -
Luxembourg LU-SYSTEM1 Cp Co P C Y Y N N Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y Y Y
Netherlands NL-NTR Cp Co P C Y Y N N Y
Norway NO-MSIS_A Cp Co P C Y Y Y N Y
Poland PL_CR Cp Co P C Y Y Y N Y
Portugal PT-TUBERCULOSIS Cp Co P C N Y N Y Y
Romania RO-NTBSy Cp Co P C N Y N Y Y
Slovakia SK-NRT Cp Co - C Y Y Y N Y
Slovenia SI-TUBERCULOSIS Cp Co A C Y Y N N Y
Spain ES-STATUTORY_DISEASES Cp Co P C N Y Y N Y
Sweden SE-SweTBReg Cp Co P C Y Y Y N Y
United Kingdom UK-TUBERCULOSIS Cp Co A C Y N Y Y Y
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• Chlamydia is the most frequently reported 
sexually transmitted infection and reportable 
disease in Europe. In 2009, 343 958 cases of 
chlamydia have been reported in 23 EU and EEA/
EFTA Member States; a rate of 185 per 100 000 
population. The true incidence of chlamydia is 
likely to be higher as this infection is liable to 
underreporting or asymptomatic disease.
• Three quarters of all chlamydia cases were 
reported in young persons. The notification rate 
among those between 15 and 24 years of age is 
976 per 100 000 population; young women are 
affected more often than young men. 
• The overall trend compared with previous years 
appears to have increased substantially. However, 
this most likely reflects changes in screening and 
testing practices in a number of countries; the 
overall reporting rate increased by 42 % between 
2006 and 2009.
Infection with the bacterium Chlamydia trachomatis is 
the most frequently reported sexually transmitted infec-
tion in Europe. Most infections are asymptomatic, and 
complications include infertility in women.
Epidemiological situation in 2009
In 2009, 23 of the EU and EEA/EFTA Member States 
reported 343 958 cases (185.1 per 100 000). Almost 
95 % of the Chlamydia infections were reported by five 
countries (United Kingdom, Sweden, Denmark, Norway 
and Finland). The highest confirmed case rates were 
reported by Iceland (711 per 100 000), Denmark (541 per 
100 000), Norway (474 per 100 000) and Sweden (408 
per 100 000) (Table 2.2.1). 
Overall the incidence of reported confirmed cases has 
increased by 42 % between 2006 and 2009 in EU and 
EEA/EFTA countries. This apparent increase is, however, 
most likely due to improved case detection, through 
screening and testing activities, in a number of coun-
tries. For example, the United Kingdom now includes 
chlamydia data from community-based test settings 
as well as from STI clinics. These have been reported 
together for the first time in 2008, accounting for at least 
part of the increase in reported cases.
National surveillance systems for STIs (chlamydia, gon-
orrhoea and syphilis) consist of a mixture of voluntary, 
sentinel or selected laboratory systems, and frequently 
do not represent true national coverage. Comparison 
between countries is also made difficult by differences 
in the reporting systems, the diagnostic methods used, 
the amount of testing and screening for chlamydia and 
the proportion of underreporting.
The availability of a screening programme in dedicated 
STI services or targeted at (sub)groups of the popula-
tion, e.g. pregnant women, may significantly affect the 
reported number of Chlamydia infections. This means 
that the true incidence and prevalence is likely to be 
higher than the rates here reported.
Age and gender distribution
Data on age were available for 339 053 of the reported 
confirmed cases (98.6 % of all cases). The age category 
20–24 years is the largest, accounting for 41 % of the 
cases; followed by the category 15–19 years, with 34 %. 
Three quarters of the cases (for which data on age were 
available) were reported in the age group 15–24 years 
(255 036 cases), which also had the highest age-specific 
rate (976 per 100 000). Compared with previous years, 
the overall notification rate for this age group has sub-
stantially increased. This could be due to increased test-
ing activities and screening programmes specifically 
targeted at young people (and women in particular). 
Information on gender was available for 342 118 cases. 
Gender was reported as unknown for 1 840 cases (0.5 %). 
Some 138 327 cases were reported in males and 203 791 
in females, with rates of 152 and 217 per 100 000, 
2.2 Sexually transmitted infections, including 
HIV and blood-borne viruses
Chlamydia trachomatis infection
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respectively, giving the male-to-female rate ratio as 
0.70:1. It should be noted that there is a known ascer-
tainment bias due to the higher index of suspicion and 
more screening opportunities for young women.
Transmission category
Data on transmission category were not available for 
85 % of the chlamydia cases (N=293 788). The high 
proportion of missing data for transmission category is 
mainly due to the countries with the highest number of 
reported cases (Denmark, Norway, Finland and United 
Kingdom) not reporting this data. Information is avail-
able for 50 170 cases (from nine countries) and was 
reported as heterosexual in 89 % and as in men who 
have sex with men (MSM) in 4 % and as ‘unknown’ in 
7 % of the cases.
Lymphogranuloma venereum
Lymphogranuloma venereum (LGV) is a systemic sexually 
transmitted disease caused by a variety of the bacterium 
Chlamydia trachomatis. It rarely occurs in the western 
world1. However, in recent years outbreaks have been 
reported from several European countries among men 
who have sex with men2,3. Only three countries reported 
confirmed LGV cases in 2009: Belgium (17 cases), the 
Netherlands (86 cases) and the United Kingdom (142 
cases). Almost all cases have been diagnosed in men 
(one female case was reported in the UK). Between 
2000 and 2009, 1 390 cases of LGV were reported from 
five countries: United Kingdom, 897 cases; Netherlands, 
413 cases; Denmark, 47 cases; Belgium, 29 cases; and 
Ireland, four cases. The number of reported LGV cases 
has increased from 183 in 2006 to 245 in 2009.
Discussion
In many European countries, the incidence rates of 
chlamydia have increased substantially over the past 10 
years. However, in a number of European countries it is 
still not a notifiable disease. The distribution of chlamy-
dia across countries appears to be very heterogeneous 
with rates varying from below 1 to more than 500 cases 
per 100 000 population. Almost 90 % of the cases are 
reported from four countries. However, this is likely to 
reflect the considerable variation in screening, diagnos-
tic and surveillance practices across EU countries. High 
rates of 200/100 000 or more are reported by countries 
in the western and northern parts of the EU/EEA. Rates in 
Table 2.2.1. Number and rate of Chlamydia infection cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Reported cases and 
rate per 100 000 
population
Reported cases and 
rate per 100 000 
population
Reported cases and 
rate per 100 000 
population
Reported cases and 
rate per 100 000 
population
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 597 - 742 - 822 - - -
Belgium Y C 2 942 - 2 601 - 2 480 - 2 060 -
Bulgaria - - - - - - - - - -
Cyprus Y C 4 0.5 1 0.1 0 - 6 0.8
Czech Republic - - - - - - - - - -
Denmark Y C 29 825 541.1 29 116 531.7 25 795 473.6 24 866 458.2
Estonia Y C 1 952 145.6 2 206 164.5 2 536 188.9 2 529 188
Finland Y C 13 317 250 13 873 261.7 13 968 264.7 13 878 264.1
France - - - - - - - - - -
Germany - - - - - - - - - -
Greece N A 327 2.9 71 0.6 - - - -
Hungary Y A 711 - 754 - 699 - 598 -
Ireland Y A 3 997 89.8 6 290 142.9 5 023 116.5 3 144 74.7
Italy - - - - - - - - - -
Latvia Y C 1 078 47.7 748 32.9 716 31.4 820 35.7
Lithuania Y C 326 9.7 403 12 403 11.9 556 16.3
Luxembourg Y C 0 - 4 0.8 0 - 0 -
Malta Y C 58 14 108 26.3 70 17.2 43 10.6
Netherlands Y C 9 788 - 9 355 - 7 821 - 7 140 -
Poland Y A 908 2.4 695 1.8 627 1.6 612 1.6
Portugal - - - - - - - - - -
Romania Y A 91 0.4 127 0.6 115 0.5 238 1.1
Slovakia Y C 228 4.2 105 1.9 78 1.4 61 1.1
Slovenia Y C 130 6.4 120 6 198 9.8 146 7.3
Spain N C 846 - 402 - 223 - 139 -
Sweden Y C 37 775 408.1 41 974 457.1 47 081 516.6 32 518 359.4
United Kingdom Y A 214 033 347.5 200 169 324.9 120 058 196.2 112 013 184.1
EU total - - 318 933 176.1 309 864 171.2 228 713 135.5 201 367 119.5
Iceland Y C 2 271 711.1 1 834 581.4 1 814 589.6 1 728 576.2
Liechtenstein - - - - - - -  -  
Norway Y C 22 754 474.1 23 488 495.8 22 847 488.1 21 259 458.1
Total - - 343 958 185.1 335 186 180.6 253 374 146.4 224 354 129.9
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
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central and eastern parts of the EU/EEA are much lower, 
at 30 or less per 100 000 population. Baltic States, with 
the exception of Estonia, have similarly low rates.
Chlamydia mainly affects young people between 15 and 
24 years of age: three quarters of the infections are 
reported to be within this age group. Infections do not 
appear to be restricted to a particular risk group, affect-
ing young people generally, especially young women 
with highest rates of 2 000 per 100 000 in 15–19 years 
age group. The interpretation of both gender and age 
distributions needs to be done cautiously as this is 
strongly associated with current testing and screening 
practices as they are often targeted at teenagers and 
young adults.
In order to control the Chlamydia infection disease 
burden in Europe, comprehensive control programmes 
should be targeted to reach the most-at-risk populations, 
i.e. teenagers and young adults. Control programmes are 
crucial for early detection and treatment of all infected 
individuals and their sexual partners.
Only a few countries have reported confirmed cases of 
LGV. Even though absolute numbers are low, the inci-
dence in these countries appears to have increased. 
Enhanced surveillance for sexually transmitted 
infections
The coordination of the European network on STI surveil-
lance has been integrated into ECDC as from 1 January 
2009. More details on the epidemiology and trends of 
chlamydia can be found in the first surveillance report 
on 1990–2009 data4.
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Figure 2.2.1. Trend and number of reported confirmed cases of Chlamydia infection by month, in EU and EEA countries, 
2006–09
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Figure 2.2.2. Rates of reported confirmed Chlamydia infection cases, by age and gender, in EU and EEA/EFTA 
countries, 2009
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Surveillance systems overview
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Austria AT-STISentinella V Se A C Y N N N N
Belgium BE-LABNET V Se A C Y N - - Y
Cyprus CY-NOTIFIED_DISEASES Cp Co P C N Y N N Y
Denmark DK-LAB Cp Co P C Y N N N Y
Estonia EE-HCV/CHLAMYDIA Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y N N N Y
Greece GR-NOTIFIABLE_DISEASES - O P A Y N Y N N
Hungary HU-STD SURVEILLANCE Cp Se P A N Y N N Y
Iceland IS-SUBJECT_TO_REGISTRATION Cp Co P C Y Y Y N Y
Ireland IE-AGGR_STI Cp Co P A Y Y Y N Y
Latvia LV-BSN Cp Co P C Y Y Y N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Luxembourg LU-CHLAMYDIA V Se P C Y N Y - N
Luxembourg LU-SYSTEM1 Cp Co P C Y Y N N Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y Y Y
Netherlands NL-STI V Se P C N Y N N Y
Norway NO-MSIS_CHLAMYDIA) Cp Co A A Y N N N Y
Poland PL-NATIONAL_SURVEILLANCE Cp Co P C Y Y Y N Y
Romania RO-RNSSy Cp Co P A N N Y N Y
Slovakia SK-EPIS Cp Co A C Y Y Y N Y
Slovenia SI-SPOSUR Cp Co P C N Y N N Y
Spain ES-MICROBIOLOGICAL V Se P C Y N N N N
Sweden SE-SMINET Cp Co P C Y N N N Y
United Kingdom UK-GUM-COM O Co P A N N N Y Y
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Gonorrhoea
• Gonorrhoea is still an STI with a notable inci-
dence in the EU and EEA/EFTA countries.
• In 2009, a total of 29 202 cases of gonorrhoea 
were reported by 28 EU and EEA/EFTA countries, 
giving a rate of 9.7 per 100 000 population. 
• Gonorrhoea is reported three times more fre-
quently in men than in women. More than 40 % 
of all gonorrhoea cases were reported in people 
below 25 years of age. 
• Compared with previous years, the number of 
cases has decreased slightly in many countries, 
although no consistent patterns can be observed 
across countries. The overall rate decreased by 
9 % between 2006 and 2009.
• In 2009, the European gonococcal antimicrobial 
surveillance programme has identified high rates 
of ciprofloxacin and azithromycin resistance 
across Europe (63 % and 13 %, respectively) and 
decreased susceptibility to cefixime (5 % of iso-
lates). This is extremely concerning as cefixime 
and ceftriaxone are recommended therapy for 
gonorrhoea across Europe.
Gonorrhoea is a sexually transmitted infection caused 
by the bacterium Neisseria gonorrhoeae. It is the second 
most commonly reported bacterial STI in Europe.
Epidemiological situation in 2009
In 2008, 29 202 cases of gonorrhoea were reported in 
28 EU and EEA countries resulting in a notification rate 
of 9.7 per 100 000 population (Table 2.2.2). No data were 
available from Germany or Liechtenstein. Almost 60 % of 
all notified gonorrhoea cases were reported from the 
United Kingdom. Between 2006 and 2009, the number 
of reported gonorrhoea cases has decreased in 10 coun-
tries but increased in 11, resulting in an overall decrease 
of 9 %. 
There is wide variation in rate of reported cases, ranging 
from less than 1.5 per 100 000 in Greece, Luxembourg, 
Portugal, Poland and Slovenia, to more than 15 per 
100 000 in Iceland, Latvia, Malta and the United 
Kingdom.
National surveillance systems for all STIs are heteroge-
neous, with a mixture of voluntary or mandatory report-
ing, sentinel or national coverage, clinical or laboratory 
reporting. Major variations in surveillance systems 
across countries in terms of coverage, completeness and 
representativeness hamper meaningful comparisons.
Age and gender distribution
Data on age was available for 26 255 of the reported 
cases (90 % of all cases). The age category 25–34 years 
is the largest, accounting for 31 % of the cases, immedi-
ately followed by the category 20–24 years, with 28 %. 
Almost 45 % of cases (for which data on age were avail-
able) were reported in the age group 15–24 years. 
Information on gender was available for 27 209 cases. 
Only for 1 992 cases (6.8 %) gender was reported as 
unknown (mainly due to missing information from 
Spain). Men account for 72 % of all gonorrhoea cases 
(19 565 cases) with an overall rate of 16 per 100 000 
compared with 4 per 100 000 women (7 644 cases). The 
male-to-female ratio was 2.6:1. If calculated without the 
United Kingdom, the ratio was 3.6:1. The male-to-female 
ratio ranged from 0.3:1 in Austria to 9.6:1 in Italy. Only 
three countries reported a ratio below 1.0:1 (Austria, 
Estonia and Iceland).
Transmission category
In 2009, information on transmission category was avail-
able for 13 countries (Austria, Cyprus, Czech Republic, 
France, Greece, Latvia, Lithuania, Malta, Netherlands, 
Norway, Slovenia, Sweden and United Kingdom) pro-
viding 80 % of the gonorrhoea cases (23 137 cases). 
Information was missing for 20 % of cases. The transmis-
sion category was unknown for 60 %, was indicated as 
heterosexual in 18 % and as in men who have sex with 
men (MSM) in 24 % of the cases. The high proportion 
of unknown transmission category is due to cases diag-
nosed in the United Kingdom (13 736 cases), which only 
collected data on confirmed transmissions among MSM. 
Cases diagnosed in MSM represent 29 % (5 523 cases) of 
all male cases reported in 2009.
Gonococcal antimicrobial resistance in 2009
In 2009, 17 EU and EEA/EFTA Member States partici-
pated in the European gonococcal antimicrobial sur-
veillance programme (Euro-GASP) by submitting 110 
consecutive gonococcal isolates. Susceptibility testing 
was performed (by E-test or agar dilution) for the fol-
lowing therapeutically relevant antimicrobials: cefixime, 
ceftriaxone, ciprofloxacin, azithromycin, spectinomycin 
and gentamicin. A total of 1 366 isolates were collected 
and tested. The majority of gonococci (84 %) were col-
lected from men. The age range of the patients was less 
than 1 year to 88 years, with a median of 29 years; 32 % 
of patients were younger than 25 years. Results from 
the gonococcal antimicrobial resistance external qual-
ity assurance (EQA) scheme showed high comparability 
between centres. This suggests that surveillance results, 
with respect to gonococcal antimicrobial susceptibility, 
can be used with confidence and are comparable. 
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Table 2.2.2. Number and rate of gonorrhoea cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Reported cases and 
rate per 100 000 
population
Reported cases and 
rate per 100 000 
population
Reported cases and 
rate per 100 000 
population
Reported cases and 
rate per 100 000 
population
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 143 - 263 - 131 - 171 -
Belgium Y C 711 - 718 - 585 - 535 -
Bulgaria Y A 191 2.5 178 2.3 149 1.9 165 2.1
Cyprus Y C 7 - 2 - 5 - 8 -
Czech Republic Y C 712 6.8 809 7.8 1 108 10.8 1 087 10.6
Denmark Y C 563 10.2 409 7.5 352 6.5 414 7.6
Estonia Y C 125 9.3 146 10.9 176 13.1 280 20.8
Finland Y C 237 4.4 198 3.7 192 3.6 231 4.4
France N C 342 - 236 - 217 - 196 -
Germany - - - - - - - - - -
Greece N A 164 1.5 208 1.9 201 1.8 190 1.7
Hungary Y A 872 - 892 - 1 041 - 916 -
Ireland Y A 400 9 444 10.1 417 9.7 431 10.2
Italy Y C 213 - 154 - 152 - 258 -
Latvia Y C 419 18.5 500 22 670 29.4 746 32.5
Lithuania Y C 391 11.7 533 15.8 471 13.9 437 12.8
Luxembourg Y C 6 1.2 18 3.7 1 0.2 4 0.9
Malta Y C 62 15 50 12.2 52 12.7 33 8.1
Netherlands Y C 2 426 - 1 969 - 1 830 - 1 778 -
Poland Y A 402 1.1 285 0.7 330 0.9 395 1
Portugal Y C 114 1.1 67 0.6 74 0.7 53 0.5
Romania Y A 622 2.9 631 2.9 815 3.8 1 348 6.2
Slovakia Y C 171 3.2 152 2.8 81 1.5 66 1.2
Slovenia Y C 30 1.5 40 2 42 2.1 34 1.7
Spain Y A 1 954 4.3 1 897 4.2 1 698 3.8 1 423 3.3
Sweden Y C 608 6.6 722 7.9 642 7 657 7.3
United Kingdom Y A 17 001 27.6 16 121 26.2 18 291 29.9 18 480 30.4
EU total - - 28 886 9.8 27 642 9.5 29 723 10.5 30 336 10.9
Iceland Y C 47 14.7 25 7.9 24 7.8 31 10.3
Liechtenstein - - - - - - -  -  
Norway Y C 269 5.6 301 6.4 238 5.1 236 5.1
Total - - 29 202 9.7 27 968 9.5 29 985 10.4 30 603 10.8
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
Figure 2.2.3. Trend and number of reported confirmed gonorrhoea cases by month, in EU and EEA/EFTA countries, 
2006–09
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Source: Country reports: Belgium, Cyprus, Czech Republic, Denmark,  Finland, Iceland, Italy, Luxembourg, Malta, Netherlands, Norway, Portugal, Slovakia, Slovenia,  
Sweden.
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The European gonococcal antimicrobial surveillance pro-
gramme has identified high rates of ciprofloxacin and 
azithromycin resistance across Europe (63 % and 13 %, 
respectively); these antimicrobials should, therefore, 
not be used for treatment, unless isolates are known to 
be susceptible or local resistance rates are known to be 
less than 5 %. Decreased susceptibility to cefixime was 
detected in 10 countries. Overall, 5 % of the isolates 
(with a cut-off of > 0.125mg/L) have decreased suscep-
tibility. In five countries, the percentage of isolates with 
decreased susceptibility to cefixime was above 5 %. 
Figure 2.2.5 displays the geographical distribution of 
these isolates.
Enhanced surveillance for sexually transmitted 
infections
The coordination of the European network on STI surveil-
lance has been integrated into ECDC as from 1 January 
2009. More details on the epidemiology and trends of 
gonorrhoea can be found in the first surveillance report 
on 1990–2009 data1. More details on the European 
Gonococcal Antimicrobial Susceptibility surveillance 
Programme (Euro-GASP) can be found in the 2009 
annual report2.
Figure 2.2.4. Rates of reported confirmed gonorrhoea cases, by age and gender, in EU and EEA/EFTA countries, 2009
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Source: Country reports: Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Greece, Hungary, Iceland, Italy, Latvia, Lithuania, Luxembourg, 
Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom.
Figure 2.2.5. Gonococcal antimicrobial susceptibility surveillance in EU and EEA/EFTA countries participating in Euro-
GASP, 2009
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Discussion
There are no consistent overall EU trends and the inter-
pretation is restricted by several factors, e.g. differences 
in reporting systems, reporting behaviour and probable 
underreporting. There also appear to be diverging trends 
in epidemiology in different countries. Data presented 
here, however, must be interpreted with caution as the 
proportions of gonorrhoea cases that are actually diag-
nosed and reported are likely to differ greatly across 
countries.
Decreased susceptibility to cefixime is extremely con-
cerning because it is a recommended therapy for gon-
orrhoea across Europe, as is ceftriaxone. The continual 
upward drift in the MIC for ceftriaxone in the European 
gonococcal population therefore needs to be monitored 
carefully. Loss of cefixime as an oral treatment option 
across Europe may have major cost and compliance 
implications if parenterally administered ceftriaxone 
becomes the only viable option. The European antibi-
otic resistance sentinel surveillance of Neisseria gon-
orrhoeae is essential to inform treatment guidelines, 
thereby preventing onward transmission and reducing 
patient morbidity.
References
1. European Centre for Disease Prevention and Control. Sexually trans-
mitted infections in Europe, 1990–2009. Stockholm: ECDC; 2011. 
2. European Centre for Disease Prevention and Control. Gonococcal an-
timicrobial susceptibility surveillance in Europe, 2009. Stockholm: 
ECDC, 2011.
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Austria AT-STISentinella V Se A C Y N N N N
Belgium BE-LABNET V Se A C Y N - - Y
Bulgaria BG-STI Cp Co P A - - Y Y -
Cyprus CY-NOTIFIED_DISEASES Cp Co P C N Y N N Y
Czech Republic CZ-STD Cp Co P C Y Y Y Y Y
Denmark DK-STI_CLINICAL Cp Co P C N Y N N Y
Estonia EE-GONOCOCC Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y Y N N Y
France FR-STI V Se A C Y Y Y Y N
Greece GR-NOTIFIABLE_DISEASES Cp Co P A Y Y Y N N
Hungary HU-STD SURVEILLANCE Cp Se P A N Y N N Y
Iceland IS-SUBJECT_TO_REGISTRATION Cp Co P C Y Y Y N Y
Ireland IE-AGGR_STI Cp Co P A Y Y Y N Y
Italy IT-NRS Cp Co P C Y Y Y N Y
Latvia LV-BSN Cp Co P C Y Y Y N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Luxembourg LU-SYSTEM1 Cp Co P C Y Y N N Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y Y Y
Netherlands NL-STI V Se P C N Y N N Y
Norway NO-MSIS_B Cp Co P C Y Y Y - Y
Poland PL-NATIONAL_SURVEILLANCE Cp Co P C Y Y Y N Y
Portugal PT-GONOCOCCAL Cp Co P C N Y N N Y
Romania RO-RNSSy Cp Co P A N N Y N Y
Slovakia SK-EPIS Cp Co A C Y Y Y N Y
Slovenia SI-SPOSUR Cp Co P C N Y N N Y
Spain ES-MICROBIOLOGICAL V Se P C Y N N N N
Spain ES-STATUTORY_DISEASES_STI_AGGR Cp Co P A N Y N N -
Sweden SE-SMINET Cp Co P C Y N N N Y
United Kingdom UK-GUM Cp Co P A N N N Y Y
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Hepatitis B virus infection
• In 2009, 5 969 confirmed cases of hepatitis B 
virus infection were reported by 29 EU and EEA/
EFTA Member States, a rate of 1.16 per 100 000 
population. 
• The most affected age groups are those between 
25 and 44 years old with 49 % of cases (2.0 cases 
per 100 000), followed by the 15–24 year-olds 
(1.7 cases per 100 000). Among females, the inci-
dence rate is, however, highest in the 15–24 years 
old age group.
• As in 2008 the numbers of cases decreased com-
pared to earlier years. However, the significant 
differences in the sensitivity of each country’s 
surveillance system, as well as reporting delays, 
may have influenced the figures. 
• Interpretation of hepatitis B data is complex due 
to the differences between surveillance systems 
across Europe and the reporting of mixtures of 
acute and chronic cases. 
• ECDC will be implementing EU-wide enhanced 
surveillance in 2012, developing surveillance 
objectives and reporting protocols in cooperation 
with Member States.
Infection with the hepatitis B virus is relatively uncom-
mon, but can cause acute or long-term illness, which is 
sometimes fatal. It is transmitted through both unpro-
tected sexual activity and contaminated blood (e.g. 
injecting drug use).
Epidemiological situation in 2009
In 2009, 28 EU and EEA/EFTA Member States reported 
5 969 cases of hepatitis B virus infection (Liechtenstein 
did not report). Of these, 5 837 were confirmed, giving an 
overall confirmed case rate of 1.16 per 100 000 popula-
tion (Table 2.2.3).
The highest confirmed case rates were observed 
in Bulgaria (6.63 cases per 100 000), Latvia (5.44), 
Luxembourg (3.85) and Denmark (3.10).
The decreasing trend of hepatitis B cases observed dur-
ing previous years of EU-wide surveillance continued 
in 2009 (Figure 2.2.6). A decrease of 12.5 % in cases 
reported compared to 2008 was observed.
Age and gender distribution 
In 2009, 3 558 confirmed cases of hepatitis B were 
reported among males (1.62 per 100 000) and 1 781 
among females (0.78 per 100 000), with a male-to-
female rate ratio of 2.1:1.
The majority of the hepatitis B cases were reported in 
the age group 25–44 years (49 % of the total) that also 
had the highest rate at 2.03 per 100 000 (Figure 2.2.7) 
followed by the 15–24 year-olds (1.70 per 100 000).
The confirmed case rate among females was highest in 
the 15–24 years group, while among men it was highest 
in the 25–44 years age group.
Figure 2.2.6. Trend and number of reported confirmed hepatitis B cases by month, in EU and EEA/EFTA countries, 
2006–09
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12-month moving average
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Source: Country reports: Austria, Cyprus, Denmark, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Malta, Norway, Portugal, Slovakia, Slovenia, Spain.
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The highest rates among young people (aged 15–24 
years) were reported in Bulgaria (18 per 100 000) and 
Latvia (12 per 100 000), followed by Slovakia (5.9 per 
100 000). In each of these countries, this was also the 
age group with the highest rate.
Discussion
Hepatitis B virus infection bears the characteristics of 
both a sexually transmitted and a blood-borne disease. 
However, the distribution patterns and proportions of 
risk groups affected may differ widely across the EU. 
Children born to infected mothers are at a higher risk 
of becoming infected and are also more likely to be 
reported. 
Newborns and infants are also at risk of acquiring infec-
tion from chronically infected household members. 
While universal childhood vaccination programmes 
in many countries have reduced the risk of hepatitis B 
infection among young injecting drug users, older popu-
lations may still be at risk in some countries. The highest 
incidence among women is seen in the age group 15–24 
years. Among men, incidence is highest in the older age 
group 25–44 years. This gender pattern is similar to that 
seen in many sexually transmitted infections.
Interpretation of the trends is complicated by differ-
ences between surveillance systems, recent changes in 
reporting, low numbers in some countries, undiagnosed 
cases, differences in case definitions used (i.e. differ-
ent use and/or interpretation of hepatitis B markers) 
and incomplete reporting in some countries. In addition, 
some countries do not distinguish between reports of 
acute and chronic cases of hepatitis B and this, together 
with the high prevalence of asymptomatic cases, makes 
comparison between countries difficult.
Establishing enhanced surveillance of hepatitis B virus 
infection will be essential to provide the necessary infor-
mation with which to monitor the trends of disease, to 
recognise and interpret real differences in epidemiology 
and to evaluate prevention and control programmes. 
ECDC is preparing to launch EU-wide enhanced surveil-
lance in 2012, developing surveillance objectives and 
Table 2.2.3. Number and rate of hepatitis B cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type*
Total 
cases
Confirmed 
cases and rate 
per 100 000 
population
Confirmed 
cases and rate 
per 100 000 
population
Confirmed 
cases and rate 
per 100 000 
population
Confirmed 
cases and rate 
per 100 000 
population
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 45 20 0.24 3 0.04 19 0.23 0 0.00
Belgium Y A 129 129 1.20 122 1.14 0 0.00 401 3.82
Bulgaria Y A 504 504 6.63 624 8.17 751 9.78 773 10.02
Cyprus Y C 7 7 0.88 7 0.89 13 1.67 7 0.91
Czech Republic Y C 247 247 2.36 304 2.93 304 2.96 306 2.99
Denmark Y C 171 171 3.10 180 3.29 278 5.10 20 0.37
Estonia Y C 29 29 2.16 53 3.95 44 3.28 45 3.35
Finland Y C 36 36 0.68 49 0.92 24 0.46 39 0.74
France Y C 111 111 0.17 145 0.23 156 0.25 182 0.29
Germany Y C 748 748 0.91 822 1.00 1 008 1.23 1 179 1.43
Greece Y C 53 52 0.46 77 0.69 77 0.69 67 0.60
Hungary Y C 66 66 0.66 88 0.88 81 0.81 83 0.82
Ireland Y C 78 77 1.73 82 1.86 52 1.21 94 2.23
Italy Y C 710 710 1.18 855 1.43 1 097 1.86 1 068 1.82
Latvia Y A 123 123 5.44 140 6.17 165 7.23 167 7.28
Lithuania Y A 58 58 1.73 90 2.67 84 2.48 0 0.00
Luxembourg Y C 19 19 3.85 21 4.34 14 2.94 9 1.92
Malta Y C 4 4 0.97 4 0.98 2 0.49 2 0.49
Netherlands Y C 202 144 0.87 225 1.37 223 1.36 - -
Poland Y A 199 154 0.40 165 0.43 269 0.71 362 0.95
Portugal Y C 67 65 0.61 52 0.49 64 0.60 40 0.38
Romania Y C 596 596 2.77 718 3.34 927 4.30 1 279 5.92
Slovakia Y C 140 140 2.59 111 2.06 103 1.91 123 2.28
Slovenia Y C 43 43 2.12 17 0.85 16 0.80 26 1.30
Spain Y C 710 710 1.55 758 1.67 645 1.45 496 1.13
Sweden Y C 110 110 1.19 177 1.93 201 2.21 162 1.79
United Kingdom Y C 684 684 1.11 620 1.01 - - - -
EU Total - - 5 889 5 757 1.15 6 509 1.31 6 617 1.52 6 930 1.66
Iceland Y C 23 23 7.20 61 19.34 47 15.28 11 3.67
Liechtenstein - - - - - - - - - - -
Norway Y C 57 57 1.19 103 2.17 120 2.56 149 3.21
Total - - 5 969 5 837 1.16 6 673 1.33 6 784 1.54 7 090 1.68
Source: Country reports.  Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U=Unspeciﬁ ed. Due to the diﬀ erences in the reporting systems 
between countries, comparisons between individual Member States should be interpreted with caution.
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Figure 2.2.7. Rates of reported confirmed hepatitis B cases, by age and gender, in EU and EEA/EFTA countries, 2009
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Lithuania, Luxembourg, Malta, Netherlands, Norway, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom. 
reporting protocols in collaboration with EU Member 
States. A dedicated network of country experts will 
participate in the work of developing a system that will 
improve the understanding of the epidemiology of these 
blood-borne viral infections in Europe.
A particular challenge for surveillance of blood-borne 
infections is the increased intra-EU cross-border 
exchange and trade of substances of human origin. 
This diverse group of materials for human therapeutic 
use includes blood and blood products, cells, tissues 
and materials derived from them, as well as organs. 
Increased exchange of these materials within the Union 
necessitates well-managed risks of blood-borne infec-
tions to maintain a high quality of the products and 
avoid the risk of outbreaks.
References
1. European Centre for Disease Prevention and Control. Hepatitis B 
and C in the EU neighbourhood: prevalence, burden of disease and 
screening policies. Stockholm: ECDC; 2010.
2. European Centre for Disease Prevention and Control. Surveillance 
and prevention of hepatitis B and C in Europe. Stockholm: ECDC; 
2010.
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Austria AT-Epidemiegesetz Cp Co P C Y Y Y Y Y
Belgium BE-FLA_FRA Cp Co P C Y Y Y Y Y
Bulgaria BG-NATIONAL_SURVEILLANCE Cp Co P A Y Y Y Y Y
Cyprus CY-NOTIFIED_DISEASES Cp Co P C N Y N N Y
Czech Republic CZ-EPIDAT Cp Co A C - Y Y N Y
Denmark DK-MIS Cp Co P C N Y N N Y
Estonia EE-HBV/GIARDIASIS Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y Y N N Y
France FR-MANDATORY_INFECTIOUS_DISEASES Cp Co P C Y Y Y Y Y
Germany DE-SURVNET@RKI-7.1/6 Cp Co P C Y Y Y Y Y
Greece GR-NOTIFIABLE_DISEASES Cp Co P C Y Y Y N Y
Hungary HU-EFRIR Cp Co P C Y Y Y N Y
Iceland IS-SUBJECT_TO_REGISTRATION Cp Co P C Y Y Y N Y
Ireland IE-CIDR Cp Co P C Y Y Y N Y
Italy IT-NRS Cp Co P C Y Y Y N Y
Latvia LV-BSN Cp Co P C Y Y Y N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Luxembourg LU-SYSTEM1 Cp Co P C Y Y N N Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y Y Y
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Country Data Source
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Netherlands NL-OSIRIS Cp Co P C Y Y N Y Y
Norway NO-MSIS_A Cp Co P C Y Y Y N Y
Poland PL-NATIONAL_SURVEILLANCE Cp Co P C N Y Y N Y
Portugal PT-HEPATITISB Cp Co P C N Y N N Y
Romania RO-RNSSy Cp Co P C Y N Y N Y
Slovakia SK-EPIS Cp Co A C Y Y Y N Y
Slovenia SI-SURVIVAL Cp Co P C Y Y Y N Y
Spain ES-STATUTORY_DISEASES Cp Co P C N Y Y N Y
Sweden SE-SMINET Cp Co P C Y N N N Y
United Kingdom UK-HEPATITISB O Co P C Y N Y N Y
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Hepatitis C virus infection
• In 2009, 27 354 confirmed cases of hepatitis C 
were reported by 26 EU and EEA/EFTA Member 
States, with an overall rate of 8.19 per 100 000 
population. 
• There are limitations to the hepatitis C data, 
resulting mainly from the inability of the routine 
tests to distinguish between acute and chronic 
infection. Nevertheless, available data suggests 
that hepatitis C virus infection is the most com-
mon type of viral hepatitis reported in the EU and 
EEA/EFTA countries. 
• The most commonly affected age group is the 
25–44 year olds (15.8 cases per 100 000); with 
twice as many males infected as females overall. 
• Interpretation of hepatitis C data is complex due 
to the differences between surveillance systems 
across Europe and the reporting of mixtures of 
acute and chronic cases. 
• ECDC will be preparing to launch EU-wide 
enhanced surveillance in 2012 by developing sur-
veillance protocols and objectives in cooperation 
with EU Member States.
Infection with the Hepatitis C virus is not uncommon in 
the EU, and commonly leads to chronic infection, which 
can lead to cirrhosis or cancer of the liver. It is mostly 
transmitted through infected blood, particularly during 
use of injecting drugs. 
Epidemiological situation in 2009
In 2009, 27 545 cases of hepatitis C virus (HCV) infection 
were reported by 26 EU and EEA/EFTA Member States, 
of which 27 354 were confirmed, giving an overall con-
firmed case rate of 8.2 per 100 000 population. No data 
were available from France, Italy, Spain or Liechtenstein 
(Table 2.2.4).
There is wide variation in reported rates of confirmed 
cases within the EU, ranging from less than one per 
100 000 in Belgium, Cyprus, Greece, Hungary, Malta, the 
Netherlands, Portugal, Romania and Slovenia; to much 
higher rates in Norway (48 per 100 000), Iceland (32), 
Ireland (28), Sweden (24), Finland (20) and the United 
Kingdom (18).
However, comparisons between countries are of limited 
value as surveillance systems, testing and screening 
practices and reporting behaviour vary widely. Several 
countries reporting the highest rates include all newly 
recognised cases, irrespective of the clinical presenta-
tion (asymptomatic, chronic, acute, etc.), while many 
other countries with very low rates only report those 
cases confirmed to have had a clinically indicated acute 
infection. Due to these differences in the reporting sys-
tems between countries, comparisons should be made 
with caution. Also, these differences make the analysis 
of trends of incidence for hepatitis C on a European level 
difficult.
Age and gender distribution
In 2009, 16 448 confirmed cases of hepatitis C virus 
infection were reported in men and 8 465 in women, with 
rates of 11.1 and 5.7 per 100 000, respectively (male-to-
female ratio 1.9:1). Slightly more than half of the hepati-
tis C cases were reported in the age group 25–44 years 
(53 % of the total) with a rate of 15.8 per 100 000. 
Figure 2.2.8. Trend and number of reported confirmed hepatitis C cases by month, in EU and EEA/EFTA countries, 
2006–09
Number of cases
12-month moving average
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Source: Country reports: Austria, Cyprus, Czech Republic, Denmark, Finland, Germany, Greece, Hungary, Iceland, Ireland, Malta, Netherlands, Norway, Portugal, 
Slovakia, Sweden, United Kingdom.
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In contrast to hepatitis B, the 25–44 age group has the 
highest confirmed case rate in both men and women 
(Figure 2.2.9). The highest rates in this age group were 
observed in Norway (101 per 100 000), Iceland (66), 
Ireland (62), the United Kingdom (39), Finland (38), 
Sweden (38) and Luxembourg (29).
The highest rates in young adults aged 15–24 years 
were reported in Finland (51 per 100 000), Iceland (42), 
Norway (40) and Sweden (35).
As for hepatitis B, children born to infected mothers 
are at a higher risk of becoming infected (and are also 
at risk of acquiring infection from other household con-
tacts). These children are more likely to be diagnosed 
and reported and, therefore, to appear in the distribu-
tion graph (Figure 2.2.9).
Discussion
Hepatitis C virus infection is mainly a blood-borne 
infection, with a high risk of establishing chronic infec-
tion, which is the main determinant of the populations 
affected by the disease. Significant proportions of older 
population cohorts within the EU/EEA region may have 
been infected by nosocomial or blood-product associ-
ated routes several decades ago, prior to comprehensive 
application of universal precautions and blood screen-
ing. Such a cohort effect may be visible over extended 
times and probably still affects newly diagnosed rates.
Currently hepatitis C transmission in Europe is closely 
associated with sharing of infection equipment among 
injecting drug users, leading to significant cohort effects 
in many countries depending on how drug use practices 
change. Sexual transmission is known to occur, but is 
estimated to have little general epidemiological impact 
outside very specific settings1.
Most European countries have implemented surveillance 
systems for hepatitis C, but due to their differences, par-
ticularly in system structures, reporting practices, data 
collection methods and case definitions in use, the sur-
veillance data are difficult to compare across countries. 
Similarly, interpretation of the trends is hampered by 
Table 2.2.4. Number and rate of confirmed hepatitis C cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type*
Total 
cases
Confirmed 
cases and rate 
per 100 000 
population
Confirmed 
cases and rate 
per 100 000 
population
Confirmed 
cases and rate 
per 100 000 
population
Confirmed 
cases and rate 
per 100 000 
population
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 277 92 1.10 1 0.01 4 0.05 0 0.00
Belgium Y A 34 34 0.32 43 0.40 434 4.10 739 7.03
Bulgaria Y A 93 93 1.22 89 1.16 98 1.28 121 1.57
Cyprus Y C 27 27 3.39 2 0.25 9 1.16 5 0.65
Czech Republic Y C 836 836 7.99 974 9.38 980 9.53 1 022 9.97
Denmark Y C 272 272 4.94 294 5.37 366 6.72 348 6.41
Estonia Y C 67 67 5.00 64 4.77 36 2.68 57 4.24
Finland Y C 1 052 1 052 19.75 1 143 21.56 1 164 22.06 0 0.00
France - - - - - - - - - - -
Germany Y C 5 411 5 411 6.60 6 195 7.53 6 858 8.33 7 509 9.11
Greece Y C 9 8 0.07 17 0.15 11 0.10 10 0.09
Hungary Y C 31 31 0.31 34 0.34 22 0.22 29 0.29
Ireland Y C 1 262 1 261 28.34 1 524 34.63 1 561 36.20 1 226 29.13
Italy - - - - - - - 308 0.52 322 0.55
Latvia Y A 91 89 3.94 116 5.11 103 4.51 105 4.58
Lithuania Y A 47 47 1.40 43 1.28 46 1.36 0 0.00
Luxembourg Y C 55 55 11.14 58 11.99 58 12.18 12 2.56
Malta Y C 1 1 0.24 1 0.24 1 0.25 11 2.72
Netherlands Y C 52 52 0.32 45 0.27 44 0.27 30 0.18
Poland Y A 1 939 1 939 5.08 2 353 6.17 2 753 7.22 2 949 7.73
Portugal Y C 85 84 0.79 44 0.41 56 0.53 82 0.78
Romania Y C 65 64 0.30 101 0.47 90 0.42 84 0.39
Slovakia Y C 339 339 6.26 315 5.83 336 6.23 31 0.58
Slovenia Y C 6 6 0.30 8 0.40 14 0.70 - -
Spain - - - - - 129 - 214 - 422 -
Sweden Y C 2 203 2 203 23.80 2 522 27.46 2 096 23.00 1 976 21.84
United Kingdom Y C 10 867 10 867 17.76 10 325 16.88 9 533 15.68 10 417 17.24
EU total - - 25 121 24 930 7.58 26 440 8.00 27 195 6.97 27 507 7.05
Iceland Y C 103 103 32.25 93 29.48 81 26.33 45 15.01
Liechtenstein - - - - - - - - - - -
Norway Y C 2 321 2 321 48.36 3 394 71.65 0 0.00 48 1.03
Total - - 27 545 27 354 8.19 29 927 8.93 27 276 6.90 27 600 6.98
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed. Due to the diﬀ erences in the reporting systems 
between countries, comparisons between individual Member States should be interpreted with caution.
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differences in surveillance systems (in terms of com-
pleteness and representativeness), recent changes in 
reporting, low numbers in some countries, undiagnosed 
cases and incomplete reporting in some countries. Also, 
there is difficulty in interpreting test results as referring 
to acute and chronic cases of hepatitis C.
Hence, surveillance data cannot as yet be used to 
describe the true incidence or trends of the disease. 
Estimating the true proportions of known transmission 
modes would be dependent on collecting transmission 
category data as part of enhanced hepatitis surveillance.
Establishing enhanced surveillance of hepatitis C virus 
infection will be essential to provide the necessary infor-
mation with which to monitor the trends of disease, to 
recognise and interpret real differences in epidemiology 
and to evaluate prevention and control programmes. 
Furthermore, the harmonisation of hepatitis B and 
hepatitis C surveillance at the European level is needed 
to improve the understanding of the epidemiology of 
these blood-borne viruses.
ECDC is preparing to launch EU-wide enhanced surveil-
lance in 2012 by developing surveillance objectives and 
reporting protocols in collaboration with EU Member 
States. A dedicated network of country experts will 
participate in the work of developing a system that will 
improve the understanding of the epidemiology of these 
blood-borne viral infections in Europe.
References
1. Esteban JI, Sauleda S, Quer J. The changing epidemiology of 
hepatitis C virus infection in Europe. Journal of Hepatology 
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Figure 2.2.9. Rates of reported confirmed hepatitis C cases, by age and gender, in EU and EEA/EFTA countries, 2009
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Source: Country reports: Austria, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Hungary, Iceland, Ireland, Latvia, Luxembourg, 
Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Sweden, United Kingdom.
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Czech Republic CZ-EPIDAT Cp Co A C - Y Y N Y
Denmark DK-MIS Cp Co P C N Y N N Y
Estonia EE-HCV/CHLAMYDIA Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y Y N N Y
Germany DE-SURVNET@RKI-7.1/6 Cp Co P C Y Y Y Y Y
Greece GR-NOTIFIABLE_DISEASES Cp Co P C Y Y Y N Y
Hungary HU-EFRIR Cp Co P C Y Y Y N Y
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Country Data Source
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Latvia LV-BSN Cp Co P C Y Y Y N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Luxembourg LU-SYSTEM1 Cp Co P C Y Y N N Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y Y Y
Netherlands NL-OSIRIS Cp Co P C Y Y N Y Y
Norway NO-MSIS_A Cp Co P C Y Y Y N Y
Poland PL-NATIONAL_SURVEILLANCE Cp Co P C N Y Y N Y
Portugal PT-HEPATITISC Cp Co P C N Y N N Y
Romania RO-RNSSy Cp Co P C Y N Y N Y
Slovakia SK-EPIS Cp Co A C Y Y Y N Y
Slovenia SI-SURVIVAL Cp Co P C Y Y Y N Y
Sweden SE-SMINET Cp Co P C Y N N N Y
United Kingdom UK-HEPATITISC O Co A C Y N Y N Y
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HIV/AIDS
• HIV infection remains of major public health 
importance in EU and EEA/EFTA countries with 
a continued increase in the number of cases. In 
contrast, the number of AIDS cases diagnosed 
has continued to decline, although in some east-
ern EU countries the number of AIDS cases con-
tinues to increase.
• In 2009, 25 917 diagnosed cases of HIV infection 
were reported in 28 EU and EEA/EFTA Member 
States, a rate of 5.7 per 100 000 population.  
• The highest proportion of the total number of HIV 
cases in Europe was reported among men who 
have sex with men (35 %) followed by individuals 
infected by heterosexual contact (24 %) and by 
injecting drug use (5 %).
Infection with the human immunodeficiency virus (HIV), 
a retrovirus, in the absence of treatment frequently leads 
to development of the acquired immunodeficiency syn-
drome (AIDS) which is usually fatal. AIDS was first rec-
ognised as a distinct entity in 1981 in the United States, 
and has since become a critical public health problem in 
many regions of the world. Major advances in the effec-
tiveness of HIV treatment have altered the epidemiology 
of HIV infection outcomes and the design of prevention 
and control programmes.
Epidemiological situation in 2009
HIV infection
In 2009, 28 EU and EEA/EFTA countries reported 25 917 
newly diagnosed cases of HIV infection, a rate of 5.7 per 
100 000 population (Table 2.2.5). No data were available 
Table 2.2.5. Number and rate of confirmed HIV infection cases diagnosed in EU and EEA/EFTA countries, 2004–09
Country
2009 2008 2007 2006 2005 2004
Cases Rate Cases Rate Cases Rate Cases Rate Cases Rate Cases Rate
Austria - - - - - - - - - - - -
Belgium 1 115 10.3 1 082 10.1 1 069 10.1 1 014 9.6 1 068 10.2 1 000 9.6
Bulgaria 171 2.3 123 1.6 126 1.6 91 1.2 83 1.1 50 0.6
Cyprus 38 4.8 37 4.7 46 5.9 35 4.5 43 5.7 25 3.4
Czech Republic 157 1.5 148 1.4 121 1.2 91 0.9 90 0.9 72 0.7
Denmark 236 4.3 285 5.2 306 5.6 245 4.5 264 4.9 306 5.7
Estonia 411 30.7 545 40.7 633 47.2 668 49.7 621 46.1 743 55.1
Finland 183 3.4 149 2.8 190 3.6 191 3.6 143 2.7 122 2.3
France 4 885 7.6 5 713 8.9 5 643 8.8 5 662 8.9 5 966 9.5 5 746 9.2
Germany 2 856 3.5 2 843 3.5 2 791 3.4 2 666 3.2 2 508 3.0 2 225 2.7
Greece 534 4.7 585 5.2 538 4.8 486 4.4 531 4.8 490 4.4
Hungary 140 1.4 145 1.4 119 1.2 81 0.8 106 1.1 75 0.7
Ireland 395 8.9 405 9.2 391 9.0 353 8.3 326 7.8 358 8.8
Italy (a) 1 951 5.5 2 012 6.7 1 662 6.3 1 535 7.8 1 496 7.7 1 667 8.7
Latvia 275 12.2 358 15.8 350 15.4 299 13.1 299 13.0 323 14.0
Lithuania 180 5.4 95 2.8 106 3.1 100 2.9 120 3.5 135 3.9
Luxembourg 47 9.4 50 10.2 40 8.3 45 9.5 46 9.9 60 13.1
Malta 17 4.1 29 7.0 14 3.4 26 6.4 18 4.5 19 4.7
Netherlands 813 4.9 1 155 7.0 1 156 7.1 1 056 6.5 1 181 7.2 1 131 6.9
Poland 630 1.7 753 2.0 706 1.9 721 1.9 663 1.7 644 1.7
Portugal 1 055 9.9 1 675 15.8 1 709 16.1 1 757 16.6 1 729 16.4 1 901 18.1
Romania 143 0.7 179 0.8 185 0.9 217 1.0 237 1.1 303 1.4
Slovakia 53 1.0 53 1.0 39 0.7 27 0.5 21 0.4 15 0.3
Slovenia 48 2.4 48 2.4 37 1.8 33 1.6 38 1.9 24 1.2
Spain (b) 2 264 7.9 2 524 9.9 2 216 9.2 1 591 9.5 1 452 8.8 1 521 9.3
Sweden 393 4.2 383 4.2 458 5.0 373 4.1 374 4.1 415 4.6
United Kingdom 6 630 10.7 7 386 12.0 7 517 12.3 7 586 12.5 7 978 13.2 7 780 13.0
EU total 25 620 5.7 28 760 6.5 28 168 6.5 26 949 6.4 27 401 6.6 27 150 6.5
Iceland 15 4.7 10 3.2 13 4.2 11 3.6 8 2.7 4 1.4
Liechtenstein
Norway 282 5.8 299 6.3 248 5.3 276 5.9 219 4.7 251 5.5
Total 25 917 5.7 29 069 6.5 28 429 6.5 27 236 6.4 27 628 6.5 27 405 6.5
(a) Aggregate reporting. (b) Sub-national reporting system only, rate calculated based on sub-national coverage.
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for Austria and Liechtenstein. The highest rates of HIV 
cases were reported by Estonia (31 per 100 000; 411 
cases), Latvia (12; 275 cases), the United Kingdom (11; 
6 630 cases) and Belgium (10; 1 115 cases). The lowest 
rates were reported by Romania (0.7; 143 cases) and 
Slovakia (1.0; 53 cases).
Among the 28 EU and EEA/EFTA countries that have 
consistently reported HIV data since 2004, the rate of 
diagnosed cases of HIV per 100 000 has been stable: 
from 6.5 per 100 000 in 2004 (27 405 cases) to 5.7 per 
100 000 (25 917 cases) in 2009, without taking into 
account the reporting delays that will affect the numbers 
in the most recent years. The trend has increased in 16 
countries and has decreased in 12 countries. Rates of 
reported cases at country level have more than tripled 
in Bulgaria, Iceland and Slovakia; increased by more 
than 50 % in Hungary and Slovenia, and decreased by 
more than 20 % in Denmark, Estonia, Luxembourg and 
Romania.
Age and gender distribution
In 2009, 18 504 HIV cases were reported in men (71 %) 
and 7 349 in women (29 %), a rate of 8.3 and 3.2, respec-
tively. The male-to-female rate ratio is 2.6:1. Data on age 
and gender were available for 25 853 cases (99.8 %). 
Almost one third of the newly diagnosed cases of HIV 
infection were reported in the age group 30–39 years for 
both men and women. On average, reported age among 
men at time of HIV diagnosis was higher than for women 
(Figure 2.2.10).
Figure 2.2.10. Number of newly diagnosed cases of HIV infection, by age and gender, in EU and EEA/EFTA countries, 
2009
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Source: Country reports: Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, 
Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom.
Figure 2.2.11. Trend in reported cases of HIV infection, by transmission group and origin, in EU and EEA/EFTA 
countries, 2004–09
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Transmission category
Among those reported HIV cases, 4 257 cases (16 %) orig-
inate from countries with a generalised HIV epidemic – 
HIV prevalence in general population (or group reflecting 
it, e.g. pregnant women) is > 1 %. Data on transmission 
mode, when HIV diagnoses in individuals from countries 
with generalised epidemics were excluded, indicate that 
sex between men is the predominant mode of transmis-
sion (35 %), followed by heterosexual contact (24 %), 
and injecting drug use with only 5 %. Transmission mode 
was reported as ‘unknown’ for 5 259 cases (20 %). The 
remaining 1 % included mother-to-child transmission, 
nosocomial infection, transfusion or use of other blood 
products.
Between 2004 and 2009, 26 EU EEA/EFTA countries 
have consistently reported data on transmission mode, 
and the following trends are seen (Figure 2.2.11):
• The number of heterosexually acquired cases 
(including cases originating from countries with 
generalised epidemics) has decreased by 24 %. 
The proportion originating from countries with a 
generalised epidemic declined from 52 % in 2004 to 
38 % in 2009 and largely affected the overall declining 
trend in heterosexually acquired cases. 
• The number of cases among men who have sex with 
men (MSM) has increased by 24 %.
• The number of cases among injecting drug users (IDU) 
has declined by 40 %.
• The number of cases transmitted from mother to child 
decreased by 44 % (based on low number). 
• The number of cases with unknown risk factors has 
increased with 40 %. 
Trends need to be interpreted with caution as the num-
bers of HIV diagnoses reported in recent years (e.g. 
2008/2009) will most likely increase in the coming years 
due to reporting delay.
AIDS diagnoses 
In 2009, 4 650 cases of AIDS were reported by 27 EU 
and EEA/EFTA countries, a rate of 1.0 cases per 100 000 
population. No data were available from Austria, 
Liechtenstein and Sweden. The highest rates were 
reported by Estonia (2.8 per 100 000; 38 cases), Latvia 
(4.3; 96 cases), Portugal (2.8; 297 cases), and Spain 
(2.3; 1 037 cases). In most EU and EEA/EFTA countries 
AIDS diagnoses have been reported to decrease con-
tinuously, from 9 011 cases (1.9 per 100 000 population) 
in 2004 to 4 650 (1.0 per 100 000) in 2009. However, an 
increase in the number of AIDS cases was reported in 
four countries: Bulgaria (36 %), Estonia (31 %), Latvia 
(8 %) and Lithuania (76 %).
Discussion
The data suggest evidence of continuing HIV transmis-
sion in many countries. However, the predominant trans-
mission mode varies by country and geographical and 
epidemiological area and these data illustrate the wide 
diversity in the HIV epidemic in Europe1.
In 2009, the highest proportion of HIV cases continues 
to be diagnosed in men who have sex with men (MSM). 
Despite the relatively low absolute number of cases 
diagnosed in these groups, intravenous drug users 
and MSM are disproportionately affected by the HIV 
epidemic compared with the heterosexual population 
because of the relatively small sizes of the populations 
and the increased levels of HIV in these groups. The 
high number of heterosexually acquired HIV infections 
also suggests a need for public health action as almost 
a third of these cases are diagnosed in individuals origi-
nating from countries with generalised HIV epidemics.
In order to monitor the epidemic and guide the public 
health response to control the transmission of HIV infec-
tion, countries in Europe need to continue to maintain 
and improve high quality surveillance of HIV and AIDS.
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Estonia EE-HIV Cp Co P C Y Y Y N Y
Finland FI-NIDR Cp Co P C Y Y N N Y
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Country Data Source
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France FR-MNOID-HIV Cp Co P C Y Y Y N Y
Germany DE-SURVNET@RKI7.3-HIV Cp Co P C Y N N N Y
Greece GR-NOTIFIABLE_DISEASES Cp Co P C Y Y Y N Y
Hungary HU-HIV/AIDS Cp Co P C Y Y Y N Y
Iceland IS-SUBJECT_TO_REGISTRATION Cp Co P C Y Y Y N Y
Ireland IE-HIV/AIDS V Co P C Y Y Y N Y
Italy IT-COA-ISS Cp Se P - Y N Y - N
Latvia LV-HIV/AIDS V Co P C N Y Y N Y
Lithuania LT-AIDS_CENTRE Cp Co P C Y Y N N Y
Luxembourg LU-HIV V Co P C Y Y N N Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y N Y
Netherlands NL-HIV/AIDS V Co P C N Y Y N Y
Norway NO-MSIS_B Cp Co P C Y Y Y N Y
Poland PL-HIV Cp Co P C Y Y N N -
Portugal PT-HIV/AIDS Cp Co P C Y Y N N Y
Romania RO-RSS Cp Co P C N Y Y N -
Slovakia SK-EPIS Cp Co A C Y Y Y N Y
Slovenia SI-HIVSUR-HIV Cp Co P C N Y N N Y
Spain ES-HIV Cp Co P C Y Y N N N
Sweden SE-SweHIVReg Cp Co P C Y Y Y N Y
United Kingdom UK-HIV V Co A C Y Y Y Y Y
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Syphilis
• In 2009, 18 317 cases of syphilis were reported by 
28 EU and EEA/EFTA Member States resulting in 
an overall rate of 4.5 per 100 000 population. 
• Syphilis was reported three times more fre-
quently in men than in women, with rates of 6.6 
and 2.2 per 100 000 population, respectively. 
Almost 70 % of the cases were diagnosed in men; 
this may be influenced by the ongoing epidemic 
in Europe among men who have sex with men. 
Syphilis is reported to mainly affect 25–44 year-
olds, who account for almost 60 % of the cases 
(9.2 cases per 100 000).
• The number of cases has decreased by 9 % over-
all since 2006. However, in a number of countries 
the number of cases has increased substantially 
in recent years.
• In 2009, 101 cases of congenital syphilis were 
reported by 21 countries, of which 71 were con-
firmed, a rate of 3.5 per 100 000 live births. It is 
very likely that the true incidence of congenital 
syphilis is underestimated.
Syphilis is a sexually transmitted infection caused by 
the spirochaete Treponema pallidum. It is the third most 
frequently reported sexually transmitted disease in the 
EU after chlamydia and gonorrhoea. 
Epidemiological situation in 2009
For 2009, 18 317 cases of syphilis were reported by 
27 EU and two EEA/EFTA Member States resulting in a 
reported case rate of 4.5 per 100 000 population (Table 
2.2.6). No data was available for Liechtenstein. Almost 
60 % of cases were reported by four countries (Germany, 
Romania, Spain and United Kingdom). 
Between 2006 and 2009, the number of reported cases 
decreased in 10 countries and increased in 18, result-
ing in an overall decrease of 7 %. This is mainly due to a 
substantial decrease of cases in a number of countries 
that have reported very high rates of syphilis in the past. 
In other countries, substantial increases were noted; 
for example, a more than 100 % increase was reported 
by Austria, Czech Republic, Denmark, Slovakia and 
Slovenia.
There is a wide variation in notification rates, with the 
lowest (below 3 per 100 000) being reported in Greece, 
Iceland, Ireland, Norway, Portugal, Slovenia and 
Sweden, and the highest being reported in the Czech 
Republic, Latvia, Lithuania and Romania.
Age and gender distribution
Information on gender was available for 15 710 cases of 
syphilis, of which 11 883 (76 %) were reported in males 
and 3 827 (24 %) in females, with rates of 6.6 and 2.2 per 
100 000, respectively. The highest rates for both men 
and women were reported by Romania (18 and 19 per 
100 000, respectively) followed by Latvia (8.5 and 6.2 
per 100 000) and Lithuania (12.1 and 7.7 per 100 000). 
The male-to-female ratio was 3.1:1, with marked differ-
ences across countries. Ratios above 10 are reported 
by Denmark, Norway, France, Slovenia, Germany and 
the Netherlands. A male-to-female ratio below one was 
reported by Austria, Cyprus and Romania (Figure 2.2.13). 
Figure 2.2.12. Trend and number of reported confirmed syphilis cases by month, in EU and EEA/EFTA countries, 
2006–09
Number of cases
12-month moving average
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Source: Country reports: Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Malta, Netherlands, 
Norway, Portugal, Slovakia, Slovenia, Sweden, United Kingdom.
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Information on age was available for 14 107 cases. The 
majority (58 %) were reported in the age group 25–44 
years (8 239 cases, 9.2 per 100 000), and only 17 % in the 
age group 15–24 years (2 465 cases, 6.5 per 100 000).
Transmission category
In 2009, information on transmission category was 
available for 14 countries, providing 20 % of the syphilis 
cases (N=3 417). Of those cases, transmission category 
was reported as unknown for 8 %, was indicated as het-
erosexual in 41 % and as in men who have sex with men 
in 51 % of the cases. Based on the information from the 
male-to-female ratio, the increase in a number of coun-
tries in the past decade may be due to increases of syph-
ilis among men who have sex with men.
Congenital syphilis
In 2009, 21 EU and EEA/EFTA countries reported data 
on congenital syphilis: 11 countries reported zero cases 
and 12 countries reported 101 cases, of which 71 were 
confirmed. The majority of the cases have been reported 
from Bulgaria (30 cases), Portugal (13), Italy (12), Spain 
(11) and Romania (7). The rate per 100 000 live births is 
3.5, with the highest rates being reported by Bulgaria 
(37 per 100 000), Portugal (13), Lithuania (11) and Latvia 
(9.2). For the period 2006–09 the majority of confirmed 
cases were reported by Bulgaria, Portugal and Spain. It 
must be noted that many countries do not report con-
genital syphilis cases and it is quite likely that the true 
incidence is underestimated.
Enhanced surveillance for sexually transmitted 
infections
The coordination of the European network on STI surveil-
lance has been integrated into ECDC as from 1 January 
2009. More details on the epidemiology and trends of 
syphilis and congenital syphilis can be found in the first 
surveillance report on 1990–2009 data1.
Discussion
Until the mid-1990s, syphilis incidence rates were very 
low in western European countries. However, over the 
past 10 years a number of countries have experienced 
a dramatic rise in the rate of syphilis cases. Initially 
Table 2.2.6. Number and rate of syphilis cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Reported cases and 
rate per 100 000 
population
Reported cases and 
rate per 100 000 
population
Reported cases and 
rate per 100 000 
population
Reported cases and 
rate per 100 000 
population
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 62 - 61 - 58 - 25 -
Belgium Y C 486 - 480 - 403 - 288 -
Bulgaria Y A 420 5.5 419 5.5 440 5.7 490 6.3
Cyprus Y C 15 - 14 - 10 - 13 -
Czech Republic Y C 686 6.6 342 3.3 205 2.0 75 0.7
Denmark Y C 294 4.6 151 2.8 92 1.7 77 1.4
Estonia Y C 56 4.2 71 5.3 78 5.8 125 9.3
Finland Y C 194 3.6 211 4.0 185 3.5 127 2.4
France N C 523 - 563 - 599 - 478 -
Germany Y C 2 550 3.1 3 188 3.9 3 277 4.0 3 160 3.8
Greece N A 259 2.3 155 1.4 197 1.8 141 1.3
Hungary Y A 489 - 549 - 393 - 559 -
Ireland Y C 97 2.2 119 2.7 62 1.4 133 3.2
Italy Y C 916 - 923 - 1 001 - 935 -
Latvia Y C 165 7.3 235 10.3 305 13.4 483 21.0
Lithuania Y C 326 9.7 326 9.7 275 8.1 336 9.9
Luxembourg Y C 13 2.6 12 2.5 14 2.9 10 2.1
Malta Y C 16 3.9 19 4.6 11 2.7 13 3.2
Netherlands Y C 711 - 792 - 657 - 806 -
Poland Y A 1 255 3.3 929 2.4 847 2.2 933 2.4
Portugal Y C 150 1.4 98 0.9 112 1.1 124 1.2
Romania Y A 3 229 15.0 4 006 18.6 4 245 19.7 5 661 26.2
Slovakia Y C 296 5.5 228 4.2 152 2.8 89 1.7
Slovenia Y C 47 2.3 63 3.1 31 1.5 16 0.8
Spain Y A 2 496 5.4 2 545 5.6 1 936 4.4 1 711 3.9
Sweden Y C 179 1.9 167 1.8 237 2.6 167 1.8
United Kingdom Y A 2 311 3.8 2 304 3.7 2 518 4.1 2 565 4.2
EU total - - 18 241 4.6 18 970 4.7 18 340 4.7 19 540 5.0
Iceland - - - - 2 0.6 1 0.3 4 1.3
Liechtenstein - - - - - - -  -  
Norway Y C 76 1.6 56 1.2 61 1.3 67 1.4
Total - - 18 317 4.5 19 028 4.7 18 402 4.6 19 611 5.0
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
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occurring predominantly among men who have sex with 
men, subsequent outbreaks have been recorded among 
subgroups including commercial sex workers and their 
clients, migrant communities and among heterosexual 
adults. 
In central European countries, high rates of syphilis 
were observed in the early 1990s. The increases were 
related to the behaviour and socioeconomic changes in 
this region. A decrease in incidence was then observed 
in the following years. Declining trends may be due to 
changes in healthcare systems, diagnostic capacity and 
reporting. 
There is no consistent overall EU trend and the interpre-
tation is confined by several factors, e.g. differences in 
reporting systems, reporting behaviour and probable 
underreporting. The overall trend is also presenting 
several diverging trends in a number of countries. 
Data presented here must be interpreted with caution 
because the proportion of syphilis cases that is actually 
diagnosed and reported is likely to differ greatly across 
countries.
It should be noted that five countries do not report 
congenital syphilis cases and it is very likely that many 
diagnoses were not reported, so the true prevalence is 
underestimated. The availability of an antenatal screen-
ing programme for syphilis in pregnant women will heav-
ily affect the number of prevented congenital cases, 
however, data on the effectiveness of these national 
screening programmes is lacking at the moment.
References
1. European Centre for Disease Prevention and Control. Sexually trans-
mitted infections in Europe, 1990–2009. Stockholm: ECDC; 2011.
Figure 2.2.13. Rates of reported confirmed syphilis cases, by age and gender, in EU and EEA/EFTA countries, 2009
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Austria AT-STISentinella V Se A C Y N N N N
Belgium BE-LABNET V Se A C Y N - - Y
Bulgaria BG-STI Cp Co P A - - Y Y -
Cyprus CY-NOTIFIED_DISEASES Cp Co P C N Y N N Y
Czech Republic CZ-STD Cp Co P C Y Y Y Y Y
Denmark DK-STI_CLINICAL Cp Co P C N Y N N Y
Estonia EE-PERTUSSIS/SHIGELLOSIS/SYPHILIS Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y Y N N Y
France FR-STI V Se A C Y Y Y Y N
Germany DE-SURVNET@RKI-7.3 Cp Co P C Y N N N Y
Greece GR-NOTIFIABLE_DISEASES Cp O P A Y Y Y Y N
Hungary HU-STD SURVEILLANCE Cp Se P A N Y N N Y
Ireland IE-SYPHILIS Cp Co P C Y Y Y N Y
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Country Data Source
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Italy IT-NRS Cp Co P C Y Y Y N Y
Latvia LV-BSN Cp Co P C Y Y Y N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Luxembourg LU-SYSTEM1 Cp Co P C Y Y N N Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y Y Y
Netherlands NL-STI V Se P C N Y N N Y
Norway NO-MSIS_B Cp Co P C Y Y Y - Y
Poland PL-NATIONAL_SURVEILLANCE Cp Co P C Y Y Y N Y
Portugal PT-SYPHILIS Cp Co P C N Y N N Y
Romania RO-RNSSy Cp Co P A N N Y N Y
Slovakia SK-EPIS Cp Co A C Y Y Y N Y
Slovenia SI-SPOSUR Cp Co P C N Y N N Y
Spain ES-STATUTORY_DISEASES_STI_AGGR Cp Co P A N Y N N -
Sweden SE-SMINET Cp Co P C Y N N N Y
United Kingdom UK-GUM Cp Co P A N N N Y Y
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Anthrax
2.3 Food- and waterborne diseases and 
zoonoses
• Anthrax remains a rare disease in the European 
Union. However, anthrax cases are of high public 
concern.
• In December 2009, UK and Germany reported 
cases of anthrax among injecting drug users due 
to contaminated heroin. This outbreak continued 
also into 2010.
• Anthrax infection is considered an emerging path-
ogen when transmitted by intravenous drug use.
Anthrax is a rare and sporadic human infection in 
Europe, caused by the spore-producing bacterium 
Bacillus anthracis. It is primarily an infection of herbiv-
ores, and human infection usually an occupational risk 
for those handling infected animals or hides and other 
animal products.
Epidemiological situation in 2009
In 2009, 27 EU and EEA/EFTA countries provided data 
(Liechtenstein, Finland and Spain did not report). 
Fourteen confirmed cases of anthrax were reported by 
four Member States: Bulgaria (2), Germany (1), Greece 
(1) and the United Kingdom (10). The overall confirmed 
case rate was 0.004 per 100 000. The low number of 
reported cases does not enable a meaningful analysis of 
the trend in incidence.
Discussion
An outbreak of anthrax infection in heroin users in 
Scotland was reported in December 2009, continuing 
into 2010 with a total of 55 cases including 21 deaths 
from the UK, mainly Scotland and London area, and 
Germany1,2,4,5. A link between the Scottish and German 
cases could not be confirmed4. The outbreak was offi-
cially declared over at the end of December 2010.
In contrast to the more common routes of transmission, 
injection with contaminated heroin was the confirmed 
route for these cases. Control options are limited by the 
lack of knowledge about drug distribution routes, low 
compliance of patients with authorities, and the high 
case fatality of this threat. In response to this outbreak, 
ECDC, together with the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) and EUROPOL, 
coordinated a risk assessment at European level and 
produced a joint threat assessment in 2010. Awareness 
was increased through alerting Member States via the 
Early Warning Response System (EWRS), and protocols 
for handling patients, corpses and samples were shared 
to ensure bio-safety2,3. More information on this threat 
can be found in Chapter 3.
References
1. Booth MG, Hood J, Brooks TJG, Hart A, on behalf of the Health 
Protection Scotland Anthrax Clinical Network. Anthrax infection 
in drug users. Lancet 2010;375(9723):1345-1346. doi:10.1016/
S0140-6736(10)60573-9.
2. European Centre for Disease Prevention and Control. Annual Threat 
Report 2009. Stockholm: ECDC; 2010.
3. European Centre for Disease Prevention and Control. Anthrax out-
break among drug users in UK and Germany – update 18 May 2010; 
Joint ECDC and EMCDDA Threat Assessment. Available from: http://
www.ecdc.europa.eu/en/activities/sciadvice/Documents/2010-02-
11-TA_anthrax_IDU_ECDC-EMCDDA.pdf
4. Radun D, Bernard H, Altmann M, Schöneberg I, Bochat V, van Treeck 
U et al. Preliminary case report of fatal anthrax in an injecting drug 
user in North-Rhine-Westphalia, Germany, December 2009. Euro 
Surveill. 2010;15(2).
5. Ramsay CN, Stirling A, Smith J, Hawkins G, Brooks T, Hood J et al. An 
outbreak of infection with Bacillus anthracis in injecting drug users 
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Surveillance systems overview
Country Data Source
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Austria AT-Epidemiegesetz Cp Co P C Y Y Y Y Y
Belgium BE-REFLAB V Co P C Y N N N Y
Bulgaria BG-NATIONAL_SURVEILLANCE Cp Co P A Y Y Y Y Y
Cyprus CY-NOTIFIED_DISEASES Cp Co P C N Y N N Y
Czech Republic CZ-EPIDAT Cp Co A C - Y Y N Y
Denmark DK-MIS Cp Co P C N Y N N Y
Estonia EE-A NT H/CHOL/DIPH/M A L A/SP OX/
TRIC/TULA/TYPH
Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y Y N N Y
France FR-MANDATORY_INFECTIOUS_DISEASES Cp Co P C Y Y Y Y Y
Germany DE-SURVNET@RKI-7.1 Cp Co P C Y N N Y -
Greece GR-NOTIFIABLE_DISEASES Cp Co P C Y Y Y N Y
Hungary HU-EFRIR Cp Co P C Y Y Y N Y
Iceland IS-SUBJECT_TO_REGISTRATION Cp Co P C Y Y Y N Y
Ireland IE-CIDR Cp Co P C Y Y Y N Y
Italy IT-NRS Cp Co P C Y Y Y N Y
Latvia LV-BSN Cp Co P C Y Y Y N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Luxembourg LU-SYSTEM1 Cp Co P C Y Y N N Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y Y Y
Netherlands NL-OSIRIS Cp Co P C Y Y N Y Y
Norway NO-MSIS_A Cp Co P C Y Y Y N Y
Poland PL-NATIONAL_SURVEILLANCE Cp Co P C Y Y Y N Y
Portugal PT-ANTRAX Cp Co P C N Y N N Y
Romania RO-RNSSy Cp Co P C N N Y N Y
Slovakia SK-EPIS Cp Co A C Y Y Y N Y
Slovenia SI-SURVIVAL Cp Co P C Y Y Y N Y
Spain ES-STATUTORY_DISEASES Cp Co P C N Y Y N Y
Sweden SE-SMINET Cp Co P C Y N N N Y
United Kingdom UK-ANTHRAX Cp Co A C Y N Y Y Y
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Botulism
• Botulism remains an uncommon disease in 
the EU, with a confirmed case rate of 0.03 per 
100 000 population.
• The EU trend was stable during 2006–2009, with 
a range in confirmed case rate between 0.02 and 
0.03 cases per 100 000 population.
• In 2009, the most affected age group, with an EU/
EEA notification rate of 0.06 cases per 100 000 
population, was the 0–4 year-olds.
Botulism is an uncommon disease caused by toxins 
produced by the spore-forming bacterium Clostridium 
botulinum. Major causes of botulism in industrialised 
countries are contaminated and inadequately cooked 
foods, and ingestion by infants of spores in the 
environment. 
Epidemiological situation in 2009
In 2009, 185 (132 confirmed) cases of botulism were 
reported by 13 countries (Table 2.3.1). Sixteen EU and 
EEA/EFTA countries reported zero cases, while Belgium 
and Liechtenstein did not report. The EU and EEA/EFTA 
confirmed case rate was 0.03 per 100 000 population, 
which is slightly higher than in 2008 but similar to 2007. 
Romania (0.13 per 100 000 population), Italy (0.05), 
France (0.04) and Poland (0.04) reported the highest 
rates of confirmed cases. The highest numbers of con-
firmed cases were reported by Romania and Italy.
Table 2.3.1. Number and rate of botulism cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 0 0 0.00 0 0.00 0 0.00 5 0.06
Belgium - - - - - 0 0.00 0 0.00 0 0.00
Bulgaria Y A 2 1 0.01 0 0.00 0 0.00 8 0.10
Cyprus Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Czech Republic Y C 1 1 0.01 1 0.01 - - 0 0.00
Denmark Y C 0 0 0.00 1 0.02 0 0.00 0 0.00
Estonia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Finland Y C 0 0 0.00 0 0.00 0 0.00 - -
France Y C 29 23 0.04 8 0.01 10 0.02 4 0.01
Germany Y C 5 5 0.01 10 0.01 9 0.01 7 0.01
Greece Y C 1 1 0.01 0 0.00 1 0.01 1 0.01
Hungary Y C 7 3 0.03 1 0.01 5 0.05 6 0.06
Ireland Y C 0 0 0.00 5 0.11 0 0.00 1 0.02
Italy Y C 32 32 0.05 23 0.04 16 0.03 12 0.02
Latvia Y C 0 0 0.00 1 0.04 0 0.00 0 0.00
Lithuania Y C 0 0 0.00 2 0.06 4 0.12 - -
Luxembourg Y C 0 0 0.00 1 0.21 0 0.00 0 0.00
Malta Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Netherlands Y C 0 0 0.00 1 0.01 1 0.01 1 0.01
Poland Y C 31 15 0.04 22 0.06 24 0.06 22 0.06
Portugal Y C 3 3 0.03 4 0.04 10 0.09 9 0.09
Romania Y C 37 29 0.13 26 0.12 31 0.14 14 0.06
Slovakia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Slovenia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Spain Y C 12 6 0.01 5 0.01 4 0.01 2 0.00
Sweden Y C 1 0 0.00 0 0.00 0 0.00 2 0.02
United Kingdom Y C 24 13 0.02 1 0.00 14 0.02 10 0.02
EU total - - 185 132 0.03 112 0.02 129 0.03 104 0.02
Iceland Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Liechtenstein - - - - - - - - - - -
Norway Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Total - - 185 132 0.03 112 0.02 129 0.03 104 0.02
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
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Figure 2.3.1. Trend and number of reported confirmed botulism cases by month, in EU and EEA/EFTA countries, 
2006–09
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Source: Country reports: Austria, Belgium, Cyprus, Denmark, Estonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Luxembourg, Malta, Netherlands, 
Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden.
Figure 2.3.2. Rates of reported confirmed botulism cases, by age and gender, in EU and EEA/EFTA countries, 2009
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Source: Country reports from all EU and EEA/ EFTA countries except Belgium, Bulgaria and Liechtenstein.
Figure 2.3.3. Seasonal distribution of reported confirmed cases of botulism, in EU and EEA/EFTA countries, 2006–09
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Source: Country reports: Austria, Belgium, Cyprus, Denmark, Estonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Luxembourg, Malta, Netherlands, 
Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden. 
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Of the 87 cases for which data on importation status 
was available, none was reported as imported.
In 2009, information on age was available for all the 132 
confirmed cases. Most cases (45 %) were in the 25–44 
years age group. The 0–4 years age group showed the 
highest confirmed case rate: 0.06 cases per 100 000 
population (Figure 2.3.2). Fourteen cases in this age 
group comprised 10 % of the total number of confirmed 
cases. Of these, nine cases were below one year of age.
The male-to-female ratio was 1.53:1 for confirmed cases. 
This ratio was higher for the age group 25–64 years. For 
the 4 year-olds and younger, the confirmed case rate 
was only slightly different between genders (approxi-
mately 0.06 per 100 000 population in females versus 
0.05 per 100 000 population in males). 
Trends and seasonality
The trend for the period 2006–09 is stable. A peak 
of cases is evident in May 2009, while for the period 
2006–08 the increase appears in August (Figure 2.3.3). 
France accounted for 12 of the 17 cases reported in May 
2009.
Discussion
The most affected age group in 2009 was 0–4 years1, 
although adults cases are also frequently reported2. 
The reported cases in France increased substantially in 
comparison with previous years. Three cases of the 23 
reported in 2009 were linked to a household outbreak in 
south-east France for consumption of hot-smoked white-
fish (vacuum packed in Canada) purchased during a visit 
to Finland2.
References
1. Arnon SS. Infant botulism. In: Feigin RD, Cherry JD, Demmler GJ, 
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Brucellosis
• In 2009, the confirmed case rate of brucellosis 
was 0.08 cases per 100 000 population.
• There were 401 confirmed cases of human brucel-
losis reported in 2009, a decrease compared with 
2008 (735).
• Reported human cases of brucellosis have fol-
lowed a significant decreasing four-year trend in 
Europe and EEA/EFTA countries.
• Human brucellosis in 2009 was reported most 
commonly in males aged 25–44 years.
Brucellosis is a systemic infection caused by bacteria of 
the genus Brucella. Human infection is primarily an occu-
pational risk for those working with infected animals or 
their tissues (e.g. farm workers, veterinarians, abattoir 
workers).
Epidemiological situation in 2009
In 2009, 401 confirmed cases of brucellosis were 
reported by 28 of the 30 EU and EEA/EFTA countries. The 
overall confirmed case rate was 0.08 cases per 100 000; 
the rate decreased by 0.07 cases per 100 000 compared 
with 2008 (Table 2.3.2, Figure 2.3.4).
As in previous years, southern European countries 
(Greece, Spain and Portugal), where brucellosis is still 
prevalent in sheep and goats, accounted for the majority 
(75 %) of confirmed reported cases (Table 2.3.2).
The gender distribution of confirmed cases for which 
information was provided for gender and age (n=396) 
Table 2.3.2. Number and rate of brucellosis cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 2 2 0.02 5 0.06 0 0 1 0.01
Belgium Y A 1 1 0.01 1 0.01 3 0.03 2 0.02
Bulgaria Y A 4 3 0.04 8 0.10 9 0.12 3 0.04
Cyprus Y U 0 0 0 0 0 0 0 0 0
Czech Republic - U 0 0 0 1 0.01 0 0 0 0
Denmark Y - - - - - - - - - -
Estonia Y U 0 0 0 0 0 0 0 0 0
Finland Y U 0 0 0 0 0 2 0.04 0 0
France Y C 21 19 0.03 21 0.03 14 0.02 24 0.04
Germany Y C 18 18 0.02 24 0.03 21 0.03 37 0.04
Greece Y C 110 106 0.94 304 2.71 101 0.90 121 1.09
Hungary Y U 0 0 0 0 0 1 0.01 - -
Ireland Y U 0 0 0 2 0.05 7 0.16 4 0.10
Italy Y C 23 23 0.04 163 0.27 179 0.30 456 0.78
Latvia Y U 0 0 0 0 0 0 0 0 0
Lithuania Y A 1 1 0.03 0 0 0 0 0 0
Luxembourg Y U 0 0 0 0 0 0 0 0 0
Malta Y U 0 0 0 0 0 0 0 0 0
Netherlands Y C 4 3 0.02 3 0.02 2 0.01 6 0.04
Poland Y C 3 2 0.01 1 0.00 1 > 0.01 0 0
Portugal Y C 81 80 0.75 56 0.53 74 0.70 76 0.72
Romania Y C 3 3 0.01 2 0.01 2 0.01 1 > 0.01
Slovakia Y U 0 0 0 1 0.02 0 0 0 0
Slovenia Y C 2 2 0.10 2 0.10 1 0.05 0 0
Spain Y C 139 114 0.25 120 0.26 201 0.45 196 0.45
Sweden Y C 7 7 0.08 8 0.09 8 0.09 4 0.04
United Kingdom - C 17 17 0.03 13 0.02 13 0.02 20 0.03
EU total Y  436 401 0.08 735 0.15 639 0.13 951 0.20
Iceland - U 0 0 0 0 0 0 0 0 0
Liechtenstein Y - - - - 0 0 0 0 - -
Norway - U 0 0 0 0 0 0 0 3 0.06
Total - C  401 0.08 735 0.15 639 0.13 954 0.20
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
69
BrucellosisSURVEILLANCE REPORT
was 269 (67.9 %) males, 126  females (31.8 %) and 1 case 
with unknown gender (0.25 %). The male-to-female ratio 
was 2.1:1 in 2009. Confirmed case rates were higher for 
males in comparison to females in each age group. The 
highest confirmed case rate was in 25–44 year-olds, 
both male (0.17 per 100 000) and females (0.06 per 
100 000) (Figure 2.3.5).
Trends and seasonality
As in previous years, in 2009 reported cases of brucel-
losis occurred throughout the year. However, reported 
cases showed some seasonality distribution, as the 
higher number of reported cases was in the late spring/
early summer months (April–June) and largely dropped 
from July onwards (Figure 2.3.6).
An overall decreasing trend (p < 0.001) in the confirmed 
case rate of human brucellosis was observed during the 
2006–09 period (Figure 2.6.4). This was based on data 
received from 25 Member States and two EEA/EFTA coun-
tries that reported consistently during these years and 
were included in the trend analysis. France, Germany, 
Italy, and Spain showed a significant decrease in the 
brucellosis confirmed case rate. No country observed a 
significant increase. 
Discussion
There was a significant decreasing trend in reported 
numbers of human brucellosis in Europe between 2006 
and 2009. This could be related to a parallel signifi-
cant decrease in infection cases detected in small and 
large domestic ruminants due to veterinary controls in 
Europe1. Small and large ruminants are the main res-
ervoir and hosts for Brucella melitensis and Brucella 
abortus to humans. These two species of Brucella are 
still prevalent in southern European countries such as 
Greece, Spain and Portugal. Although eradication cam-
paigns in ruminants are ongoing in these countries, they 
still accounted for the majority of human cases reported.
References
1 European Food Safety Authority (EFSA). The Community Summary 
Report on Trends and Sources of Zoonoses and Zoonotic Agents and 
Food-borne Outbreaks in the European Union in 2009. EFSA Journal 
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Figure 2.3.4. Trend and number of reported confirmed brucellosis cases by month, in EU and EEA/EFTA countries, 
2006–09
Number of cases
12-month moving average
Nu
m
be
r o
f c
as
es
0
30
60
90
120
150
Jan 2010Jul 2009Jan 2009Jul 2008Jan 2008Jul 2007Jan 2007Jul 2006Jan 2006
Source: Country reports: Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, 
Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, United Kingdom.
Figure 2.3.5. Rates of reported confirmed brucellosis cases, by age and gender, in EU and EEA/EFTA countries, 2009
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Figure 2.3.6. Seasonal distribution of reported confirmed cases of brucellosis, in EU and EEA/EFTA countries, 2006–09
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Source: Country reports: Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, 
Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, United Kingdom.
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Campylobacteriosis
• Campylobacteriosis remains the most commonly 
reported infectious gastrointestinal disease in EU 
and EEA/EFTA countries.
• The rate of confirmed cases of human campylo-
bacteriosis remained stable during 2006–09.
• In 2009, the confirmed case rate of campylobac-
teriosis was 53.07 cases per 100 000 population.
• Human campylobacteriosis was more common 
in children 0–4 years old, with a confirmed case 
rate for males of 144.34 cases per 100 000 popu-
lation and for females of 114.71 cases per 100 000 
population in 2009.
Infection with bacteria of the genus Campylobacter 
causes mostly sporadic cases of campylobacteriosis, 
but also clusters and outbreaks. Consumption of con-
taminated and undercooked poultry is thought to be the 
major risk for infection.
Epidemiological situation in 2009
In 2009, 201 605 confirmed cases of campylobacte-
riosis were reported by 28 EU and EEA/EFTA countries. 
The overall confirmed case rate was 53.07 cases per 
100 000, similar to previous years (Table 2.3.3, Figure 
2.3.7). It should be noted that confirmed cases reported 
by France, the Netherlands and Spain were not included 
in the calculation of confirmed case rates, as their sen-
tinel surveillance systems do not cover the national 
population.
Table 2.3.3. Number and rate of campylobacteriosis cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 1 516 1 516 18.14 4 280 51.45 5 822 70.29 5 020 60.82
Belgium Y C 5 697 5 697 53.41 5 111 47.91 5 895 55.69 5 771 54.90
Bulgaria Y A 26 26 0.34 19 0.25 38 0.49 75 0.97
Cyprus Y C 37 37 4.64 23 2.91 17 2.18 2 0.26
Czech Republic Y C 20 370 20 259 193.54 20 067 193.30 24 137 234.63 22 571 220.18
Denmark Y C 3 353 3 353 60.84 3 470 63.37 3 868 71.01 3 239 59.68
Estonia Y C 170 170 12.68 154 11.48 114 8.49 124 9.22
Finland Y C 4 050 4 050 76.04 4 453 84.01 4 107 77.83 3 439 65.44
France N C 3 956 3 956 - 3 424 - 3 058 - 2 675 -
Germany Y C 62 787 62 787 76.57 64 731 78.73 66 107 80.31 52 035 63.12
Greece - - - - - - - - - - -
Hungary Y C 6 583 6 579 65.59 5 516 54.91 5 809 57.71 6 807 67.55
Ireland Y C 1 819 1 810 40.67 1 752 39.81 1 885 43.71 1 812 43.05
Italy Y C 531 531 0.88 265 0.44 676 1.14 801 1.36
Latvia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Lithuania Y C 812 812 24.24 762 22.64 564 16.66 0 0.00
Luxembourg Y C 523 523 105.98 439 90.74 345 72.45 285 60.76
Malta Y C 132 132 31.91 77 18.77 91 22.31 54 13.33
Netherlands N C 3 782 3 739 - 3 341 - 3 289 - 3 186 19.51
Poland Y C 360 360 0.94 270 0.71 192 0.50 156 0.41
Portugal - - - - - - - - - - -
Romania Y C 328 254 1.18 2 - 0 0.00 - -
Slovakia Y C 3 902 3 813 70.45 3 064 56.73 3 380 62.67 2 728 50.62
Slovenia Y C 952 952 46.84 898 44.67 1 127 56.06 - -
Spain N C 5 106 5 106 - 5 160 - 5 331 - 5 883 -
Sweden Y C 7 178 7 178 77.55 7 692 83.76 7 106 77.97 6 078 67.18
United Kingdom Y C 65 043 65 043 106.32 55 609 90.90 57 849 95.18 52 543 86.95
EU total - - 199 013 198 683 53.01 190 579 54.36 200 807 54.18 175 284 48.90
Iceland Y C 74 74 23.17 98 31.07 93 30.23 117 39.01
Liechtenstein - - - - - 2 5.66 0 0.00 - -
Norway Y C 2 848 2 848 59.34 2 875 60.69 2 836 60.58 2 588 55.77
Total - - 201 935 201 605 53.07 193 554 54.43 203 736 54.24 177 989 48.99
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
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The countries with highest reported confirmed case 
rates were the Czech Republic and the United Kingdom 
(193.30 and 106.32 cases per 100 000 population, 
respectively) (Table 2.3.3).
Information on gender and age was provided for 197 928 
confirmed cases. The male-to-female ratio was 1.1:1 in 
2009. The highest confirmed case rate was in 0–4 year-
old male children (144.34 per 100 000), which is almost 
three times more than the overall confirmed case rate 
(Figure 2.3.8). However, this probably reflects, at least 
in part, increased likelihood of medical consultation 
and testing for diarrhoeal illness for this age group com-
pared with adults, although infection is common at all 
ages above young childhood (Fig 2.3.8). 
Data on Campylobacter species were available from the 
zoonoses report 20091. The most frequently reported 
Campylobacter species in 2009 was Campylobacter 
jejuni (36.4 %), C. coli (2.5 %), C. lari (0.19 %) and C. 
upsaliensis (0.01 %). In 2009, there was still a high pro-
portion of confirmed cases (51 %) not characterised at 
species level or the species were unknown. 
Trends and seasonality
In the EU, human cases of campylobacteriosis followed 
a constant marked seasonality during the period 2006–
09. Most cases were reported during June–August 
months (Figure 2.3.9). At EU level, the confirmed case 
rate of human campylobacteriosis has remained almost 
at a constant level during this four-year period (2006–
09) (Figures 2.3.7 and 2.3.9).
Discussion
Human campylobacteriosis remained the most com-
monly reported gastrointestinal disease in Europe since 
20051. As in previous years, the people most commonly 
affected by campylobacter infection were 0–4 year-old 
children. Campylobacter infection in young children is 
of concern as it can also lead to post-infection chronic 
complications1.
References
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Figure 2.3.7. Trend and number of reported confirmed campylobacteriosis cases by month, in EU and EEA/EFTA 
countries, 2006–09
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Source: Country reports: Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, Germany, Hungary, Iceland, Ireland, Latvia, Luxembourg, Norway, 
Poland, Slovakia, Sweden, United Kingdom.
Figure 2.3.8. Rates of reported confirmed campylobacteriosis cases, by age and gender, in EU and EEA/EFTA countries, 
2009
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Figure 2.3.9. Seasonal distribution of reported confirmed cases of campylobacteriosis, in EU and EEA/EFTA countries, 
2006–09
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Poland, Slovakia, Sweden, United Kingdom.
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Cholera
• Cholera remains a rare disease in Europe. 
• All cases in Europe during 2006–09 were 
imported.
• In 2009, the most affected age group, with a noti-
fication rate of 0.06 cases per 100 000 popula-
tion, was the 0–4 year-olds.
• The trend has been stable during 2006–2009.
Cholera is an acute infection caused by the bacterium 
Vibrio cholerae. It is a rare infection in Europe, and all 
cases in recent years have been in travellers returning 
from countries where the disease is endemic.
Epidemiological situation in 2009
In 2009, 19 confirmed (22 total) cases of cholera were 
reported by four countries (Table 2.3.4). The United 
Kingdom reported 16 of these cases; France, Romania 
and Sweden each reported one case. Liechtenstein did 
not report. All reported cases were imported from out-
side the EU/EEA area. Given the rarity of the disease, the 
trend for the period 2006–09 is stable.
Information on age in 2009 was available for all the 22 
reported cases. Seven cases occurred among the 0–4 
year-old age group. The male-to-female ratio was 1.44:1 
for all the reported cases. 
Table 2.3.4. Number and rate of cholera cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 0 0 0.00 1 0.01 0 0.00 0 0.00
Belgium Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Bulgaria Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Cyprus Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Czech Republic Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Denmark Y C 0 0 0.00 1 0.02 0 0.00 - -
Estonia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Finland Y C 0 0 0.00 1 0.02 0 0.00 0 0.00
France Y C 1 1 <0.01 2 0.00 4 0.01 2 -
Germany Y C 0 0 0.00 0 0.00 2 0.00 1 0.00
Greece Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Hungary Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Ireland Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Italy Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Latvia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Lithuania Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Luxembourg Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Malta Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Netherlands Y C 3 0 0.00 5 0.03 3 0.02 3 0.02
Poland Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Portugal Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Romania Y C 1 1 <0.01 0 0.00 0 0.00 0 0.00
Slovakia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Slovenia Y C 0 0 0.00 0 0.00 1 0.05 0 0.00
Spain Y C 0 0 0.00 0 0.00 2 0.00 0 0.00
Sweden Y C 1 1 0.01 0 0.00 0 0.00 1 0.01
United Kingdom Y C 16 16 0.03 16 0.03 4 0.01 1 0.00
EU total - - 22 19 <0.01 26 0.01 16 0.00 8 0.00
Iceland Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Liechtenstein - - - - - - - - - - -
Norway Y C 0 0 0.00 0 0.00 1 0.02 1 0.02
Total - - 22 19 <0.01 26 0.01 17 0.00 9 0.00
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
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Seasonality
In 2009, most cases were reported in August (7 out of 
22). This is consistent with previous years’ reports, when 
summer months had the higher number of reported 
cases.
Discussion
As in previous years, most of the cholera cases were 
reported by the United Kingdom. All of them were 
imported and occurred among non-vaccinated per-
sons. Most cases were reported in August. This could 
be attributed to people returning from holidays from 
endemic countries.
Although the EU was not directly affected by the large 
cholera outbreak in Haiti following the earthquake in 
2009, ECDC supported Haitian authorities through pro-
vision of field epidemiology teams (see Chapter 3 for 
further details).
Figure 2.3.10. Trend and number of reported confirmed cholera cases by month, in EU and EEA/EFTA countries, 
2006–09
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Figure 2.3.11. Rates of reported confirmed cholera cases, by age and gender, in EU and EEA/EFTA countries, 2009
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Figure 2.3.12. Seasonal distribution of reported confirmed cases of cholera, in EU and EEA/EFTA countries, 2006–09
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United Kingdom UK-CHOLERA O Co P C Y N Y Y Y
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Cryptosporidiosis
• In 2009, the confirmed case rate of cryptosporidi-
osis increased to 2.74 per 100 000 population 
from 2.44 per 100 000 in 2008.
• The disease is likely to be underdiagnosed and 
underreported in several EU countries. Reports 
were provided by 21 out of 31 EU and EEA/EFTA 
countries. Zero cases were reported by eight 
countries.
• Cryptosporidiosis is mainly reported in children 
less than five years of age.
• As in previous years, a seasonal trend is observed 
with a peak of reported infections in late summer/
early autumn, probably related to behavioural 
risk factors at this time of year.
Cryptosporidiosis is an infection caused by the proto-
zoan parasite Cryptosporidium parvum, which infects 
cattle and other domestic animals. Oocysts of the para-
site survive well in the environment and human infection 
arises from a range of environmental contacts, including 
contaminated water and care centres for young children. 
Epidemiological situation in 2009
In 2009, 8 016 confirmed cases were reported by 13 EU 
and EEA/EFTA countries while a further eight countries 
reported zero cases. Similar to last year, the highest 
confirmed case rate was reported in Ireland (10.0 per 
100 000 population) followed by the United Kingdom 
(9.3 per 100 000) and Belgium (4.1 per 100 000) (Table 
2.3.5). The overall confirmed case rate was 2.74 per 
100 000 population, which was an increase compared to 
2.44 per 100 000 population in 2008.
Table 2.3.5. Number and rate of cryptosporidiosis cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 0 0 0.00 13 0.16 9 0.11 14 0.17
Belgium Y C 470 470 4.37 397 3.72 259 2.45 402 3.82
Bulgaria Y A 1 1 0.01 0 0.00 0 0.00 4 0.05
Cyprus Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Czech Republic Y C 0 0 0.00 0 0.00 - - 0 0.00
Denmark - - - - - - - - - - -
Estonia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Finland Y C 11 11 0.21 11 0.21 11 0.21 6 0.11
France - - - - - - - - - - -
Germany Y C 1 106 1 106 1.35 1 014 1.23 1 459 1.77 1 204 1.46
Greece - - - - - - - - - - -
Hungary Y C 15 15 0.15 10 0.10 6 0.06 0 0.00
Ireland Y C 445 445 10.00 412 9.36 611 14.17 366 8.70
Italy - - - - - - - - - - -
Latvia Y A 9 9 0.40 0 0.00 0 0.00 0 0.00
Lithuania Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Luxembourg Y C 0 0 0.00 0 0.00 0 0.00 2 0.43
Malta Y C 0 0 0.00 0 0.00 0 0.00 1 0.25
Netherlands - - - - - - - - - - -
Poland Y A 5 5 0.01 1 0.00 0 0.00 0 0.00
Portugal - - - - - - - - - - -
Romania Y C 8 8 0.04 0 0.00 - - - -
Slovakia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Slovenia Y C 3 3 0.15 6 0.30 1 0.05 9 0.45
Spain N C 197 197 - 75 - 136 - 262 -
Sweden Y C 159 159 1.72 148 1.61 110 1.21 103 1.14
United Kingdom Y C 5 587 5 587 9.07 4 941 8.08 3 653 6.01 4 428 7.33
EU total - - 8 016 8 016 2.74 7 028 2.44 6 255 2.42 6 801 2.49
Iceland - - - - - - - - - - -
Liechtenstein - - - - - - - - - - -
Norway - - - - - - - - - - -
Total - - 8 016 8 016 2.74 7 028 2.44 6 255 2.42 6 801 2.49
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
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Age and gender distribution 
Data on age was available for 7 915 cases. As in previous 
years, the highest confirmed case rates were observed 
in the 0–4 year-olds (18.6 per 100 000) followed by the 
5–14 year-olds (7.4 per 100 000) (Figure 2.3.14). The 
male-to-female ratio was largely balanced (3.2 vs. 3.3 
per 100 000; n=7 917).
Seasonality
As described in previous years, the overall monthly case 
distribution shows a peak in late summer and autumn 
in most countries (Figure 2.3.15). In Ireland, the highest 
number of cases was reported in April/May.
Discussion
The number of reported cryptosporidiosis cases shows 
an increasing trend in the EU1,2. However, this increase 
was mostly due to an increase in the number of cases 
reported in the United Kingdom over the period. An out-
break was reported from Norway among children staying 
in a wild life reserve3. 
Despite the increased coverage in terms of the number 
of reporting countries, however, the disease is likely to 
be underreported. Eight countries reported zero cases 
and another eight did not provide any data.
References
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Figure 2.3.13. Trend and number of reported confirmed cryptosporidiosis cases by month, in EU and EEA/EFTA 
countries, 2006–09
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Source: Country reports: Belgium, Bulgaria, Cyprus, Estonia, Finland, Germany, Hungary, Ireland, Lithuania, Luxembourg, Malta, Poland, Slovakia, Slovenia, Sweden, 
United Kingdom.
Figure 2.3.14. Rates of reported confirmed cryptosporidiosis cases, by age and gender, in EU and EEA/EFTA countries, 
2009
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Figure 2.3.15. Seasonal distribution of reported confirmed cases of cryptosporidiosis, in EU and EEA/EFTA countries, 
2006–09
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Source: Country reports: Belgium, Bulgaria, Cyprus, Estonia, Finland, Germany, Hungary, Ireland, Lithuania, Luxembourg, Malta, Poland, Slovakia, Slovenia, Sweden, 
United Kingdom.
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Echinococcosis
• Echinococcosis is a rare disease, although still 
reported from many EU countries.
• There was a significant four-year decreasing 
trend in the rate of confirmed cases of human 
echinococcosis at EU level.
• In 2009, the confirmed case rate of echinococ-
cosis in the EU and EEA/EFTA countries was 0.18 
cases per 100 000 population.
• Bulgaria had the highest confirmed case rate, 
425 cases per 100 000 population, accounting for 
323 confirmed cases, 41 % of the total number 
reported.
Echinococcosi (hydatid disease) is an uncommon dis-
ease in the EU, caused by infections with the larval stage 
of Echinococcus tapeworms. Human infection occurs 
through ingestion of tapeworm eggs, most commonly 
through contact with infected dogs or their environment.
Epidemiological situation in 2009
In 2009, 789 confirmed cases of human echinococ-
cosis were reported by 26 of the 30 EU and EEA/EFTA 
countries. The number of reported confirmed cases 
decreased by 12.4 % in 2009 compared to 2008 (Figure 
2.3.16). The overall notification rate was 0.18 cases per 
100 000 (Table 2.3.6). 
Table 2.3.6. Number and rate of echinococcosis cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 21 20 0.24 6 0.07 16 0.19 26 0.31
Belgium Y A 14 14 0.13 0 0.00 1 0.01 6 0.06
Bulgaria Y A 323 323 4.25 386 5.05 461 6.00 485 6.28
Cyprus Y C 1 1 0.13 1 0.13 4 0.51 6 0.78
Czech Republic Y C 1 1 0.01 2 0.02 3 0.03 2 0.02
Denmark - - - - - - - - - - -
Estonia Y C 0 0 0.00 1 0.07 2 0.15 0 0.00
Finland Y C 1 1 0.02 1 0.02 1 0.02 0 0.00
France Y C 27 27 0.04 14 0.02 25 0.04 16 0.03
Germany Y C 106 106 0.13 102 0.12 89 0.11 124 0.15
Greece Y C 22 22 0.20 28 0.25 10 0.09 5 0.04
Hungary Y C 8 8 0.08 7 0.07 8 0.08 6 0.06
Ireland Y C 1 1 0.02 2 0.05 0 0.00 0 0.00
Italy - - - - - - - - - - -
Latvia Y C 15 15 0.66 21 0.92 12 0.53 22 0.96
Lithuania Y A 36 36 1.07 32 0.95 12 0.35 0 0.00
Luxembourg Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Malta Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Netherlands N A 25 25 - 12 - 6 0.04 31 -
Poland Y C 25 25 0.07 28 0.07 40 0.10 65 0.17
Portugal Y C 4 4 0.04 4 0.04 10 0.09 9 0.09
Romania Y C 42 42 0.20 119 0.55 99 0.46 - -
Slovakia Y C 4 4 0.07 5 0.09 4 0.07 6 0.11
Slovenia Y C 9 9 0.44 7 0.35 1 0.05 3 0.15
Spain Y C 86 86 0.19 109 0.24 131 0.29 123 0.28
Sweden Y C 12 12 0.13 13 0.14 24 0.26 7 0.08
United Kingdom Y C 7 7 0.01 9 0.01 7 0.01 14 0.02
EU total - - 790 789 0.18 909 0.22 966 0.22 956 0.24
Iceland - - - - - - - - - 0 0.00
Liechtenstein - - - - - 0 0.00 0 0.00 - -
Norway Y C 0 0 0.00 2 0.04 0 0.00 0 0.00
Total - - 790 789 0.18 911 0.21 966 0.22 956 0.23
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
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Three countries, Bulgaria, Germany and Spain, 
accounted for 65.2 % of reported confirmed cases in 
2009. Bulgaria and Lithuania had the highest notifica-
tion rates, 4.25 and 1.07 cases per 100 000 population, 
respectively (Table 2.3.6).
Information on age and gender was provided for 384 
confirmed cases. The male-to-female ratio was 1.1:1 in 
2009. The highest confirmed case rate was in 65-year-
old or older males (0.15 per 100 000), followed by 
45–64-year-old male and females (0.14 per 100 000) 
(Figure 2.3.17).
Trends and seasonality
A statistically significant decreasing trend in the con-
firmed case rate of human echinococosis was detected 
during a four year period (2006–2009) at EU level 
(p < 0.001). This was based on data received from 24 EU 
Member States and one EEA/EFTA country that reported 
consistently during these years and were included in the 
trend analysis (Figure 2.3.17).  
Echinococcosis cases were reported throughout the 
year, in 2009 (Figure 2.3.18). 
Discussion
Echinococcosis is still present in many countries of the 
EU. While uncommon, the rate of reported confirmed 
cases has followed a significant four-year decreas-
ing trend. A contribution to this could be a decreasing 
prevalence over time of Echinococcus granulosus in 
farm animals and dogs, as a result of sustained eradi-
cation campaigns in several countries. However, some 
countries, including Romania and Bulgaria, still report 
an increasing proportion of positive cattle and sheep to 
Echinococcus1.
References
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Figure 2.3.16. Trend and number of reported confirmed echinococcosis cases by month, in EU and EEA/EFTA countries, 
2006–09
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Source: Country reports: Cyprus, Czech Republic, Estonia, Finland, France, Greece, Hungary, Ireland, Latvia, Luxembourg, Malta, Norway, Poland, Portugal, Slovakia, 
Slovenia, Spain, Sweden, United Kingdom.
Figure 2.3.17. Rates of reported confirmed echinococcosis cases, by age and gender, in EU and EEA/EFTA countries, 
2009
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Figure 2.3.18. Seasonal distribution of reported confirmed cases of echinococcosis, in EU and EEA/EFTA countries, 
2006–09
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Source: Country reports: Cyprus, Czech Republic, Estonia, Finland, France, Greece, Hungary, Ireland, Latvia, Luxembourg, Malta, Norway, Poland, Portugal, Slovakia, 
Slovenia, Spain, Sweden, United Kingdom.
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Vero/shiga toxin-producing 
Escherichia coli (VTEC/STEC) infection
• Reported human cases of VTEC have followed a 
significant increasing four-year trend in EU and 
EEA/EFTA countries since 2006.
• In 2009, the notification rate of VTEC in the EU 
and EEA/EFTA countries was 0.86 cases per 
100 000 population.
• The highest notification rate was in male chil-
dren aged 0–4 years, 6.73 cases per 100 000 
population;
• In 2009, the number of reported VTEC cases that 
developed haemolytic uremic syndrome (242) 
increased by 66 % compared to 2008 (146).
STEC/VTEC is a potentially fatal disease caused by infec-
tion with verocytotoxin- or Shiga toxin-producing strains 
of the usually innocuous bacterium Escherichia coli. The 
main hosts for these strains are cattle. Transmission 
occurs primarily by eating undercooked infected beef, 
and then, secondarily, by person-to-person transmis-
sion. The disease remains relatively uncommon in EU 
countries but there is concern the occurrence of severe 
disease may be increasing.
Epidemiological situation in 2009
In 2009, 3 689 confirmed cases of STEC/VTEC were 
reported by 27 EU and EEA countries. The overall noti-
fication rate was 0.86 cases per 100 000, an increase of 
15 % compared with 2008 (Table 2.3.7).  
Table 2.3.7. Number and rate of STEC/VTEC cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 91 91 1.09 69 0.83 82 0.99 41 0.50
Belgium Y C 96 96 0.90 103 0.97 47 0.44 46 0.44
Bulgaria Y C 0 0 0.00 0 0.00 0 0.00  
Cyprus Y C 0 0 0.00 2 0.25 0 0.00  
Czech Republic - - - - - - - - - –  
Denmark Y C 173 160 2.90 161 2.94 156 2.86 146 2.69
Estonia Y C 4 4 0.30 3 0.22 3 0.22 8 0.59
Finland Y C 29 29 0.54 8 0.15 12 0.23 14 0.27
France Y C 93 93 0.14 85 0.13 58 0.09 67 0.11
Germany Y C 878 878 1.08 876 1.07 870 1.06 1 183 1.44
Greece - - - - - 0 0.00 1 0.01 1 0.01
Hungary Y C 1 1 0.01 0 0.00 1 0.01 3 0.03
Ireland Y C 240 237 5.33 213 4.84 115 2.67 153 3.64
Italy Y C 71 51 0.08 26 0.04 27 0.05 17 0.03
Latvia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Lithuania Y A 0 0 0.00 0 0.00 0 0.00 0 0.00
Luxembourg Y C 5 5 1.01 4 0.83 1 0.21 2 0.43
Malta Y C 8 8 1.93 8 1.95 4 0.98 21 5.19
Netherlands Y C 313 313 1.90 92 0.56 88 0.54 41 0.25
Poland Y C 0 0 0.00 3 0.01 2 0.01 4 0.01
Portugal - - - - - - - - - –  
Romania Y C 0 0 0.00 4 - 0 0.00 –  
Slovakia Y C 14 14 0.26 8 0.15 6 0.11 8 0.15
Slovenia Y C 12 12 0.59 7 0.35 4 0.20 30 1.50
Spain N C 14 14 0.03 24 0.05 19 0.04 13 0.03
Sweden Y C 228 228 2.46 304 3.31 262 2.87 265 2.93
United Kingdom Y C 1 339 1 339 2.19 1 164 1.90 1 149 1.89 1 294 2.14
EU total - - 3 609 3 573 0.75 3 164 0.77 2 907 0.67 3 357 0.76
Iceland Y C 8 8 2.50 4 1.27 13 4.23 1 0.33
Liechtenstein - - - - - 0 0.00 - - -  
Norway Y C 108 108 2.25 22 0.46 26 0.56 50 1.08
Total - - 3 734 3 689 0.86 3 190 0.76 2 946 0.67 3 408 0.76
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
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Five EU Member States (United Kingdom, Germany, 
Netherlands, Ireland and Sweden) accounted for 81 % 
of the total number of confirmed cases reported in 
2009. The number of cases reported by the Netherlands 
showed a threefold increase from 2008 (92) to 2009 
(313) due to a nationwide outbreak associated to con-
sumption of contaminated beef steak tartare with VTEC 
O:1571 (Table 2.3.7).
The rate of reported confirmed VTEC cases has followed 
a steadily increasing trend since 2007 (Figure 2.3.19). 
This was based on data received from 25 EU Member 
States and two EEA/EFTA countries that reported con-
sistently during the four-year period. By country, only 
six Member States had a significant increasing trend 
from 2006 to 2009 (Belgium, France, Italy, Luxembourg, 
Malta and the Netherlands). No significant decreasing 
trends were observed in any countries.
The highest rate of confirmed cases was reported in 0–4 
year-old males (6.98 cases per 100 000 population) fol-
lowed by 0-4 year old females (5.82 cases per 100 000 
population). Notification rates were remarkably lower in 
older groups of age (Figure 2.3.20).
Trends and seasonality
Reported cases of VTEC were distributed unevenly dur-
ing the year presenting a marked seasonality with the 
highest number reported in late summer/early autumn 
(July–September) for the last four years. Moreover, the 
number of reported cases during September 2009 was 
higher than in the previous three years (Figure 2.3.21).
Enhanced surveillance
More than half (52 %) of reported confirmed human 
VTEC infections in 2009 were associated with the O:157 
serogroup. The majority of O:157-associated confirmed 
cases (80 %) were reported by the United Kingdom and 
Ireland2.
A total of 242 confirmed VTEC cases developed haemo-
lytic uremic syndrome (HUS). This represents an increase 
of 66 % compared with the number of HUS cases reported 
in 2008 (146). Sixty-three per cent of HUS cases (n=153) 
were reported in 0–4 year-old children2. 
Figure 2.3.19. Trend and number of reported confirmed STEC/VTEC cases by month, in EU and EEA/EFTA countries, 
2006–09
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Figure 2.3.20. Rates of reported confirmed STEC/VTEC cases, by age and gender, in EU and EEA/EFTA countries, 2009
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Discussion
Several VTEC outbreaks were detected in the United 
Kingdom and the Netherlands in 20091,4. One of the larg-
est VTEC outbreaks was linked to an open farm in the 
United Kingdom with most of the cases (76/93) under 
10 years of age5. In the Netherlands, this increase was 
mainly due to a nationwide outbreak associated to con-
sumption of contaminated beef steak tartare with VTEC 
O:1571. 
These large nationwide outbreaks in two countries have 
contributed to the increasing trend in Europe, strength-
ened the seasonal pattern, and increased the number of 
HUS cases2. As in previous years, VTEC O:157 was the 
most commonly reported serotype; however, this may be 
overestimated as some countries focus surveillance on 
this serotype. As in previous years, two countries, the 
United Kingdom and Ireland, accounted for most of the 
reported VTEC O:157 cases.
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Figure 2.3.21. Seasonal distribution of reported confirmed cases of STEC/VTEC, in EU and EEA/EFTA countries, 
2006–09
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Country Data Source
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Giardiasis
• The rate of confirmed giardiasis cases has been 
relatively stable over the last four years in the EU 
and EEA/EFTA countries, with a rate of 5.6 per 
100 000 in 2009.
• 82 % of cases were reported from Romania. 
However, due to uncertainty on whether the con-
firmed cases from Romania conform to the Giardia 
lamblia case definition, only the total number 
of cases is reported this year from Romania. 
Although the total number of cases of giardia-
sis reported from Romania has been decreasing 
since 2006, the rate is still considerably higher 
than for other EU and EEA/EFTA countries.
Giardiasis is the most frequently reported parasitic 
gastrointestinal infection in the EU. It is caused by the 
protozoan parasite Giardia lamblia. Humans are the pri-
mary reservoir, and infection arises from contact with 
the oocysts in various settings, including contaminated 
water and care centres for young children who are not 
toilet trained1,2. 
Epidemiological situation in 2009
In 2009, 93 375 cases were reported by 22 EU and EEA/
EFTA countries (Table 2.3.8). Eighty-two per cent of the 
total cases were reported from Romania but due to 
uncertainties regarding laboratory confirmation, and 
inclusion of cases from screening programmes, these 
cases were not classified as confirmed. Therefore, only 
Table 2.3.8. Number and rate of giardiasis cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 65 31 0.37 47 0.56 66 0.80 84 1.02
Belgium Y C 1 218 1 218 11.42 1 213 11.37 1 081 10.21 1 238 11.78
Bulgaria Y A 2 096 2 096 27.56 2 141 28.02 0 0.00 2 212 28.66
Cyprus Y C 2 2 0.25 7 0.89 4 0.51 6 0.78
Czech Republic - - - - - - - - - 141 1.38
Denmark - - - - - - - - - - -
Estonia Y C 207 207 15.44 264 19.69 418 31.14 469 34.88
Finland Y C 378 378 7.10 427 8.06 294 5.57 0 0.00
France - - - - - - - - - - -
Germany Y C 3 962 3 962 4.83 4 763 5.79 3 651 4.44 3 661 4.44
Greece - - - - - - - - - - -
Hungary Y C 100 100 1.00 138 1.37 86 0.85 31 0.31
Ireland Y C 62 62 1.39 70 1.59 62 1.44 65 1.54
Italy - - - - - - - - - - -
Latvia Y A 36 36 1.59 28 1.23 34 1.49 9 0.39
Lithuania Y A 13 13 0.39 15 0.45 23 0.68 0 0.00
Luxembourg Y C 2 2 0.41 1 0.21 0 0.00 0 0.00
Malta Y C 2 2 0.48 2 0.49 10 2.45 11 2.72
Netherlands - - - - - - - - - - -
Poland Y A 2 280 2 184 5.73 3 096 8.12 2 981 7.82 2 875 7.53
Portugal - - - - - - - - - - -
Romania(a) Y A 76 671 - - - - - - - -
Slovakia Y C 139 139 2.57 125 2.31 122 2.26 93 1.73
Slovenia Y C 9 9 0.44 14 0.70 17 0.85 - -
Spain(b) N C 869 869 - 683 - 904 - 909 -
Sweden Y C 1 210 1 210 13.07 1 529 16.65 1 413 15.50 1 282 14.17
United Kingdom Y C 3 719 3 719 6.08 3 632 5.94 3 257 5.36 3 167 5.24
EU total - - 93 040 16 239 5.60(c) 18 195 6.38(c) 14 423 4.93(c) 16 253 5.44(c)
Iceland Y C 27 27 8.45 33 10.46 46 14.95 39 13.00
Liechtenstein - - - - - - - - - - -
Norway Y C 308 308 6.42 270 5.70 290 6.20 294 6.34
Total - - 93 375 16 574 5.61(c) 18 498 6.37(c) 14 759 4.96(c) 16 586 5.46(c)
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed. (a) Only the total number of cases is reported, 
as case deﬁ nition not suﬃ  ciently speciﬁ c for conﬁ rmed cases. (b) Sentinel surveillance system based on a limited number of select laboratories. (c) Overall rate 
excludes data from Spain.
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16 574 cases are reported here as confirmed across the 
EU/EEA area. The Romanian data has also not been 
included in European rate calculations for confirmed 
cases.
The highest rate of confirmed cases was reported by 
Bulgaria (28 per 100 000), followed by Estonia (15 per 
100 000), Sweden (13 per 100 000) and Iceland (8 per 
100 000). The overall confirmed case rate was 5.61 per 
100 000 population. This reported rate has been rela-
tively consistent over the last four years throughout the 
EU and EEA/EFTA.
Information on the importation status of reported cases 
was only available from 10 countries and for 5 371 cases. 
Of these, 1 629 cases (30 %) were reported as imported 
cases.
In Norway, 228 out of 272 cases with importation sta-
tus were reported as being imported (84 %). In Germany, 
1 201 out of 3 765 cases with importation status were 
reported as being imported (32 %).
Age and gender distribution
Nineteen countries provided information on the age and 
gender of their cases. Age and gender data was reported 
for 12 077 cases. Similar to the previous years, the high-
est notification rate occurred in the age group 0–4 years 
for both males and females (Figure 2.3.23).
Seasonality
Data on seasonality for 2009 was available for 11 435 
reported cases from 15 countries. Cases occur all year 
round, although a slight increase has consistently been 
observed in the autumn months. Figure 2.3.24 shows the 
seasonality of reported cases between 2006 and 2009.
Figure 2.3.22. Trend and number of reported confirmed giardiasis cases by month, in EU and EEA/EFTA countries, 
2006–09
Number of cases
12-month moving average
Nu
m
be
r o
f c
as
es
600
900
1200
1500
Jan 2010Jul 2009Jan 2009Jul 2008Jan 2008Jul 2007Jan 2007Jul 2006Jan 2006
Source: Country reports: Belgium, Cyprus, Czech Republic,  Finland, Germany, Hungary, Iceland, Ireland, Malta, Norway, Slovakia, Sweden, United Kingdom.
Figure 2.3.23. Rates of reported confirmed giardiasis cases, by age and gender, in EU and EEA/EFTA countries, 2009
Female
Male
Ca
se
s/
10
0 
00
0
0
3
6
9
12
15
≥ 6545–6425–4415–245–140–4
Source: Country reports: Austria, Belgium, Cyprus, Estonia, Finland, Germany, Hungary, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Malta, Norway, Slovakia, 
Slovenia, Spain, Sweden, United Kingdom.
89
GiardiasisSURVEILLANCE REPORT
Discussion
Romania reported 82 % of total cases of giardiasis in the 
EU/EEA region in 2009. However, reports from Romania 
have included screening and other cases beyond the 
case definition. No major threats or outbreaks of giar-
diasis were reported in 2009.
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Figure 2.3.24. Seasonal distribution of reported confirmed cases of giardiasis, in EU and EEA/EFTA countries, 2006–09
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The hepatitis A virus remains a relatively common source 
of gastrointestinal illness in some areas of the EU/EEA. 
Humans are the only reservoir and transmission is from 
person to person by the faecal-oral route in a variety of 
settings. Outbreaks can be prolonged and difficult to 
control.
Epidemiological situation in 2009
In 2009, 17 370 confirmed cases of hepatitis A (total 
18 269) were reported by 29 countries in the EU and 
EEA/EFTA (Liechtenstein did not report) (Table 2.3.9). 
The overall confirmed case rate was 3.44 per 100 000 
population, which is slightly higher than the rate in 2007 
(2.79 per 100 000) and 2008 (3.34 per 100 000). As in 
2008, Latvia (101 per 100 000) reported the highest con-
firmed case rate, followed by Slovakia (27 per 100 000), 
Romania (17 per 100 000), Bulgaria (14 per 100 000), and 
Hepatitis A
• The overall confirmed case rate of hepatitis A in 
2009, 3.4 per 100 000 population, was similar to 
the one in 2008 (3.3 per 100 000 population).
• As observed in previous years, children aged 
5–14 years have the highest confirmed case 
rates. The true burden of infection in children is 
probably underestimated, as younger children 
under five years often have asymptomatic hepa-
titis A infection.
• In general, the second half of the year (late sum-
mer and autumn) shows the highest number of 
reported cases. 
• The majority (82 %) of cases with information on 
importation status were indigenous.
Table 2.3.9. Number and rate of hepatitis A cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 27 1 0.01 4 0.05 5 0.06 1 0.01
Belgium Y C 130 130 1.22 365 3.42 209 1.97 225 2.14
Bulgaria Y A 1 064 1 064 13.99 907 11.87 2 790 36.33 7 266 94.13
Cyprus Y C 4 4 0.50 4 0.51 4 0.51 3 0.39
Czech Republic Y C 1 104 1 104 10.55 1 649 15.88 126 1.22 131 1.28
Denmark Y C 45 45 0.82 44 0.80 306 5.62 42 0.77
Estonia Y C 19 19 1.42 13 0.97 10 0.74 5 0.37
Finland Y C 22 22 0.41 22 0.42 15 0.28 0 0.00
France Y C 1 547 1 547 2.40 1 204 1.88 1 010 1.59 1 336 2.12
Germany Y C 929 929 1.13 1 072 1.30 936 1.14 1 226 1.49
Greece Y C 88 86 0.76 120 1.07 286 2.56 123 1.11
Hungary Y C 107 107 1.07 168 1.67 251 2.49 286 2.84
Ireland Y C 50 49 1.10 41 0.93 29 0.67 38 0.90
Italy Y C 1 500 1 500 2.50 1 350 2.26 1 159 1.96 890 1.51
Latvia Y A 2 291 2 276 100.65 2 798 123.21 15 0.66 47 2.05
Lithuania Y A 16 16 0.48 20 0.59 23 0.68 0 0.00
Luxembourg Y C 5 5 1.01 3 0.62 1 0.21 3 0.64
Malta Y C 9 9 2.18 4 0.97 3 0.74 7 1.73
Netherlands Y C 176 154 0.93 87 0.53 165 1.01 262 1.60
Poland Y A 652 644 1.69 189 0.50 36 0.09 105 0.28
Portugal Y C 27 27 0.25 21 0.20 17 0.16 40 0.38
Romania(a) Y C 3 840 3 731 17.35 3 161 14.68 4 982 23.10 5 351 24.76
Slovakia Y C 1 449 1 447 26.74 729 13.50 383 7.10 461 8.55
Slovenia Y C 12 12 0.59 17 0.85 15 0.75 10 0.50
Spain(b) Y C 2 522 1 808 3.95 1 877 4.15 698 1.57 1 079 2.47
Sweden Y C 154 154 1.66 78 0.85 68 0.75 80 0.88
United Kingdom Y C 437 437 0.71 794 1.30 377 0.62 417 0.69
EU total - - 18 226 17 327 3.47 16 741 3.36 13 919 2.81 19 434 3.94
Iceland Y C 3 3 0.94 1 0.32 2 0.65 2 0.67
Liechtenstein - - - - - - - - - - -
Norway Y C 40 40 0.83 49 1.03 29 0.62 41 0.88
Total - - 18 269 17 370 3.44 16 791 3.34 13 950 2.79 19 477 3.91
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
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the Czech Republic (11 per 100 000). All other countries 
reported confirmed case rates below 5 per 100 000.
Data on the importation status of reported cases 
(n=4 560) was available from 13 EU Member States plus 
Norway and Iceland. The majority of the infections were 
reported as indigenous (82 % of all cases with informa-
tion on importation status). Indigenous cases domi-
nated in Spain (100 %), Malta (100 %), United Kingdom 
(94 %), Hungary (91 %), Greece (90 %), Ireland (74 %), 
France (71 %), Germany (70 %), Slovenia (67 %), Iceland 
(67 %) and the Netherlands (54 %). In all other reporting 
countries, however, imported cases accounted for more 
than 50 % of all cases.
In Spain, an outbreak of hepatitis A related to men who 
have sex with men was observed between September 
2008 and March 2009, including at least 87 cases. 
Another outbreak of hepatitis A was continuing in Latvia 
from 2008.
Age and gender distribution
Data on age groups were available from 28 countries. 
As in the previous two years, the highest confirmed 
case rate occurred in children 5–14 years of age (8.4 
per 100 000) followed by children under five with 7.5 per 
100 000 (Figure 2.3.26). Data on gender distribution was 
available for 16 648 cases and from 27 of 29 countries 
with confirmed cases of hepatitis A. The male-to-female 
ratio was 1.5:1, with an overall confirmed case rate of 4.3 
per 100 000 among men compared with 2.8 per 100 000 
among women.
Seasonality
Data on seasonality was available for 12 875 cases from 
25 countries (Latvia, Luxembourg, Lithuania and Poland 
reported unknown seasonality for all cases). In general, 
a peak in reported cases was observed from September 
to November in 2009 (Figure 2.3.27). Seasonality pat-
terns showed considerable variations among the 
Figure 2.3.25. Trend and number of reported confirmed hepatitis A cases by month, in EU and EEA/EFTA countries, 
2006–09
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Figure 2.3.26. Rates of reported confirmed hepatitis A cases, by age and gender, in EU and EEA/EFTA countries, 2009
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different countries, with a pronounced autumn peak in 
Romania, Slovenia, Bulgaria and the Czech Republic, 
while in Spain and Italy most cases were reported in late 
winter and spring.
Discussion
As in previous years, the majority of hepatitis A infec-
tions were reported as indigenous, thus confirming 
the relevance of hepatitis A as an endemic infection in 
the EU. However, epidemiologic patterns show a con-
siderable variation among EU countries, most likely 
related to different routes of infection. There is increas-
ing evidence from molecular epidemiology that many 
apparently indigenous cases are secondary to imported 
cases1. Besides food-borne transmission of hepatitis A, 
other risk factors with different transmission character-
istics and risk groups may play a significant role.
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Figure 2.3.27. Seasonal distribution of reported confirmed cases of hepatitis A, in EU and EEA/EFTA countries, 
2006–09
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Leptospirosis
• In 2009, the confirmed case rate of leptospirosis 
slightly decreased from 0.15 per 100 000 popula-
tion in 2008 to 0.14. The disease remains a rela-
tively rare infection in EU countries.
• Men of working age were the most affected by 
leptospirosis, and most infections were con-
tracted in late summer and autumn.
Leptospirosis is an uncommon infection in the EU, 
caused by bacteria of the genus Leptospira. The bacte-
rium colonises a wide range of domestic and wild animal 
hosts; human infection results from contact with the 
urine of infected animals.
Epidemiological situation in 2009
In 2009, 544 confirmed cases were reported from 26 EU 
countries (Table 2.3.20). This gives an overall confirmed 
case rate of 0.14 cases per 100 000 population, which 
is slightly lower than that reported in 2008 (0.15 per 
100 000). 
Information on the importation status of reported cases 
was only available from 13 countries and for 235 cases. 
Of these, 51 cases (28 %) were related to travelling out-
side their home countries. 
Age and gender distribution
Gender was reported for all 544 confirmed cases. Out of 
these, 437 were reported in males and 107 in females 
Table 2.3.10. Number and rate of leptospirosis cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 9 9 0.11 11 0.13 9 0.11 8 0.10
Belgium Y A 8 8 0.07 5 0.05 8 0.08 21 0.20
Bulgaria Y A 11 11 0.15 9 0.12 16 0.21 20 0.26
Cyprus Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Czech Republic Y C 32 32 0.31 17 0.16 24 0.23 18 0.18
Denmark Y C 2 2 0.04 8 0.15 8 0.15 5 0.09
Estonia Y C 1 1 0.08 2 0.15 2 0.15 6 0.45
Finland Y C 12 12 0.23 8 0.15 2 0.04 5 0.10
France - - - - - - - - - - -
Germany Y C 92 92 0.11 66 0.08 165 0.20 46 0.06
Greece Y C 31 31 0.28 12 0.11 13 0.12 16 0.14
Hungary Y C 9 9 0.09 15 0.15 31 0.31 27 0.27
Ireland Y C 25 25 0.56 29 0.66 22 0.51 18 0.43
Italy Y C 36 36 0.06 40 0.07 45 0.08 22 0.04
Latvia Y A 5 5 0.22 3 0.13 2 0.09 5 0.22
Lithuania Y A 5 5 0.15 2 0.06 6 0.18 0 0.00
Luxembourg Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Malta Y C 3 3 0.73 2 0.49 1 0.25 1 0.25
Netherlands Y C 25 25 0.15 37 0.23 37 0.23 23 0.14
Poland Y C 5 4 0.01 2 0.01 7 0.02 3 0.01
Portugal Y C 33 32 0.30 15 0.14 38 0.36 35 0.33
Romania Y C 143 127 0.59 200 0.93 296 1.37 386 1.79
Slovakia Y C 16 16 0.30 23 0.43 17 0.32 22 0.41
Slovenia Y C 2 2 0.10 6 0.30 7 0.35 5 0.25
Spain(a) N C 0 0 - 5 - 3 - 3 -
Sweden Y C 4 4 0.04 6 0.07 1 0.01 2 0.02
United Kingdom Y C 53 53 0.09 76 0.12 81 0.13 56 0.09
EU Total - - 562 544 0.14(b) 599 0.15(b) 841 0.22(b) 753 0.19(b)
Iceland - - - - - - - - - - -
Liechtenstein - - - - - - - - - - -
Norway - - - - - - - - - - -
Total - - 562 544 0.14(b) 599 0.15(b) 841 0.22(b) 753 0.19(b)
Source: Country reports. A: Aggregated data report; C: Case-based report; —: No report. (a) Sentinel surveillance system based on a limited number of select 
laboratories. (b) Overall rate excludes data from Spain.
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(male-to-female ratio of 4.0:1). Information on age 
was reported for all confirmed cases. As in 2008, the 
confirmed case rate was highest in individuals aged 
between 15–64 years old. In all adult age groups, con-
firmed case rates in males were higher than in females 
(Figure 2.3.29).
Seasonality
Information on seasonality was provided for all 544 
confirmed cases. In line with earlier annual reports, the 
majority of confirmed cases in 2009 were reported in 
late summer and fall (Figure 2.3.30).
Discussion
Leptospirosis still remains a relatively rare disease in 
EU countries. Highest incidences are reported in men 
of working age (25–64 years of age), most likely related 
to occupational exposures in some of these cases. The 
infection is frequently contracted by contact to contami-
nated water or mud, e.g. during surface water sports1, 
thus explaining the seasonality observed in 2009 and 
the previous years. Infection can also be acquired dur-
ing international travel2.
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Figure 2.3.28. Trend and number of reported confirmed leptospirosis cases by month, in EU and EEA/EFTA countries, 
2006–09
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Source: Country reports: Cyprus, Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Hungary, Ireland, Italy, Luxembourg, Malta, Netherlands, Poland, 
Portugal, Slovakia, Slovenia, Sweden, United Kingdom.
Figure 2.3.29. Rates of reported confirmed leptospirosis cases, by age and gender, in EU and EEA/EFTA countries, 
2009
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Figure 2.3.30. Seasonal distribution of reported confirmed cases of leptospirosis, in EU and EEA/EFTA countries, 
2006–09
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Listeriosis
• The EU/EEA rate of confirmed human cases of 
Listeria infection has been relatively stable in the 
last four years.
• Listeriosis had the highest impact among the eld-
erly (those over 64 years) with the highest con-
firmed case rates and high mortality.
• Most listeriosis cases were indigenous. 
• There appeared to be two main high seasons, one 
in summer, peaking in August–September, and 
one in winter, peaking in January.
Listeriosis is a disease caused by infection with the 
bacterium Listeria monocytogenes. Infection can cause 
meningitis, encephalitis or septicaemia in immunocom-
promised individuals or pregnant women, and babies 
may be stillborn or develop infection at or after birth. 
The bacterium occurs widely in the environment and its 
public health importance is particularly related to its 
potential for contamination of raw and uncooked foods. 
Epidemiological situation in 2009
In 2009 1 685 confirmed cases (1 688 total) were 
reported by 28 countries (Table 2.3.11). Portugal and 
Liechtenstein did not report any data while Cyprus, 
Malta and Iceland reported zero cases. The EU/EEA con-
firmed case rate was 0.35 per 100 000 population, which 
is slightly higher than in 2008, but no significant trend 
was observed for the years 2006–09.  
Table 2.3.11. Number and rate of listeriosis cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 46 46 0.55 31 0.37 20 0.24 10 0.12
Belgium Y C 58 58 0.54 64 0.60 57 0.54 67 0.64
Bulgaria Y A 5 5 0.07 5 0.07 11 0.14 6 0.08
Cyprus Y C 0 0 0.00 0 0.00 0 0.00 1 0.13
Czech Republic Y C 32 32 0.31 37 0.36 51 0.50 78 0.76
Denmark Y C 97 97 1.76 51 0.93 58 1.06 56 1.03
Estonia Y C 3 3 0.22 8 0.60 3 0.22 1 0.07
Finland Y C 34 34 0.64 40 0.75 40 0.76 46 0.88
France Y C 328 328 0.51 276 0.43 319 0.50 290 0.46
Germany Y C 394 394 0.48 306 0.37 356 0.43 508 0.62
Greece Y C 4 4 0.04 1 0.01 10 0.09 7 0.06
Hungary Y C 16 16 0.16 19 0.19 9 0.09 14 0.14
Ireland Y C 10 10 0.22 13 0.30 21 0.49 7 0.17
Italy Y C 88 88 0.15 118 0.20 89 0.15 59 0.10
Latvia Y C 4 4 0.18 5 0.22 5 0.22 2 0.09
Lithuania Y A 5 5 0.15 7 0.21 4 0.12 0 0.00
Luxembourg Y C 3 3 0.61 1 0.21 6 1.26 4 0.85
Malta Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Netherlands Y C 47 44 0.27 45 0.27 68 0.42 64 0.39
Poland Y C 32 32 0.08 33 0.09 43 0.11 28 0.07
Portugal - - - - - - - - - - -
Romania Y C 6 6 0.03 0 0.00 0 0.00 - -
Slovakia Y C 10 10 0.18 8 0.15 9 0.17 12 0.22
Slovenia Y C 6 6 0.30 3 0.15 4 0.20 7 0.35
Spain(a) N C 121 121 - 88 - 82 - 79 -
Sweden Y C 73 73 0.79 60 0.65 56 0.61 42 0.46
United Kingdom Y C 235 235 0.38 206 0.34 260 0.43 209 0.35
EU total - - 1 657 1 654 0.35(b) 1 425 0.30(b) 1 581 0.34(b) 1 597 0.36(b)
Iceland Y C 0 0 0.00 0 0.00 4 1.30 0 0.00
Liechtenstein - - - - - 0 0.00 0 0.00 - -
Norway Y C 31 31 0.65 34 0.72 49 1.05 27 0.58
Total - - 1 688 1 685 0.35(b) 1 459 0.31(b) 1 634 0.35(b) 1 624 0.37(b)
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed. (a) Surveillance system currently estimated to 
cover 25 % of the total population. (b) Overall rate excludes data from Spain.
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The highest rates for confirmed cases were observed in 
the Scandinavian countries: Denmark (1.76 per 100 000), 
Sweden (0.79 per 100 000), Norway (0.65 per 100 000) 
and Finland (0.64 per 100 000), followed by Luxembourg 
(0.61 per 100 000). All other countries reported less than 
0.60 cases per 100 000. Germany and France reported 
the highest number of confirmed cases.
Only 25 (2 %) of the 1 273 cases with data on importation 
status were reported to have been acquired outside their 
home country.
Age and gender distribution
Of the 1 676 confirmed listeriosis cases with informa-
tion on age in 2009, the majority (58 %) occurred among 
individuals 65 years of age and over (Figure 2.3.32). With 
1.21 cases per 100 000, this age group had the highest 
confirmed case rate in 2009 followed by children under 
the age of five and persons aged 45–64 years (both with 
0.31 cases per 100 000).  
The notification rates by gender were 0.39 per 100 000 
in males and 0.31 per 100 000 in females. As described 
in previous years, this ratio varied between age groups. 
It is higher for older males, especially for the 65 years or 
older, while the rates among the age groups 15–24 and 
25–44 are higher for females.
Seasonality
The seasonal trend for listeriosis in 2009 followed that of 
the previous three years with steadily increasing number 
of cases from May, peaking in August and September 
(Figure 2.3.33). There also appears to be a winter peak in 
December and January.
Enhanced surveillance
In 2009 a new variable was collected in the European 
Surveillance System (TESSy) – admission to hospital. 
Information on hospitalisation was known for only 317 
cases of which 99 % had been admitted to hospital. 
Seventeen per cent of the cases with known outcome 
(785 cases) had died as a cause of the Listeria infection 
and 19 % in the oldest age group (45 years and older).
Figure 2.3.31. Trend and number of reported confirmed listeriosis cases by month, in EU and EEA/EFTA countries, 
2006–09
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Source: Country reports: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, 
Latvia, Luxembourg, Malta, Netherlands, Norway, Poland, Slovakia, Slovenia, Spain, Sweden, United Kingdom.
Figure 2.3.32. Rates of reported confirmed listeriosis cases, by age and gender, in EU and EEA/EFTA countries, 2009
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Information on pregnancy-associated cases was also 
collected in 2009. Out of the 706 cases with this infor-
mation reported, 56 (8 %) were pregnancy-associated.
Discussion
Listeriosis is a rare but severe disease and the risk for 
the elderly population, in addition to that for pregnant 
women, warrants increased awareness in the EU/EEA. 
Denmark, which had the highest confirmed case rate 
reported in 2008, experienced a marked increase in 
2009. This increase was seen particularly in the group of 
patients over 70 years of age and could not be explained 
by increasing number of cases in outbreaks1. One of the 
possible explanations is the increase in consumption of 
ready-to-eat (RTE) products in Denmark, especially in 
older age groups1. 
There was one multinational listeriosis outbreak identi-
fied in the EU in 2009 and continuing in 20102,3. The out-
break was due to consumption of a semi-soft sour milk 
cheese. There were in total 34 cases identified, 25 in 
Austria, eight in Germany and one in the Czech Republic. 
The median age was 72 years and eight cases had a fatal 
outcome.
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Figure 2.3.33. Seasonal distribution of reported confirmed cases of listeriosis, in EU and EEA/EFTA countries, 2006–09
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Austria AT-Epidemiegesetz Cp Co P C Y Y Y Y Y
Belgium BE-LABNET V Se A C Y N - - Y
Bulgaria BG-NATIONAL_SURVEILLANCE Cp Co P A Y Y Y Y Y
Cyprus CY-NOTIFIED_DISEASES Cp Co P C N Y N N Y
Czech Republic CZ-EPIDAT Cp Co A C - Y Y N Y
Denmark DK-LAB Cp Co P C Y N N N Y
Estonia EE-LISTERIOSIS Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y Y N N Y
France FR-MANDATORY_INFECTIOUS_DISEASES Cp Co P C Y Y Y Y Y
Germany DE-SURVNET@RKI-7.1 Cp Co P C Y N N Y Y
Greece GR-NOTIFIABLE_DISEASES Cp Co P C Y Y Y N Y
Hungary HU-Zoonoses Cp Co P C Y Y Y N Y
Iceland IS-SUBJECT_TO_REGISTRATION Cp Co P C Y Y Y N Y
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Country Data Source
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Latvia LV-BSN Cp Co P C Y Y Y N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Luxembourg LU-LNS-Microbio - - - - Y N Y N Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y Y Y
Netherlands NL-OSIRIS Cp Co P C Y Y N Y Y
Norway NO-MSIS_A Cp Co P C Y Y Y N Y
Poland PL-NATIONAL_SURVEILLANCE Cp Co P C N Y Y N Y
Romania RO-RNSSy Cp Co P C Y N Y N Y
Slovakia SK-EPIS Cp Co A C Y Y Y N Y
Slovenia SI-SURVIVAL Cp Co P C Y Y Y N Y
Spain ES-MICROBIOLOGICAL V Se P C Y N N N N
Sweden SE-SMINET Cp Co P C Y N N N Y
United Kingdom UK-LISTERIOSIS V Co A C Y N Y Y Y
101
SalmonellosisSURVEILLANCE REPORT
Salmonellosis
• There has been a steady decrease in the EU con-
firmed case rates for salmonellosis over the last 
four years, although it continues to be one of the 
most common gastrointestinal infections in the 
EU/EEA. 
• The reported case rates are very high in children, 
in particular in the 0–4 year-olds (124 per 100 000 
population).
• There continues to be a clear peak in cases over 
the summer months, although decreasing in mag-
nitude over the years due to the general decrease 
of the disease.
• The number of outbreaks reported due to 
Salmonella infections continues to be large and 
different sources in addition to food (e.g. travel, 
pet products and live animal trade) were linked to 
multinational outbreaks in 2009.
Infection by bacteria belonging to the genus Salmonella 
continues to be one of the most common gastrointesti-
nal illnesses reported in the EU/EEA. A rage of wild and 
domesticated animals host Salmonella species, and 
humans are usually infected through ingesting contami-
nated, undercooked food. Other means of transmission 
occur and outbreaks are frequent, sometime multina-
tional in scope.
Epidemiological situation in 2009
In 2009, a total of 111 115 (non-typhoidali) salmonellosis 
cases were reported, of which 109 885 were confirmed, 
by all EU and EEA/EFTA countries, except Liechtenstein 
i For information on typhoid and paratyphoid cases, see page 116.
(Table 2.3.12). The overall confirmed case rate was 23.6 
per 100 000 population, which is a significant decrease 
over the last four years (Figure 2.3.34). 
The Czech Republic (100.1 cases per 100 000), Slovakia 
(77.3), Lithuania (61.6) and Hungary (58.5) reported 
the highest confirmed case rates, although still lower 
rates than in 2008. Five countries reported fewer than 
10 cases per 100 000 population: Greece, Ireland, Italy, 
Portugal and Romania. Over a four-year period (2006-
09), 10 countries had a statistically significant decreas-
ing trend in reported cases (Austria, Czech Republic, 
Germany, Greece, Hungary, Luxembourg, Poland, 
Portugal, Slovakia and the UK). 
In 2009, the percentage of cases in the EU that were 
imported was 15 % of all confirmed cases with known 
importation status (n=72 440). The percentage of 
imported cases was highest in the Nordic countries of 
Finland, Sweden and Norway (over 80 %), followed by 
Iceland, Ireland and the United Kingdom (over 50 %). Of 
the imported cases, other EU and EEA/EFTA countries 
were mentioned as the probable country of infection 
in 21 % of cases where this information was available 
(n=9 735).
Age and gender distribution
As in previous years, the age-specific confirmed case 
rate in 2009 was very high in children, in particular in 
the 0–4 year-old age group (124 per 100 000 population) 
(Figure 2.3.35). The rate in the young children was almost 
three times higher than in older children and more than 
five times as high as in the other age groups. This may 
be due to the higher proportion of symptomatic infec-
tions among the young, as well as a higher tendency by 
Figure 2.3.34. Trend and number of reported confirmed salmonellosis cases by month, in EU and EEA/EFTA countries, 
2006–09
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Table 2.3.13.  Salmonella serotypes most frequently 
reported from EU and EEA/EFTA countries 
and percentage change, 2008–09
Serotype 2008 2009 Percentage change
Enteritidis 70 936 53 951 -24 %
Typhimurium 27 170 23 990 -12 %
Infantis 1 378 1 632 18 %
Newport 838 788 -6 %
Virchow 935 774 -17 %
Derby 662 675 2 %
Hadar 545 513 -6 %
Saintpaul 444 473 7 %
Kentucky 518 469 -9 %
Stanley 619 456 -26 %
Source: Country reports: Austria, Belgium, Cyprus, Czech Republic, Denmark, 
Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, 
Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, 
Portugal, Romania, Slovakia, Slovenia, Sweden, Spain, United Kingdom.
paediatricians of taking samples. There were no differ-
ences in the overall rates between males and females 
(ratio 1.0:1).
Seasonality
There is a clear seasonal trend for salmonellosis cases 
(Figure 2.3.36), with rates increasing over the sum-
mer months, peaking in August/September, and then 
decreasing sharply. The seasonal variation is more 
prominent for S. Enteritidis than for S. Typhimurium1.
Enhanced surveillance in 2009
As in previous years, the two most common Salmonella 
serotypes in 2009 in the EU and EEA/EFTA countries 
were S. Enteritidis and S. Typhimurium, representing 
57 % and 25 %, respectively, of all known serotypes 
(Table 2.3.13). The number of cases with S. Enteritidis 
decreased by 24 % compared with 2008, while cases 
with S. Typhimurium decreased by 12 %.
Table 2.3.12. Number and rate of salmonellosis cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 2 775 2 775 33.2 2 312 27.8 3 386 40.9 4 787 58.0
Belgium Y C 3 113 3 113 29.2 3 831 35.9 3 915 37.0 3 630 34.5
Bulgaria Y A 1 315 1 247 16.4 1 516 19.8 1 136 14.8 1 056 13.7
Cyprus Y C  134  134 16.8  169 21.4  158 20.3  99 12.9
Czech Republic Y C 10 670 10 480 100.1 10 707 103.1 17 655 171.6 24 186 235.9
Denmark Y C 2 130 2 130 38.6 3 669 67.0 1 648 30.3 1 662 30.6
Estonia Y C  261  261 19.5  647 48.2  428 31.9  453 33.7
Finland Y C 2 329 2 329 43.7 3 126 59.0 2 738 51.9 2 576 49.0
France Y C 7 153 7 153 11.1 7 186 11.2 5 313 8.3 6 008 9.5
Germany Y C 31 395 31 395 38.3 42 885 52.2 55 399 67.3 52 575 63.8
Greece Y C  409  403 3.6  795 7.1  706 6.3  890 8.0
Hungary Y C 6 029 5 873 58.5 6 637 66.1 6 578 65.3 9 389 93.2
Ireland Y C  336  335 7.5  447 10.2  440 10.2  420 10.0
Italy Y C 4 156 4 156 6.9 6 662 11.2 6 731 11.4 6 272 10.7
Latvia Y A  816  795 35.2 1 229 54.1  619 27.1  781 34.0
Lithuania Y C 2 063 2 063 61.6 3 308 98.3 2 270 67.1 - -
Luxembourg Y C  162  162 32.8  153 31.6  163 34.2  308 65.7
Malta Y C  125  125 30.2  161 39.2  85 20.8  63 15.6
Netherlands(a) N C 1 205 1 205 - 1 627 - 1 224 - 1 644 10.1
Poland Y A 8 964 8 521 22.3 9 148 24.0 11 155 29.3 12 502 32.8
Portugal Y C  222  220 2.1  332 3.1  438 4.1  387 3.7
Romania Y C 1 115 1 105 5.1 624 2.9 620 2.9  645 3.0
Slovakia Y C 4 515 4 182 77.3 6 849 126.8 8 367 155.1 8 191 152.0
Slovenia Y C  616  616 30.3 1 033 51.4 1 336 66.5 - -
Spain(b) N C 4 304 4 304 - 3 833 - 3 842 - 5 117 -
Sweden Y C 3 054 3 054 33.0 4 185 45.6 3 930 43.1 4 056 44.8
United Kingdom Y C 10 479 10 479 17.1 11 511 18.8 13 557 22.3 14 124 23.4
EU total - - 109 845 108 615 23.6(c) 134 582 29.6(c) 153 837 34.2(c) 161 821 35.3(c)
Iceland Y C  35  35 11.0  134 42.5  93 30.2  114 38.0
Liechtenstein - - - - -  0.0  1 2.8 - -
Norway Y C 1 235 1 235 25.7 1 941 41.0 1 649 35.2 1 813 39.1
Total - - 111 115 109 885 23.6(c) 136 657 29.7(c) 155 580 34.2(c) 163 748 35.3(c)
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed. (a) Coverage by the Dutch sentinel system is 
about 64 %. (b) Surveillance system currently estimated to cover 25 % of the total population. (c) Rates calculated excluding the Dutch and Spanish data.
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Discussion
The large decrease of salmonellosis at the EU/EEA level 
continued in 2009. This statistically significant decreas-
ing trend has been observed during the last four and 
even five years1. This is most likely due to the increasing 
implementation of control measures against Salmonella 
within the poultry industry, especially vaccination of lay-
ing hens and broilers. The large decrease observed espe-
cially in S. Enteritidis cases supports this observation. 
Salmonellosis, however, continued to have a high con-
firmed case rate in the EU and EEA/EFTA countries (23.6 
per 100 000 population), and Salmonella was the cause 
of a large number of food-borne outbreaks at national 
level in 2009. During the year, 1 454 outbreaks, and of 
these 324 verified with 4 500 cases, were reported by 
the EU/EEA countries1.  
Among the multinational outbreaks detected was an 
extensive outbreak of S. Goldcoast involving six EU coun-
tries2. The outbreak evolved into two branches – one 
Figure 2.3.35. Rates of reported confirmed salmonellosis cases, by age and gender, in EU and EEA/EFTA countries, 
2009
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Figure 2.3.36. Seasonal distribution of reported confirmed cases of salmonellosis, in EU and EEA/EFTA countries, 
2006–09
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Source: Country reports: Austria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Luxembourg, 
Malta, Norway, Portugal, Slovakia, Sweden, United Kingdom.
travel-related and one possibly linked to pig trade, as 
a variety of pork products were involved. Another large 
multinational outbreak with S. Typhimurium definitive 
type (DT) 191a was also identified in 2009 with over 200 
cases in the United Kingdom and more than 30 cases in 
the United States, where the outbreak continued into 
20103,4,5. Most of the cases were children and the source 
was eventually found to be frozen feeder mice for rep-
tiles imported from the United States. The most common 
monophasic S. Typhimurium overall in the EU during 
2009 was DT193, which continued to increase in several 
Member States, with several outbreaks reported6.   
An overview of the food- and waterborne outbreaks due 
to Salmonella infections in 2010 reported through EPIS 
can be found in Chapter 3.
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Denmark DK-LAB Cp Co P C Y N N N Y
Estonia EE-SALMONELLOSIS Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y N N N Y
France FR-NATIONAL_REFERENCE_CENTRES V Co P C Y N N N Y
Germany DE-SURVNET@RKI-7.1 Cp Co P C Y N N Y Y
Greece GR-NOTIFIABLE_DISEASES Cp Co P C Y Y Y N Y
Hungary HU-Zoonoses Cp Co P C Y Y Y N Y
Iceland IS-SUBJECT_TO_REGISTRATION Cp Co P C Y Y Y N Y
Ireland IE-CIDR Cp Co P C Y Y Y N Y
Italy IT-NRS Cp Co P C Y Y Y N Y
Latvia LV-BSN Cp Co P C Y Y Y N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Luxembourg LU-LNS-Microbio V Co P C Y N Y N Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y Y Y
Netherlands NL-LSI V Se P C Y N N N N
Netherlands NL-OSIRIS Cp Co P C Y Y N Y Y
Norway NO-MSIS_A Cp Co P C Y Y Y N Y
Poland PL-NATIONAL_SURVEILLANCE Cp Co P C Y Y Y N Y
Portugal PT-SALMONELLOSIS Cp Co P C N Y N N Y
Romania RO-RNSSy Cp Co P C Y N Y N Y
Slovakia SK-EPIS Cp Co A C Y Y Y Y Y
Slovenia SI-SURVIVAL Cp Co P C Y Y Y N Y
Spain ES-MICROBIOLOGICAL V Se P C Y N N N N
Sweden SE-SMINET Cp Co P C Y N N N Y
United Kingdom UK-SALMONELLOSIS O Co P C Y N Y Y Y
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Shigellosis
• In 2009, the confirmed case rate of shigellosis in 
Europe was 1.63 cases per 100 000 population.
• Shigellosis continues to be most prevalent in chil-
dren under five years old.
• Travel-associated cases, predominantly to 
regions outside of EU/EEA, were more frequently 
reported than indigenous cases.
Shigellosis is a relatively uncommon infection in the 
EU, caused by bacterial of the genus Shigella. However 
infections can sometimes cause severe illness and 
death, and outbreaks may occur. Humans are the only 
significant reservoir. Transmission occurs by the faecal-
oral route, either through person-to-person contact, or 
through contaminated food or water. 
Epidemiological situation in 2009
In 2009, 7 261 confirmed shigellosis cases were reported 
in 28 EU and EEA/EFTA countries, similar to the num-
bers reported in 2008 (7 258) (Table 2.3.14). Shigellosis 
remains a relatively uncommon infection; the overall 
EU confirmed case rate was 1.63 cases per 100 000 
population in 2009. Bulgaria reported the highest con-
firmed case rate with 9.87 cases per 100 000 followed 
by Slovakia with 6.84 and Sweden with 5.07 cases per 
100 000 (Table 2.3.14). Cases reported from France 
increased due to changes in reporting arrangements.  
Sixteen countries provided information on travel asso-
ciation for 2 583 cases. Of those, 1 590 were imported 
(62 %) compared with 993 indigenous infections (38 %). 
This is a higher proportion of indigenous infections com-
pared to 2008 (22 %) but could be the result of more 
countries reporting geographical origin of their cases. 
Table 2.3.14. Number and rate of shigellosis cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 80 80 0.96 120 1.44 136 1.64 77 0.93
Belgium Y C 348 348 3.26 418 3.92 330 3.12 - -
Bulgaria Y A 754 751 9.87 1 094 14.32 1 072 13.96 879 11.39
Cyprus Y C 2 2 0.25 1 0.13 0 0.00 2 0.26
Czech Republic Y C 178 177 1.69 227 2.19 331 3.22 276 2.69
Denmark Y C 106 106 1.92 90 1.64 - - - -
Estonia Y C 52 52 3.88 69 5.15 114 8.49 53 3.94
Finland Y C 118 118 2.22 124 2.34 112 2.12 74 1.41
France Y C 1 042 1 042 1.62 517 0.81 827 1.30 - -
Germany Y C 617 617 0.75 575 0.70 867 1.05 814 0.99
Greece Y C 37 37 0.33 19 0.17 49 0.44 26 0.23
Hungary Y C 42 42 0.42 43 0.43 62 0.62 73 0.72
Ireland Y C 71 71 1.60 63 1.43 43 1.00 53 1.26
Italy - - - - - - - - - - -
Latvia Y C 68 66 2.92 102 4.49 73 3.20 73 3.18
Lithuania Y A 37 37 1.10 81 2.41 150 4.43 0 0.00
Luxembourg Y C 18 18 3.65 9 1.86 8 1.68 13 2.77
Malta Y C 1 1 0.24 3 0.73 0 0.00 0 0.00
Netherlands Y C 465 438 2.66 343 2.09 359 2.19 248 1.52
Poland Y A 30 21 0.06 31 0.08 53 0.14 30 0.08
Portugal Y C 3 3 0.03 7 0.07 12 0.11 1 0.01
Romania Y C 414 414 1.93 371 1.72 733 3.40 559 2.59
Slovakia Y C 404 370 6.84 446 8.26 525 9.73 436 8.09
Slovenia Y C 42 42 2.07 44 2.19 39 1.94 36 1.80
Spain Y(a) C 216 216 0.47 133 - 119 - 148 -
Sweden Y C 469 469 5.07 596 6.49 470 5.16 429 4.74
United Kingdom Y C 1 568 1 568 2.56 1 595 2.61 1 746 2.87 1 425 2.36
EU total - - 7 182 7 106 1.62 7 121 1.78(b) 8 230 2.10(b) 5 725 1.79(b)
Iceland Y C 2 2 0.63 3 0.95 2 0.65 0 0.00
Liechtenstein - - - - - - - - - - -
Norway Y C 153 153 3.19 134 2.83 148 3.16 138 2.97
Total - - 7 337 7 261 1.63 7 258 1.79(b) 8 380 2.11(b) 5 863 1.81(b)
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed. (a) Surveillance system changed to full national 
coverage in 2009 compared to previously estimated coverage of 25 % of the population. (b) Rates calculated excluding the Spanish data.
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Ninety-six per cent of imported cases were associated 
with travel to non-EU/EEA countries with the highest 
number of cases linked to travel to Egypt (493), followed 
by India (231) and Morocco (70).
Age and gender distribution
As in previous years, the highest confirmed case rate 
was among children aged 0–4 years with 4.1 cases per 
100 000. This figure was, however, substantially lower 
than in 2008 (9.0), mainly because Bulgaria, which 
normally reports very high notification rates in this age 
group, was not included in the 2009 rates (since it was 
not possible to distinguish the confirmed cases from the 
aggregated reporting). In addition, France and Spain, 
two countries with very large population but relatively 
low notification rates in this age group, were included 
in 2009. Slovakia reported the highest confirmed case 
rate, 69 cases per 100 000, in this age group. 
There was a higher rate of confirmed cases reported in 
women (1.7 cases per 100 000) than in men (1.6 cases 
per 100 000); male-to-female ratio was 0.91:1 (based on 
6 403 cases for which this information was provided) 
(Figure 2.3.38). 
Seasonality
Shigellosis cases in the EU/EEA area normally follow a 
seasonal pattern with most cases reported in late sum-
mer/early autumn, peaking in September. The season-
ality in 2009 differed from previous ones with more 
cases being reported in January and two smaller peaks 
observed in July and September (Figure 2.3.39).
Discussion
As in previous years, the highest confirmed case rate 
occurred in children under five. Even though travel-
related cases to countries outside of Europe are the 
most common, a considerable proportion of cases are 
also indigenous. In April to May and May to June, first 
Denmark1 and then Norway2 and Sweden3 experienced 
shigellosis outbreaks from sugar peas imported from 
Kenya, involving in total over 70 cases. 
Figure 2.3.37. Trend and number of reported confirmed shigellosis cases by month, in EU and EEA/EFTA countries, 
2006–09
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Source: Country reports: Austria, Cyprus, Czech Republic, Finland, Germany, Greece, Hungary, Iceland, Ireland, Luxembourg, Malta, Netherlands, Norway, Portugal, 
Slovakia, Slovenia, Spain, Sweden, United Kingdom. 
Figure 2.3.38. Rates of reported confirmed shigellosis cases, by age and gender, in EU and EEA/EFTA countries, 2009
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Figure 2.3.39. Seasonal distribution of reported confirmed cases of shigellosis, in EU and EEA/EFTA countries, 
2006–09
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Austria AT-Epidemiegesetz Cp Co P C Y Y Y Y Y
Belgium BE-REFLAB V Co P C Y N N N Y
Bulgaria BG-NATIONAL_SURVEILLANCE Cp Co P A Y Y Y Y Y
Cyprus CY-NOTIFIED_DISEASES Cp Co P C N Y N N Y
Czech Republic CZ-EPIDAT Cp Co A C - Y Y N Y
Denmark DK-MIS Cp Co P C N Y N N Y
Estonia EE-PERTUSSIS/SHIGELLOSIS/SYPHILIS Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y Y N N Y
France FR-NATIONAL_REFERENCE_CENTRES V Co P C Y N N N Y
Germany DE-SURVNET@RwKI-7.1 Cp Co P C Y N N Y Y
Greece GR-NOTIFIABLE_DISEASES Cp Co P C Y Y Y N Y
Hungary HU-EFRIR Cp Co P C Y Y Y N Y
Iceland IS-SUBJECT_TO_REGISTRATION Cp Co P C Y Y Y N Y
Ireland IE-CIDR Cp Co P C Y Y Y N Y
Latvia LV-BSN Cp Co P C Y Y Y N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Luxembourg LU-LNS-Microbio V Co P C Y N Y N Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y Y Y
Netherlands NL-OSIRIS Cp Co P C Y Y N Y Y
Norway NO-MSIS_A Cp Co P C Y Y Y N Y
Poland PL-NATIONAL_SURVEILLANCE Cp Co P C Y Y Y N Y
Portugal PT-SHIGELLOSIS Cp Co P C N Y N N Y
Romania RO-RNSSy Cp Co P C Y N Y N Y
Slovakia SK-EPIS Cp Co A C Y Y Y Y Y
Slovenia SI-SURVIVAL Cp Co P C Y Y Y N Y
Spain ES-STATUTORY_DISEASES Cp Co P C N Y N N Y
Sweden SE-SMINET Cp Co P C Y N N N Y
United Kingdom UK-SHIGELLOSIS O Co P C Y N Y Y Y
2. Heier BT, Nygard K, Kapperud G, Lindstedt BA, Johannessen GS, 
Blekkan H. Shigella sonnei infections in Norway associated with 
sugar peas, May–June 2009. Euro Surveill. 2009;14(24):pii=19243. 
3. Löfdahl M, Ivarsson S, Andersson S, Långmark J, Plym-Forshell 
L. An outbreak of Shigella dysenteriae in Sweden, May–June 
2009, with sugar snaps as the suspected source. Euro Surveill. 
2009;14(28):pii=19.
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Toxoplasmosis (congenital)
• Toxoplasmosis remains a rare disease in EU and 
EEA/EFTA countries.
• In 2009, 26 congenital toxoplasmosis cases were 
reported by 18 EU countries. 
• Nine EU countries do not conduct surveillance for 
toxoplasmosis.
Toxoplasmosis is an infection with the protozoan para-
site Toxoplasma gondii. Cats are the primary host for the 
parasite, and humans are infected by ingestion of the 
oocysts. Toxoplasmosis is mild or without symptoms for 
most individuals, but infection in early pregnancy can 
result in stillbirth, abnormality or severe illness in the 
newborn baby.  
Due to the change in the EU case definition for toxoplas-
mosis in 2008, only congenital cases are required to be 
reported from 2009 onwards. This section, therefore, 
reports only data from cases < 1 year of age.
Epidemiological situation in 2009
In 2009, 27 congenital toxoplasmosis cases (26 con-
firmed) were reported by 18 EU Member States. Ten 
countries reported zero cases (Table 2.3.15). While the 
United Kingdom reported the most cases, Hungary and 
Slovenia had the highest confirmed case rates (0.06 and 
0.05 per 100 000 population). The overall EU confirmed 
case rate was 0.01 per 100 000 population, which is the 
same as the previous three years.
Table 2.3.15. Number and rate of congenital toxoplasmosis cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 1 1 0.01 0 0.00 1 0.01 - -
Belgium - - - - - - - - - - -
Bulgaria Y C 0 0 0.00 - - - - - -
Cyprus Y C 0 0 0.00 0 0.00 0 0.00 - -
Czech Republic Y C 2 2 0.02 2 0.02 1 0.01 2 0.02
Denmark - - - - - - - - - - -
Estonia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Finland Y C 0 0 0.00 0 0.00 1 0.02 0 0.00
France - - - - - - - - - - -
Germany - - - - - - - - - - -
Greece - - - - - - - - - - -
Hungary Y C 6 6 0.06 1 0.01 - - 1 0.01
Ireland Y C 0 0 0.00 2 0.05 2 0.05 6 0.14
Italy - - - - - - - - - - -
Latvia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Lithuania Y A 0 0 0.00 0 0.00 0 0.00 0 0.00
Luxembourg Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Malta Y C 0 0 0.00 0 0.00 0 0.00 - -
Netherlands - - - - - - - - - - -
Poland Y C 3 3 0.01 8 0.02 8 0.02 7 0.02
Portugal - - - - - - - - - - -
Romania Y C 3 2 0.01 - - - - - -
Slovakia Y C 0 0 0.00 0 0.00 2 0.04 1 0.02
Slovenia Y C 1 1 0.05 0 0.00 2 0.10 2 0.10
Spain(a) N C 1 1 - 1 - 0 - 1 -
Sweden - - - - - 0 0.00 0 0.00 - -
United Kingdom Y C 10 10 0.02 5 0.01 3 0.00 0 0.00
EU Total - - 27 26 0.01(b) 19 0.01(b) 20 0.01(b) 20 0.01(b)
Iceland - - - - - 0 0.00 0 0.00 - -
Liechtenstein - - - - - - - - - - -
Norway - - - - - - - - - - -
Total - - 27 26 0.01(b) 19 0.01(b) 20 0.01(b) 20 0.01(b)
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed. (a) Surveillance system currently estimated to 
cover 25 % of the total population. (b) Rates calculated excluding the Spanish data.
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Gender distribution
Congenital cases were defined as those < 1 year of age. 
Information on age in months is not yet collected. Data 
on gender were available for all 26 confirmed cases. Of 
these, 10 cases were male and 16 were female, giving a 
male-to-female ratio of 0.7:1.
Discussion
Congenital toxoplasmosis is a rare disease in the EU1,2,3 
but can result in very severe outcomes, e.g. abortion or 
congenital lesions in child’s brains, eyes or other organs, 
particularly if the mother acquires her primary infection 
during the first trimester of pregnancy.
By harmonising the reporting at EU level to only congeni-
tal cases, it is possible to get a clearer overview of the 
disease situation in the EU to better assess the disease 
burden. Nine Member States, however, do not currently 
conduct surveillance for toxoplasmosis.
References
1. Villena I, Ancelle T, Delmas C, et al. for Toxosurv network and 
National Reference Centre for Toxoplasmosis. Congenital toxoplas-
mosis in France in 2007: ﬁ rst results from a national surveillance 
system. Euro Surveill. 2010 Jun 24;15(25). pii: 19600.
2. Hofhuis A, van Pelt W, van Duynhoven YT, et al. Decreased preva-
lence and age-speciﬁ c risk factors for Toxoplasma gondii IgG an-
tibodies in the Netherlands between 1995/1996 and 2006/2007. 
Epidemiol Infect 2011 Apr;139(4):530-8. Epub 2010 May 24.
3. Ajzenberg D. Unresolved questions about the most successful 
known parasite. Expert Rev Anti Infect Ther 2011 Feb;9(2):169-71.
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Austria AT-Reflab V O P C Y N N N Y
Bulgaria BG-NATIONAL_SURVEILLANCE Cp Co P A Y Y Y Y Y
Cyprus CY-NOTIFIED_DISEASES Cp Co P C N Y N N Y
Czech Republic CZ-EPIDAT Cp Co A C - Y Y N Y
Estonia EE-TOXOPLASMOSIS Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y N N N Y
France FR-NATIONAL_REFERENCE_CENTRES V Co P C Y N N N -
Hungary HU-Zoonoses Cp Co P C Y Y Y N Y
Ireland IE-CIDR Cp Co P C Y Y Y N Y
Latvia LV-BSN Cp Co P C Y Y Y N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Luxembourg LU-SYSTEM1 Cp Co P C Y Y N N Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y Y Y
Poland PL-NATIONAL_SURVEILLANCE Cp Co P C N Y Y N Y
Romania RO-RNSSy Cp Co P C Y N Y N Y
Slovakia SK-EPIS Cp Co A C Y Y Y N Y
Slovenia SI-SURVIVAL Cp Co P C Y Y Y N Y
Spain ES-MICROBIOLOGICAL V Se P C Y N N N N
Sweden SE-SMINET Cp Co P C Y N N N Y
United Kingdom UK-TOXOPLASMOSIS V Co P C Y N Y Y Y
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Trichinellosis
• Trichinellosis remains an uncommon disease in 
the EU/EEA overall. In 2009, the confirmed case 
rate of trichinellosis was 0.15 cases per 100 000 
population (750 cases).
• Bulgaria and Romania accounted for 90 % of all 
confirmed cases reported.
• Confirmed cases in 2009 were most common in 
adults of both sexes (15–64 years).
Trichinellosis is a disease caused by infection with the 
intestinal nematode Trichinella spiralis. A wide range 
of animals act as hosts, like pigs (including wild boar), 
dogs, cats and horses. Infection in humans occurs 
through ingesting the larvae through eating undercooked 
meat of infected animals. The infection is uncommon in 
the EU, but occurs more frequently in some countries 
associated with the consumption of wild boar.
Epidemiological situation in 2009 
In 2009, 750 confirmed cases of human trichinellosis 
were reported by 26 of the 30 EU and EEA/EFTA coun-
tries. The overall confirmed case rate was 0.15 cases per 
100 000. The rate of confirmed cases has been relatively 
stable over the 2006–09 period (Table 2.3.16). Bulgaria 
and Romania accounted for 89 % of the total number of 
confirmed cases reported in the EU in 2009.
The highest confirmed case rate was reported in 25–44 
year-old males (0.1 cases per 100 000 population) fol-
lowed by 15–24 year-old males (0.9 cases per 100 000 
population) (Figure 2.3.40). There were eight reported 
Table 2.3.16. Number and rate of trichinellosis cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 0 0 0.00 0 0.00 0 0.00 1 0.01
Belgium Y C 0 0 0.00 5 0.05 3 0.03 0 0.00
Bulgaria Y A 443 407 5.35 67 0.88 62 0.81 180 2.33
Cyprus Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Czech Republic Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Denmark - - - - - - - - - 0 0.00
Estonia Y C 1 0 0.00 0 0.00 0 0.00 0 0.00
Finland Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
France Y C 9 9 0.01 3 0.00 1 0.00 10 0.02
Germany Y C 1 1 0.00 1 0.00 10 0.01 22 0.03
Greece Y C 2 2 0.02 0 0.00 0 0.00 0 0.00
Hungary Y C 9 9 0.09 5 0.05 2 0.02 - -
Ireland Y C 0 0 0.00 0 0.00 2 0.05 0 0.00
Italy Y C 1 1 0.00 0 0.00 1 0.00 1 0.00
Latvia Y C 9 9 0.40 4 0.18 4 0.18 11 0.48
Lithuania Y A 115 20 0.60 31 0.92 8 0.24 0 0.00
Luxembourg Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Malta Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Netherlands Y C 1 1 0.01 1 0.01 0 0.00 0 0.00
Poland Y C 36 18 0.05 4 0.01 217 0.57 89 0.23
Portugal Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Romania Y C 440 265 1.23 503 2.34 432 2.00 350 1.62
Slovakia Y C 0 0 0.00 18 0.33 8 0.15 5 0.09
Slovenia Y C 1 1 0.05 1 0.05 0 0.00 1 0.05
Spain Y C 7 7 0.02 27 0.06 36 0.08 18 0.04
Sweden Y C 0 0 0.00 0 0.00 1 0.01 0 0.00
United Kingdom Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
EU total - - 1 075 750 0.15 670 0.14 787 0.16 688 0.14
Iceland - - - - - - - - - 0 0.00
Liechtenstein - - - - - 0 0.00 - - - -
Norway Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Total - - 1 075 750 0.15 670 0.13 787 0.16 688 0.14
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
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confirmed cases of trichinellosis (five female and three 
male) in 0–4 year old children in Romania.
Seasonality
In 2009, reported cases of trichinellosis occurred mainly 
from January to March. It should be noted, however, that 
this figure is based on countries other than Bulgaria and 
Romania, the main reporters of these infections, as they 
do not provide data on occurrence by month.
Discussion
Trichinellosis is an uncommon but serious human dis-
ease that is still present in the EU. The majority of 
these cases occurred in four Member States: Bulgaria, 
Latvia, Lithuania and Romania. The human cases in 
these countries may be associated with traditional 
practices such as raising pigs in backyards for private 
consumption, and wild boar hunting. The risk with such 
practices is that meat may not have a veterinary inspec-
tion for trichinella, increasing the risk of infection and 
outbreaks. 
In 2009, there were 31 household-associated out-
breaks in Romania and a large outbreak associated to 
consumption of sausages made from wild boar meat in 
Lithuania1,2.
References
1. Bartuliene A, Liausediene R, Motiejuniene V. Trichinellosis out-
break in Lithuania, Ukmerge region, June 2009. Euro Surveill 
2009;14(38):pii=19336.
2 European Food Safety Authority (EFSA). The Community Summary 
Report on Trends and Sources of Zoonoses and Zoonotic Agents and 
Food-borne Outbreaks in the European Union in 2009. EFSA Journal 
2011;9(3):2090 [378 pp.]. doi:10.2903/j.efsa.2011.2090.
Figure 2.3.40. Rates of reported confirmed trichinellosis cases, by age and gender, in EU and EEA/EFTA countries, 
2009
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Spain, United Kingdom.
Figure 2.3.41. Seasonal distribution of reported confirmed cases of trichinellosis, in EU and EEA/EFTA countries, 
2006–09
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Source: Country reports: Cyprus, Czech Republic, Estonia, Finland, France, Greece, Hungary, Ireland, Italy, Latvia, Luxembourg, Malta, Netherlands, Norway, Poland, 
Portugal, Slovakia, Slovenia, Sweden, United Kingdom.
112
SURVEILLANCE REPORTAnnual epidemiological report 2011
Surveillance systems overview
Country Data Source
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Austria AT-Epidemiegesetz Cp Co P C Y Y Y Y Y
Belgium BE-FLA_FRA Cp Co P C Y Y Y Y Y
Bulgaria BG-NATIONAL_SURVEILLANCE Cp Co P A Y Y Y Y Y
Cyprus CY-NOTIFIED_DISEASES Cp Co P C N Y N N Y
Czech Republic CZ-EPIDAT Cp Co A C - Y Y N Y
Estonia EE-A NT H/CHOL/DIPH/M A L A/SP OX/
TRIC/TULA/TYPH
Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y N N N Y
France FR-NATIONAL_REFERENCE_CENTRES V Co P C Y N N N Y
Germany DE-SURVNET@RKI-7.1 Cp Co P C Y N N Y Y
Greece GR-NOTIFIABLE_DISEASES Cp Co P C Y Y Y N Y
Hungary HU-Zoonoses Cp Co P C Y Y Y N Y
Ireland IE-CIDR Cp Co P C Y Y Y N Y
Italy IT-NRS Cp Co P C Y Y Y N Y
Latvia LV-BSN Cp Co P C Y Y Y N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Luxembourg LU-SYSTEM1 Cp Co P C Y Y N N Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y Y Y
Netherlands NL-OSIRIS Cp Co P C Y Y N Y Y
Norway NO-MSIS_A Cp Co P C Y Y Y N Y
Poland PL-NATIONAL_SURVEILLANCE Cp Co P C N Y Y N Y
Portugal PT-TRICHINOSIS Cp Co P C N Y N N Y
Romania RO-RNSSy Cp Co P C Y N Y N Y
Slovakia SK-EPIS Cp Co A C Y Y Y N Y
Slovenia SI-SURVIVAL Cp Co P C Y Y Y N Y
Spain ES-STATUTORY_DISEASES Cp Co P C N Y Y N Y
Sweden SE-SMINET Cp Co P C Y N N N Y
United Kingdom UK-TRICHINOSIS V Co P C Y N Y Y Y
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Tularaemia
• The confirmed case rate of tularaemia has 
remained stable since 2008.
• As observed in previous years, males older than 
24 years of age were primarily affected by the 
disease. 
• In 2009, no large outbreaks of tularaemia were 
reported.
Tularaemia is a disease caused by infection with the 
bacterium Francisella tularensis. It is a relatively uncom-
mon disease in the EU. Many wild animals host the bac-
terium, and transmission to humans is usually through 
the bite of an infected tick or mosquito. The disease 
can occasionally be fatal if untreated, but this is rare in 
Europe with good antibiotic treatment.
Epidemiological situation in 2009
In 2009, 838 confirmed cases (853 in total) of tularae-
mia were reported from 26 countries (Table 2.3.17). The 
total number is slightly lower than the number of cases 
reported for the previous two years. Finland reported the 
highest confirmed case rate (7.60 per 100 000 popula-
tion), followed by Sweden (2.64) and the Czech Republic 
(0.61). For all other countries, confirmed case rates were 
< 0.5 per 100 000. The overall confirmed case rate was 
0.18 cases per 100 000.
Age and gender distribution
Ten countries provided information on the age and 
gender of their cases. Out of the 838 confirmed cases 
with gender information, 522 (62 %) were males and 316 
were females (male-to-female ratio 1.7:1). As in previ-
ous years, the highest confirmed case rate occurred in 
Table 2.3.17. Number and rate of reported confirmed tularaemia cases in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 2 2 0.02 8 0.10 4 0.05 6 0.07
Belgium Y C 0 0 0.00 0 0.00 - - 0 0.00
Bulgaria Y A 7 7 0.09 3 0.04 3 0.04 14 0.18
Cyprus Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Czech Republic Y C 64 64 0.61 109 1.05 51 0.50 79 0.77
Denmark - - - - - - - - - - -
Estonia Y C 0 0 0.00 1 0.07 2 0.15 0 0.00
Finland Y C 405 405 7.60 116 2.19 403 7.64 0 0.00
France Y C 31 16 0.02 104 0.16 48 0.08 24 0.04
Germany Y C 10 10 0.01 15 0.02 20 0.02 1 0.00
Greece Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Hungary Y C 38 38 0.38 25 0.25 20 0.20 139 1.38
Ireland Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Italy Y C 2 2 0.00 43 0.07 0 0.00 2 0.00
Latvia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Lithuania Y A 1 1 0.03 2 0.06 1 0.03 0 0.00
Luxembourg Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Malta Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Netherlands - - - - - - - - - - -
Poland Y C 1 1 0.00 0 0.00 1 0.00 0 0.00
Portugal - - - - - - - - - - -
Romania Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Slovakia Y C 22 22 0.41 25 0.46 11 0.20 49 0.91
Slovenia Y C 1 1 0.05 2 0.10 1 0.05 1 0.05
Spain Y C 12 12 0.03 58 0.13 493 1.11 1 0.00
Sweden Y C 244 244 2.64 382 4.16 174 1.91 241 2.66
United Kingdom Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
EU total - - 840 825 0.18 893 0.19 1 232 0.27 557 0.12
Iceland Y C 0 0 0.00 0 0.00 - - - -
Liechtenstein - - - - - - - - - - -
Norway Y C 13 13 0.27 66 1.39 49 1.05 11 0.24
Total - - 853 838 0.18 959 0.20 1 281 0.28 568 0.12
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
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Figure 2.3.42. Trend and number of reported confirmed tularaemia cases by month, in EU and EEA/EFTA countries, 
2006–09
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Source: Country reports: Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Luxembourg, Malta, Norway, Poland, 
Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom.
Figure 2.3.43. Rates of reported confirmed tularaemia cases, by age and gender, in EU and EEA/EFTA countries, 2009
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Figure 2.3.44. Seasonal distribution of reported confirmed cases of tularaemia, in EU and EEA/EFTA countries, 
2006–09
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the age group 45–64 years for both males and females 
(Figure 2.3.43).
Seasonality
Seasonality data was provided by all countries that 
reported confirmed cases. As for 2006–08, the major-
ity of the cases occur in summer and the early autumn 
months (Figure 2.3.44). 
Discussion
When compared to 2007 and 2008, the number of cases 
of tularaemia reported in 2009 further decreased. There 
is some concern, however, regarding a possible re-emer-
gence of the disease in Germany1. In Finland, the number 
of reported cases increased from 116 in 2008 to 405 in 
2009. An outbreak was reported in Norway in 20112.
References
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Austria AT-Epidemiegesetz Cp Co P C Y Y Y Y Y
Belgium BE-REFLAB V Co P C Y N N N Y
Bulgaria BG-NATIONAL_SURVEILLANCE Cp Co P A Y Y Y Y Y
Cyprus CY-NOTIFIED_DISEASES Cp Co P C N Y N N Y
Czech Republic CZ-EPIDAT Cp Co A C - Y Y N Y
Estonia EE-A NT H/CHOL/DIPH/M A L A/SP OX/
TRIC/TULA/TYPH
Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y N N N Y
France FR-MANDATORY_INFECTIOUS_DISEASES Cp Co P C Y Y Y Y Y
Germany DE-SURVNET@RKI-7.1 Cp Co P C Y N N Y Y
Greece GR-NOTIFIABLE_DISEASES Cp Co P C Y Y Y N Y
Hungary HU-EFRIR Cp Co P C Y Y Y N Y
Iceland IS-SUBJECT_TO_REGISTRATION Cp Co P C Y Y Y N Y
Ireland IE-CIDR Cp Co P C Y Y Y N Y
Italy IT-NRS Cp Co P C Y Y Y N Y
Latvia LV-BSN Cp Co P C Y Y Y N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Luxembourg LU-SYSTEM1 Cp Co P C Y Y N N Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y Y Y
Norway NO-MSIS_A Cp Co P C Y Y Y N Y
Poland PL-NATIONAL_SURVEILLANCE Cp Co P C Y Y Y N Y
Romania RO-RNSSy Cp Co P C N N Y N Y
Slovakia SK-EPIS Cp Co A C Y Y Y N Y
Slovenia SI-SURVIVAL Cp Co P C Y Y Y N Y
Spain ES-STATUTORY_DISEASES Cp Co P C N Y Y N Y
Sweden SE-SMINET Cp Co P C Y N N N Y
United Kingdom UK-TULARAEMIA V Co P C Y N Y Y Y
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Typhoid/paratyphoid fever
• In 2009, 1 349 cases of typhoid and paratyphoid 
fever were reported in the EU/EEA region.
• Over 80 % of cases were imported, mainly from 
South Asian countries.
• Salmonella Paratyphi A was the most common 
serotype identified in cases of paratyphoid fever.
These systemic bacterial diseases are caused by infec-
tion with Salmonella typhi, or Salmonella enterica. 
Humans can be short- or long-term carriers of these bac-
teria; transmission is by the faecal-oral route, through 
person-to-person contact or water or food contamina-
tion. The infection is uncommon in the EU/EEA and the 
majority of cases occur in travellers returning from coun-
tries where the disease is endemic.
Epidemiological situation in 2009
In 2009, 1 347 confirmed cases (total 1 349) of human 
typhoid or paratyphoid cases were reported by 25 EU 
Member States plus Iceland and Norway, with a con-
firmed case rate of 0.29 per 100 000 population (Table 
2.3.18). The number of cases and confirmed case rates 
has been fairly stable over the last four years except for 
2007 when the numbers were markedly lower. This was 
most likely due to the change implemented between 
2006 and 2007 in the way these cases were reported to 
the European Surveillance System (TESSy)i. 
A high proportion (84 %) of cases was imported among 
the 495 for which this information was provided. The 
i The change meant that rather than being reported as separate 
diseases, typhoid and paratyphoid cases should now be reported 
under salmonellosis.
Table 2.3.18. Number and confirmed case rates of typhoid and paratyphoid cases in EU and EEA/EFTA countries, 
2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 0 0 0.00 14 0.17 0 0.00 17 0.21
Belgium Y C 104 104 0.97 61 0.57 42 0.40 - -
Bulgaria - - - - - - - - - 0 0.00
Cyprus Y C 4 4 0.50 5 0.63 1 0.13 0 0.00
Czech Republic Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Denmark Y C 17 17 0.31 19 0.35 14 0.26 0 0.00
Estonia Y C 3 3 0.22 0 0.00 2 0.15 1 0.07
Finland Y C 9 9 0.17 6 0.11 20 0.38 0 0.00
France Y C 264 264 0.41 236 0.37 167 0.26 165 0.26
Germany Y C 141 141 0.17 179 0.22 0 0.00 148 0.18
Greece Y C 4 4 0.04 1 0.01 18 0.16 15 0.13
Hungary Y C 0 0 0.00 3 0.03 0 0.00 2 0.02
Ireland Y C 17 17 0.38 13 0.30 12 0.28 9 0.21
Italy Y C 116 116 0.19 120 0.20 182 0.31 219 0.37
Latvia Y C 0 0 0.00 0 0.00 1 0.04 0 0.00
Lithuania Y C 0 0 0.00 2 0.06 - - 0 0.00
Luxembourg Y C 0 0 0.00 1 0.21 0 0.00 0 0.00
Malta Y C 1 1 0.24 0 0.00 0 0.00 0 0.00
Netherlands Y C 62 62 0.38 63 0.38 59 0.36 54 0.33
Poland - - - - - - - - - 5 0.01
Portugal Y C 36 34 0.32 21 0.20 44 0.42 41 0.39
Romania Y C 2 2 0.01 3 0.01 5 0.02 15 0.07
Slovakia Y C 0 0 0.00 0 0.00 1 0.02 3 0.06
Slovenia Y C 2 2 0.10 5 0.25 10 0.50 5 0.25
Spain Y C 26 26 0.06 21 0.05 33 0.07 44 0.10
Sweden Y C 38 38 0.41 49 0.53 47 0.52 12 0.13
United Kingdom Y C 503 503 0.82 596 0.97 20 0.03 547 0.91
EU total - - 1 349 1 347 0.30 1 418 0.31 678 0.15 1 302 0.27
Iceland Y C 0 0 0.00 2 0.63 0 0.00 2 0.67
Liechtenstein - - - - - 0 0.00 0 0.00 - -
Norway Y C 0 0 0.00 0 0.00 0 0.00 36 0.78
Total - - 1 349 1 347 0.29 1 420 0.31 678 0.15 1 340 0.27
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
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three countries that were the most frequently reported 
as probable country of infection were India (153 cases), 
Pakistan (62) and Turkey (57).
Belgium reported the highest confirmed case rate in 
2009 (0.97 per 100 000 population) followed by the 
United Kingdom (0.82 per 100 000).
Age and gender distribution
The highest confirmed case rate (0.74 per 100 000) was 
reported for those under five years of age, followed by 
the 5–14 year-olds (0.48 per 100 000). There was no 
major difference in the overall confirmed case rates of 
males and females (0.30 and 0.27 per 100 000, respec-
tively; ratio: 1.12:1), although females had a slightly 
higher confirmed case rate among the 0–4 and 15–24 
year-olds whilst males had slightly higher rates among 
5–14 year-olds and above 25 years (Figure 2.3.46).
Seasonality
The seasonality for typhoid and paratyphoid fever fol-
lowed that of the previous three years with a clear peak 
in September (Figure 2.3.47). This is most likely related 
to travel patterns to high risk countries, with disease 
reported on return.
Enhanced surveillance
In 2009, 764 cases of typhoid fever and 583 of paraty-
phoid fever were reported. The most common serotype 
of paratyphoid fever was S. Paratyphi A (Table 2.3.19).
Table 2.3.19.  Salmonella enterica serotypes of typhoid 
and paratyphoid cases reported in EU and 
EEA/EFTA countries, 2009
Serotype Number of cases
Typhi 764
Paratyphi A 293
Paratyphi B 200
Paratyphi C 5
Paratyphi (unspecified) 85
Total 1 347
Discussion
Typhoid and paratyphoid fever remain uncommon infec-
tions in the EU and EEA/EFTA countries. The disease is 
mainly associated with travel to endemic areas outside 
of the EU1,2,3. The confirmed case rate is highest in young 
children. The age distribution, however, differs from 
non-typhoid salmonellosis in that the confirmed case 
rates for young adults are higher, which most likely is a 
reflection of the high proportion of travel-related cases.
References
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Figure 2.3.45. Trend and number of reported confirmed typhoid and paratyphoid fever cases by month, in EU and EEA/
EFTA countries, 2006–09
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Figure 2.3.46. Rates of reported confirmed typhoid and paratyphoid fever cases, by age and gender, in EU and EEA/
EFTA countries, 2009
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Figure 2.3.47. Seasonal distribution of reported confirmed cases of typhoid and paratyphoid fever, in EU and EEA/EFTA 
countries, 2006–09
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Surveillance systems overview
Country Data Source
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Cyprus CY-NOTIFIED_DISEASES Cp Co P C N Y N N Y
Czech Republic CZ-EPIDAT Cp Co A C - Y Y N Y
Finland FI-NIDR Cp Co P C Y Y N N Y
France FR-NATIONAL_REFERENCE_CENTRES V Co P C Y N N N Y
Greece GR-NOTIFIABLE_DISEASES Cp Co P C Y Y Y N Y
Iceland IS-SUBJECT_TO_REGISTRATION Cp Co P C Y Y Y N Y
Ireland IE-CIDR - - - - - - - - -
Italy IT-NRS - - - - - - - - -
Latvia LV-BSN Cp Co P C Y Y Y N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y Y Y
Netherlands NL-OSIRIS Cp Co P C Y Y N Y Y
Norway NO-MSIS_A Cp Co P C Y Y Y N Y
Romania RO-RNSSy Cp Co P C Y N Y N Y
Slovakia SK-EPIS Cp Co A C Y Y Y N Y
Slovenia SI-SURVIVAL Cp Co P C Y Y Y N Y
Sweden SE-SMINET Cp Co P C Y N N N Y
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Variant Creutzfeldt–Jakob disease
• Variant Creutzfeldt–Jakob disease (vCJD) remains 
a rare but fatal disease in the EU/EEA.
• Since the peak in the number of reported 
cases (and deaths) in year 2000, the number of 
deaths from vCJD in EU and EEA/EFTA countries 
continues to decline.
Variant Creutzfeldt–Jakob disease (vCJD) is a prion dis-
ease resulting in a fatal encephalopathy. Transmission 
to humans is thought to be through consumption of 
infected beef products; infection through blood transfu-
sion has also been documented.
Epidemiological situation in 2009
In 2009, eight vCJD cases (including two probable cases) 
died in five EU Member States, which is five more than 
the number reported in 2008. Three cases were reported 
by the United Kingdom, two by France and one each in 
the Netherlands, Portugal and Spain. No cases were 
blood donors or recipients of blood or blood prod-
ucts. The overall mortality rate remains low at 0.01 per 
1 000 000 population.
The following EUROCJD (European Creutzfeldt–Jakob 
Disease Surveillance Network) countries reported 
zero deaths in 2009: Austria, Belgium, Cyprus, Czech 
Republic, Denmark, Estonia, Finland, France, Germany, 
Hungary, Greece, Iceland, Ireland, Israel, Italy, Latvia, 
Netherlands, Norway, Poland, Portugal, Slovakia, 
Slovenia, Sweden and Switzerland.
Age and gender distribution
The age of cases ranged between 16 and 54 years. Two 
of the cases were male and six female.
Discussion
Countries throughout Europe continue surveillance of 
vCJD through the collaboration within the EuroCJD net-
work1. Methods for case classification have been har-
monised and the EU case definition is fully adopted 
by all reporting countries. The transmission of vari-
ant CJD through prions in the food to humans has had 
profound political, humanitarian, social and economic 
implications.  
A recent scientific opinion by the European Food Safety 
Authority (EFSA) and ECDC has highlighted the uncer-
tainty related to transmissibility of other animals’ trans-
missible spongiform encephalopathies (TSEs, such as 
atypical scrapie) to humans2.
References
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Yersiniosis
• In 2009, the confirmed case rate of yersinio-
sis in the EU/EEA was 2.02 cases per 100 000 
population.
• There were 7 686 confirmed cases of human yers-
iniosis reported in 2009, decreasing from the 
8 193 cases reported in 2008.
• The highest confirmed case rate was detected 
in 0–4 year-old males, 12.89 cases per 100 000 
population.
Yersiniosis is a disease caused by the bacteria Yersinia 
enterocoliticus or Yersinia pseudotuberculosis. It is not 
an uncommon cause of gastroenteritis (sometimes 
mimicking appendicitis) in a number of EU and EEA/
EFTA countries. Pigs are important reservoirs, and many 
cases are considered to be related to the consumption of 
undercooked infected pork. 
Epidemiological situation in 2009
In 2009, 7 686 confirmed cases of yersiniosis were 
reported by 26 EU and EEA/EFTA countries (overall 
confirmed case rate 2.02 per 100 000 population). As 
in previous years, Germany accounted for the highest 
proportion of reported cases (48.54 %). Lithuania and 
Finland were the countries with the highest confirmed 
case rates, 14.42 and 11.88 cases per 100 000 popula-
tion respectively (Table 2.3.20).
Table 2.3.20. Number and rate of yersiniosis cases in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 140 140 1.68 93 1.12 142 1.71 158 1.91
Belgium Y C 238 238 2.23 273 2.56 248 2.34 264 2.51
Bulgaria Y A 8 8 0.11 10 0.13 8 0.10 5 0.06
Cyprus Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Czech Republic Y C 463 463 4.42 557 5.37 576 5.60 534 5.21
Denmark Y C 238 238 4.32 331 6.04 274 5.03 215 3.96
Estonia Y C 54 54 4.03 42 3.13 76 5.66 42 3.12
Finland Y C 633 633 11.88 608 11.47 480 9.10 795 15.13
France N A 208 208 - 0 - - - - -
Germany Y C 3 731 3 731 4.55 4 352 5.29 4 987 6.06 5 161 6.26
Greece - - - - - - - - - - -
Hungary Y C 51 51 0.51 40 0.40 55 0.55 38 0.38
Ireland Y C 3 3 0.07 3 0.07 6 0.14 1 0.02
Italy Y C 11 11 0.02 - - - - 0 0.00
Latvia Y C 70 66 2.92 50 2.20 41 1.80 92 4.01
Lithuania Y A 483 483 14.42 536 15.92 569 16.81 0 0.00
Luxembourg Y C 36 36 7.29 17 3.51 22 4.62 5 1.07
Malta Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Netherlands - - - - - - - - - - -
Poland Y C 288 288 0.76 214 0.56 182 0.48 111 0.29
Portugal - - - - - - - - - 0 0.00
Romania Y C 32 32 0.15 9 0.04 0 0.00 - -
Slovakia Y C 168 167 3.09 68 1.26 71 1.32 82 1.52
Slovenia Y C 27 27 1.33 31 1.54 32 1.59 79 3.94
Spain N C 291 291 - 315 - 381 - 375 -
Sweden Y C 397 397 4.29 546 5.95 567 6.22 558 6.17
United Kingdom Y C 61 61 0.10 48 0.08 86 0.14 59 0.10
EU total - - 7 631 7 626 2.03 8 143 2.69 8 803 2.91 8 574 2.43
Iceland - - - - - - - - - 0 0.00
Liechtenstein - - - - - 0 0.00 - - - -
Norway Y C 60 60 1.25 50 1.06 71 1.52 86 1.85
Total - - 7 691 7 686 2.02 8 193 2.67 8 874 2.88 8 660 2.42
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
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There has been a significant decreasing trend in the rate 
of confirmed cases of yersiniosis in the EU and EEA/EFTA 
countries over 2006–09 (Figure 2.3.48). By country, con-
firmed case rates decreased significantly in Germany, 
Slovenia, Sweden and Norway, while increasing in 
Luxembourg, Slovakia and Poland.
The gender distribution of confirmed cases for which 
information was provided (n=6 886), was 53.8 % males 
and 46.2 % females. The male-female ratio was 1.2:1 
in 2009. Confirmed case rates were higher for males 
in comparison to females in the age group 0–24 years 
while reminded fairly similar in both gender groups from 
25 years and over. The highest confirmed case rates 
were detected in 0–4 year-old children, both in males 
(11.89 cases per 100 000) and females (10.59 cases per 
100 000) (Figure 2.3.49).
Yersinia enterocolitica was, as in previous years, the 
most common Yersinia species reported in human 
cases, 93.7 % of all confirmed cases in 2009 followed by 
Y. pseudotuberculosis in 1.3 % of cases1.
Seasonality
Cases of yersiniosis were reported throughout the year 
with no marked seasonality. 
Discussion
Human yersiniosis is still a relatively commonly reported 
gastrointestinal disease in Europe although the trend 
is declining. Pigs are considered the main reservoir 
of Yersinia enterocolitica as the bacterium is mainly 
detected in pork meat and pigs1. The most frequent 
route of transmission to humans is consumption of 
undercooked contaminated pork.
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Figure 2.3.48. Trend and number of reported confirmed yersiniosis cases by month, in EU and EEA/EFTA countries, 
2006–09
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Source: Country reports: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, Germany, Hungary, Ireland, Latvia, Luxembourg, Malta, 
Norway, Poland, Portugal, Slovakia, Slovenia, Sweden, United Kingdom. 
Figure 2.3.49. Rates of reported confirmed yersiniosis cases, by age and gender, in EU and EEA/EFTA countries, 2009
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Figure 2.3.50. Seasonal distribution of reported confirmed cases of yersiniosis, in EU and EEA/EFTA countries, 
2006–09
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Norway, Poland, Portugal, Slovakia, Slovenia, Sweden, United Kingdom.
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Romania RO-RNSSy Cp Co P C Y N Y N Y
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Malaria
2.4 Emerging and vector-borne diseases
• The confirmed case rate of malaria reported 
by EU and EEA/EFTA countries remains stable, 
fluctuating around one per 100 000 population.
• 99.5 % of cases (where origin is specified) are 
imported; these are reported by EU and EEA/
EFTA countries that have strong traditional ties 
with endemic areas (France and United Kingdom). 
Greece forms an exception, with nearly 16 % of 
indigenous cases.
Malaria is caused by infection with protozoa of the 
genus Plasmodium, transmitted through the bite of an 
infected mosquito. In the EU almost all cases are seen 
in travellers returning from countries where the disease 
is endemic.
Epidemiological situation in 2009
In 2009, 6 049 confirmed cases of malaria were reported 
by 26 EU and one EEA/EFTA countries in continental 
Europei. Eighty per cent of the cases are reported by four 
countries (France, United Kingdom, Italy and Germany) 
(Table 2.4.1). Highest rates of confirmed cases were 
reported by the United Kingdom (2.4 per 100 000 popu-
lation), Ireland (2.0), the Netherlands (1.4) and Belgium 
(1.3). Data were not available for Denmark, Iceland and 
Liechtenstein.
The overall confirmed case rate was 0.89 per 100 000 
in 2009. The individual country rates varied between 
< 0.1 and 2.44 cases per 100 000 population (United 
Kingdom). These figures are smaller than the ones 
observed in 2008.
Most of the malaria cases are reported as imported – the 
definition of imported cases refers to cases imported to 
continental Europe, and does not include cases reported 
in overseas départements and territories. Information on 
the probable country of infection was not consistently 
i The term ‘continental Europe’ is used to mean EU and EEA/EFTA 
countries on the European continent, i.e. it excludes overseas 
territories, protectorates or départements.
Figure 2.4.1. Trend and number of reported confirmed malaria cases by month, in EU and EEA/EFTA countries, 2006–09
Number of cases
12-month moving average
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Source: Country reports: Austria, Belgium, Cyprus, Czech Republic, Estonia, Finland, Greece, Hungary, Ireland, Italy, Malta, Netherlands, Norway, Poland, Portugal, 
Slovakia, Slovenia, Spain, Sweden, United Kingdom. Data excludes overseas territories, protectorates or départements.
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Table 2.4.1. Number and rate of malaria cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 44 44 0.53 57 0.69 34 0.41 50 0.61
Belgium Y C 144 144 1.35 181 1.70 193 1.82 195 1.86
Bulgaria Y A 8 8 0.11 0 0.00 4 0.05 14 0.18
Cyprus Y C 1 1 0.13 0 0.00 1 0.13 1 0.13
Czech Republic Y C 10 10 0.10 22 0.21 23 0.22 16 0.16
Denmark - - - - - - - - - - -
Estonia Y C 4 4 0.30 0 0.00 5 0.37 6 0.45
Finland Y C 34 34 0.64 42 0.79 22 0.42 0 0.00
France N A 2 199 2 199 - 2 246 3.51 - - - -
Germany Y C 523 523 0.64 547 0.67 540 0.66 566 0.69
Greece Y C 51 51 0.45 39 0.35 21 0.19 22 0.20
Hungary Y C 8 8 0.08 5 0.05 7 0.07 18 0.18
Ireland Y C 90 90 2.02 82 1.86 71 1.65 94 2.23
Italy Y C 632 632 1.05 586 0.98 501 0.85 630 1.07
Latvia Y A 6 6 0.27 2 0.09 3 0.13 4 0.17
Lithuania Y A 3 3 0.09 3 0.09 4 0.12 0 0.00
Luxembourg Y C 3 3 0.61 2 0.41 4 0.84 4 0.85
Malta Y C 1 1 0.24 3 0.73 3 0.74 1 0.25
Netherlands Y C 238 237 1.44 229 1.40 210 1.28 250 1.53
Poland Y C 22 22 0.06 22 0.06 11 0.03 19 0.05
Portugal Y C 44 44 0.41 42 0.40 43 0.41 48 0.45
Romania Y C 12 12 0.06 13 0.06 24 0.11 16 0.07
Slovakia Y C 0 0 0.00 2 0.04 1 0.02 10 0.19
Slovenia Y C 7 7 0.34 3 0.15 9 0.45 3 0.15
Spain Y C 356 356 0.78 290 0.64 385 0.87 338 0.77
Sweden Y C 81 81 0.88 91 0.99 89 0.98 93 1.03
United Kingdom Y C 1 495 1 495 2.44 1 371 2.24 1 548 2.55 1 758 2.91
EU total - - 6 016 6 015 0.89 5 880 1.19 3 756 0.88 4 156 0.98
Iceland - - - - - - - 1 0.33 - -
Liechtenstein - - - - - - - - - - -
Norway Y C 34 34 0.71 32 0.68 28 0.60 44 0.95
Total - - 6 050 6 049 0.89 5 912 1.19 3 785 0.88 4 200 0.98
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed. Data excludes overseas territories, 
protectorates or départements.
Figure 2.4.2. Rates of reported confirmed malaria cases, by age and gender, in EU and EEA/EFTA countries, 2009
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available. Eleven cases were confirmed indigenous 
cases (eight from Greece, one from Cyprus, one from 
Ireland and one from the Netherlands). The two latter 
ones could be ‘airport malaria’ cases. Indigenous cases 
of malaria have been reported sporadically in continen-
tal Europe over the last 10 years1–4.
Outside continental Europe, some countries or territo-
ries are endemic for malaria (e.g. Mayotte and French 
Guiana) for which data are not collected at this level. The 
caseload on these territories is high and the Institut de 
Veille Sanitaire in France reports that in 2009 there were 
2 800 confirmed cases reported in French Guiana, some 
of which may have been imported from neighbouring 
countries (Brazil and Suriname), 88 indigenous cases 
and 268 imported cases notified in Mayotte, which rep-
resents a decrease in indigenous cases (from 600 in 
2003) and also a decrease in overall incidence, and 94 
imported cases notified in La Réunion5.
Age and gender distribution
The confirmed case rate of malaria is twice as high in 
males as in females (1.19 and 0.56 per 100 000, respec-
tively), giving a male-to-female ratio of 2.13:1 (98.5 % of 
cases). Information on age group was available for 61 % 
of the cases. The age group 25–44 years had the high-
est rates (1.37 per 100 000, 1.84 in males and 0.83 in 
females) (Figure 2.4.2). This is consistent with the pic-
ture described in 2008 and likely reflects population 
travel patterns rather than other risk factors6.
Seasonality
Information on month of report was available for 61 % 
of cases. A clear seasonal trend in monthly reports 
is observed across all countries, with cases increas-
ing during the summer holiday months (June–October) 
and peaking in September, and with a lower increase 
in January, possibly related to the winter holiday period 
(Figure 2.4.3). These observations most likely reflect 
travel to malaria-endemic countries.
Figure 2.4.3. Seasonal distribution of reported confirmed cases of malaria, in EU and EEA/EFTA countries, 2006–09
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Source: Country reports: Austria, Belgium, Cyprus, Czech Republic, Estonia, Finland, Greece, Hungary, Ireland, Italy, Malta, Netherlands, Norway, Poland, Portugal, 
Slovakia, Slovenia, Spain, Sweden, United Kingdom. Data excludes overseas territories, protectorates or départements.
Discussion
Historically, malaria was endemic in Europe but it has 
been eliminated in most parts of the EU and EEA/EFTA. 
Cases of indigenous transmission of malaria have been 
reported over the last 10 years1–4,7, but sustained local 
transmission has not been identified to date. However, 
a cluster of vivax malaria infected patients from Lakonia, 
in Greece, has been reported in the summer of 2009. 
This report indicated that local transmission remains 
possible and stresses the need for surveillance and 
prevention also by improving sanitary conditions of sea-
sonal workers6.
In 2010, the first indigenous cases of malaria due to 
Plasmodium vivax were reported from Spain after being 
malaria-free since 1964 (for more details see Chapter 3).
The overall rate of reported confirmed malaria cases 
diagnosed in the EU and EEA/EFTA decreased in 2009 
compared to 2008, reaching a rate comparable to the 
one of 2007, despite integration of French data since 
2008, thus indicating a decreasing trend in all countries. 
Nowadays, travellers visiting friends and relatives con-
stitute the most significant group for malaria importa-
tion in developed countries. They demonstrate travel 
and behavioural patterns that render them at high risk 
for infection8. However, the annual number of imported 
malaria cases shows a continuing declining trend, even 
with an increasing number of travellers visiting malaria 
endemic countries9. Seasonality, age and gender distri-
bution of cases are similar to those observed in previous 
years. Surveillance of malaria continues to be important 
both in identifying possible indigenous transmission 
within EU and EEA/EFTA countries, but also to support 
assessment of prophylaxis recommendations for travel 
medicine8,9. 
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s
Austria AT-Epidemiegesetz Cp Co P C Y Y Y Y Y
Belgium BE-REFLAB V Co P C Y N N N Y
Bulgaria BG-NATIONAL_SURVEILLANCE Cp Co P A Y Y Y Y Y
Cyprus CY-NOTIFIED_DISEASES Cp Co P C N Y N N Y
Czech Republic CZ-EPIDAT Cp Co A C - Y Y N Y
Estonia EE-A NT H/CHOL/DIPH/M A L A/SP OX/
TRIC/TULA/TYPH
Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y Y N N Y
France FR-NATIONAL_REFERENCE_CENTRES V Co P C Y N N N N
Germany DE-SURVNET@RKI-7.3 Cp Co P C Y N N N Y
Greece GR-NOTIFIABLE_DISEASES Cp Co P C Y Y Y N Y
Hungary HU-EFRIR Cp Co P C Y Y Y N Y
Ireland IE-CIDR Cp Co P C Y Y Y N Y
Italy IT-NRS Cp Co P C Y Y Y N Y
Latvia LV-BSN Cp Co P C Y Y Y N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Luxembourg LU-SYSTEM1 Cp Co P C Y Y N N Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y Y Y
Netherlands NL-OSIRIS Cp Co P C Y Y N Y Y
Norway NO-MSIS_A Cp Co P C Y Y Y N Y
Poland PL-NATIONAL_SURVEILLANCE Cp Co P C N Y Y N Y
Portugal PT-MALARIA Cp Co P C N Y N N Y
Romania RO-RNSSy Cp Co P C N N Y N Y
Slovakia SK-EPIS Cp Co A C Y Y Y N Y
Slovenia SI-SURVIVAL Cp Co P C Y Y Y N Y
Spain ES-STATUTORY_DISEASES Cp Co P C N Y Y N Y
Sweden SE-SMINET Cp Co P C Y N N N Y
United Kingdom UK-MALARIA O Co A C Y N Y Y Y
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Plague (Yersinia pestis infection)
• There were no cases of indigenous plague 
reported in the EU and EEA/EFTA region during 
2009.
Plague is a bacterial infection of rodents and their fleas, 
which can transfer the bacterium (Yersinia pestis) to 
humans. Untreated plague is often fatal. While urban 
plague has been controlled in most of the world, it 
remains a public health problem in many countries.
Epidemiological situation in 2009
No cases of plague were reported by 29 EU and EEA/
EFTA countries in 2009. Data was not available for 
Liechtenstein.
Surveillance systems overview
Country Data Source
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Austria AT-Epidemiegesetz Cp Co P C Y Y Y Y Y
Belgium BE-FLA_FRA Cp Co P C Y Y Y Y Y
Bulgaria BG-NATIONAL_SURVEILLANCE Cp Co P A Y Y Y Y Y
Cyprus CY-NOTIFIED_DISEASES Cp Co P C N Y N N Y
Czech Republic CZ-EPIDAT Cp Co A C - Y Y N Y
Denmark DK-MIS Cp Co P C N Y N N Y
Estonia EE-VHF Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y Y N N Y
France FR-MANDATORY_INFECTIOUS_DISEASES Cp Co P C Y Y Y Y Y
Germany DE-SURVNET@RKI-7.1/6 Cp Co P C Y Y Y Y Y
Greece GR-NOTIFIABLE_DISEASES Cp Co P C Y Y Y N Y
Hungary HU-EFRIR Cp Co P C Y Y Y N Y
Iceland IS-SUBJECT_TO_REGISTRATION Cp Co P C Y Y Y N Y
Ireland IE-CIDR Cp Co P C Y Y Y N Y
Italy IT-NRS Cp Co P C Y Y Y N Y
Latvia LV-BSN Cp Co P C Y Y Y N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Luxembourg LU-SYSTEM1 Cp Co P C Y Y N N Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y Y Y
Netherlands NL-OSIRIS Cp Co P C Y Y N Y Y
Norway NO-MSIS_A Cp Co P C Y Y Y N Y
Poland PL-NATIONAL_SURVEILLANCE Cp Co P C Y Y Y N Y
Portugal PT-PLAGUE Cp Co P C N Y N N Y
Romania RO-RNSSy Cp Co P C N N Y N Y
Slovakia SK-EPIS Cp Co A C Y Y Y N Y
Slovenia SI-SURVIVAL Cp Co P C Y Y Y N Y
Spain ES-STATUTORY_DISEASES Cp Co P C Y Y Y N Y
Sweden SE-SMINET Cp Co P C Y N N N Y
United Kingdom UK-PLAGUE O Co P C Y N Y Y Y
Discussion
Plague is still endemic in several countries in Africa, in 
the former Soviet Union, the Americas and Asia1. A con-
firmed plague outbreak was reported by WHO in China 
on the 11 August 2009: a cluster outbreak of pulmonary 
plague cases in the remote town of Ziketan, Qinghai 
province2. In North Africa, in 2009, an outbreak of 
bubonic plague was reported in Tobruk, Libya3,4.
References
1. Human plague: review of regional morbidity and mortality, 2004-
2009. Wkly Epidemiol Rec. 2009 Feb 5;85(6):40-5.
2. World Health Organization (website). Global Alert and Response 
(GAR) – Plague. Available from: http://www.who.int/csr/don/ar-
chive/disease/plague/en/index.html.
3. Tarantola A, Mollet T, Gueguen J, Barboza P, Bertherat E. Plague out-
break in the Libyan Arab Jamahiriya. Euro Surveill 2009 Jul 2;14(26). 
pii: 19258.
4. Neerinckx S, Bertherat E, Leirs H. Human plague occurrences in 
Africa: an overview from 1877 to 2008. Trans R Soc Trop Med Hyg. 
2010 Feb;104(2):97-103.
130
SURVEILLANCE REPORTAnnual epidemiological report 2011
Q fever
• A total of 1 988 confirmed Q fever infections 
were reported in 2009 from 25 EU and EEA/EFTA 
countries.
• Most of these cases were reported from the 
Netherlands. The outbreak in the Netherlands 
since 2007 is the largest community outbreak of 
Q fever ever reported in the literature. 
• Small outbreaks and sporadic cases were 
reported from some other countries.
Q fever is an infection caused by the rickettsia Coxiella 
burnetti. It occurs in a range of domesticated and wild 
animals, and humans acquire the infection by inhala-
tion of dusts containing Coxiellae. It is particularly an 
occupational risk for those working with animals and 
animal tissues (abattoirs, etc.). It is usually a rela-
tively uncommon disease in the EU and EEA/EFTA, 
although large outbreaks have been reported from the 
Netherlands in recent years.
Epidemiological situation in 2009
Twenty-five EU and EEA/EFTA countries reported 2 687 
cases of Q fever in 2009 (10 countries reported zero 
cases), of which 1 988 were confirmed (Table 2.4.2). No 
data were reported from Austria, Denmark, France, Italy 
and Liechtenstein. The overall confirmed case rate was 
0.61 per 100 000 population. The Netherlands reported 
the highest rate (9.8 per 100 000), and accounted for 
82 % of all confirmed cases reported in 2009, due to an 
ongoing outbreak1,2. Other European countries reported 
Table 2.4.2. Number and rate of Q fever cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria - - - - - - - - - - -
Belgium Y A 33 33 0.31 27 0.25 14 0.13 8 0.08
Bulgaria Y A 24 22 0.29 17 0.22 33 0.43 27 0.35
Cyprus Y C 3 2 0.25 31 3.93 8 1.03 2 0.26
Czech Republic Y C 0 0 0.00 0 0.00 - - - -
Denmark - - - - - - - - - - -
Estonia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Finland Y C 1 1 0.02 2 0.04 2 0.04 0 0.00
France - - - - - - - - - - -
Germany Y C 191 191 0.23 370 0.45 83 0.10 204 0.25
Greece Y C 3 3 0.03 3 0.03 0 0.00 2 0.02
Hungary Y C 19 19 0.19 11 0.11 7 0.07 12 0.12
Ireland Y C 17 17 0.38 10 0.23 4 0.09 8 0.19
Italy - - - - - - - - - 0 0.00
Latvia Y C 0 0 0.00 1 0.04 0 0.00 1 0.04
Lithuania Y A 0 0 0.00 0 0.00 0 0.00 0 0.00
Luxembourg Y C 0 0 0.00 0 0.00 - - - -
Malta Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Netherlands Y C 2 317 1 623 9.84 1 007 6.14 132 0.81 12 0.07
Poland Y C 3 3 0.01 4 0.01 0 0.00 0 0.00
Portugal Y C 14 14 0.13 12 0.11 8 0.08 9 0.09
Romania Y C 4 2 0.01 3 0.01 6 0.03 0 0.00
Slovakia Y C 0 0 0.00 0 0.00 1 0.02 0 0.00
Slovenia Y C 0 0 0.00 0 0.00 93 4.63 3 0.15
Spain(a) N C 34 34 - 119 - 159 - 145 -
Sweden Y C 5 5 0.05 7 0.08 0 0.00 1 0.01
United Kingdom Y C 19 19 0.03 56 0.09 62 0.10 146 0.24
EU total - - 2 687 1 988 0.62 1 680 0.50 612 0.15 580 0.12
Iceland Y C 0 0 0.00 0 0.00 - - - -
Liechtenstein - - - - - 0 0.00 - - - -
Norway Y C 0 0 0.00 0 0.00 0 0.00 - -
Total - - 2 687 1 988 0.61 1 680 0.49 612 0.15 580 0.12
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed. (a) Sentinel surveillance system based on a 
limited number of selected laboratories.
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variable trends for Q fever cases, including some small 
outbreaks. 
Fourteen of the 1 815 confirmed cases with information 
on importation status were imported.
Age and gender distribution
The highest rates were seen in the age group 45–64 
years, with confirmed case rates of 1.09 per 100 000 
population (Figure 2.4.5). Only 38 of the 1 964 cases 
(2.6 %) for which information was available were 
reported among children under the age of 15. The overall 
rate was higher in men than in women (0.76 and 0.48 
per 100 000, respectively), with a male-to-female ratio of 
1.58:1 (1.85:1 in 2008).
Seasonality
Most cases occurred in May, June and July (65 %). This 
was earlier and case numbers higher than in previous 
years, reflecting the dominance of the Netherlands out-
break in the 2009 reports.
Discussion
Q fever is generally an underreported disease due to its 
non-specific clinical features. Increased awareness due 
to the ongoing outbreak the Netherlands (since 2007) 
may have contributed to enhanced case detection also 
in other countries. 
In 2009, the main outbreak occurred in the Netherlands 
between May and mid-September with a peak during 
weeks 20–24 (mid-May to mid-June)1. In 2008, the major-
ity of cases occurred during June and August. The 2009 
outbreak started earlier and was much stronger, causing 
public health concern in the Netherlands. The outbreak 
was also more widespread than in 2008 but still mainly 
affecting the province of Noord Brabant. Proximity 
(< 5 km) to infected dairy goat farms was proven to be the 
major risk factor for getting the infection. 
In the Netherlands, veterinary public health measures 
were taken. Since June 2008, case notification of Q 
fever in goats and sheep (abortion clusters) was made 
mandatory and the exact location of farms with animals 
that had clinical Q fever was reported to the municipal 
health service. Such measures facilitated the detection 
of related human cases or clusters. Stringent hygiene 
protocols and vaccination of dairy goats and sheep has 
become mandatory since 2009 and selective culling 
of pregnant goats from infected premises was imple-
mented in addition from December 20091,2.  
Several measures to prevent infection or severe out-
come in humans were also implemented, including 
possible vaccination of at-risk populations. The sharp 
decrease in case numbers in the second half of 2009 
may be the consequence of the implemented meas-
ures1,3. Risk assessments of Q fever were produced by 
the European Food Safety Authority (EFSA) and ECDC4,5. 
Other European countries have reported variable trends 
of Q fever, including a number of outbreaks6.
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Figure 2.4.4. Trend and number of reported confirmed Q fever cases by month, in EU and EEA/EFTA countries, 2006–09
Number of cases
12-month moving average
Nu
m
be
r o
f c
as
es
0
100
200
300
400
500
Jan 2010Jul 2009Jan 2009Jul 2008Jan 2008Jul 2007Jan 2007Jul 2006Jan 2006
Source: Country reports: Cyprus, Estonia, Finland, Germany, Greece, Hungary, Ireland, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, 
Romania, Slovakia, Slovenia, Sweden. Data excludes overseas territories, protectorates or départements.
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Figure 2.4.5. Rates of reported confirmed Q fever cases, by age and gender, in EU and EEA/EFTA countries, 2009
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Source: Country reports: Belgium, Cyprus, Finland, Germany, Greece, Hungary, Ireland, Netherlands, Poland, Portugal, Romania, Spain, Sweden and United Kingdom. 
Czech Republic, Iceland, Estonia, Latvia, Lithuania, Luxembourg, Malta, Norway, Slovakia and Slovenia reported zero cases. Data excludes overseas territories, 
protectorates or départements.
Figure 2.4.6. Seasonal distribution of reported confirmed cases of Q fever, in EU and EEA/EFTA countries, 2006–09
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Surveillance systems overview
Country Data Source
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Estonia EE-VHF Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y N N N Y
Germany DE-SURVNET@RKI-7.1 Cp Co P C Y N N Y Y
Greece GR-NOTIFIABLE_DISEASES Cp Co P C Y Y Y N Y
Hungary HU-Zoonoses Cp Co P C Y Y Y N Y
Iceland IS-SUBJECT_TO_REGISTRATION Cp Co P C Y Y Y N Y
Ireland IE-CIDR Cp Co P C Y Y Y N Y
Latvia LV-BSN Cp Co P C Y Y Y N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Luxembourg LU-SYSTEM1 Cp Co P C Y Y N - Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y Y Y
Netherlands NL-OSIRIS Cp Co P C Y Y N Y Y
Norway NO-MSIS_A Cp Co P C Y Y Y N -
Poland PL-NATIONAL_SURVEILLANCE Cp Co P C N Y Y N Y
Portugal PT-QFEVER Cp Co P C N Y N N Y
Romania RO-RNSSy Cp Co P C N N Y N Y
Slovakia SK-EPIS Cp Co A C Y Y Y N Y
Slovenia SI-SURVIVAL Cp Co P C Y Y Y N Y
Spain ES-MICROBIOLOGICAL V Se P C Y N N N N
Sweden SE-SMINET Cp Co P C Y N N N Y
United Kingdom UK-Q-FEVER V Co P C Y N Y Y Y
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Severe acute respiratory syndrome (SARS)
• Knowledge about the epidemiology and 
ecology of SARS coronavirus infection remains 
incomplete.
• It remains very difficult to predict when or 
whether SARS will re-emerge in epidemic form.
• SARS has been shown to spread rapidly 
worldwide; therefore surveillance should be 
maintained during the post-epidemic period.
Severe acute respiratory syndrome (SARS) is a respira-
tory disease in humans caused by the SARS coronavi-
rus (SARS-CoV). In 2002–03 an epidemic originating in 
Hong Kong spread globally with over 8 000 known cases 
and a case fatality rate of about 10 %. The last known 
community case occurred in 2003, but SARS is not eradi-
cated and may still be present in its natural animal host 
reservoirs. 
Epidemiological situation in 2009
For 2009, despite ongoing surveillance, there were zero 
reports of the SARS virus infection in humans from 29 EU 
and EEA/EFTA countries (no report from Liechtenstein). 
Nor were there any reports of SARS virus infection in 
humans worldwide.
Discussion
SARS is believed to have been an animal virus that 
recently crossed the species barrier to infect humans. 
Bats have been identified as potential reservoir hosts 
of coronaviruses associated with SARS in different 
studies1–3.
The SARS outbreak illustrates the importance of sen-
sitive detection tools in the response to public health 
threats4. Studies since the SARS outbreak suggest that 
many novel viruses exist in animals and some may 
present a risk to humans5.
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Smallpox
• There were no reports of smallpox or potential 
smallpox in the EU and EEA/EFTA countries (or 
worldwide) in 2009.
Smallpox is a systemic infectious disease, unique to 
humans, caused by either of two virus variants, Variola 
major and Variola minor. In 1980, the World Health 
Organization declared smallpox eradicated from the 
world.
Epidemiological situation in 2009
There were no reports of smallpox or potential smallpox 
in the EU and EEA/EFTA countries (or worldwide) in 2009.
Discussion
Mass smallpox vaccination campaigns have ceased 
after eradication. Therefore, the population that is 
immunologically naïve to orthopoxviruses has increased 
significantly. Thirty years after cessation of vaccination, 
human monkeypox (a related orthopoxvirus present in 
Central Africa ) incidence has dramatically increased, 
for example in rural Democratic Republic of Congo. 
Improved surveillance and epidemiological analysis is 
needed to better assess the public health burden and 
develop strategies for reducing the risk of wider spread 
of this monkeypox infection1.
Smallpox viruses are considered one of the viruses with 
potential use as a biological weapon. Legitimately, the 
virus exists in only two WHO reference laboratories in 
the world. Any new case of smallpox would have to be 
the result of human accidental or deliberate release.
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Viral haemorrhagic fevers (VHF)
• In 2009, the reporting of viral haemorrhagic fevers 
has been divided into the following groups of 
diseases: hantavirus infections, Crimean–Congo 
haemorrhagic fever, dengue fever, Rift Valley fever, 
Ebola and Marburg infection and Lassa fever.
• For hantavirus infection, 2 471 cases of have been 
reported from 23 countries, which is nearly half 
the cases reported in 2008, but it is still the most 
commonly reported disease with potential haem-
orrhagic features in the EU and EEA/EFTA.
• Three cases of Crimean–Congo have been reported 
by Bulgaria (one of unknown origin) and Germany 
(two imported cases).
• Some 522 confirmed cases of dengue fever were 
notified by EU and EEA/EFTA countries, and none 
was confirmed to be indigenous.
• Two cases of Lassa fever imported from Nigeria 
and Mali have been reported by the United 
Kingdom.
Hantavirus
Epidemiological situation in 2009
In 2009, 2 459 reports of confirmed hantavirus infection 
were received from 23 EU and EEA/EFTA countries. Five 
countries reported no cases (Table 2.4.3). Data were not 
available from Cyprus, Denmark, France, Italy, Portugal, 
Iceland or Liechtenstein. 
The overall confirmed case rate was 1.68 per 100 000 
population, varying from 0.01 to 36.18 in Finland 
(Finland reported 80 % of all cases). Information about 
the source of infection was not available. All or most 
cases from Austria, Czech Republic, Estonia, Germany, 
Hungary and Romania were indigenous; six cases of 
hantavirus infection were identified as imported cases.
Age and gender distribution
Hantavirus infections are predominantly reported in 
adults, with 77 % of cases in the age groups 25–44 and 
45–64 years. A few cases are reported in children (2.5 % 
of the cases) with a confirmed case rate of 0.09 per 
100 000 in the 0–4 year age group and 0.14 per 100 000 
population for the 5–14 year-olds.
The highest incidence is observed in the 45–64 year-
old group (1.24 per 100 000 population) followed by the 
25–44 year-olds (0.95 per 100 000 population) (Figure 
2.4.7). The incidence is higher among males (0.92 per 
100 000 population) than females (0.65 per 100 000 
population) and the male-to-female ratio is 1.41:1.
Seasonality
Cases are reported all year round with a significant 
peak in January and a decreasing trend until April. This 
Table 2.4.3. Number and rate of hantavirus cases reported in EU and EEA/EFTA countries, 2008–09
Country
2009 2008
National 
Coverage
Report 
type
Total 
cases
Confirmed cases and 
notification rate
Confirmed cases and 
notification rate
Cases Rate Cases Rate
Austria Y C 29 29 0.35 1 0.01
Belgium(a) Y C 187 187 1.75 336 3.15
Bulgaria Y A 5 2 0.03 2 0.03
Cyprus - - - - - - -
Czech Republic Y C 6 6 0.06 - -
Denmark - - - - - - -
Estonia Y C 17 17 1.27 11 0.82
Finland Y C 1 927 1 927 36.18 3 259 61.48
France - - - - - - -
Germany Y C 181 181 0.22 243 0.30
Greece Y C 2 2 0.02 2 0.02
Hungary Y C 11 11 0.11 3 0.03
Ireland Y C 0 0 0.00 0 0.00
Italy - - - - - - -
Latvia Y A 1 1 0.04 1 0.04
Lithuania Y C 0 0 0.00 0 0.00
Luxembourg Y C 1 1 0.20 0 0.00
Malta Y C 0 0 0.00 0 0.00
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Country
2009 2008
National 
Coverage
Report 
type
Total 
cases
Confirmed cases and 
notification rate
Confirmed cases and 
notification rate
Cases Rate Cases Rate
Netherlands Y C 8 1 0.01 0 0.00
Poland Y A 5 4 0.01 0 0.00
Portugal - - - - - - -
Romania Y C 9 8 0.04 4 0.02
Slovakia Y C 3 3 0.06 1 0.02
Slovenia Y C 5 5 0.25 45 2.24
Spain Y C 0 0 0.00 2 0.00
Sweden Y C 53 53 0.57 569 6.20
United Kingdom Y C 0 0 0.00 0 0.00
EU total - - 2 450 2 438 0.68 4 479 1.29
Iceland - - - - - - -
Liechtenstein - - - - - - -
Norway Y C 21 21 0.44 50 1.06
Total - - 2 471 2 459 0.68 4 529 1.29
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed. (a) Sentinel surveillance system based on a 
limited number of selected laboratories.
distribution of the cases reflects primarily the epidemio-
logical situation in Finland, which reported 80 % of all 
cases (Figure 2.4.8).
Discussion
Hantavirus infections are widely distributed across 
Europe, with the exception of some Mediterranean coun-
tries1, and are particularly prevalent in Scandinavia. 
Haemorrhagic fever with renal syndrome is caused by 
different viruses, mostly Puumala virus carried by bank 
voles and Dobrava virus by yellow-necked mice. 
Extension of the known endemic area may occur dur-
ing epidemic years, as reported in 2005 in several west 
European countries2. Hantavirus infections are still 
underdiagnosed in some areas. 
The number of cases and incidence rates have decreased 
significantly in the more affected countries (Finland, 
Belgium, Germany and Sweden) compared to 2008. In 
south-western Germany, Puumala virus incidence is sig-
nificantly linked with bank vole habitats, vole food sup-
ply, climate factors and human population density3.
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Figure 2.4.7. Rates of reported confirmed hantavirus infection cases in EU and EEA/EFTA countries, by age and gender, 
2009
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Crimean–Congo haemorrhagic 
fever
Epidemiological situation in 2009
Six cases (one confirmed) of Crimean–Congo haemor-
rhagic fever (CCHF) have been reported from Bulgaria, 
and two confirmed cases from Germany.
Discussion
CCHF is endemic in the Balkan region – cases have been 
previously reported from Kosovoi, Albania, Bulgaria1 and 
Greece in 20082. The cases in Germany were imported: 
one from Afghanistan and one from Turkey3. In Turkey, 
where the disease first emerged in 2002–03, 1 300 
cases were reported in 2009, including 62 deaths4.
Potential reasons for the emergence or re-emergence of 
CCHF include climate changes, which may have a sig-
nificant impact on the reproduction rate of the vector 
Hyalomma ticks, as well as anthropogenic factors (e.g. 
changes in agricultural and hunting activities). There are 
models that show the probability of CCHF extending to 
other countries around the Mediterranean basin, sug-
gesting that vector, veterinarian and human surveillance 
should be enhanced5.
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Dengue fever
Epidemiological situation in 2009
In 2009, 577 cases of dengue fever (522 confirmed) were 
reported by 12 of 23 EU and EEA/EFTA countries (Table 
2.4.4). All were probably imported (40 of unknown 
origin). Data were not available for Bulgaria, Cyprus, 
Denmark, Netherlands, Portugal, Liechtenstein and 
Norway. Nevertheless, a case of imported dengue in 
Norway has been described in the literature1. 
The overall confirmed case rate was 0.11 per 100 000. 
The individual country rates varied between < 0.01 and 
1.08 cases per 100 000 population. The higher rates 
reported by Sweden (1.08 per 100 000) and Finland (0.66 
per 100 000) reflect predominant choices of travel des-
tinations to countries where dengue fever is endemic. 
The data below vary rather widely as some countries 
reported all diagnosed dengue fever cases while others 
only reported dengue haemorrhagic fever.
Age and gender distribution
The confirmed case rate was similar in males (0.11 cases 
per 100 000) and females (0.10 per 100 000), with a 
male-to-female ratio of 1.1:1. The age-groups with the 
highest rates were 25–44 years (0.19 cases per 100 000), 
15–24 years (0.17 per 100 000) and 45–65 (0.11 per 
100 000); these are most likely related to preferences 
for travel to tropical countries among these age groups 
(Figure 2.4.9).
Seasonality
Cases were reported more frequently in the European 
colder months, reflecting probably also travel-related 
exposure (Figure 2.4.10).
Discussion
The number of persons who visit countries endemic for 
dengue is continually rising, and dengue infection is the 
second most frequent reason, after malaria, for hospital-
isation after their return. Cases reported in 2009 related 
Figure 2.4.8. Seasonal distribution of reported confirmed cases of hantavirus infections in the EU and EEA/EFTA 
countries, 2009
Nu
m
be
r o
f c
as
es
0
100
200
300
400
500
600
700
800
DecNovOctSepAugJulJunMayAprMarFebJan
Sources: Country reports: Finland, Germany, Greece, Hungary, Ireland, Lithuania, Malta, Netherlands, Norway, Slovakia, Slovenia, Spain, Sweden, United Kingdom. 
Data excludes overseas territories, protectorates or départements.
139
Viral haemorrhagic fevers (VHF)SURVEILLANCE REPORT
Table 2.4.4. Number and rate of dengue fever cases reported in EU and EEA/EFTA countries, 2008–09
Country
2009 2008
National 
Coverage
Report 
type
Total 
cases
Confirmed cases and 
notification rate
Confirmed cases and 
notification rate
Cases Rate Cases Rate
Austria Y C 0 0 0.00 0 0.00
Belgium Y A 53 53 0.50 60 0.56
Bulgaria - - - - - - -
Cyprus - - - - - - -
Czech Republic Y C 0 0 0.00 - -
Denmark - - - - - - -
Estonia Y C 0 0 0.00 0 0.00
Finland Y C 35 35 0.66 35 0.66
France Y C 64 13 0.02 15 0.02
Germany Y C 298 298 0.36 273 0.33
Greece Y C 0 0 0.00 0 0.00
Hungary Y C 1 1 0.01 6 0.06
Ireland Y C 0 0 0.00 0 0.00
Italy Y C 10 10 0.02 12 0.02
Latvia Y A 1 1 0.04 0 0.00
Lithuania Y C 0 0 0.00 0 0.00
Luxembourg Y C 0 0 0.00 0 0.00
Malta Y C 0 0 0.00 0 0.00
Netherlands - - - - - - -
Poland Y C 4 0 0.00 0 0.00
Portugal - - - - - - -
Romania Y C 0 0 0.00 1 0.00
Slovakia Y C 0 0 0.00 0 0.00
Slovenia Y C 4 4 0.20 6 0.30
Spain Y C 4 4 0.01 0 0.00
Sweden Y C 100 100 1.08 73 0.79
United Kingdom Y C 3 3 0.00 6 0.01
EU total - - 577 522 0.11 487 0.11
Iceland Y C 0 0 0.00 - -
Liechtenstein - - - - - - -
Norway - - - - - - -
Total - - - - - - -
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
Figure 2.4.9. Rates of reported confirmed dengue fever cases in EU and EEA/EFTA countries, by age and gender, 2009
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mainly to travel to Thailand, India and Indonesia. It is 
cogent to consider whether introduction of these viruses 
is likely to lead to indigenous and even endemic trans-
mission in Europe, where there is evidence that condi-
tions are already suitable for transmission5.
During 2010, two indigenous cases of dengue fever were 
indeed reported from metropolitan France (Nice), living 
in the same neighbourhood. The first indigenous case of 
dengue fever was reported in a returning traveller from 
Croatia, in addition to 14 indigenous cases living in the 
same area in Croatia (for further information see Chapter 
3).
Although this report concerns continental Europei, den-
gue fever is endemic in most tropical regions. According 
to the Pan American Health Organization, in the three 
French départements in the Americas, 5 191 confirmed 
cases of dengue fever have been reported for 2009 with 
an incidence ranging from 107.3 per 100 000 popula-
tion in Guadeloupe, to 57.9 in Martinique and 2 200 in 
French Guiana2. The year 2009 was characterised by a 
i The term ‘continental Europe’ is used to mean EU and EEA/EFTA 
countries on the European continent, i.e. it excludes overseas 
territories, protectorates or départements.
high dengue virus activity especially in French Guiana 
(the estimated number of cases is 13 900 for a popula-
tion of 206 000) and a lower activity in Martinique. In the 
Indian Ocean, La Réunion island reported one confirmed 
imported case of dengue fever in 2009 (DEN2 case) and 
11 probable cases (including three imported cases)3; the 
island is therefore still in an interepidemic situation. In 
2009, WHO also reported the first outbreak of dengue in 
Cape Verde4.
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Figure 2.4.10. Seasonal distribution of reported confirmed dengue cases in the EU and EEA/EFTA countries, 2009 
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Source: Country reports: Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Lithuania, Luxembourg, Malta, Poland, Slovakia, Slovenia, Spain, 
Sweden. Data excludes overseas territories, protectorates or départements.
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Rift Valley fever
Epidemiological situation in 2009
No cases were reported in continental Europei in 2009.
Discussion
In 2009, the outbreak in Madagascar continued and two 
smaller outbreaks occurred in South Africa (Kwazulu-
Natal in March and the Northern Cape Province in mid-
October); all laboratory confirmed human cases (n=25) 
in 2008–09 in South Africa had very close contact with 
infected animals and/or their tissues, including the two 
most recent cases in Northern Cape1,2.
The Rift Valley fever outbreak continued into 2010 in 
several regions of South Africa, and peaked prior to the 
FIFA football World Cup in (European) summer 2010. No 
EU citizen was affected (for more information on surveil-
lance during the World Cup, see Chapter 3).
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Marburg and Ebola virus
Epidemiological situation in 2009
No imported cases have been reported in continental 
EuropeII in 2009.
In Germany, a case of needle stick injury has been 
reported with a needle used to inject Ebola into mice, 
but contamination has not been proven. The person was 
given an experimental vaccine and did not show any 
symptoms of the disease1. 
No further cases of Marburg virus infections were 
reported in Africa. However, an outbreak of Ebola 
virus (32 cases, 15 deaths) was notified by WHO in 
the Democratic Republic of Congo, Province of Kasai 
Occidental2. It was declared to have ended on 16 
February 2009; the last person infected by the virus 
died on 1 January 2009. 
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Lassa fever
Epidemiological situation in 2009
Two cases of imported Lassa fever have been reported 
in the United Kingdom in 2009. The first case of Lassa 
fever was imported from Nigeria1, and the second was 
imported from Mali2. Both patients died. Seven contacts 
were considered to be at high risk of infection in the sec-
ond incident and were actively monitored for 21 days.
Discussion
Lassa fever is known to be endemic in parts of West 
Africa, with most cases reported from Guinea, Liberia, 
Sierra Leone and Nigeria. People living in rural areas of 
West Africa are most at risk of Lassa fever. Transmission 
of the virus to humans usually occurs via direct or indi-
rect contact with rodent excreta.
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Chikungunya fever
Epidemiological situation in 2009
In 2009, 94 confirmed cases of chikungunya fever were 
reported by 22 EU and EEA/EFTA countries, which is 
nearly four times more than the case number for 2008 
(Table 2.4.5). No data were provided by Bulgaria, Cyprus, 
Denmark, Netherlands, Portugal, Iceland, Liechtenstein 
or Norway. 
Cases were reported by Austria (eight cases), Finland 
(nine cases), France (13 cases), Germany (54 cases), Italy 
(three cases), Spain (six cases) and the United Kingdom 
(56 cases, of which eight confirmed). All cases were 
imported (three were of unknown origin). Information 
regarding the probable country of infection was not 
available.
Age and gender
The notification rate is identical in males and females 
(0.02 per 100 000). Most of the cases were identified in 
the age group 25–44 years (0.04 cases per 100 000) and 
45–65 (0.03 per 100 000), most likely related to these 
age groups’ preferences for travel to tropical countries 
(Figure 2.4.11). 
Seasonality
Cases were reported especially in the autumn (Figure 
2.4.12) in relation with travel to countries where active 
transmission was occurring.
Discussion
Reported confirmed case numbers showed a significant 
increase in 2009, especially in Austria, France, Germany 
and the United Kingdom. Notification rates are higher 
in 25–64 year-old females than in males. Cases were 
detected in travellers returning mostly from India, the 
Maldives and Thailand. 
The first identified outbreak of chikungunya fever in a 
temperate climate (Italy), in 2007, demonstrated the 
potential of the Aedes albopictus mosquito to trans-
mit the virus at EU latitudes. The absence of reported 
indigenous cases in the previously affected region may 
be due to the inability of the virus to sustain transmis-
sion in temperate climate, possibly in combination with 
important vector control activities. 
During 2008 and 2009 only imported cases of chikun-
gunya were reported from EU and EEA/EFTA countries. 
In 2010, indigenous transmission was reported for the 
second time in Europe with the first two indigenous 
cases identified in metropolitan France in autumn 2010 
through enhanced surveillance (see Chapter 3). 
From the beginning of 2008 and also in 2009, increas-
ing numbers of cases of chikungunya fever were also 
reported in several countries in Asia, such as Indonesia, 
Malaysia, Sri Lanka, Thailand and India. In La Réunion, 
a French départment in the Indian Ocean where a major 
outbreak occurred during 2005–06, five confirmed 
cases (four indigenous) and three probable cases (one 
imported) were reported in 2009. The island is still con-
sidered to be in interepidemic situation1.
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Figure 2.4.11. Rates of reported confirmed chikungunya cases reported in EU and EEA/EFTA countries, by age and 
gender, 2009
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Table 2.4.5. Number and rate of reported cases of chikungunya fever in EU and EEA/EFTA countries, 2008–09
Country
2009 2008
National 
Coverage
Report 
type
Total 
cases
Confirmed cases and 
notification rate
Confirmed cases and 
notification rate
Cases Rate Cases Rate
Austria Y C 8 8 0.10 0 0.00
Belgium Y C 0 6 0.06 0 0.00
Bulgaria - - - - - - -
Cyprus - - - - - - -
Czech Republic Y C 0 0 0.00 0 0.00
Denmark - - - - - - -
Estonia Y C 0 0 0.00 0 0.00
Finland Y C 3 3 0.06 0 0.00
France Y C 13 13 0.02 1 0.00
Germany Y C 54 54 0.07 17 0.02
Greece Y C 0 0 0.00 0 0.00
Hungary Y C 0 0 0.00 0 0.00
Ireland Y C 0 0 0.00 0 0.00
Italy Y C 3 2 0.00 1 0.00
Latvia Y C 0 0 0.00 0 0.00
Lithuania Y C 0 0 0.00 0 0.00
Luxembourg Y C 0 0 0.00 0 0.00
Malta Y C 0 0 0.00 0 0.00
Netherlands - - - - - - -
Poland Y C 0 0 0.00 0 0.00
Portugal - - - - - - -
Romania Y C 0 0 0.00 0 0.00
Slovakia Y C 0 0 0.00 0 0.00
Slovenia Y C 0 0 0.00 0 0.00
Spain(a) N C 6 6 - 5 -
Sweden Y C 0 0 0.00 - -
United Kingdom Y C 56 8 0.01 1 0.00
EU Total - - 143 94 0.02 25 0.00
Iceland - - - - - - -
Liechtenstein - - - - - - -
Norway - - - - - - -
Total - - 143 94 0.02 25 0.00
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed. (a) Sentinel surveillance system based on a 
limited number of selected laboratories.
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Figure 2.4.12. Seasonal distribution of reported confirmed chikungunya cases in EU and EEA/EFTA countries, 2009 
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Source: Country reports: Estonia, Finland, France, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Poland, Romania, Slovakia, Slovenia, 
Sweden, United Kingdom. Data excludes overseas territories, protectorates or départements.
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West Nile fever
• A total of 28 confirmed cases of West Nile virus 
infection were reported across the EU and EEA/
EFTA countries in 2009: 18 cases in Italy (two 
imported), seven cases in Hungary, two cases in 
Romania and one imported case in France.
West Nile fever is a disease caused by an arthropod-
borne virus (genus Flavivirus) whose reservoir is shared 
by wild birds and mosquitoes. Transmission to humans 
is primarily through mosquito bites. The disease can 
lead to serious illness in some cases, and no treatment 
or vaccination is available; prevention is primarily avoid-
ance of mosquito bites. The West Nile virus (WNV) was 
first recognised in Europe in a large outbreak in Romania 
in 1996.
Epidemiological situation in 2009
Twenty-eight confirmed cases of WNV infection were 
reported in 2009 by 24 EU and EEA/EFTA countries. No 
data were available from Bulgaria, Denmark, Germany, 
Iceland, Liechtenstein or Portugal. 
Eighteen confirmed cases were reported by Italy, seven 
cases by Hungary, two cases by Romania and one by 
France. Trends are increasing, as only four cases were 
reported in 2006. At country level, this is particularly 
true for Italy and, to a lesser extend, for Hungary. The 
overall confirmed case rate in Europe was below 0.01 
and the highest rate was 0.07 per 100 000 reported by 
Hungary. The surveillance in Italy and France does not 
cover the whole country. Most cases were indigenous, 
but the French case and two Italian cases were imported. 
Age and gender distribution
As in 2008, most cases in 2009 occurred in individuals 
older than 45 years, but some young females were also 
affected. The majority of cases (n=18) were male (male-
to-female ratio=1.8:1). 
Seasonality
Although the numbers were small, most cases were 
reported between July and October 2009. The majority 
of cases (17) was reported in September, which is con-
sistent with observations from 2006 to 2008 (Figure 
2.4.13).
Discussion
Since the first large outbreak of West Nile fever in 
Romania in 19961, in which 835 patients were hospital-
ised and 393 cases laboratory-confirmed with West Nile 
fever, WNV has been recognised as a public health con-
cern in Europe. 
Sporadic cases have been reported in recent years in 
several countries in southern and eastern Europe. The 
large outbreak in horses and humans in 2008 in Northern 
Italy clearly demonstrated that West Nile virus can occur 
in regions that combine high densities of competent vec-
tors, suitable amplifying hosts (birds) and susceptible 
human and horse populations. Further investigations 
in Italy confirmed WN infection in a total of 16 clinical 
cases in 20092, mostly in the 2008 outbreak area. The 
re-occurrence of WNV transmission in 2009 in areas far 
from localities with a high density of migratory birds and 
the positive virological results consistently obtained 
from sampled resident birds suggest the establishment 
Figure 2.4.13. Number of reported confirmed West Nile fever cases by month, in EU and EEA/EFTA countries, by month, 
2006–09
2006
2007
2008
2009
Nu
m
be
r o
f c
as
es
0
2
4
6
8
10
12
14
16
18
20
DecNovOctSepAugJulJunMayAprMarFebJan
Source: Country reports: Belgium, Cyprus, Estonia, Finland, France, Greece, Hungary, Ireland, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, 
Slovakia, Slovenia, Spain, Sweden, United Kingdom.
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of an efficient local overwintering mechanism with the 
possible involvement of these bird species3.
Six new human cases of West Nile neuroinvasive disease 
were identified in the Veneto region, following the six 
cases already reported in 2008. A human WNV isolate 
was obtained for the first time from an asymptomatic 
blood donor, which showed a new mutation, a trait asso-
ciated with avian virulence, increased virus transmission 
and the occurrence of outbreaks in humans4. 
In 2010, the WNV affected areas with confirmed human 
cases further spread and the number of confirmed 
cases of infection in humans in Europe increased mark-
edly to 340 (compared to 28 in 2009). The majority of 
cases were reported from Greece (242). Other countries 
affected were Hungary, Romania and Italy and, for the 
first time, Spain (see Chapter 3 for more information). 
Continued close monitoring of the situation (in terms 
of human, veterinary and entomological surveillance) 
is required. Personal protective measures against 
mosquito bites need to be considered by residents or 
persons visiting these areas in the months when trans-
mission occurs. Early detection is crucial for appropriate 
control measures particularly regarding blood and organ 
donations5.
The WNV circulation in Italy coincided with the first 
detection in the same areas of two cases of Usutu virus 
infections, another flavivirus transmitted by mosqui-
toes among birds6,7, which could represent an emerging 
threat to human health.
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Yellow fever
• One case of imported yellow fever was reported 
by Spain in 2009.
• While imported cases are rare, non-vaccinated 
travellers visiting affected areas without the 
effective protection of yellow fever 17D vaccina-
tion expose themselves to risk of infection.
Yellow fever occurs due to infection with the yellow 
fever virus (genus Flavivirus). Transmission to humans is 
through the bite of an infected mosquito. Cases in the 
EU occur occasionally in travellers returning from coun-
tries where the disease is endemic.
Epidemiological situation in 2009
One case of yellow fever was reported by Spain among 
29 reporting EU and EEA/EFTA countries in 2009 (data 
not available from Liechtenstein). The case had travelled 
to Spain from Ghana.
Discussion
In 2009, WHO reported 75 laboratory-confirmed cases 
for Africa and Central and South Americas, including 
21 deaths. Eleven outbreaks were reported, occurring 
in Guinea, Côte d’Ivoire, Republic of Congo, Liberia, 
Cameroon and Central African Republic, reflecting 
intense virus circulation across the western and central 
parts of Africa. Targeted immunisation campaigns were 
conducted in these countries as a result1–6.
Yellow fever is commonly underreported in the affected 
areas since the symptoms may be easily misinterpreted 
and most areas lack effective surveillance systems. WHO 
estimates that there are approximately 200 000 cases of 
yellow fever every year, resulting in 30 000 deaths1.
In November 2009, the largest-ever yellow fever mass 
vaccination campaign commenced across three African 
countries. The week-long event targeted 11.9 million 
people across Benin, Liberia and Sierra Leone, all three 
of which are at high risk of yellow fever outbreaks. 
Between 2007 and 2010, 57 million people were vac-
cinated against yellow fever in 10 countries at risk in 
Africa, and during the same period, 17 million peo-
ple were protected through emergency vaccination7. 
Furthermore, thirty-seven countries in Africa and the 
Americas have introduced yellow fever vaccine in their 
routine childhood immunisation schedule up from 12 
countries a decade ago. However, 160 million people 
could still be at risk in Africa if further funding is not 
secured for the emergency stockpile and preventive vac-
cination in remaining high-risk countries, especially as 
yellow fever is re-appearing in countries that have not 
reported cases in many years8.
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Diphtheria
2.5 Vaccine-preventable diseases
• In 2009, 16 cases of diphtheria were reported 
across the EU with an overall rate of confirmed 
cases of < 0.01 per 100 000 population.  
• The most affected age group was the 45–64 year-
olds (n=7, incidence rate=0.01 per 100 000) fol-
lowed by the 65-year-olds or older (n=4, < 0.01 per 
100 000).
• Although diphtheria is a rare disease in the EU, 
the indigenous transmission of the disease per-
sists in certain countries and underlines the need 
for maintaining a high coverage through the child-
hood vaccination programmes of the European 
Union. 
• High vaccination coverage must be sustained, 
adult booster coverage increased, and epidemio-
logical surveillance and laboratory capacity main-
tained despite the small number of cases.
Diphtheria is a very rare respiratory infection in the EU, 
caused by the bacterium Corynebacterium diphtheriae. 
Some strains are toxin-producing and can cause fatal ill-
ness. The disease is subject to WHO elimination targets 
for the European region.
Epidemiological situation in 2009
Twenty-nine EU and EEA/EFTA countries provided 
reports, four countries reported case-based data and 
one country (Latvia) reported aggregated data. 
Five countries reported 15 confirmed diphtheria cases 
and one probable case in 2009 (Table 2.5.1). 
Although historically diphtheria was more common in 
the winter months, in the post-epidemic period cases 
seem to be distributed throughout the year (Figure 
2.5.1). Detailed analysis of seasonality is not possible 
due to the small number of reported cases.
Corynebacterium diphtheriae accounted for 11 cases in 
2009. The majority (n=6) were reported by Latvia (con-
firmed case rate of 0.22 cases per 100 000 population). 
One case was reported by Sweden, two by Germany and 
two by the United Kingdom.
Figure 2.5.1. Number of reported confirmed diphtheria cases by month, in EU and EEA/EFTA countries, 2006–09
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C. ulcerans cases were reported by the United Kingdom 
(2) and France (1), and two cases with unspecified diph-
theria pathogen were reported by Germany.  
The overall rate of confirmed cases of diphtheria is simi-
lar in the last three years (Table 2.5.1). At present, these 
rates include both diseases caused by C. diphtheriae 
and by C. ulcerans.
Age and gender distribution
The most affected age group (including both dis-
eases) was the 45–64 year-olds (n=7, incidence 
rate=0.01/100 000) followed by the 65+ (4, < 0.01 per 
100 000). The higher number of cases among 45–64 
year-olds could be attributed to the low level of immu-
nity in this age group. Ten of the 15 confirmed cases 
were female.
Discussion
In this report, disease caused by both C. ulcerans and 
C. diphtheriae have been analysed together even though 
one is more of a zoonosis while the other involves 
human-to-human transmission. Although the aggre-
gated data format currently used for these diseases has 
limitations, the data still shows that diphtheria appears 
to be under control in the EU. 
The indigenous transmission of the disease continues 
in Latvia and suggests that epidemic diphtheria could 
return to any country in the EU. Therefore, high vaccina-
tion coverage must be sustained, adult booster coverage 
increased, and epidemiological surveillance and labora-
tory capacity maintained.
Future diphtheria surveillance activities are aimed at 
integrating surveillance programmes, which cover all 
diphtheria diseases caused by toxigenic C. diphtheriae 
and C. ulcerans, from both an epidemiology and labora-
tory point of view.
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Table 2.5.1. Number and rate of diphtheria cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Belgium Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Bulgaria Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Cyprus Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Czech Republic Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Denmark Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Estonia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Finland Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
France Y C 1 1 0.00 5 0.01 1 0.00 3 0.00
Germany Y C 4 4 0.00 0 0.00 2 0.00 0 0.00
Greece Y C 0 0 0.00 0 0.00 0 0.00 - -
Hungary Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Ireland Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Italy Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Latvia Y A 6 5 0.22 29 1.28 15 0.66 64 2.79
Lithuania Y C 0 0 0.00 2 0.06 0 0.00 0 0.00
Luxembourg Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Malta Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Netherlands Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Poland Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Portugal Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Romania Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Slovakia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Slovenia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Spain Y C 0 0 0.00 0 0.00 0 0.00 - -
Sweden Y C 1 1 0.01 1 0.01 0 0.00 0 0.00
United Kingdom Y C 4 4 0.01 6 0.01 3 0.00 3 0.00
EU total - - 16 15 0.00 43 0.01 21 0.00 70 0.02
Iceland Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Liechtenstein - - - - - - - - - - -
Norway Y C 0 0 0.00 4 0.08 0 0.00 0 0.00
Total - - 16 15 0.00 47 0.01 21 0.00 70 0.02
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
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Surveillance systems overview
Country Data Source
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Austria AT-Epidemiegesetz Cp Co P C Y Y Y Y Y
Belgium BE-REFLAB V Co P C Y N N N Y
Bulgaria BG-NATIONAL_SURVEILLANCE Cp Co P A Y Y Y Y Y
Cyprus CY-NOTIFIED_DISEASES Cp Co P C N Y N N Y
Czech Republic CZ-EPIDAT Cp Co A C - Y Y N Y
Denmark DK-MIS Cp Co P C N Y N N Y
Estonia EE-A NT H/CHOL/DIPH/M A L A/SP OX/
TRIC/TULA/TYPH
Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y Y N N Y
France FR-MANDATORY_INFECTIOUS_DISEASES Cp Co P C Y Y Y Y Y
Germany DE-SURVNET@RKI-7.1/6 Cp Co P C Y Y Y Y Y
Greece GR-NOTIFIABLE_DISEASES Cp Co P C Y Y Y N Y
Hungary HU-EFRIR Cp Co P C Y Y Y N Y
Iceland IS-SUBJECT_TO_REGISTRATION Cp Co P C Y Y Y N Y
Ireland IE-CIDR Cp Co P C Y Y Y N Y
Italy IT-NRS Cp Co P C Y Y Y N Y
Latvia LV-BSN Cp Co P C Y Y Y N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Luxembourg LU-SYSTEM1 Cp Co P C Y Y N N Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y Y Y
Netherlands NL-OSIRIS Cp Co P C Y Y N Y Y
Norway NO-MSIS_A Cp Co P C Y Y Y N Y
Poland PL-NATIONAL_SURVEILLANCE Cp Co P C Y Y Y N Y
Portugal PT-DIPHTERIA Cp Co P C N Y N N Y
Romania RO-RNSSy Cp Co P C Y N Y N Y
Slovakia SK-EPIS Cp Co A C Y Y Y N Y
Slovenia SI-SURVIVAL Cp Co P C Y Y Y N Y
Spain ES-STATUTORY_DISEASES Cp Co P C Y Y Y N Y
Sweden SE-SMINET Cp Co P C Y N N N Y
United Kingdom UK-DIPHTHERIA O Co P C Y N Y Y Y
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Invasive Haemophilus inﬂ uenzae disease
• The incidence of invasive Haemophilus influenzae 
remains stable in Europe, with a notification rate 
of 0.39 per 100 000 population in 2009. 
• The highest rates in the EU for 2009 were reported 
by Sweden and Norway.
• All EU countries have the Hib vaccine included in 
the national immunisation schedule, and routine 
vaccination continues to have a great impact on 
the reduction of incidence of the disease due to 
serotype b.
This is a systemic infection due to the bacterium 
Haemophilus influenza, often presenting as meningitis. 
With widespread vaccine use in early childhood, it is 
now an uncommon disease.
Epidemiological situation in 2009
In 2009, 2 016 confirmed cases of invasive Haemophilus 
influenzae disease (all serotypes) were reported by 29 
countries (see Table 2.5.2). The overall confirmed case 
rate was 0.39 per 100 000 in 2009, similar to 2008 (0.41 
per 100 000). These figures cannot be compared with 
2006 data, as only serotype b (Hib) was included in that 
year. 
The highest rates in 2009 were reported by Sweden (1.58 
per 100 000) and Norway (1.48 per 100 000), followed by 
the United Kingdom (1.21 per 100 000), Ireland (0.97 per 
100 000) and Finland (0.88 per 100 000).
Table 2.5.2. Number and rate of invasive Haemophilus influenzae disease cases reported in EU and EEA/EFTA 
countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 14 14 0.17 5 0.06 4 0.05 7 0.08
Belgium Y C 76 76 0.71 49 0.46 55 0.52 - -
Bulgaria Y A 15 15 0.20 14 0.18 19 0.25 - -
Cyprus Y C 2 2 0.25 0 0.00 0 0.00 - -
Czech Republic Y C 10 10 0.10 7 0.07 13 0.13 11 0.11
Denmark Y C 31 31 0.56 40 0.73 15 0.28 4 0.07
Estonia Y C 1 1 0.07 1 0.07 2 0.15 7 0.52
Finland Y C 47 47 0.88 45 0.85 54 1.02 32 0.61
France N C 417 417 - 442 - 658 - 103 0.16
Germany Y C 199 199 0.24 312 0.38 93 0.11 55 0.07
Greece Y C 13 13 0.12 4 0.04 7 0.06 3 0.03
Hungary Y C 3 3 0.03 12 0.12 2 0.02 - -
Ireland Y C 43 43 0.97 22 0.50 31 0.72 34 0.81
Italy Y C 56 56 0.09 50 0.08 33 0.06 23 0.04
Latvia Y C 1 1 0.04 2 0.09 0 0.00 - -
Lithuania Y C 2 1 0.03 3 0.09 0 0.00 2 0.06
Luxembourg Y C 0 0 0.00 0 0.00 1 0.21 0 0.00
Malta Y C 3 3 0.73 0 0.00 1 0.25 - -
Netherlands Y C 0 0 0.00 0 0.00 - - 121 0.74
Poland Y C 19 19 0.05 28 0.07 39 0.10 19 0.05
Portugal Y C 8 8 0.08 5 0.05 16 0.15 17 0.16
Romania Y C 22 22 0.10 2 0.01 - - - -
Slovakia Y C 5 5 0.09 8 0.15 6 0.11 0 0.00
Slovenia Y C 18 18 0.89 12 0.60 13 0.65 0 0.00
Spain N C 53 53 - 73 - 66 - - -
Sweden Y C 146 146 1.58 163 1.78 144 1.58 112 1.24
United Kingdom Y C 742 742 1.21 773 1.26 696 1.15 624 1.03
EU total - - 1 946 1 945 0.38 2 072 0.40 1 968 0.36 1 174 0.30
Iceland Y C 0 0 0.00 0 0.00 1 0.33 - -
Liechtenstein - - - - - - - - - - -
Norway Y C 71 71 1.48 75 1.58 83 1.77 73 1.57
Total - - 2 017 2 016 0.39 2 147 0.41 2 052 0.37 1 247 0.31
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
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Age and gender distribution
In 2009, the disease was predominantly found in infants 
younger than five years and in the oldest age group, 65 
years old and older. The rate of confirmed cases for chil-
dren under five years of age was 1.3 per 100 000 popula-
tion (1.2 per 100 000 for males and 1.0 per 100 000 for 
females). Adults aged 65 years or older had a confirmed 
case rate of 1.0 per 100 000 population (1.4 per 100 000 
for males and 0.9 per 100 000 for females), with highest 
rates reported by Sweden (4.80 per 100 000), Norway 
(4.40 per 100 000) and the United Kingdom (3.42 per 
100 000). The male to female ratio was 1.08:1.
Seasonality
The distribution of observed invasive Haemophilus influ-
enzae cases clearly follows a seasonal pattern, with the 
highest number reported in the winter months, followed 
by a steady decrease until August and a further increase 
to a peak in January. The pattern is the same for the 
years 2006–08, as shown in Figure 2.5.3.
Discussion
The disease was predominantly reported in infants 
younger than one year old and in the oldest age group 
(65 years and older).
The enhanced surveillance data show that the disease 
was dominated by non-capsulated and non-b serotype. 
The variations between countries reflect real differences 
in disease incidence, but are also influenced by sub-
stantial differences in health and surveillance systems, 
and variations in methods used for confirming probable 
cases1.
References
1. European Centre for Disease Prevention and Control. Surveillance 
of invasive bacterial diseases in Europe 2008/2009. Stockholm: 
ECDC; 2011.
Figure 2.5.2. Rates of reported confirmed invasive Haemophilus influenzae disease cases, by age and gender, in EU 
and EEA/EFTA countries, 2009
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Figure 2.5.3. Seasonal distribution of reported confirmed cases of invasive Haemophilus influenzae disease, in EU and 
EEA/EFTA countries, 2006–09
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Surveillance systems overview
Country Data Source
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Austria AT-Epidemiegesetz Cp Co P C Y Y Y Y Y
Belgium BE-LABNET V Se A C Y N - - Y
Bulgaria BG-NATIONAL_SURVEILLANCE Cp Co P A Y Y Y Y Y
Cyprus CY-NOTIFIED_DISEASES Cp Co P C N Y N N Y
Czech Republic CZ-EPIDAT Cp Co A C Y Y Y N Y
Denmark DK-MIS Cp Co P C N Y N N Y
Estonia EE-HIB Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y N N N Y
France FR-EPIBAC V Se A C Y N Y N N
Germany DE-SURVNET@RKI-7.1 Cp Co P C Y N N Y Y
Greece GR-NOTIFIABLE_DISEASES Cp Co P C Y Y Y N Y
Hungary HU-EFRIR Cp Co P C Y Y Y N Y
Iceland IS-SUBJECT_TO_REGISTRATION Cp Co P C Y Y Y N Y
Ireland IE-CIDR Cp Co P C Y Y Y N Y
Italy IT-MENINGITIS Cp Co P C N Y Y Y Y
Latvia LV-BSN Cp Co P C Y Y Y N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Luxembourg LU-SYSTEM1 Cp Co P C Y Y N N Y
Malta MT-DISEASE_SURVEILLANCE Cp Co P C Y Y Y Y Y
Netherlands NL-OSIRIS Cp Co P C Y Y N N Y
Norway NO-MSIS_A Cp Co P C Y Y Y N Y
Poland PL-NATIONAL_SURVEILLANCE Cp Co P C N Y Y N Y
Portugal PT-HAEMOPHILUS_INFLUENZAE Cp Co P C N Y N N Y
Romania RO-RNSSy Cp Co P C N N Y N Y
Slovakia SK-EPIS Cp Co A C Y Y Y N Y
Slovenia SI-SURVIVAL Cp Co P C Y Y Y N Y
Spain ES-MICROBIOLOGICAL V Se P C Y N N N N
Sweden SE-SMINET Cp Co P C Y N N N Y
United Kingdom UK-HIB O Co P C Y N Y Y -
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Invasive meningococcal disease
• The confirmed case rate of meningococcal disease 
remains low across Europe (0.89 per 100 000), 
and appears to have stabilised over recent years, 
following a major decrease since 1999 (1.9 per 
100 000) mainly due to meningococcal C (MenC) 
vaccine introduction.
• Most invasive meningococcal infections are 
caused by the serogroups B and C. Commonly 
used vaccines in Europe cover only serogroup C. 
• Infants and children under four years old are at 
greatest risk, with relatively few cases above 25 
years of age.
This is an uncommon but severe acute systemic bacte-
rial disease, appearing as meningitis or septicaemia. 
Rates have decreased by about one half as a result of 
introduction of childhood vaccination against one of the 
main serogroups. Case fatality rates, however, remain 
about 5–10 %, despite modern diagnosis and treatment.
Epidemiological situation in 2009
In 2009, 4 495 confirmed cases of invasive meningococ-
cal disease were reported. Twenty-nine EU and EEA/EFTA 
countries provided reports with an overall confirmed 
case rate of 0.89 per 100 000. Ireland and the United 
Kingdom reported the highest rates of confirmed cases 
with 3.01 per 100 000 and 1.93 per 100 000, respec-
tively. The lowest confirmed case rates were reported 
by Cyprus (0.13), Bulgaria (0.21) and Latvia (0.22) (Table 
2.5.3).
Table 2.5.3. Number and rate of invasive meningococcal disease cases reported in EU and EEA/EFTA, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 100 89 1.07 84 1.01 61 0.74 68 0.82
Belgium Y C 104 104 0.97 110 1.03 158 1.49 137 1.30
Bulgaria Y A 25 16 0.21 20 0.26 24 0.31 39 0.51
Cyprus Y C 1 1 0.13 4 0.51 4 0.51 3 0.39
Czech Republic Y C 80 80 0.76 82 0.79 75 0.73 75 0.73
Denmark Y C 73 71 1.29 131 2.39 78 1.43 75 1.38
Estonia Y C 5 5 0.37 6 0.45 11 0.82 11 0.82
Finland Y C 33 33 0.62 28 0.53 43 0.81 45 0.86
France Y C 618 614 0.95 673 1.05 680 1.07 575 0.91
Germany Y C 493 493 0.60 904 1.10 436 0.53 544 0.66
Greece Y C 81 77 0.68 78 0.70 106 0.95 98 0.88
Hungary Y C 37 37 0.37 30 0.30 43 0.43 32 0.32
Ireland Y C 150 134 3.01 152 3.45 162 3.76 173 4.11
Italy Y C 181 181 0.30 178 0.30 178 0.30 127 0.22
Latvia Y C 9 5 0.22 13 0.57 15 0.66 9 0.39
Lithuania Y C 65 39 1.16 48 1.43 50 1.48 44 1.29
Luxembourg Y C 3 3 0.61 2 0.41 2 0.42 2 0.43
Malta Y C 4 4 0.97 6 1.46 6 1.47 14 3.46
Netherlands Y C 153 150 0.91 323 1.97 195 1.19 171 1.05
Poland Y C 304 301 0.79 321 0.84 335 0.88 185 0.48
Portugal Y C 66 65 0.61 60 0.57 98 0.92 103 0.97
Romania Y C 111 102 0.47 99 0.46 145 0.67 - -
Slovakia Y C 40 39 0.72 48 0.89 35 0.65 36 0.67
Slovenia Y C 15 15 0.74 24 1.19 18 0.90 8 0.40
Spain Y C 533 533 1.16 590 1.30 619 1.39 595 1.36
Sweden Y C 65 65 0.70 49 0.53 49 0.54 51 0.56
United Kingdom Y C 1 246 1 190 1.93 1 355 2.21 1 522 2.50 1 220 2.02
EU total - - 4 595 4 446 0.89 5 418 1.09 5 148 1.04 4 440 0.94
Iceland Y C 5 5 1.57 4 1.27 4 1.30 3 1.00
Liechtenstein - - - - - - - - - - -
Norway Y C 44 44 0.92 36 0.76 30 0.64 34 0.73
Total - - 4 644 4 495 0.89 5 458 1.09 5 182 1.04 4 477 0.94
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
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Following the introduction of meningococcal C vaccine 
around 1999, there has been a steady decline in con-
firmed case rates across Europe1,2. Since 2006, how-
ever, rates have been stable, with no further decrease in 
incidence of reported cases (see Table 2.5.3 and Figure 
2.5.4).
Age and gender distribution
Children younger than five years of age continue to 
experience the highest confirmed case rates of invasive 
meningococcal disease (7.37 per 100 000), followed by 
the 15–24 years age group (1.44 per 100 000) (Figure 
2.5.5). In the older age groups, the disease is extremely 
rare.
In the youngest age group (< 5 years old), the confirmed 
case rate was highest in Ireland (21 per 100 000), in the 
United Kingdom (17 per 100 000) and in Lithuania (11 
per 100 000). The highest confirmed case rate among 
15–24 year-olds was reported by Ireland (5.24 per 
100 000), Iceland (4.24 per 100 000) and Austria (2.64 
per 100 000). 
Information on gender was available for 4 445 cases. 
The incidence rates among males (0.97 per 100 000) 
and females (0.82 per 100 000) are comparable, with a 
slightly higher rate among males. The male-to-female 
ratio was 1.12:1.
Seasonality
Information on seasonal distribution was available 
for 4 637 cases. Reported cases peak in winter months 
(January 2009, n=748), declining by late summer 
(September 2009, n=214) (Figure 2.5.6).
Discussion
The reported rate of confirmed cases of meningococcal 
disease varies widely across countries, ranging from 
0.13 to 3.01 per 100 000. In addition to real differences 
in incidence, reported figures also reflect differences 
between surveillance systems and in methods used for 
confirming cases. 
While reported incidence decreased by about half fol-
lowing widespread introduction of MenC vaccine from 
around 1999, confirmed case rates have been stable 
over recent years.
Figure 2.5.4. Trend and number of reported confirmed invasive meningococcal disease cases by month, in EU and EEA/
EFTA countries, 2006–09
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Figure 2.5.5. Rates of reported confirmed invasive meningococcal disease cases, by age and gender, in EU and EEA/
EFTA countries, 2009
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Figure 2.5.6. Seasonal distribution of reported confirmed cases of invasive meningococcal disease, in EU and EEA/
EFTA countries, 2006–09
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Cyprus CY-NOTIFIED_DISEASES Cp Co P C N Y N N Y
Czech Republic CZ-EPIDAT Cp Co A C Y Y Y N Y
Denmark DK-MIS Cp Co P C N Y N N Y
Estonia EE-MENINGOCOCC Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y Y N N Y
France FR-MANDATORY_INFECTIOUS_DISEASES Cp Co P C Y Y Y Y Y
Germany DE-SURVNET@RKI-7.1/6 Cp Co P C Y Y Y Y Y
Greece GR-NOTIFIABLE_DISEASES Cp Co P C Y Y Y N Y
Hungary HU-EFRIR Cp Co P C Y Y Y N Y
Iceland IS-SUBJECT_TO_REGISTRATION Cp Co P C Y Y Y N Y
Ireland IE-CIDR Cp Co P C Y Y Y N Y
Italy IT-MENINGITIS Cp Co P C N Y Y N Y
Latvia LV-LABORATORY Cp Co P C Y N N N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Luxembourg LU-SYSTEM1 Cp Co P C Y Y N N Y
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Norway NO-MSIS_A Cp Co P C Y Y Y N Y
Poland PL-NATIONAL_SURVEILLANCE Cp Co P C Y Y Y N Y
Portugal PT-MENINGOCOCAL Cp Co P C Y Y N N Y
Romania RO-RNSSy Cp Co P C N N Y N Y
Slovakia SK-EPIS Cp Co A C Y Y Y N Y
Slovenia SI-SURVIVAL Cp Co P C Y Y Y N Y
Spain ES-STATUTORY_DISEASES Cp Co P C N Y Y N Y
Sweden SE-SMINET Cp Co P C Y N N N Y
United Kingdom UK-MENINGOCOCCAL O Co P C Y N Y Y Y
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Invasive pneumococcal disease (IPD)
• The overall confirmed case rate of invasive 
pneumococcal disease (IPD) in 24 EU and EEA/
EFTA Member States was 4.3 per 100 000 
population in 2009.
• There is a wide heterogeneity of IPD surveillance 
systems in the EU, particularly in the type of 
surveillance systems in place, their coverage and 
the case definition used; in some countries there 
are no surveillance systems in place.
Despite good access to antibiotics, the bacterium 
Streptococcus pneumoniae is still a significant cause 
of illness and death in EU and EEA/EFTA countries. 
Very young children and the elderly are most at risk. 
Conjugate vaccines have been introduced into the child-
hood vaccination schedule in a number of EU and EEA/
EFTA countries.
Epidemiological situation in 2009
In 2009, 14 352 cases were reported, of which 14 272 
(99 %) were confirmed. Six countries did not provide 
data. The overall rate for reporting countries was 4.3 per 
100 000, with highest rates being reported by Belgium 
(19 per 100 000), Sweden (17), Norway (16), Finland (16) 
and Slovenia (12). The Netherlands reported the lowest 
confirmed case rate in 2009, 0.21 per 100 000.
The rate of confirmed cases has decreased since 2006 
(Table 2.5.4). Compared to the previous year, there were 
Table 2.5.4. Number and rate of invasive pneumococcal disease cases reported in EU and EEA/EFTA countries, 
2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 296 296 3.54 133 1.60 361 4.36 141 1.71
Belgium Y A 2 051 2 051 19.23 1 875 17.58 1 728 16.33 1 484 14.12
Bulgaria Y A 46 46 0.60 35 0.46 39 0.51 1 0.01
Cyprus Y C 10 9 1.13 21 2.66 6 0.77 7 0.91
Czech Republic Y C 143 143 1.37 117 1.13 89 0.87 - -
Denmark Y C 129 129 2.34 120 2.19 101 1.85 92 1.70
Estonia Y C 14 14 1.04 32 2.39 36 2.68 37 2.75
Finland Y C 855 855 16.05 925 17.45 791 14.99 0 0.00
France - - - - - - - - - - -
Germany - - - - - - - - - - -
Greece Y C 66 66 0.59 63 0.56 - - - -
Hungary Y C 49 49 0.49 65 0.65 57 0.57 56 0.56
Ireland Y C 436 359 8.07 400 9.09 313 7.26 407 9.67
Italy Y C 738 738 1.23 694 1.16 - - - -
Latvia Y A 6 5 0.22 3 0.13 4 0.18 0 0.00
Lithuania Y A 16 16 0.48 18 0.53 32 0.95 10 0.29
Luxembourg - - - - - 0 0.00 2 0.42 0 0.00
Malta Y C 8 8 1.93 0 0.00 0 0.00 0 0.00
Netherlands Y C 35 35 0.21 0 0.00 0 0.00 - -
Poland Y C 274 274 0.72 212 0.56 250 0.66 196 0.51
Portugal - - - - - - - - - - -
Romania Y C 123 122 0.57 0 0.00 - - - -
Slovakia Y C 29 29 0.54 36 0.67 37 0.69 44 0.82
Slovenia Y C 253 253 12.45 204 10.15 192 9.55 13 0.65
Spain N C 1 339 1 339 - 1 648 - 1 428 - 2 587 -
Sweden Y C 1 618 1 618 17.48 1 789 19.48 1 441 15.81 1 334 14.74
United Kingdom Y C 5 019 5 019 8.20 5 514 9.01 5 624 9.25 5 820 9.63
EU total - - 13 553 13 473 4.10 13 904 4.15 12 531 5.49 12 229 5.50
Iceland - - - - - - - - - - -
Liechtenstein - - - - - - - - - - -
Norway Y C 799 799 16.65 855 18.05 958 20.47 1 006 21.68
Total - - 14 352 14 272 4.30 14 759 4.37 13 489 5.82 13 235 5.92
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
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increases in the confirmed case rate of invasive pneu-
mococcal disease reported by Belgium (17 in 2008 to 
19 per 100 000 in 2009), Slovenia (from 10 to 12), and 
Austria (from 1.60 to 3.54), which are most likely due to 
recent improvements in the effectiveness of their sur-
veillance systems. Some other countries show a mod-
est decrease in comparison to 2008 (Cyprus, Estonia, 
Finland, Norway, Sweden and United Kingdom). 
Considering the absence of surveillance of invasive 
pneumococcal disease in several countries, the hetero-
geneity of the existing systems and variable application 
of case definitions in place across the Member States, 
country comparisons should be made with caution 
(Table 2.5.4). In addition, some countries collect data on 
pneumococcal meningitis only1.
Age and gender distribution
The most affected age groups were the youngest (under 
five years old), with a case rate of 6.57 cases per 100 000, 
and the oldest (over 64 years old), with a confirmed case 
rate of 9.84 cases per 100 000 (Figure 2.5.8). However, 
a decrease in this last group is observed, from 12.10 in 
2008 to 9.84 in 2009.
The confirmed case rate was slightly higher for males 
(4.61 per 100 000) than females (3.96 per 100 000), giv-
ing an overall male-to-female ratio of 1.16:1.
Seasonality
The seasonal distribution of cases of pneumococcal dis-
ease follows a pattern similar to that of other respira-
tory diseases. The lowest rates were observed during 
summer, increasing rapidly with the onset of autumn 
and winter. This pattern was similar in 2006–08 (Figure 
2.5.9).
Discussion
The confirmed case rate varied widely across countries, 
ranging from 0.21 to 19 per 100 000, probably reflecting 
not only true intercountry variation in incidence but also 
significant differences in the application of case defini-
tions and operation of national surveillance systems1.
Figure 2.5.7. Trend and number of reported confirmed invasive pneumococcal disease cases by month, in EU and EEA/
EFTA countries, 2006–09
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Figure 2.5.8. Rates of reported confirmed invasive pneumococcal disease cases, by age and gender, in EU and EEA/
EFTA countries, 2009
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There are concerns regarding the possibility that, after 
introduction of the conjugate vaccine PCV7, serotypes 
covered by the vaccine could be replaced by serotypes 
not covered by it, as this has already been observed 
in some EU countries1–3. Moreover, the introduction of 
new conjugate vaccines in 2010 (PCV10, PCV13) requires 
close monitoring. For this purpose, more enhanced sur-
veillance, also involving laboratory surveillance, is being 
introduced in the EU by ECDC.
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Figure 2.5.9. Seasonal distribution of reported confirmed cases of invasive pneumococcal disease, in EU and EEA/EFTA 
countries, 2006–09
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Measles
• The number of measles cases reported in the EU 
and EEA/EFTA countries in 2009 was lower than 
the previous year but still too high to reach the 
goal of eliminating measles in the EU in 2010.
• A total of 4 238 confirmed cases were reported in 
2009, with an overall rate of 0.84 per 100 000.
• Only three countries (representing about 1.5 % 
of the EU and EEA/EFTA population) have been 
measles-free during the last five years.
Measles is an acute illness caused by the measles virus, 
of the genus Morbillivirus. It is one of the most conta-
gious diseases known, and clusters and outbreaks of 
disease are common. Infection can sometimes cause 
significant disability and death. It is included in the 
childhood vaccination schedule in all EU countries, and 
WHO Europe Region has a target for elimination of indig-
enous measles by 2015.
Epidemiological situation in 2009
A total of 4 238 confirmed measles cases were reported 
in 2009 (6 698 in total), with an overall confirmed case 
rate of 0.84 per 100 000 population (Table 2.5.5). Eight 
countries (Cyprus, Estonia, Iceland, Latvia, Lithuania, 
Luxembourg, Slovakia and Slovenia) reported zero 
cases, and 18 countries reported rates below one per 
million inhabitants. The highest confirmed case rates 
were reported by Bulgaria (9.15 per 100 000), Ireland 
(2.31 per 100 000) and the United Kingdom (1.91 per 
100 000). 
Table 2.5.5. Number and rate of measles cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 53 31 0.37 156 1.88 20 0.24 15 0.18
Belgium Y D 33 24 0.22 98 0.92 0 0.00 15 0.14
Bulgaria Y D 2 249 696 9.15 1 0.01 1 0.01 1 0.01
Cyprus Y C 0 0 0.00 1 0.13 0 0.00 0 0.00
Czech Republic Y C 5 5 0.05 2 0.02 0 0.00 7 0.07
Denmark Y C 6 6 0.11 14 0.26 2 0.04 27 0.50
Estonia Y C 0 0 0.00 0 0.00 1 0.07 27 2.01
Finland Y C 2 2 0.04 5 0.09 0 0.00 0 0.00
France Y C 1 544 832 1.29 305 0.48 24 0.04 45 0.07
Germany Y C 574 534 0.65 779 0.95 485 0.59 1 475 1.79
Greece Y C 2 1 0.01 1 0.01 0 0.00 257 2.31
Hungary Y C 1 1 0.01 0 0.00 0 0.00 1 0.01
Ireland Y C 162 103 2.31 13 0.30 20 0.46 24 0.57
Italy Y C 705 705 1.17 5 311 8.91 595 1.01 563 0.96
Latvia Y D 0 0 0.00 3 0.13 0 0.00 6 0.26
Lithuania Y C 0 0 0.00 1 0.03 0 0.00 0 0.00
Luxembourg Y D 0 0 0.00 1 0.21 0 0.00 8 1.71
Malta Y C 1 1 0.24 0 0.00 0 0.00 0 0.00
Netherlands Y C 11 8 0.05 109 0.66 4 0.02 1 0.01
Poland Y C 115 62 0.16 89 0.23 30 0.08 90 0.24
Portugal Y D 3 3 0.03 1 0.01 0 0.00 0 0.00
Romania(a) Y C 8 8 0.04 0 0.00 345 1.60 3 524 16.31
Slovakia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Slovenia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Spain Y C 42 42 0.09 198 0.44 224 0.50 363 0.83
Sweden Y C 3 3 0.03 25 0.27 1 0.01 19 0.21
United Kingdom Y C 1 177 1 169 1.91 1 442 2.36 1 026 1.69 762 1.26
EU total - - 6 696 4 236 0.85 8 555 1.72 2 778 0.56 7 230 1.47
Iceland Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Liechtenstein - - - - - - - - - - -
Norway Y C 2 2 0.04 4 0.08 17 0.36 0 0.00
Total - - 6 698 4 238 0.84 8 559 1.70 2 795 0.56 7 230 1.45
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; D: Data from disease surveillance network; –: No report; U: Unspeciﬁ ed. 
(a) A more speciﬁ c case deﬁ nition was implemented in 2009.
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The situation in terms of total reported cases has slightly 
decreased when compared to 2008. In some countries 
a decline in the number of cases was reported (includ-
ing Italy, Spain, Netherlands, Austria), while others 
have reported an increase in cases (including Bulgaria, 
France, Ireland). Outbreaks and sustained virus circula-
tion were reported in Bulgaria1,2, France3, Austria4, and 
Ireland5. 
Only Slovenia and Iceland have maintained their status 
as consistently reporting zero cases (since 2004) while 
Slovakia has achieved uninterrupted ‘zero-reporting’ 
since 2005.
Age and gender distribution*
Age was reported in 3 511 confirmed cases. The most 
affected age group was the 0–4 year-olds (4.02 cases 
per 100 000) followed by the 5–14 year-olds (2.20 per 
100 000) and the 15–24 year-olds (1.34 per 100 000). 
No significant differences in gender overall or within 
age groups were observed (Figure 2.5.11). Gender was 
reported in 3 486 of all confirmed measles cases.
Seasonality
In 2009 there appeared to be a seasonal pattern of 
measles with a peak in spring/early summer (February–
June). The pattern was the same in the countries with 
the highest numbers of cases. Figure 2.5.12 gives the 
monthly distribution of cases from 2006 to 2009.
Enhanced surveillance in 2009
A total of 7 175 cases of measles were reported by the 
surveillance community network for vaccine prevent-
able infectious diseases (EUVAC.NET) in 2009 for EU 
and EFTA countries6. Of these, 91 % occurred in five 
countries: Bulgaria, France, Switzerland (not reporting 
to ECDC), the United Kingdom and Germany. Fifty-two 
per cent of the cases were laboratory-confirmed, 23 % 
epidemiologically linked and 24 % were only clinically 
diagnosed. Importation status was known for 72 % of 
the cases. Only 2 % of these (101 cases) had a known 
importation status. 
Figure 2.5.10. Trend and number of reported confirmed measles cases by month, in EU and EEA/EFTA countries, 
2006–09
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Source: Country reports: Austria, Cyprus, Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Hungary, Iceland, Ireland, Italy, Luxembourg, Malta, 
Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, United Kingdom. 
Figure 2.5.11. Rates of reported confirmed measles cases, by age and gender, in EU and EEA/EFTA countries, 2009
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Vaccination status was known for 82 % of all reported 
cases. Of these, 77 % were unvaccinated. According to 
the EUVAC.NET report6, 10 measles-related deaths (all 
but one laboratory confirmed) were reported by Bulgaria 
(seven deaths), France (two deaths) and the Netherlands 
(one case). Eight cases were complicated with encepha-
litis (Bulgaria: three; France: two; the United Kingdom: 
two; Switzerland: one). Three had not been vaccinated 
against measles while two had received one dose. The 
vaccination status was unknown in the other cases.
Discussion
The number of measles cases in EU and EEA/EFTA coun-
tries has slightly decreased in 2009 compared with 
2008. Large increases in the number of cases were 
reported in some countries while in others a decrease 
was observed. Outbreaks were reported in Bulgaria, 
France, Austria, Ireland and the United Kingdom.
However, measles activity again increased markedly in 
2010, with the highest number of reported cases and 
deaths (overall incidence 5.15 cases per 100 000 popu-
lation) for at least five years. The measles outbreak in 
Bulgaria continued into 2010, and accounted for the 
majority of cases. Several clusters in other EU coun-
tries were linked to this outbreak. In addition several 
outbreaks and clusters unrelated to the Bulgarian out-
break were reported from other EU countries (see 
Chapter 3 for more information).
Only two countries (Iceland and Slovenia) have main-
tained ‘zero-reporting’ since 2004. The goal of eliminat-
ing indigenous measles in Europe was not reached in 
2010. Efforts by all countries to increase and maintain 
vaccination coverage at a high level in order to achieve 
elimination of measles will need to be strengthened.
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Figure 2.5.12. Seasonal distribution of reported confirmed cases of measles, in EU and EEA/EFTA countries, 2006–09
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Mumps
• Mumps is one of the vaccine-preventable viral 
infections that continue to occur frequently 
across Europe.
• The number of mumps cases reported in EU and 
EAA/EFTA countries in 2009 was 17 558, while 
11 384 were confirmed; rate of confirmed cases 
was 3.2 per 100 000 population.
• The age group most frequently affected was the 
15–24 year-olds.
• Larger outbreaks were mainly noted in Ireland, 
Luxembourg and the United Kingdom. 
• Enhanced surveillance showed that 40 % of 
mumps cases were unvaccinated, 31 % had 
received one dose, 23 % had received at least 
two doses and in 6 % the number of doses was 
unknown.
• Breakthrough infections occurred after vacci-
nation with one and two doses in a significant 
number of cases, possibly due to waning immu-
nity and reduced vaccine effectiveness against 
certain genotypes.
Mumps is an infection caused by the mumps virus, of 
the genus Paramyxovirus. It is not an uncommon infec-
tion, although serious complications are rare. Outbreaks 
can occur, and it is included in the primary vaccination 
schedule of all EU countries.
Epidemiological situation in 2009
A total of 11 384 confirmed cases of mumps (17 558 total 
cases) were reported in 2009 by 27 EU and EEA/EFTA 
countries, with an overall confirmed case rate of 3.2 per 
100 000 population. This rate is similar to the rate for 
2008 (2.8 per 100 000). There has been a decrease in 
the rate of confirmed cases since 2006 (8.7 per 100 000).
Only Malta reported zero cases in 2009. Eight countries 
reported confirmed case rates below one per million 
inhabitants: Finland, Greece, Hungary, Latvia, Malta, 
Slovakia, Portugal and Norway. The highest confirmed 
case rates were reported from Ireland (31.0 per 100 000), 
the United Kingdom (13.0) and Luxembourg (5.1). Further 
details are reported on larger outbreaks in the first two 
quarters of 2009 in England and Wales, mainly occurring 
in school or college settings1.
Several EU and EEA/EFTA countries did not confirm 
cases (see Table 2.5.6).
Age and gender distribution
Age was reported in 11 085 (97 %) of reported confirmed 
mumps cases. Mumps occur in all age groups, but the 
most affected were 15–24 year-olds (18 per 100 000), 
5–14 year-olds (4.3), 0–4 year-olds (3.2) and 25–44 
year-olds (2.8), although the pattern differed among 
countries.
Gender was reported in 11 027 (97 %) of all reported con-
firmed mumps cases. The confirmed case rates were 
higher in males in age groups up to 44 years: 0–4 years 
(3.8 per 100 000 for males versus 2.4 per 100 000 in 
females), 5–14 years (5.0 versus 3.4), 15–24 years (19.3 
versus 16.6) and 25–44 years (3.0 versus 2.5).
Seasonality
Information on month of infection was available for 
10 982 of all reported confirmed mumps cases (96 %). 
The previously observed winter-spring outbreaks in 
2006–07 were also seen in 2009.
Figure 2.5.13. Trend and number of reported confirmed mumps cases by month, in EU and EEA/EFTA countries, 
2006–09
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Source: Country reports: Austria, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Ireland, Italy, Norway, Slovakia, Slovenia, Spain, Sweden, United 
Kingdom.
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Enhanced surveillance in 2009
A total of 21 048 mumps cases in 26 countries (25 EU/
EEA countries and Croatia) were reported through the 
surveillance community network for vaccine preventable 
infectious diseases (EUVAC.NET) in 2009. Of the 19 273 
cases reported by those countries that carry out labora-
tory confirmation, 10 856 cases (56 %) were laboratory 
confirmed. 
Vaccination status was known for 14 792 of reported 
mumps cases (reports from 25 countries). Of these, 
5 904 (40 %) were unvaccinated, 4 646 (31 %) were vac-
cinated with one dose, 3 355 (23 %) were vaccinated with 
at least two doses, and 887 (6 %) were vaccinated with 
an unspecified number of doses. 
In total 664 (4 %) reported mumps cases were hospital-
ised in 20 countries reporting and among those, 459 of 
cases developed complications (reports from 17 coun-
tries). The distribution of complications and the outcome 
is not known2.
Table 2.5.6. Number and rate of mumps cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 14 14 0.17 22 0.26 7 0.08 227 2.75
Belgium Y A 43 43 0.40 50 0.47 68 0.64 35 0.33
Bulgaria Y D 1 111 185 2.43 1 155 15.12 875 11.39 911 11.80
Cyprus Y C 5 3 0.38 3 0.38 5 0.64 0 0.00
Czech Republic Y C 357 279 2.67 260 2.50 735 7.14 3 969 38.72
Denmark Y C 17 17 0.31 24 0.44 12 0.22 11 0.20
Estonia Y C 11 11 0.82 14 1.04 18 1.34 17 1.26
Finland Y C 1 1 0.02 5 0.09 6 0.11 0 0.00
France - - - - - - - - - - -
Germany - - - - - - - - - - -
Greece Y C 20 3 0.03 1 0.01 3 0.03 3 0.03
Hungary Y C 5 5 0.05 11 0.11 16 0.16 7 0.07
Ireland Y C 1 832 1 381 31.03 698 15.86 69 1.60 209 4.97
Italy Y C 1 021 1 021 1.70 1 387 2.33 1 312 2.22 1 406 2.39
Latvia Y D 1 1 0.04 3 0.13 2 0.09 3 0.13
Lithuania Y A 74 74 2.21 82 2.44 81 2.39 0 0.00
Luxembourg Y D 25 25 5.07 26 5.37 0 0.00 0 0.00
Malta Y D 0 0 0.00 0 0.00 2 0.49 0 0.00
Netherlands Y C 32 31 0.19 7 0.04 0 0.00 - -
Poland Y A 2 954 1 0.00 0 0.00 0 0.00 20 0.05
Portugal Y D 154 9 0.08 15 0.14 48 0.45 34 0.32
Romania(a) Y C 741 104 0.48 2 302 10.69 5 291 24.53 14 671 67.89
Slovakia Y C 5 5 0.09 5 0.09 3 0.06 13 0.24
Slovenia Y C 27 3 0.15 13 0.65 9 0.45 4 0.20
Spain Y C 1 114 185 0.40 1 012 2.23 3 147 7.08 1 440 3.29
Sweden Y C 32 21 0.23 51 0.56 47 0.52 60 0.66
United Kingdom Y C 7 946 7 946 12.99 2 644 4.32 2 702 4.45 6 129 10.14
EU total - - 17 542 11 368 3.22 9 790 2.79 14 458 4.14 29 169 8.81
Iceland Y D 4 4 1.25 0 0.00 1 0.33 29 9.67
Liechtenstein - - - - - - - - - - -
Norway Y C 12 12 0.25 16 0.34 23 0.49 24 0.52
Total - - 17 558 11 384 3.18 9 806 2.75 14 482 4.09 29 222 8.69
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; D: Data from disease surveillance network; –: No report; U: Unspeciﬁ ed. (a) 
A more speciﬁ c case deﬁ nition was implemented in 2009.
Discussion
An overall decrease in the number of reported mumps 
cases has been observed during the past three years, 
a reduction from 8.7 per 100 000 in 2006 to 3.2 per 
100 000 in 2009. This is at least in part due to the greater 
uptake of mumps-containing vaccines throughout EU 
and EEA/EFTA countries. However, high confirmed case 
rates were still observed in Ireland, Luxembourg and the 
United Kingdom. 
The disease has shifted up in age groups to mainly 
affect the 15–24 year-olds, largely influenced by a large 
outbreak among university-age students in the United 
Kingdom, related to the history of vaccine schedule 
development in that country1. Waning immunity leading 
to secondary vaccine failure has also been suggested to 
further contribute to these outbreaks1.
Of specific interest is the high number of individuals with 
breakthrough infections reported in the enhanced sur-
veillance after one or more doses of mumps-containing 
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settings, as successfully tested in the Luxembourg out-
break among military personnel, may be considered5.
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Figure 2.5.14. Rates of reported confirmed mumps cases, by age and gender, in EU and EEA/EFTA countries, 2009
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Figure 2.5.15. Seasonal distribution of reported confirmed cases of mumps, in EU and EEA/EFTA countries, 2006–09
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vaccine. Mismatch between the circulating wild-type 
mumps virus genotype and the genotype of the vac-
cine strain has been suggested to influence the vaccine 
effectiveness3. Studies to further analyse cross-immu-
nity between different mumps strains are needed 
since results may influence the formulation of future 
mumps-containing vaccines or the current immunisation 
schedules. 
Little is known about the severity of disease in the mainly 
affected age groups, but complications are according to 
the literature more frequently reported in young adults 
compared to younger children. Interestingly, the clinical 
severity of cases that previously have been immunised 
according to recommendations and then develop clinical 
symptoms compatible with classic mumps disease have 
in general been milder than in non-immune individuals4. 
The possibility of providing a third dose of mumps-con-
taining vaccine in certain outbreak situations in closed 
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Pertussis
• The increase in the number of reported cases 
(observed since 2003) continued until 2009, 
when a slight decrease was observed. The 
overall confirmed case rate in 2009 was 4.89 per 
100 000 population.
• There is heterogeneity of pertussis surveillance 
in the EU and EEA/EFTA area, particularly in 
the surveillance systems, coverage, laboratory 
methods used and case definition applied.
Pertussis is an acute respiratory infection caused by the 
bacterium Bordetella pertussis. It is an endemic infec-
tion common to children everywhere and included in the 
primary vaccination schedule of all EU countries. It is 
often unrecognised, and may be increasingly occurring 
in adults.
Epidemiological situation in 2009
In 2009, 17 596 confirmed cases (20 233 total cases), 
were reported by 28 EU and EEA/EFTA countries. 
Germany and Liechtenstein did not report. The overall 
confirmed case rate remains low with 4.89 per 100 000, 
slightly decreasing over the previous year (Table 2.5.7).
As in previous years, Norway reported the highest con-
firmed case rate with 115.52 per 100 000; Estonia and 
the Netherlands followed with 47 and 35 per 100 000, 
respectively. Overall, Norway, Estonia (36 in 2008), 
Slovenia (8.06 in 2008 to 17 in 2009), Slovakia (1.83 in 
2008 to 5.32 in 2009), Lithuania (1.51 in 2008 to 6.96 in 
2009) and Italy (0.56 in 2008 to 1.01 in 2009) reported 
an increase in their confirmed case rates, whereas 
Austria (2.1 in 2008 to 0.02 in 2009), Finland (9.64 in 
2008 to 5.01 in 2009), Spain (0.44 in 2008 to 0.27 in 
Table 2.5.7. Number and rate of pertussis cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 2 2 0.02 175 2.10 136 1.64 78 0.94
Belgium Y A 160 160 1.50 174 1.63 214 2.02 197 1.87
Bulgaria Y D 251 133 1.75 130 1.70 235 3.06 335 4.34
Cyprus Y C 8 5 0.63 3 0.38 9 1.16 3 0.39
Czech Republic Y C 954 953 9.10 763 7.35 184 1.79 233 2.27
Denmark Y C 91 91 1.65 106 1.94 94 1.73 54 0.99
Estonia Y C 629 629 46.93 485 36.17 409 30.47 153 11.38
Finland Y D 267 267 5.01 511 9.64 480 9.10 0 0.00
France N C 83 82 - 55 - 61 - 125 -
Germany - - - - - - - - - - -
Greece Y C 27 16 0.14 10 0.09 6 0.05 5 0.04
Hungary Y C 33 31 0.31 33 0.33 48 0.48 17 0.17
Ireland Y C 78 61 1.37 71 1.61 47 1.09 38 0.90
Italy Y C 604 604 1.01 336 0.56 795 1.34 796 1.35
Latvia Y D 8 8 0.35 7 0.31 15 0.66 10 0.44
Lithuania Y A 233 233 6.96 51 1.51 17 0.50 4 0.12
Luxembourg Y D 1 1 0.20 2 0.41 4 0.84 0 0.00
Malta Y D 0 0 0.00 0 0.00 0 0.00 0 0.00
Netherlands Y C 6 461 5 751 34.88 8 557 52.16 7 185 43.92 4 174 25.55
Poland Y A 2 390 1 056 2.77 1 272 3.34 1 667 4.37 1 368 3.59
Portugal Y D 64 63 0.59 68 0.64 20 0.19 21 0.20
Romania Y C 10 10 0.05 0 0.00 2 0.01 14 0.06
Slovakia Y C 288 288 5.32 99 1.83 21 0.39 21 0.39
Slovenia Y C 441 351 17.27 162 8.06 533 26.51 446 22.26
Spain Y C 473 126 0.27 200 0.44 151 0.34 102 0.23
Sweden Y C 281 279 3.01 459 5.00 690 7.57 795 8.79
United Kingdom Y C 852 852 1.39 1 051 1.72 65 0.11 3 0.00
EU Total - - 14 689 12 052 3.39 14 780 4.19 13 088 3.17 8 992 2.19
Iceland Y D 0 0 0.00 1 0.32 2 0.65 3 1.00
Liechtenstein - - - - - - - - - - -
Norway Y C 5 544 5 544 115.52 3 887 82.05 5 373 114.78 6 587 141.95
Total - - 20 233 17 596 4.89 18 668 5.22 18 463 4.42 15 582 3.75
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; D: Data from disease surveillance network; –: No report; U: Unspeciﬁ ed.
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2009) and the Netherlands (52 in 2008 to 35 in 2009) 
showed a decrease.
The Netherlands reported the highest total number 
of cases (n=6 461), representing 31.9 % of the total 
reported number of cases, followed by Norway (n=5 544, 
27.4 %) and Poland (n=2 390, 11.8 %). Malta and Iceland 
reported zero cases.
Age and gender distribution
Information on age and gender was available for 88 % 
of the confirmed cases (compared to 69 % in 2008). 
Similar to previous years, the most affected group was 
the 5–14 year-olds with a confirmed case rate slightly 
above 17 per 100 000 (Figure 2.5.17), which is mainly due 
to this group having been the most affected age group 
in countries reporting the highest confirmed case rates, 
mainly northern countries. For most of the remaining 
countries, the most affected group were young children 
under five years old, with a confirmed case rate of near 
10 per 100 000. Overall, females (5.86 per 100 000) 
were slightly more often affected than males (4.99 per 
100 000) for all the age groups, with a male-to-female 
ratio of 0.85:1.
Seasonality
Reported pertussis cases show a slight seasonality, with 
a usually modest increase in cases in the summer and 
autumn. 
Discussion
There was a wide variation across countries in reported 
rates of confirmed cases, ranging from 0.02 to 115.52 per 
100 000, with northern countries reporting higher con-
firmed case rates; a picture also seen in previous years. 
The most affected age group in these countries is 5–14 
year-old children and adolescents. Some of the countries 
recently introduced additional booster doses of the vac-
cine to cover this age group. Norway, for example, intro-
duced a booster for seven-year-olds in 2006, although it 
is still early to assess the impact of this policy change1.
Comparisons between countries should be made with 
caution. The variation in rates in different countries may 
in part be related by different vaccination policies, but 
also to different levels of awareness towards the clini-
cal presentation of the disease (that is very often not 
perceived as pertussis), differences in reporting proce-
dures and surveillance systems2,3, the case definition in 
Figure 2.5.16. Trend and number of reported confirmed pertussis cases by month, in EU and EEA/EFTA countries, 
2006–09
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Figure 2.5.17. Rates of reported confirmed pertussis cases, by age and gender, in EU and EEA/EFTA countries, 2009
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use and the different extent of use and methods in place 
for laboratory confirmation; or to real differences in dis-
ease incidence. All these aspects have an impact on the 
variation in the reported confirmed case rates and which 
of these possible explanations contributes most to the 
observed variation remains unclear.
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Figure 2.5.18. Seasonal distribution of reported confirmed cases of pertussis, in EU and EEA/EFTA countries, 2006–09
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Polio
• Prior to vaccination, poliomyelitis was a common 
childhood disease, sometimes causing meningi-
tis and paralysis.
• Inactivated poliovirus vaccines are used in all EU 
and EEA/EFTA countries.
• Oral live attenuated vaccines are still used in a 
majority of countries worldwide. Besides the 
wild-type polioviruses causing natural disease, 
live attenuated vaccine viruses may cause vac-
cine-associated polio paralysis (VAPP).
• The WHO European Region was declared polio-
free in 2002 and neither wild-type nor vac-
cine-type associated poliomyelitis cases were 
reported in EU EEA/EFTA countries in 2009.
• However, persistent pockets of wild-type and vac-
cine-type poliovirus transmission were reported 
from several African and Asian countries in 2009. 
Imported wild-type and vaccine-type polioviruses 
still remain a threat to unvaccinated European 
populations and, in fact, in 2010 an outbreak 
occurred in the eastern WHO European region 
(mainly Tajikistan) with nearly 500 confirmed 
cases.
Poliomyelitis is a disease caused by polioviruses (sero-
type 1–3). Prior to vaccination, it was a common child-
hood disease, sometimes causing meningitis and 
paralysis. WHO Europe was declared polio free in 2002.
Epidemiological situation in 2009 
No cases of poliomyelitis disease were reported in any 
of the 29 reporting EU and EAA/EFTA countries in 2009. 
There was no report from Lichtenstein. 
Inactivated poliovirus vaccines containing all three sero-
types are offered within the EU/EEA. Current immunisa-
tion programmes provide an excellent immune response. 
Enhanced surveillance in 2009
The Global Polio Laboratory Network (GPLN), comprising 
145 laboratories in 100 countries and operating in EU and 
EEA/EFTA countries and all six WHO regions, perform 
laboratory surveillance for wild-type and vaccine-type 
polioviruses in patients with acute flaccid paralysis and 
in sewage water. The GPLN evaluates progress towards 
polio eradication. 
Screening of sewage water samples for wild-type and 
vaccine-type polioviruses is performed in seven EU and 
EEA/EFTA countries. During 2009 infectious vaccine-type 
polio viruses of all serotypes were recurrently isolated 
from sewage water in Tampere, Finland1,2. The isolated 
strains were highly divergent and more virulent than 
the corresponding vaccine strains. Molecular analy-
sis revealed that all strains originated from an oral live 
attenuated vaccine dose given more than 10 years ago. 
In addition, it is most likely that all three divergent sero-
types originally were established in one single individual 
who is a chronic carrier of the three poliovirus strains. 
Such carriers have occasionally been described in the sci-
entific literature and commonly are immunosuppressed 
and, therefore, unable to mount an immune response 
and clear the viruses3. Of further significance is that the 
three isolated strains were shown to be neurovirulent in 
transgenic susceptible mice inducing paralysis or death 
in at least some of the animals and, therefore, most likely 
capable of inducing poliomyelitis in susceptible humans 
exposed to this contaminated sewage water. The risk for 
sewage workers, as well as close contacts to the chronic 
carrier, may be reduced by booster vaccinations. The sit-
uation requires careful and continued monitoring.
Discussion
Persistent pockets of wild-type and vaccine-type polio-
virus transmission were reported in 2009 in African and 
Asian countries; mainly in Afghanistan, India, Nigeria 
and Pakistan where both wild-type poliovirus type 1 
and 3 and vaccine-types were identified. In addition, 
15 other countries were affected by outbreaks: Angola, 
Benin, Burkina Faso, Central African Republic, Chad, 
Democratic Republic of Congo, Côte d’Ivoire, Ethiopia, 
Ghana, Kenya, Mali, Niger, Togo, Sudan and Uganda. 
The WHO European Region was declared polio-free in 
2002. However, imported wild-type and vaccine-type 
polioviruses through individuals excreting polioviruses 
in their stools still remain a threat to unvaccinated 
European individuals. This is the reason for an outbreak 
of polio occurring in undervaccinated populations in 
the eastern WHO European region in 2010 with nearly 
500 confirmed cases. This outbreak mainly affected 
Tajikistan, but also its neighbouring countries, and 
challenged the polio free certification status of Europe. 
Major supplementary immunisation activities (still ongo-
ing) were required to stop transmission. No cases in EU 
and EEA/EFTA countries were reported in 2010 (more 
information on this outbreak can be found in Chapter 3).
Furthermore, several EU countries have identified vac-
cine-derived poliovirus strains in their sewage water 
originating either from newly vaccinated visitors or 
immigrants to Europe or chronic carriers. This needs 
to be further monitored and immunity in the European 
populations must be ensured including among sewage 
workers.
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High vaccination coverage using inactivated poliovirus 
vaccines is obtained in all EU and EEA/EFTA countries, 
and needs to be maintained in view of the continuing 
importation of polioviruses. Obtaining high vaccina-
tion coverage will also provide herd immunity to still 
susceptible individuals, e.g. children belonging to fami-
lies refraining from vaccination, migrant populations, 
and individuals suffering from congenital or acquired 
immunodeficiency.
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Rabies
• One autochthonous human case was reported in 
2009 in the EU and EEA/EFTA.
• Rabies is still endemic in wild and domestic 
animals in different areas of the EU. Thirty-seven 
cases in bats have been reported.
Rabies is an infection caused by the rabies virus, which 
is hosted by a wide range of domestic and wild animals. 
It is a rare disease in the EU, although usually fatal. The 
infection is transmitted by the bite of a rabies-infected 
animal. Vaccination should be given as soon as possible 
after exposure.
Epidemiological situation in 2009
In 2009, one confirmed human case of rabies was 
reported in 29 EU and EEA/EFTA countries (Liechtenstein 
did not report). The case was an elderly Romanian citi-
zen, living in a rural area close to a forest, who sought 
medical attention when symptoms, compatible with 
rabies, started. She had been bitten by a fox in her 
left forearm and hand one month before, however, she 
had not consulted nor notified the incident. Laboratory 
results were positive. Despite treatment, the patient 
died four days later.
Animal cases of rabies in the EU
In 2009, 859 cases of rabies were reported in animals in 
the EU, mainly from Romania, Latvia, Italy, Bulgaria and 
Lithuania: 151 in domestic animals, 671 in wild animals 
and 37 in bats. Bats were mainly reported from France 
(13) and the Netherlands (11). The number of cases in 
animals shows a slight decrease compared to previous 
years1. 
Discussion
Although the incidence of human rabies is very low, 
the risk is still present in Europe. A few sporadic severe 
human cases are still reported in EU and EEA/EFTA coun-
tries, often travellers that were exposed to rabid animals 
outside Europe. Autochthonous cases also occur occa-
sionally, as rabies is still prevalent in wildlife (foxes and 
racoons) in several central and eastern Member States. 
This is the second year that Romania has notified an 
indigenous case of rabies. Because of the high fatal-
ity rate, the prevention of rabies infection is of utmost 
importance2. This case highlights the importance of 
continuous monitoring for this disease in wildlife reser-
voirs. Insectivorous bats can also play a significant role 
throughout the entire European territory, even though it 
is difficult to assess the real magnitude of this phenom-
enon because surveillance and monitoring of rabies in 
animals vary greatly between Member States.
References
1. Rabies Information System of the WHO Collaboration Centre 
for Rabies Surveillance and Research. Rabies surveillance. 
Available from: http://www.who-rabies-bulletin.org/Queries/
Surveillance.aspx
2. Rabies Information System of the WHO Collaboration Centre for 
Rabies Surveillance and Research. Prevention of rabies in humans. 
Available from: http://www.who-rabies-bulletin.org/about_rabies/
Prevention_Humans.aspx
175
RabiesSURVEILLANCE REPORT
Surveillance systems overview
Country Data Source
Co
m
pu
ls
or
y 
(C
p)
 /
 
Vo
lu
nt
ar
y 
(V
) /
 O
th
er
(O
)
Co
m
pr
eh
en
si
ve
 (C
o)
 /
 
Se
nt
in
el
 (S
e)
 /
 O
th
er
(O
)
Ac
ti
ve
 (A
) /
 
Pa
ss
iv
e 
(P
)
Ca
se
-B
as
ed
 (C
)/
Ag
gr
eg
at
ed
 (A
)
Data reported by
Na
tio
na
l C
ov
er
ag
e
La
bo
ra
to
ri
es
Ph
ys
ic
ia
ns
Ho
sp
it
al
s
O
th
er
s
Austria AT-Epidemiegesetz Cp Co P C Y Y Y Y Y
Belgium BE-REFLAB V Co P C - - - - -
Bulgaria BG-NATIONAL_SURVEILLANCE Cp Co P A Y Y Y Y Y
Cyprus CY-NOTIFIED_DISEASES Cp Co P C N Y N N Y
Czech Republic CZ-EPIDAT Cp Co A C - Y Y N Y
Denmark DK-MIS Cp Co P C N Y N N Y
Estonia EE-RABIES Cp Co P C Y Y Y Y Y
Finland FI-NIDR Cp Co P C Y Y N N Y
France FR-MANDATORY_INFECTIOUS_DISEASES Cp Co P C Y Y Y Y Y
Germany DE-SURVNET@RKI-7.1/6 Cp Co P C Y Y Y Y Y
Greece GR-NOTIFIABLE_DISEASES Cp Co P C Y Y Y N Y
Hungary HU-Zoonoses Cp Co P C Y Y Y N Y
Iceland IS-SUBJECT_TO_REGISTRATION Cp Co P C Y Y Y N Y
Ireland IE-CIDR Cp Co P C Y Y Y N Y
Italy IT-NRS Cp Co P C Y Y Y N Y
Latvia LV-BSN Cp Co P C Y Y Y N Y
Lithuania LT-COMMUNICABLE_DISEASES Cp Co P C Y Y N N Y
Luxembourg LU-SYSTEM1 Cp Co P C Y Y N N Y
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176
SURVEILLANCE REPORTAnnual epidemiological report 2011
Rubella
• The number of reported and laboratory-confirmed 
rubella cases decreased between 2008 and 
2009. 
• The overall proportion of laboratory-confirmed 
cases is very low (6 % of all cases) in the context 
of planned rubella elimination. 
• Despite an overall large decrease in the number 
of cases of congenital rubella infection following 
introduction of vaccination, sporadic cases still 
occur in Europe. Sub-optimal coverage with the 
measles-mumps-rubella vaccine can lead to 
pockets of susceptible individuals and increasing 
reports of these diseases, including congenital 
rubella infection.
Epidemiological situation in 2009
In 2009, 492 rubella cases were confirmed out of 8 827 
cases reported from 26 EU and EEA/EFTA countries (Table 
2.5.8). Belgium, France, Germany and Liechtenstein did 
not report. In several countries the surveillance system 
is not national; in Germany, for example, mandatory 
reporting of rubella cases is established in some fed-
eral states, whereas nationwide mandatory reporting is 
restricted to congenital rubella.
The number of rubella cases has significantly decreased, 
since 2006, but most of these cases are not laboratory-
confirmed. Only 5.5 % of the reported cases were labora-
tory confirmed in 2009 (492 out of 8 827), in comparison 
to 32.5 % in 2008 (6 355 out of 19 559) and 14.8 % in 
Table 2.5.8. Number and rate of rubella cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria Y C 308 247 2.96 5 0.06 14 0.17 - -
Belgium - - - - - - - - - - -
Bulgaria Y D 44 1 0.01 0 0.00 3 0.04 247 3.20
Cyprus Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Czech Republic Y C 5 0 0.00 2 0.02 0 0.00 5 0.05
Denmark Y C 0 0 0.00 4 0.07 0 0.00 0 0.00
Estonia Y C 1 1 0.07 4 0.30 10 0.74 5 0.37
Finland Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
France - - - - - - - - - - -
Germany - - - - - - - - - - -
Greece Y C 4 3 0.03 0 0.00 0 0.00 0 0.00
Hungary Y C 0 0 0.00 0 0.00 0 0.00 2 0.02
Ireland Y C 20 1 0.02 2 0.05 3 0.07 1 0.02
Italy Y C 205 205 0.34 6 183 10.37 758 1.28 252 0.43
Latvia Y D 7 1 0.04 2 0.09 1 0.04 2 0.09
Lithuania Y C 0 0 0.00 0 0.00 13 0.38 0 0.00
Luxembourg Y D 0 0 0.00 0 0.00 0 0.00 0 0.00
Malta Y D 0 0 0.00 3 0.73 0 0.00 0 0.00
Netherlands Y C 7 2 0.01 2 0.01 4 0.02 5 0.03
Poland Y A 7 587 8 0.02 70 0.18 153 0.40 103 0.27
Portugal Y D 3 3 0.03 1 0.01 1 0.01 0 0.00
Romania Y C 605 2 0.01 0 0.00 2 958 13.72 0 0.00
Slovakia Y C 0 0 0.00 0 0.00 0 0.00 2 0.04
Slovenia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Spain Y C 20 7 0.02 40 0.09 14 0.03 27 0.06
Sweden Y C 1 1 0.01 0 0.00 2 0.02 3 0.03
United Kingdom Y C 10 10 0.02 36 0.06 34 0.06 36 0.06
EU total - - 8 827 492 0.14 6 354 1.86 3 968 1.17 690 0.21
Iceland Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Liechtenstein - - - - - - - - - - -
Norway Y C 0 0 0.00 1 0.02 0 0.00 2 0.04
Total - - 8 827 492 0.14 6 355 1.84 3 968 1.15 692 0.21
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; D: Data from disease surveillance network; –: No report; U: Unspeciﬁ ed.
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2007 (3 968 out of 26 823). Poland reported the high-
est number of clinical rubella cases, with almost all of 
them not being laboratory confirmed (eight out of 7 587). 
Austria reported a large increase in cases due to an out-
break of over 300 cases (247 confirmed) in 2009. Italy 
reported a decrease in total cases from 6 183 in 2008 to 
205 in 2009 (all confirmed).
Age and gender distribution
This section relates to confirmed cases only, and should 
be interpreted with caution due to the low and variable 
laboratory confirmation rate of cases between countries 
and years.
The age group (males and females) with the highest 
confirmed case rate was the group of adolescents and 
young adults between 15 and 24 years of age (0.68 per 
100 000), and then very young children aged 0–4 years 
(rate of 0.60 per 100 000) (Figure 2.5.19).
Seasonality
In 2009, the peak confirmed case rate was seen in late 
winter and early spring with a pronounced decrease 
over summer and autumn, a pattern similar to the one 
observed in previous years (Figure 2.5.20).
Enhanced surveillance in 2009
A total of 8 951 rubella cases (391 laboratory confirmed) 
were reported by 28 countries to the enhanced surveil-
lance network EUVAC.NET in 20091. The vaccination sta-
tus was known for 7 031 reported rubella cases (81 %): 
57 % were unvaccinated, 41 % were vaccinated with one 
dose, and 2 % were vaccinated with at least two doses.
Discussion
The main aim of rubella vaccination is the prevention of 
congenital rubella infection (CRI). Many countries origi-
nally had started to selectively vaccinate adolescent 
girls. After introduction of the measles-mumps-rubella 
vaccine (MMR) most countries moved to vaccinating 
all young children. The emphasis of the vaccination 
Figure 2.5.19. Rates of reported confirmed rubella cases, by age and gender, in EU and EEA/EFTA countries, 2009
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Figure 2.5.20. Seasonal distribution of reported confirmed cases of rubella, in EU and EEA/EFTA countries, 2009
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programme changed from protecting the individual 
woman directly to indirect protection by creating herd 
immunity. To keep herd immunity sufficiently high, vac-
cination coverage is essential.
Austria experienced a rubella outbreak in two regions 
in 2009, and the most affected age group was young 
adults between 15 and 24 years of age2,3. Rubella has 
been a notifiable disease since 2007 in Austria. Italy, 
Poland and Romania have reported a decrease in the 
total number of cases. 
The overall proportion of laboratory-confirmed cases 
represented only 5.5 % of the total cases. This appears 
low in the context of the rubella elimination and preven-
tion of congenital rubella infection that was set for 2010. 
Strengthening laboratory capacity in order to ensure 
investigation of clinical rubella cases appears a key ele-
ment to reach the goal of elimination.
References
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Tetanus
• Tetanus appears to be under control in all EU 
and EEA/EFTA countries thanks to good general 
public health and hygiene supported by effective 
universal vaccination in all countries.
• The overall confirmed case rate remains very 
low (0.02 per 100 000 population) and a slightly 
decreasing trend can be observed in recent years.
• In the EU and EEA/EFTA countries, no cases of 
neonatal tetanus were reported. 
• The most affected group was elderly women (65 
years or older). Additional efforts should be put 
in place in order to improve the immunisation 
status of the adult and elderly population.
Tetanus is a sporadic and relatively uncommon infec-
tion in EU and EEA/EFTA countries, caused by the bac-
terium Clostridium tetani. Contamination of wounds with 
tetanus spores in unimmunised persons can cause an 
illness with muscular spasms and sometimes death. 
Tetanus is included in the primary vaccination schedule 
of all EU countries, and periodic vaccination in adult-
hood is required to maintain immunity.
Epidemiological situation in 2009
In 2009, 128 cases, including 79 confirmed cases, were 
reported by 25 EU and EEA/EFTA countries. Austria, 
Finland, Germany, Iceland and Liechtenstein did not 
report. Italy, Poland, Romania, France, United Kingdom, 
Spain, Portugal and Hungary reported most of the cases. 
Table 2.5.9. Number and rate of tetanus cases reported in EU and EEA/EFTA countries, 2006–09
Country
2009 2008 2007 2006
National 
Coverage
Report 
type
Total 
cases
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Confirmed cases 
and notification 
rate
Cases Rate Cases Rate Cases Rate Cases Rate
Austria - - - - - - - - - - -
Belgium Y C 0 0 0.00 1 0.01 1 0.01 1 0.01
Bulgaria Y C 0 0 0.00 2 0.03 0 0.00 4 0.05
Cyprus Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Czech Republic Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Denmark Y C 0 0 0.00 2 0.04 3 0.06 2 0.04
Estonia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Finland - - - - - - - - - - -
France Y C 8 8 0.01 3 0.00 7 0.01 17 0.03
Germany - - - - - - - - - - -
Greece Y C 2 0 0.00 0 0.00 8 0.07 5 0.04
Hungary Y C 6 0 0.00 0 0.00 0 0.00 7 0.07
Ireland Y C 0 0 0.00 2 0.05 1 0.02 0 0.00
Italy Y C 58 58 0.10 53 0.09 59 0.10 64 0.11
Latvia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Lithuania Y C 0 0 0.00 1 0.03 1 0.03 3 0.09
Luxembourg Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Malta Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Netherlands Y C 1 0 0.00 0 0.00 0 0.00 - -
Poland Y C 19 1 0.00 14 0.04 19 0.05 22 0.06
Portugal Y C 6 0 0.00 1 0.01 9 0.08 7 0.07
Romania Y C 9 7 0.03 11 0.05 9 0.04 10 0.05
Slovakia Y C 0 0 0.00 0 0.00 0 0.00 0 0.00
Slovenia Y C 0 0 0.00 1 0.05 1 0.05 4 0.20
Spain Y C 7 3 0.01 10 0.02 8 0.02 13 0.03
Sweden Y C 3 0 0.00 0 0.00 0 0.00 1 0.01
United Kingdom Y C 8 1 0.00 0 0.00 0 0.00 3 0.00
EU Total - - 127 78 0.02 101 0.03 126 0.03 163 0.04
Iceland - - - - - 0 0.00 0 0.00 0 0.00
Liechtenstein - - - - - - - - - - -
Norway Y C 1 1 0.02 2 0.04 0 0.00 0 0.00
Total - - 128 79 0.02 103 0.03 126 0.03 163 0.04
Source: Country reports. Y: Yes; N: No; A: Aggregated data report; C: Case-based report; –: No report; U: Unspeciﬁ ed.
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The overall confirmed case rate remains very low at 0.02 
per 100 000 population. The highest rate was reported 
by Italy (0.10 per 100 000). No cases of neonatal tetanus 
were reported.
Age and gender distribution
The most affected group was the elderly (≥ 65 years) 
with 80 of the 97 (82 %) reported cases with this infor-
mation (0.12 per 100 000), followed by the age group 
45–64 years with 12 cases. One case from Romania was 
reported in the age group 5–14 years. Females accounted 
for 68 % of the reported cases, almost all of them in the 
≥ 65 years group. 
Seasonality
A peak of tetanus confirmed cases is seen from June to 
October, even though the number of cases is low. This is 
probably related to more outdoor activities during this 
period.
Discussion
The confirmed case rate for tetanus remains very low 
in the EU, and the number of reported cases shows a 
slightly decreasing trend over the last few years. The 
cases reported in the elderly were probably related to 
lower coverage or waning immunity. The high proportion 
of women could be explained by different vaccination 
strategies during their youth, particularly in relation to 
vaccination on enrolment to obligatory military service 
for men1. This emphasizes the need to maintain high 
vaccination rates in all age groups and to implement 
catch-up strategies in those countries with higher rates 
of disease.
References
1. Reed DB, Westneat SC. Exposure risks and tetanus immunization 
status in farmers ages 50 and over. South Med J 2009;102(3):251-5.
Figure 2.5.21. Trend and number of reported confirmed tetanus cases by month, in EU and EEA/EFTA countries, 
2006–09
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Figure 2.5.22. Rates of reported confirmed tetanus cases, by age and gender, in EU and EEA/EFTA countries, 2009
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Figure 2.5.23. Seasonal distribution of reported confirmed cases of tetanus, in EU and EEA/EFTA countries, 2006–09
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Source: Country reports: Cyprus, Czech Republic, Denmark, Estonia, France, Greece, Hungary, Ireland, Italy, Luxembourg, Malta, Norway, Poland, Portugal, Slovakia, 
Slovenia, Spain, Sweden.
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Antimicrobial resistance
2.6 Antimicrobial resistance and healthcare-
associated infection
• Antimicrobial resistance constitutes an increas-
ingly important human health hazard in Europe. 
• Resistance in Escherichia coli, the most common 
cause of bacteraemia by Gram-negative bac-
teria and of urinary tract infections, increases 
Europe-wide for all antimicrobial classes under 
surveillance.
• Combined resistance to several antimicrobi-
als continues to increase in some bacteria (e.g. 
Escherichia coli, Pseudomonas aeruginosa and 
Klebsiella pneumoniae) and further reduces the 
available treatment options.
• The occurrence of meticillin-resistant 
Staphylococcus aureus (MRSA) shows a decrease 
in some countries, although the MRSA propor-
tions remain above 25 % in more than one third of 
the reporting countries.
• The use of antimicrobials shows wide variations 
across Europe, however, penicillins remain the 
most frequently prescribed antimicrobial class in 
all countries.
• Prevention and control of antimicrobial resistance 
call for international cooperation and concerted, 
multidisciplinary efforts at the national level.
The data presented in this section were collected by the 
European Antimicrobial Resistance Surveillance Network 
(EARS-Net, previously EARSS) which is coordinated by 
ECDC. EARS-Net collects data on antimicrobial resistance 
in seven invasive pathogens of public health importance 
(Streptococcus pneumoniae, Staphylococcus aureus, 
Enterococcus faecalis, Enterococcus faecium, Escherichia 
coli, Klebsiella pneumoniae, Pseudomonas aeruginosa). 
The surveillance is based on national networks collect-
ing data from clinical laboratories and reporting these 
data to ECDC. At present EARS-Net includes more than 
900 public health laboratories serving over 1 400 hos-
pitals in Europe and providing services to an estimated 
population of 100 million European citizens. The maps 
and trend figures presented in this summary show the 
occurrence of antimicrobial resistance in selected bac-
teria causing invasive infections and are based on lab-
oratory results reported by countries participating in 
EARS-Net. For more detailed information on EARS-Net 
and EARS-Net surveillance results please refer to the 
EARS-Net Annual Report 2009 and the EARS-Net web-
site (http://ecdc.europa.eu/en/activities/surveillance/
EARS-Net). 
Escherichia coli
Escherichia coli is the most frequent cause of bacterae-
mia by Gram-negative bacteria, as well as community- 
and hospital-acquired urinary tract infections. 
The occurrence of antimicrobial resistance in E. coli con-
tinues to increase Europe-wide for both multidrug resist-
ance and for single antimicrobials under surveillance. 
The occurrence of resistance to third-generation cepha-
losporins in E. coli in 2009 is displayed in Figure 2.6.1. 
Nine of 28 countries reported third-generation cepha-
losporin resistance higher than 10 % and ranging up to 
19.2 %. Among 19 countries reporting less than 10 % 
resistance, the lowest proportions were reported by 
Iceland (1.8 %), Estonia (2.2 %) and Norway (2.3 %). 
Third-generation cephalosporin resistance in E. coli 
increased significantly during the last four years in more 
than half of the 28 reporting countries (Figure 2.6.2). A 
high proportion (85–100 %) of the isolates was identi-
fied as producing an extended-spectrum beta-lacta-
mase (ESBL). These data indicate that ESBL production 
is highly prevalent in third-generation cephalosporin-
resistant E. coli in European hospitals.
Meticillin-resistant Staphylococcus aureus
Meticillin-resistant Staphylococcus aureus (MRSA) is the 
most important cause of antimicrobial-resistant health-
care-associated infections worldwide. In 2009, nine 
countries reported less than 10 % MRSA, nine countries 
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reported between 10 % and 25 %, another nine countries 
reported between 25 % and 50 %, while one country 
reported proportions above 50 % (Figure 2.6.3). Eight 
countries reported decreasing trends for MRSA while 
only one country reported an increase (Figure 2.6.4).
Although proportions of MRSA seem to stabilise, or even 
decrease in some European countries, MRSA remains a 
public health priority, since the proportion of MRSA is 
still above 25 % in more than one third of the reporting 
countries.
Klebsiella pneumoniae
Klebsiella pneumoniae is an important cause of urinary 
and respiratory tract infections, especially in patients 
with impaired immune systems. Regarding K. pneumo-
niae, high proportions of resistance to third-generation 
cephalosporins (Figure 2.6.5), fluoroquinolones and 
aminoglycosides are reported in central and south-east-
ern European countries. Many of these isolates have 
acquired resistance to all of the above mentioned anti-
microbial classes.
Pseudomonas aeruginosa
Pseudomonas aeruginosa is an important cause of infec-
tion among patients with impaired immune systems. 
High proportions of resistance to several antimicrobials 
in P. aeruginosa isolates have been reported by many 
countries, especially in southern and eastern Europe. 
Multidrug resistance is frequent and resistance to car-
bapenems is above 10 % in more than half of the report-
ing countries (Figure 2.6.6). 
Discussion
In 2009, the most concerning resistance results come 
from the rapidly decreasing susceptibility of invasive 
Escherichia coli to basically all antimicrobial agents 
included in the EARS-Net surveillance except carbap-
enems, and from the high prevalence of resistance 
in Klebsiella pneumoniae to third-generation cepha-
losporins, fluoroquinolone and aminoglycosides. In half 
of the reporting countries, the proportion of multiresist-
ant K. pneumoniae isolates (combined resistance to 
third-generation cephalosporins, fluoroquinolones and 
aminoglycosides) is above 10 %, and a few countries 
are now also reporting high proportions of resistance 
to carbapenems. These antibiotics have been widely 
used in many countries due to the increasing rate of 
extended-spectrum beta-lactamase (ESBL)-producing 
Enterobacteriaceae with a consequent impact on the 
emergence of carbapenemase production (VIM, KPC and 
NDM-1), especially in K. pneumoniae.   
The first detection of Enterobacteriaceae carrying the 
New Delhi metallo-beta-lactamase (NDM-1) carbapene-
mase enzyme, which is an enzyme resulting in extensive 
antibiotic resistance, was reported in 2008. In 2010, a 
Lancet article about the spread of NDM-1 was published 
raising considerable concern. The results of an ad-hoc 
Figure 2.6.1. Escherichia coli: invasive isolates resistant to third-generation cephalosporins, 2009
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Source: EARS-Net. Only data from countries reporting more than 10 isolates are shown.
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Figure 2.6.2. Escherichia coli: trends in the proportion of invasive isolates resistant to third-generation 
cephalosporins, by country, 2006–09
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Source: EARS-Net. Only countries reporting 20 isolates or more per year were included. The symbols > and < indicate a signiﬁ cant increasing and decreasing trend, 
respectively. The symbol * indicates that the signiﬁ cant trend in the overall data was not supported by data from laboratories that consistently reported for all four 
years.
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Figure 2.6.3. Staphylococcus aureus: invasive isolates resistant to meticillin (MRSA), 2009
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Source: EARS-Net. Only data from countries reporting more than 10 isolates are shown.
survey in EU countries in 2010 revealed that among 77 
NDM-1 cases identified between 2008 and 2010,  39 
were isolated during 2010 in 13 EU countries (for more 
information see Chapter 3).
Other trends in the occurrence of resistance reported 
to EARS-Net bring hope that national efforts on infec-
tion control and efforts targeted at containment of 
resistance may in some cases bring the development of 
resistance to a halt, or even reverse undesirable resist-
ance trends, as exemplified by the development for 
meticillin-resistant Staphylococcus aureus (MRSA). Even 
though the proportion of MRSA among Staphylococcus 
aureus is still above 25 % in 10 out of 28 countries, the 
occurrence of MRSA is stabilising or decreasing in some 
countries and a sustained decrease was observed in 
Austria, France, Ireland, Latvia and the United Kingdom. 
Reference
European Centre for Disease Prevention and Control (ECDC). 
Antimicrobial resistance surveillance in Europe 2009. Annual Report of 
the European Antimicrobial Resistance Surveillance Network (EARS-Net). 
Stockholm: ECDC; 2010.
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Figure 2.6.4. Staphylococcus aureus: trends in the proportion of invasive isolates resistant to meticillin (MRSA) by 
country, 2006–09
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Source: EARS-Net. Only countries reporting 20 isolates or more per year were included. The symbols > and < indicate a signiﬁ cant increasing and decreasing trend, 
respectively. The symbol * indicates that the signiﬁ cant trend in the overall data was not supported by data from laboratories that consistently reported for all four 
years.
188
SURVEILLANCE REPORTAnnual epidemiological report 2011
Figure 2.6.5. Klebsiella pneumoniae: invasive isolates resistant to third-generation cephalosporins, 2009
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Source: EARS-Net. Only data from countries reporting more than 10 isolates are shown.
Figure 2.6.6. Pseudomonas aeruginosa: invasive isolates resistant to carbapenems, 2009
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Source: EARS-Net. Only data from countries reporting more than 10 isolates are shown.
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Figure 2.6.7. Outpatient antibiotic (ATC group J01) use subdivided into major antibiotic classes according to the 
Anatomical Therapeutical Chemical (ATC) classification, EU and EFA/EFTA countries, 2009
0 5 10 15 20 25 30 35 40
Greece
Cyprus*
France
Italy
Luxembourg
Belgium
Slovakia
Poland
Portugal
Malta
Ireland
Lithuania*
Estonia**
Iceland
Bulgaria
Czech Republic
Finland
United Kingdom
Hungary
Denmark
Austria
Norway
Germany
Slovenia
Sweden
Netherlands
Estonia
Latvia
Cephalosporins and other beta-lactams 
(J01D)
Penicillins (J01C)
Macrolides, lincosamides and 
streptogramins (J01F)
Quinolones (J01M)
Sulfonamides and trimethoprim (J01E)
Other J01 classes
Tetracyclines (J01A)
DDD per 1 000 inhabitants and per day
 
Source: ESAC. * Total use, i.e. including inpatients, for Cyprus and Lithuania. ** Reimbursement data, i.e. not including over-the-counter sales without a prescription, 
for Spain.
Antimicrobial use in the EU
Data on antibiotic use are currently available from 28 
EU and EEA/EFTA countries and were collected by the 
European Surveillance of Antimicrobial Consumption 
(ESAC) project, coordinated by the University of Antwerp, 
Belgium. ESAC is funded by ECDC.
Figure 2.6.7 shows antibiotic use measured in defined 
daily doses (DDD) per 1 000 inhabitants and per day 
according to the Anatomical Therapeutical Chemical 
(ATC)/DDD index1. Each bar refers to a specific country 
while the colours show the recorded volume of use of the 
different antimicrobial classes used in that country. The 
reported data refer to antibiotic use outside hospitals 
(outpatient use), which accounts for the largest propor-
tion of human consumption of antibiotics. 
Total outpatient antibiotic use ranged from 10.5 DDD per 
1 000 inhabitants and per day in Latvia to 38.6 DDD per 
1 000 inhabitants and per day in Greece. As in previous 
years, penicillins were the most frequently prescribed 
antibiotic class in all countries, ranging from 28.7 % 
(Germany) to 66 % (Slovenia) whereas the proportion 
of use of other antibiotic classes varied widely among 
the countries, e.g. cephalosporins, from 4.5 % (Sweden) 
to 29.9 % (Greece); macrolides, from 2.8 % (United 
Kingdom) to 13.3 % (Portugal); and quinolones, from 
0.02 % (Slovenia) to 26.3 % (Iceland).
Temporal trends in total outpatient antibiotic consump-
tion from 2007 to 2009 are presented in Figure 2.6.8. Six 
countries (Lithuania, Bulgaria, Greece, Ireland, Estonia, 
Iceland) showed a decrease of more than 5 % of DDD 
per 1 000 inhabitants and per day between 2008 and 
2009, while six other countries – Poland, France, Austria 
(although antibiotic consumption data in 2009 versus 
total care data in 2008), Hungary, Czech Republic and 
Cyprus – showed an increase of more than 5 % during 
the same period. Total outpatient antibiotic use con-
tinuously decreased during the last three years (2007 to 
2009) in six countries (Estonia, Ireland, Latvia, Sweden, 
Slovenia and Spain).
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Figure 2.6.8. Trends in total outpatient antibiotic consumption (ATC group J01) in EU and EEA/EFTA Member States, 
from 2007 (top bar) to 2009 (green bottom bar)
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Discussion
Antimicrobial consumption and in particular the con-
sumption of antibacterials for systemic use expressed in 
DDD per 1 000 inhabitants per day is a potential indica-
tor2 for healthcare professionals and national policymak-
ers to improve the prudent use of antibiotics through 
national infection control strategies. Irresponsible use 
of antibiotics has shown to be associated with the devel-
opment and spread of antimicrobial resistance.
However, the broad variation of outpatient use of anti-
bacterials for systemic use in 2009 in EU and EEA/EFTA 
countries (Figure 2.6.7), which measures between 10.5 
DDD per 1 000 inhabitants and per day and a 3.7-fold 
higher consumption of 38.6 DDD per 1 000 inhabitants 
per day (median 19.0), should be interpreted with cau-
tion for comparison of data between countries. It arises 
from the facts that some countries reported data on 
overall consumption, covering both outpatient and hos-
pital care, or data sources may have changed over the 
time. Consolidating a continuous collection of compre-
hensive antimicrobial consumption data appears diffi-
cult and there are still differences in the national data 
sources used and in the disposability of national reg-
isters of available antibiotics, which are a prerequisite 
for correct calculations of DDD per 1 000 inhabitants and 
per day.
Based on reliable data on antimicrobial use, a future 
option is to link these data with surveillance data 
on antimicrobial resistance, e.g. from the European 
Antimicrobial Resistance Surveillance Network (EARS-
Net), to evaluate the timely association between antimi-
crobial use and the occurrence resistant bacteria.
References
1. WHO Collaborating Centre for Drug Statistics Methodology [web-
site]. Oslo (Norway): Norwegian Institute of Public Health. Available 
from: http://www.whocc.no/atc_ddd_index/
2. Coenen S, Ferech M, Haaĳ er-Ruskamp FM, Butler CC, Vander 
Stichele RH, Verheĳ  TJ, et al. European Surveillance of Antimicrobial 
Consumption (ESAC): quality indicators for outpatient antibiotic use 
in Europe. Qual Saf Health Care. 2007 Dec;16(6):440-5.
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Healthcare-associated infections
• For the first time since the transition of the coor-
dination of the healthcare-associated infections 
(HAI) surveillance to ECDC in July 2008, data 
were collected through ECDC’s surveillance sys-
tem (TESSy) (2009 data with follow-up until 31 
December 2010). Seventeen countries submit-
ted data for at least one of the HAI surveillance 
components. 
• Decreasing trends previously observed for surgi-
cal site infections following hip prosthesis were 
confirmed in 2009.
• The distribution of micro-organisms associated 
with infections acquired in intensive care units 
showed a high proportion of third-generation 
cephalosporin-resistant Enterobacteriaceae (in 
particular, Klebsiella spp. and Enterobacter spp.) 
isolates.
During January–February 2011, surveillance data for 
healthcare-associated infections (HAI) were for the 
first time collected through the European Surveillance 
System (TESSy) (2009 data with partial follow-up until 
31 December 2010). This followed the integration of 
European surveillance of surgical site infections (formerly 
HELICS-SSI) and of infections acquired in intensive care 
units (formerly HELICS-ICU) during the second half of 
2010. More information about HAI-Net is available on the 
ECDC website (http://www.ecdc.europa.eu/en/activities/
surveillance/hai).
Data for at least one of the HAI-Net surveillance mod-
ules were received from 17 countries and 20 surveillance 
networks.
Surveillance of surgical site infections
Data on surveillance of surgical site infections (SSIs) in 
2009 were collected using the patient-based methodol-
ogy described in the 2009 edition of this report. 
Two indicators were used to express the risk of SSI: 
the cumulative incidence, which is the crude percent-
age of surgical interventions resulting in a SSI, and the 
incidence density, which is the number of SSI per 1 000 
post-operative days at risk in the hospital. The incidence 
density is the preferred measure for comparison of inci-
dence between countries as it uses only observations 
during the hospital stay in both numerator and denomina-
tor. Comparisons are therefore less affected by variation 
in length of post-operative stay or intensity of post-dis-
charge case-finding. However, the incidence density can 
only be calculated when the discharge date is known.
SSI surveillance data for 2009 (with partial follow-up of 
patients who had undergone orthopaedic surgery until 
December 2010) were received from 16 networks and 13 
countries and included 339 702 surgical interventions 
from 1 407 hospitals (compared with 315 935 surgical 
interventions from 1 434 hospitals in 2008). Finland sub-
mitted data for 2008 and 2009. The types and numbers 
of surgical interventions reported by each country are 
shown in Table 2.6.1.
The percentage of SSI varied according to the type of sur-
gical intervention with the highest rates in colon surgery 
(9.2 %) and the lowest rates in knee prosthesis (0.7 %). 
Similarly to 2008, the SSI cumulative incidence for hip 
prosthesis (HPRO) interventions showed a significant 
decreasing trend (p < 0.001) as shown in Figure 2.6.9.
Table 2.6.1. Number of interventions included in the surveillance of surgical site infections by category and country, 2009
  Number of hospitals CABG CHOL COLO CSEC HPRO KPRO LAM Total
Austria 31 40 372 81 3 301 4 467 297 37 8 595
Germany 247 8 579 10 472 6 435 9 700 27 412 15 177 2 543 80 318
Finland 11 6 060 4 641 10 701
France 579 910 10 293 5 537 14 666 19 842 9 090 1 289 61 627
Hungary 29 201 2 534 108 3 290 325 331 246 7 035
Italy 82 170 2 320 1 679 3 766 1 273 315 253 9 776
Lithuania 20 603 986 323 2 043 539 385 4 879
Malta 1 276 276
Netherlands 31 1 598 1 179 1 664 5 182 3 490 13 113
Norway 54 746 412 219 2 171 2 530 6 078
Portugal 20 1 951 807 2 283 964 584 122 6 711
Spain 31 578 855 975 759 1 830 1 308 450 6 755
United Kingdom(a) 271 5 756 0 2 762 24 462 43 914 46 944 0 123 838
Total 1 407 17 859 31 793 20 105 68 105 114 338 82 562 4940 339 702
Source: HAI-Net SSI. CABG: coronary artery bypass graft; CHOL: cholecystectomy; COLO: colon surgery; CSEC: Caesarean section; HPRO: hip prosthesis; KPRO: knee 
prosthesis; LAM: laminectomy; –: no data. (a) Comprises data from England, Northern Ireland, Scotland and Wales.
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Intra-country trends for SSI rates associated with hip 
prosthesis from 2004 to 2009 were analysed both for 
cumulative incidence adjusting for case-mix (risk index) 
and to eliminate the effect of post-discharge surveillance, 
for infections detected before patient discharge adjust-
ing for the length of stay in the hospital (and the risk 
index) using Poisson regression analysis (trend analysis 
of incidence density). Significant risk-adjusted decreasing 
trends for SSI cumulative incidence after hip prosthesis 
were observed in Austria (p = 0.026), Germany (p < 0.001), 
Finland (p < 0.001), France (p < 0.001), Hungary (p < 0.05) 
and the United Kingdom (p < 0.001, despite an increase 
in 2008), but an increasing trend was observed in Italy 
(p = 0.019). 
The trend analysis of the in-hospital incidence density 
showed decreasing trends in Finland, Germany, Hungary, 
Spain and the United Kingdom. In Germany, the percent-
age of data for which the hospital discharge date was 
unknown further decreased in 2009 (Figure 2.6.10). The 
Figure 2.6.9. Trends in cumulative incidence of surgical site infections in Europe by category of surgical intervention, 
2004–09
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Source: HAI-Net SSI. CABG: coronary artery bypass graft; CHOL: cholecystectomy; COLO: colon surgery; CSEC: Caesarean section; HPRO: hip prosthesis; KPRO: 
knee prosthesis; LAM: laminectomy. Since data of all countries were pooled, methodological variations between and within countries may account for a part of the 
observed trends (see Discussion).
Figure 2.6.10. Trends in cumulative incidence of surgical site infections in hip prosthesis (HPRO) by country, 2004–09
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Source: HAI-Net SSI. Belgium and Poland did not submit data for 2008–09 and trends for these countries were not analysed. New surveillance network in Spain since 
2006. Arrows indicate statistically signiﬁ cant trends from 2004 to 2009, full line p < 0.001, dotted line p < 0.05. Interpretation of the data should be done with caution 
because on inter- and intra-country variations in methodology.
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Table 2.6.2. Intubation-associated pneumonia rates by country, 2009
  Number of patients
Average 
length of 
ICU stay 
(days)
Intubation 
days 
per 100 
patient days
Intubation-associated pneumonia episodes 
per 1 000 intubation days
Pooled 
country 
mean
Mean of 
ICUs
25th 
percentile Median
75th 
percentile 
Austria 6 975 10.2 59.1 13.5 10.9 0.0 7.6 20.5
Belgium 3 209 7.7 37.1 17.4 21.7 4.7 23.4 30.0
France 24 533 11.8 60.8 13.7 13.1 7.8 12.1 17.8
Italy 929 10.7 65.7 12.8 11.2 7.6 10.7 14.4
Lithuania 2 311 8.3 40.3 10.8 8.2 0.0 2.3 10.9
Luxembourg 2 307 9.8 31.4 3.4 3.6 0.7 4.5 5.9
Portugal 3 472 12.2 74.4 13.0 13.0 6.0 10.7 17.2
Slovakia 176 9.5 82.4 11.6 11.3 6.8 11.2 14.8
Spain 21 609 9.6 46.9 14.3 15.5 6.4 12.9 23.8
United Kingdom(a) 1 154 6.8 50.2 13.5 13.5 13.5 13.5 13.5
Total 66 675 10.4 54.9 12.2 13.5 6.1 11.7 19.9
Source: HAI-Net ICU. ICUs that reported data on less than 20 patients were excluded. Patients with discordant exposure data excluded. (a) Data from Scotland only.
increasing trend of SSI cumulative incidence after hip 
prosthesis in Italy was not confirmed by incidence den-
sity analysis as it was entirely explained by an increase 
of the proportion of post-discharge infections while the 
in-hospital incidence decreased. 
Overall, the percentage of SSI detected after discharge 
from the hospital in 2009 was 48 % (all intervention cat-
egories combined), and the highest in Caesarean sec-
tion (79 %) and the lowest in colon surgery (13 %). After 
hip prosthesis, the percentage of SSI detected post-dis-
charge was the highest in Norway (80 %), Portugal (76 %), 
Italy (72 %), the Netherlands (67 %) and France (61 %), and 
increased markedly in Italy and Portugal (Figure 2.6.10). 
Inter-country comparisons of SSI rates should be made 
with caution because at least part of the inter-country dif-
ferences can be explained by one or several of the follow-
ing factors:
• Differences in post-discharge surveillance methods 
(e.g. more intensive in Norway and the Netherlands); 
post-discharge surveillance in England only started 
with infections detected at re-admission in 2009).  
• Differences in post-operative length of stay (because 
infections are more likely to be detected in the hospi-
tal than in the community) and variations over time in 
post-operative length of stay within the same country.
• Bias due to selection of hospitals with specific prob-
lems in countries with low participation in HAI-Net SSI. 
• Differences in the mix of hospitals that participated 
each year.
• Differences in patient case-mix and mix of types of 
intervention, although these are partly taken into 
account by the risk index (e.g. some countries perform 
more total hip prosthesis interventions and less partial 
hip prosthesis interventions (the latter have a higher 
intrinsic risk of infection), which affects the mix of 
interventions within the HPRO category).
• Different interpretations of the same case definitions, 
resulting in different reported percentages of superfi-
cial infections.
• Follow-up of orthopaedic surgery until one year after 
surgery, as foreseen in the case definition of surgical 
site infections, is not implemented consistently in all 
countries or data until one year after the operation were 
not available for all operations/hospitals within a coun-
try at the time of the data collection. Surgical site infec-
tions detected after 30 days until one year of follow-up 
represented 12 % of all SSI reported in HPRO and KPRO, 
varying between 2 % until more than 30 %, according to 
the country.
• Organisational aspects such as mandatory participa-
tion with public disclosure of SSI indicators (e.g. in the 
United Kingdom).
Surveillance of infections acquired in intensive 
care units
There are two protocols for surveillance of infections 
acquired in intensive care units (ICUs) as part of HAI-Net 
ICU: a patient-based (‘standard’) protocol and a unit-
based (‘light’) protocol. In patient-based surveillance, 
data include risk factors for risk adjusted inter-hospital 
comparisons and are collected for each patient, infected 
or not. In unit-based surveillance, denominator data, i.e. 
patient days, are collected for the entire ICU. 
In 2009, 13 countries (Austria, Belgium, Estonia, France, 
Germany, Italy, Lithuania, Luxembourg, Malta, Portugal, 
Slovakia, Spain and UK-Scotland) contributed data from 
846 hospitals and 1 007 ICUs on 10 512 episodes of ICU-
acquired pneumonia and 5 653 episodes of ICU-acquired 
bloodstream infections. Two countries (Germany and 
Malta) only provided unit-based data and two countries 
(Belgium and Slovakia) provided unit-based and patient-
based data. The remaining nine countries submitted 
patient-based data only. As in previous years, Germany 
did not provide denominator data for patients stay-
ing more than two days in the ICU. Therefore, data from 
Germany were only included in the descriptive analysis of 
the ICU-acquired infections and excluded from the calcu-
lation of infection rates. Estonia provided data for a single 
ICU, which was not included in the analysis.
Of 70 648 patients staying more than two days in the 
ICU (patient-based data), 7.1 % acquired a pneumonia 
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(intubation-associated in 91 % of the cases). The mean 
incidence density was 7.8 pneumonia episodes per 1 000 
patient days, varying from 5.4 in ICUs with less than 30 % 
intubated patients to 7.3 in ICUs with 30–59 % intubated 
patients, and 8.8 in ICUs with ≥ 60 % intubated patients. 
The mean device-adjusted rate was 14.5 intubation-
associated pneumonia episodes per 1 000 intubation-
days and varied between 3.9 per 1 000 intubation-days in 
Luxembourg to 19.1 per 1 000 intubation-days in Belgium 
(Table 2.6.2).
The most frequently isolated micro-organisms from ICU-
acquired pneumonia, bloodstream infections and urinary 
tract infections are shown in Tables 2.6.3, 2.6.4 and 2.6.5.
Overall, the most frequently isolated micro-organisms in 
ICU-acquired pneumonia episodes were Pseudomonas 
aeruginosa and Staphylococcus aureus with an aver-
age proportion of meticillin-resistant isolates (MRSA) of 
34.6 %. Inter-country differences showed higher rela-
tive frequencies of Acinetobacter spp. in Italy, Lithuania, 
Portugal, Slovakia and Spain, while Enterobacter spp. was 
more frequent in Belgium and Luxembourg. Enterococcus 
spp. was more frequently reported in Austria, Germany 
and Italy. The high percentage of Candida spp. reported 
by ICUs in Austria, Germany and Slovakia may indicate 
different diagnostic practices for ICU-acquired pneumo-
nia in these countries or reflect differences in reporting 
this micro-organism, which is often isolated in respiratory 
samples but only rarely involved in the pathogenesis of 
pneumonia.
On average, ICU-acquired bloodstream infections 
occurred in 4.7 % of patients staying more than two days 
in the ICU. Bloodstream infections were catheter-related 
in 41.3 % cases, secondary to another infection in 35.7 % 
cases and of unknown origin in 23.0 % cases. For cases 
where the bloodstream infection was secondary, the pri-
mary infection site was pulmonary in 46.3 % cases, the 
gastrointestinal tract in 22.1 % cases, the urinary tract in 
12.4 % cases, a surgical site in 4.1 % cases, skin and soft 
tissue in 5.6 % cases and other/unknown in 9.4 % cases. 
The mean device-adjusted rate in patients staying more 
than two days in the ICU was 4.2 central line-associated 
bloodstream infection episodes per 1 000 central line-
days (25th percentile: 0.5, median: 2.8, 75th percentile: 
5.6). The central vascular catheter (CVC) utilisation rate 
was on average 70.1 CVC days per 1 000 patient days (low-
est: Luxembourg, 58.5; highest Portugal, 87.6).
The most frequently isolated micro-organisms in blood-
stream infection episodes were coagulase-negative sta-
phylococci, followed by Enterococcus spp., S. aureus 
(proportion of MRSA: 47 %), P. aeruginosa and Candida 
spp. (Table 2.6.4). As in pneumonia episodes, the 
percentage of Acinetobacter spp. was higher in Italy, 
Lithuania, Slovakia and Spain. The large differences in 
the proportion of coagulase-negative staphylococci prob-
ably indicate differences in reporting skin contaminants 
isolated from blood cultures.
Urinary tract infections (UTIs) were reported in 4.0 % 
of patients staying more than two days in the ICU, with 
98.5 % of the infections associated with use of a urinary 
catheter. The mean device-adjusted was 4.7 catheter-
associated UTI episodes per 1 000 urinary catheter-days 
(25th percentile: 1.1, median: 3.3, 75th percentile: 6.4). 
Urinary catheters were used in 79 % of the patient days on 
average. The most frequently isolated micro-organisms in 
UTI episodes were E. coli, Enterococcus spp. and Candida 
spp. (Table 2.6.5).
Overall proportions of resistant isolates in selected 
micro-organisms associated with ICU-acquired infec-
tions were the following: 36 % oxacillin resistance (MRSA) 
in S. aureus isolates, 2.7 % vancomycin resistance in 
Enterococcus spp. isolates, 26 % ceftazidime resistance 
in P. aeruginosa isolates, 16 % ceftriaxone or cefotax-
ime resistance in E. coli isolates (increasing from 12 % 
in 2008), 28 % ceftriaxone or cefotaxime resistance in 
Klebsiella spp. isolates (increasing from 23 % in 2008) and 
51 % ceftriaxone or cefotaxime resistance in Enterobacter 
spp. isolates (increasing from 44 % in 2008). 
The six countries (Belgium, Italy, Malta, Portugal, Slovakia 
and Spain) that collected detailed resistance data from 
micro-organisms associated with ICU-acquired infections 
reported 4.6 % carbapenem resistance in Klebsiella spp., 
Table 2.6.3.  Ten most frequently isolated micro-organisms in ICU-acquired pneumonia by country, 2009
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Number of isolates 797 684 3 259 4 834 101 151 30 420 33 101 1 961 93 12 363
Pseudomonas 
aeruginosa
20.2% 18.1% 21.8% 12.4% 19.8% 15.2% 40.0% 26.4% 27.3% 19.8% 19.5% 15.3% 17.5%
Staphylococcus aureus 8.3% 7.5% 18.2% 15.1% 6.9% 13.2% 6.7% 20.7% 3.0% 6.9% 12.9% 18.4% 14.8%
Candida spp. 18.4% 2.8% 4.1% 15.1% 5.9% 6.0% 3.3% 4.0% 24.2% 5.9% 7.0% 12.2% 9.8%
Escherichia coli 4.4% 10.2% 10.3% 10.6% 1.0% 9.9% 3.3% 4.8% 3.0% 1.0% 6.2% 7.1% 9.1%
Klebsiella spp. 11.0% 7.5% 6.0% 10.1% 7.9% 13.9% 13.3% 9.0% 27.3% 7.9% 6.4% 11.2% 8.4%
Enterobacter spp. 8.0% 11.8% 7.2% 6.9% 3.0% 2.0% 13.3% 5.5% 0.0% 3.0% 6.1% 6.1% 7.1%
Stenotrophomonas spp. 3.0% 6.1% 3.3% 3.1% 3.0% 2.0% 3.3% 5.5% 0.0% 3.0% 4.3% 9.2% 3.6%
Acinetobacter spp. 0.8% 2.0% 2.6% 1.4% 21.8% 11.3% 0.0% 8.3% 9.1% 21.8% 9.8% 0.0% 3.6%
Haemophilus spp. 2.0% 2.6% 5.1% 1.9% 0.0% 3.3% 0.0% 3.6% 0.0% 0.0% 4.6% 9.2% 3.3%
Enterococcus spp. 6.3% 1.3% 1.2% 5.2% 8.9% 2.0% 3.3% 1.0% 3.0% 8.9% 1.7% 1.0% 3.2%
Source: HAI-Net ICU.
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confirmed when including 2009 data. This illustrates the 
contribution of HAI surveillance, including inter-hospital, 
risk-adjusted comparisons of HAI rates, to prevention and 
control of HAIs. However, inter-country differences in sur-
veillance methods persist and further emphasis should 
be put on harmonisation.
Data from the surveillance in intensive care units showed 
a steady increase of several antimicrobial resistance 
markers in Gram-negative bacteria. Resistance to last 
resort antimicrobials such as carbapenems and colistin 
was also reported. 
ECDC will continue to support Member States in their 
efforts to set up national HAI surveillance networks that 
are compatible with HAI-Net by providing free software 
for hospitals and network coordination centres, organis-
ing training courses and performing country visits for on-
site technical support.
References
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Table 2.6.5.  Ten most frequently isolated micro-organisms in ICU-acquired urinary tract infections by country, 2009
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Number of isolates 531 45 1 406 880 63 42 39 86 34 1 034 4 161
Escherichia coli 16.6% 24.4% 33.8% 26.7% 14.3% 21.4% 33.3% 23.3% 0.0% 22.4% 26.2%
Enterococcus spp. 21.1% 15.6% 12.4% 22.5% 14.3% 11.9% 30.8% 11.6% 14.7% 13.6% 16.2%
Candida spp. 22.6% 20.0% 11.9% 8.9% 7.9% 23.8% 12.8% 23.3% 23.5% 23.4% 16.0%
Pseudomonas 
aeruginosa 16.8% 11.1% 15.1% 14.5% 15.9% 7.1% 15.4% 16.3% 17.6% 12.4% 14.5%
Klebsiella spp. 5.6% 13.3% 7.0% 8.4% 9.5% 7.1% 0.0% 5.8% 29.4% 7.0% 7.3%
Enterobacter spp. 3.0% 6.7% 5.1% 5.8% 4.8% 2.4% 5.1% 7.0% 2.9% 2.5% 4.3%
Proteus spp. 2.1% 0.0% 3.8% 4.8% 0.0% 9.5% 0.0% 5.8% 2.9% 3.4% 3.7%
Coagulase-negative 
staphylococci 6.0% 0.0% 2.6% 1.1% 15.9% 2.4% 0.0% 0.0% 0.0% 1.9% 2.6%
Acinetobacter spp. 0.0% 0.0% 0.6% 0.1% 4.8% 11.9% 0.0% 3.5% 5.9% 4.0% 1.5%
Citrobacter spp. 1.1% 2.2% 1.9% 1.3% 1.6% 0.0% 2.6% 0.0% 0.0% 0.7% 1.3%
Source: HAI-Net ICU.
0.8 % in E. coli and 4.7 % in Enterobacter spp. isolates. In 
these countries, the percentage of carbapenem-resistant 
isolates in P. aeruginosa and Acinetobacter bauman-
nii was 40.5 % and 80.0 %, respectively. Among isolates 
that were tested for colistin susceptibility, colistin resist-
ance was reported in 4.5 % of A. baumannii, 2.8 % of P. 
aeruginosa and 30.0 % of Stenotrophomonas maltophilia 
isolates.
Discussion
For the first time, HAI-Net surveillance data on surgical 
site infections and infections acquired in intensive care 
units in 2009 were collected through ECDC’s TESSy sys-
tem. Seventeen countries submitted data for at least one 
surveillance component, which is similar to last year’s 
report1. However, the number of surgical interventions 
included in HAI-Net (2009 data) increased by 9.6 % and 
the number of participating ICUs increased by 22.7 % 
compared to last year (2008 data).
The decreasing overall trend of surgical site infection 
after hip prosthesis reported last year (2008 data) was 
Table 2.6.4.  Ten most frequently isolated micro-organisms in ICU-acquired bloodstream infections by country, 2009
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Number of isolates 280 130 902 1 783 25 41 51 53 286 15 2 298 83 5 947
Coagulase-negative 
staphylococci 51.8% 17.7% 16.7% 28.5% 28.0% 26.8% 7.8% 5.7% 23.8% 20.0% 29.7% 26.5% 27.4%
Enterococcus spp. 10.4% 10.8% 7.2% 17.5% 8.0% 7.3% 17.6% 20.8% 8.0% 6.7% 10.2% 10.8% 12.0%
Staphylococcus aureus 6.4% 8.5% 13.4% 15.0% 0.0% 0.0% 9.8% 11.3% 12.2% 0.0% 4.7% 13.3% 9.9%
Pseudomonas 
aeruginosa 4.6% 11.5% 12.4% 4.6% 8.0% 4.9% 7.8% 35.8% 13.3% 26.7% 9.0% 3.6% 8.4%
Candida spp. 8.6% 13.1% 7.1% 7.5% 8.0% 0.0% 15.7% 3.8% 8.0% 0.0% 8.3% 4.8% 7.9%
Klebsiella spp. 3.6% 10.8% 6.3% 5.6% 4.0% 14.6% 11.8% 7.5% 8.4% 13.3% 6.7% 9.6% 6.5%
Escherichia coli 3.9% 8.5% 11.3% 5.3% 0.0% 7.3% 13.7% 1.9% 4.9% 6.7% 4.7% 15.7% 6.1%
Enterobacter spp. 2.1% 10.0% 9.1% 3.9% 8.0% 4.9% 9.8% 3.8% 7.3% 0.0% 5.0% 1.2% 5.3%
Acinetobacter spp. 0.0% 0.8% 1.3% 0.8% 8.0% 17.1% 0.0% 0.0% 4.9% 13.3% 5.6% 0.0% 3.0%
Serratia spp. 0.4% 1.5% 1.9% 1.3% 8.0% 7.3% 0.0% 1.9% 2.8% 0.0% 2.8% 0.0% 2.0%
Source: HAI-Net ICU.
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Temporal analysis
Threats monitored through daily epidemic 
intelligence activities
From June 2005 to December 2010, ECDC actively moni-
tored 889 threats, with a minimum of 93 threats in 2010 
and a maximum of 251 threats in 2008 (Figure 3.1). A 
median of 12 threats were monitored per month with 
a range of 3–39. The seasonal distribution of threats 
shows a tendency to peak around summer and autumn. 
3.1 Descriptive analysis of emerging 
threats
The peaks are mainly due to legionellosis and food- and 
waterborne disease threats (Figure 3.2). 
In 2010, ECDC monitored 93 threats, of which 83 were cre-
ated in 2010, five were carried over from 2009 (influenza 
A(H1N1) pandemic, measles outbreak in Bulgaria affect-
ing mainly Roma, Q-fever in the Netherlands, Salmonella 
Goldcoast in several EU countries, and anthrax in heroin 
users in the United Kingdom and Germany), while few 
threats are being followed on a continuous basis since 
Figure 3.2. Seasonal distribution of threats monitored by ECDC, by month and group of disease, January 2006–
December 2010
0
20
40
60
80
100
120
De
c
No
v
O
ct
Se
p
Au
g
Ju
n Ju
l
M
ay
M
ar Ap
r
Ja
n
Fe
b
Food- and waterborne diseases
Legionelliosis
Other threats
Nu
m
be
r o
f n
ew
ly
 o
pe
ne
d 
th
re
at
s
Figure 3.1. Number of monitored threats by ECDC, 2005–10
Ca
se
s/
10
0 
00
0
0
50
100
150
200
250
300
201020092008200720062005
200
SURVEILLANCE REPORTAnnual epidemiological report 2011
2006 (cholera and dengue fever) and since 2005 (chikun-
gunya fever, poliomyelitis and influenza A(H5N1)).
The 93 threats monitored in 2010 represent a 52 % 
decrease of monitored threats compared with 2009. This 
decrease is largely related to the decision not to open 
a threat for every reported travel-associated legionel-
losis cluster, as the European Legionnaires’ Disease 
Surveillance Network (ELDSNet) has been transferred 
and fully integrated to ECDC in 2010 and the EU action 
following each legionellosis threat is coordinated 
through a well-organised network and there is little role 
for additional action. Due to this transition, the number 
of monitored legionellosis threats in ECDC decreased 
from 92 in 2009 to 28 in 2010 (70 % decrease). 
The median duration of monitored threats increased 
from three days in 2009, (mean 6.8 days, range 0–42 
days) to 10 days (mean 20.4 days, range 0–184 days) 
in 2010. This was again mainly due to the fact that 
fewer legionellosis threats were monitored in 2010. The 
median time for monitoring legionellosis threats in the 
five-year observation period was one day (mean 5.4 
days, range 0–284 days). Threats which were carried 
over to the next year (eight) or with inconsistent infor-
mation (six legionellosis threats and one threat related 
to meningitis) were excluded from this analysis.
One third of threats monitored through the daily ECDC 
activities (29/93) met the Early Warning and Response 
System (EWRS) reporting criteria in 2010.
Messages circulated in EWRS
From January 2005 until the end of 2010, 1 023 new mes-
sage threads were posted in the EWRS, of which 982 
were related to threats and 41 were not and, therefore, 
excluded from further analysis. In 2010, the number of 
message threads was similar to previous years, exclud-
ing the ones related to influenza (Figure 3.3). The 1 911 
comments posted as reply to messages in 2010 were 
also similar to other years, excluding the year 2009, 
when messages and comments were significantly higher 
due to the influenza A(H1N1) pandemic (Table 3.1 and 
Figure 3.3). Consistently, in all five years of observation, 
most message threads were posted on Fridays (24 %) 
and fewest during the weekends.
During the five-year observation period, 34 % of selec-
tive messages stated contact tracing (CT) in the title. In 
2010, this proportion was similar (36 %). CT related to air 
travel accounted for 25 % of CT threats and CT related to 
cruise ships, for 11 %. There was no further specification 
in 64 % of all threats related to CT in 2010. 
Between 2005 and 2010, four countries (France, 
Germany, Spain and Sweden) posted more than 200 
message threats each, including comments and selec-
tive messages; 12 countries between 100 and 200; and 
the remaining 14 countries, less than 100.
Table 3.1. Distribution of Early Warning and Response System (EWRS) messages, by year of posting, 2005–10
Year of posting Message threads posted
Message threads 
(related to threats)
Excluded messages 
(not related to 
threats)
Comments posted Selective exchange messages posted
2005 103 88 15 131 2
2006 138 135 3 223 50
2007 85 79 6 300 208
2008 99 93 6 230 169
2009 509 502 7 820 720
2010 89 85 4 227 211
Total 1 023 982 41 1 931 1 360
Figure 3.3. Distribution of message threats monitored by ECDC related to influenza and other pathogens, by year of 
posting, 2005–10
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Table 3.2. Number of message threads, comments and selective messages posted, by country of posting, 2010 and 
2005–10
2010 2005–10
Message threads 
posted
Comments 
posted
Selective 
messages 
posted
Selective 
messages 
received 
Total number 
of messages 
posted 
Total number 
of messages 
posted 
Austria 1 2 16 27 19 164
Belgium 2 3 4 9 9 132
Bulgaria 2 5 3 8 10 50
Cyprus 9 1 9 53
Czech Republic 5 6 17 11 104
Denmark 1 4 3 8 8 160
Estonia 5 1 2 6 84
Finland 4 3 5 15 12 97
France 10 10 16 42 36 212
Germany 8 8 13 40 29 240
Greece 3 4 4 10 11 66
Hungary 3 7 5 11 15 86
Iceland 1 4 2 3 7 66
Ireland 1 5 5 8 11 131
Italy 6 4 12 24 22 169
Latvia 4 2 3 6 95
Liechtenstein 0 0 0
Lithuania 1 10 2 6 13 119
Luxembourg 2 0 2 54
Malta 1 2 1 2 4 54
Netherlands 4 10 25 14 138
Norway 2 4 1 12 7 82
Poland 1 1 4 8 6 69
Portugal 2 19 4 9 25 177
Romania 2 7 4 7 13 174
Slovakia 7 2 11 26 20 122
Slovenia 2 3 1 5 61
Spain 4 10 29 55 43 205
Sweden 5 14 19 31 38 204
United Kingdom 6 13 15 40 34 165
European 
Commission 14 52 13 50 79 720
ECDC 2 1 74 3 41
Total 89 227 211 574 527 4 294
Figure 3.4. Proportion of message threads monitored by ECDC, by weekday of posting, 2005–10
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Analysis by disease group
During the 5.5-year monitoring period, the number of 
food- and waterborne disease (FWD) threats constantly 
decreased from 42 in the second half of 2005 to 9 in 
2010. In contrast, the number of diseases related to 
environmental and zoonotic origin (EVD) increased from 
20 in 2005 to 44 in 2010, with the highest number of 
114 EVD monitored threats in 2009. This increase was 
mainly due to monitored legionellosis threats, which 
are included in the EVD programme. The transition of 
the European Working Group on Legionella Infections 
(EWGLINET) to the European Legionnaire’s Disease 
Surveillance Network (ELDSNet) within ECDC contrib-
uted significantly to this change (Figure 3.5). 
The other groups of diseases remained similar when 
compared to previous years: 13 vaccine-preventable 
and invasive bacterial diseases (VPD) threats were 
monitored in 2010 (range in previous years 11–28). For 
the first time during the observation period, no threat 
related to tuberculosis was monitored in 2010.
In 2010, nearly half of monitored threats were of envi-
ronmental and zoonotic origin (47 %), followed by vac-
cine-preventable and invasive bacterial diseases (13 %), 
food- and waterborne diseases (10 %) and influenza 
(8 %) (Table 3.3). Among the 18 monitored threats not 
related to any of the disease-specific programmes of 
ECDC, eight were related to the FIFA World Cup in South 
Africa, four to other large international mass gathering 
events, and one each to deaths linked to cold weather in 
Europe, heatwave and forest fires in Russia, flooding in 
Pakistan, the volcanic eruption of the Eyjafjallajökull in 
Iceland, the earthquake in Haiti and iodine contamina-
tion in soya milk in Japan and Australia.
The decision was taken to intensely monitor the FIFA 
World Cup in South Africa due to ongoing measles and 
Rift Valley fever outbreaks and the start of the influenza 
season in the Southern Hemisphere. This resulted in an 
increase of monitored threats related to mass gathering 
events from three in 2009 to 12 in 2010. 
Figure 3.5. Proportion of threats related to disease-specific programmes in ECDC, by year, June 2005–December 2010
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Table 3.3. Percentage of threats monitored by ECDC, by year and group of disease, EU/EEA, 2005–2010
ECDC disease-specific programmes 2005 (%) 2006 (%) 2007 (%) 2008 (%) 2009 (%) 2010 (%)
Antimicrobial resistance and healthcare-associated infections 3 2 1 0 0 1
Food- and waterborne diseases 42 38 25 22 15 10
Hepatitis, HIV, STI, blood-borne diseases 1 1 1 1 2 2
Influenza 6 3 2 4 7 8
Other environmental or zoonotic diseases 20 30 38 47 59 47
Tuberculosis 2 2 10 5 4 0
Vaccine-preventable and invasive bacterial diseases 13 6 10 11 9 13
Not applicable 12 18 13 9 3 19
Number of monitored threats per year 99 179 168 251 192 93
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Table 3.4. Initial sources of information for newly opened threats, by year, EU/EEA, 2005–2010
Origin of new threats 2005 (%) 2006 (%) 2007 (%) 2008 (%) 2009 (%) 2010 (%) Total (%)
Confidential sources
EPIS for food- and waterborne diseases 2 2
EWGLI/ELDSNet 2 18 28 34 49 30 29
EWRS 23 32 30 32 24 19 28
WHO 17 9 4 1 2 6 5
Information from Member States 1 3 1 3 1 5 2
European disease surveillance networks 9 7 6 2 3 2 4
Other confidential sources 1 3 4 2 11 3
Total (%) 53 70 71 77 80 76 72
Public sources
PROMED 36 9 14 4 3 1 10
MedISYS 2 3 4 2
GPHIN 4 12 3 2 4
Eurosurveillance 0 1 1 0
Public reports available on the Internet 5 6 8 7 5 8 7
Other public sources 2 11 6 14 6
Total (%) 47 30 29 23 20 24 27
Total number of new threats 99 163 142 228 174 83 889
The number of threats in this table does not correspond to the number of threats monitored as only threats opened in the respective year are considered.
Analysis by initial source of 
notiﬁ cation
Confidential sources are defined as sources with 
restricted access, like disease-specific surveillance net-
works, EWRS or information sent to ECDC by Member 
States or the World Heath Organization (WHO). All sources 
publicly accessible on the internet are considered public 
sources. In 2010, the main source of new threats was the 
European Legionnaires’ Disease Surveillance Network 
(ELDSNet) previously called European Working Group on 
Legionella Infections (EWGLINET) in relation to clusters 
of travel-associated legionellosis. ELDSNet/EWGLINET 
accounted for 30 % (25 threats) and EWRS for 19 % (16 
threats) of threats from all sources. The proportion of 
newly monitored threats originating from confidential 
sources was 76 % in 2010 (range 70–80 % excluding the 
incomplete year 2005 (Table 3.4).
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Analysis by region of origin and 
aﬀ ected countries
Forty-five per cent of monitored threats in 2010 affected 
EU and EEA/EFTA Members States, followed by Asia 
(14 %), Africa (13 %) and other European countries (10 %) 
(Figure 3.6).
Fourteen of the 30 EU and EEA/EFTA countries were 
affected by the monitored threats, excluding the non-
infectious disease threats. Italy was the country affected 
by the highest number of events (6 threats), followed by 
Spain and France (5 each), Greece and United Kingdom 
(4 each), Germany (3), the Netherlands and Portugal (2 
each) and Austria, Bulgaria, Finland, Iceland, Ireland 
and Latvia (1 each).
Figure 3.6. Number of monitored threats in 2010, by affected region(s)
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Published rapid risk 
assessments
In 2010, 33 rapid risk assessments (RRA) were produced 
and shared with the Member States: 23 original assess-
ments and 10 updates. While the majority of the RRAs 
were directly related to communicable diseases – such 
as the measles outbreak in Bulgaria, the polio outbreak 
in Tajikistan or emergence of vector-borne diseases (e.g. 
3.2 Response to threats
West Nile virus in Europe, indigenous cases of dengue 
fever in Croatia and France, indigenous cases of chikun-
gunya fever in metropolitan France) – assessments were 
also prepared for the health impact of the volcano erup-
tion in Iceland or the summer wildfires in Russia and for 
narcolepsy being a suspected adverse event of a pan-
demic influenza vaccine (Table 3.5). RRAs were spread 
throughout the year, with exception of June and July, 
when no RRA was published. All RRAs were distributed 
to Member State authorities using the EWRS restricted 
Table 3.5. Distribution of ECDC rapid risk assessments by month of publication, subject and number of updates, 2010
Month of publication Subject Number of updates
January Meningitis case on an international flight
Human cases of anthrax among intravenous drug users in the United Kingdom and Germany 1
Outbreak of listeriosis in Austria and Germany
February Human cases of West Nile virus infection in Portugal
Outbreak of hepatitis A associated to consumption of sun-dried tomatoes in France and the 
Netherlands
March Measles outbreak in Bulgaria 
Norovirus outbreaks associated with oyster consumption with cases reported from Norway, 
France, Ireland, Denmark and the Netherlands
Rabies in animals in northern Italy
Forward look risk assessment for seasonal influenza following the pandemic  1
April Ash plume after Icelandic volcano eruption 1
Rift Valley fever imported case from South Africa
May Polio in Tajikistan 4
Hand, foot and mouth disease epidemic in Asia 
August Human cases of West Nile virus infection in Greece 1
Health impact of heatwave and wild fires in Russia
New Delhi metallo-beta-lactamase (NDM-1) carbapenemase-producing Enterobacteriaceae related 
to the Indian subcontinent
Reports of cases of narcolepsy in children in the context of pandemic influenza and pandemic 
influenza vaccination reported from Finland, Sweden, France 1
September West Nile virus infection in Europe 1
Autochthonous cases of dengue virus transmission in France 1
Autochthonous cases of chikungunya fever in France
Autochthonous dengue fever case in Croatia
October Malaria (P. vivax) case in Spain
November Cholera in Haiti
December Severe clinical presentation of influenza in the United Kingdom
Total number of rapid 
risk assessments and 
updates
24 11
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platform, and three were published on the ECDC web-
site (anthrax in intravenous drug users, human cases of 
West Nile virus infections in Greece and hand, foot and 
mouth disease in Asia).
Mobilisation of expertise
ECDC may support a Member States in the coordination 
of the investigation for threats involving other Member 
States. In 2010, this was for example the case for the 
outbreak of Salmonella Goldcoast, for which cases 
were reported by six Member States. Field visits to sup-
port the Member States from the European perspec-
tive in their response to outbreaks were carried out in 
Bulgaria for measles and in Greece and Romania for 
West Nile virus. Additionally, two European Programme 
for Intervention Epidemiology Training (EPIET) fellows 
supported Portugal and Serbia during mass gathering 
activities.
Finally, the European Commission’s Directorate-General 
for Humanitarian Aid and Civil Protection (DG ECHO) 
requested support from ECDC outside of the EU, fol-
lowing the cholera outbreak in Haiti. ECDC facilitated 
the mobilisation of Member State experts and sent two 
teams of EPIET fellows through the office of the Pan 
American Health Organization (PAHO) to strengthen 
rapid alert investigation teams in the country. In addi-
tion, three ECDC staff members were dispatched to the 
ECHO office in Port-au-Prince to contribute to a support 
mission of the EU Centre for Information Monitoring 
(MIC).
Targeted expert consultations
In 2010, ECDC organised two expert consultations on 
emerging threats, for which the final reports can be 
downloaded from the ECDC website1,2. An expert con-
sultation on tick-borne diseases with emphasis on Lyme 
borreliosis (LB) and tick-borne encephalitis (TBE) with 
34 participants from EU Member States and relevant 
institutions was held in November 2010 in Stockholm. 
The consultation concluded that ECDC should propose a 
case definition for LB based on the European Concerted 
Action on Lyme Borreliosis (EUCALB) definition and a 
case classification to conform to the system applied with 
notifiable diseases. Furthermore, the value and the limi-
tations of the different laboratory tests used for LB and 
for TBE should be further assessed and quality stand-
ards should be defined1. A follow-up meeting is planned 
for the end of 2011 to finalise the case definition for TBE 
and to work on the harmonisation of the case definition 
for LB. A study on epidemiology and surveillance of LB 
in the EU using the EUCALB case definition is currently 
underway and the results are expected by the end of 
September 2011.
An expert consultation on mosquito-borne disease trans-
mission risk in Europe was held in Paris in November 
20102, following the West Nile virus outbreak in Greece 
and the emergence of indigenous cases of chikungunya 
fever in France and dengue fever in Croatia and France. 
The meeting was attended by 28 participants from EU 
Member States, WHO and ECDC. The meeting partici-
pants concluded that the recent notifications of vector-
borne diseases in the EU Member States in 2010 where 
unusual but not unexpected. The early detection of the 
presence of vectors such Aedes albopictus and Aedes 
aegypti would increase the chance for control, although 
the effectiveness of vector control methods to prevent 
and contain West Nile virus and other mosquito-borne 
virus outbreaks is not well known. Increased awareness 
is needed to timely detect importation of viruses other 
than chikungunya and dengue (e.g. St Louis encephalitis 
virus) as well as other viruses transmitted in enzootic 
cycles (e.g. Usutu virus). The risk of transmission through 
blood, cells and tissues needs further consideration.
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The selection of threats in this section covers threats of 
particular interest, characterised by:
• continuous close monitoring (e.g. influenza, food- and 
waterborne diseases);
• unexpectedness (e.g. outbreak of anthrax in injecting 
drug users);
• (re)-emergence (e.g. mosquito-borne and vaccine 
preventable diseases); and
• non-infectious nature by origin with a potential for 
infectious disease outbreaks (e.g. mass gathering 
events, natural disasters). 
Food- and waterborne threats
The Food- and Waterborne Diseases and Zoonoses 
(FWD) network consists of a network of epidemiologists 
and microbiologists in EU and EEA/EFTA Member States, 
Australia, Canada, Japan, New Zealand, South Africa, 
Switzerland, Turkey and the United States. One objective 
of the network is to identify multicountry FWD outbreaks 
at an early stage through sending urgent inquiries (UI) 
in a web-based application named Epidemic Intelligence 
Information System (EPIS), launched in March 2010. 
EPIS-FWD is currently targeting six priority diseases 
3.3 Threats of particular interest
(salmonellosis, campylobacteriosis, verocytotoxin-pro-
ducing Escherichia coli (VTEC) infection, listeriosis, yers-
iniosis and shigellosis) but the platform aims at covering 
all human diseases related to food, water and animals.
General overview
In 2010, 31 UIs were issued, compared to 28 in 2009 and 
33 in 2008. The number of UIs reported has remained 
stable in spite of their transfer to the EPIS-FWD platform 
in 2010.  
Fifteen different countries have posted UIs (Figure  3.7) 
in 2010. Twenty-eight (90 %) were initiated by EU and 
EEA/EFTA Member States and three were initiated by 
Australiai, Canada and the United Statesii. In 2010, France 
(4), Sweden (4) and the United Kingdom (4), posted most 
UIs, followed by Germany (3) and the Netherlands (3). 
The number of UIs launched by EU and EEA/EFTA coun-
tries slightly increased from 2009 (n=23) to 2010 (n=28). 
i This urgent inquiry was launched by Australia in 2009, however the 
cases in Europe were identified in 2010 and the urgent inquiry was 
re-launched.
ii The United States launched an urgent inquiry related to the cholera 
outbreak in Haiti with the objective to share laboratory information.
Figure 3.7. Number of urgent enquiries launched by country, 2010 (n=31)
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Three hundred messages (initial posts and replies) were 
posted, with an average of nine replies per UI (range 
0–17) in 2010 (Figure 3.8).
Twenty-nine of the 38 FWD network member countries 
(76 %) were activeiii in 2010. Of these, 24 were EU and 
EEA/EFTA countries.
Pathogens and vehicles of infection
In 2010, the majority (61 %) of the UIs was related to 
Salmonella spp. infections, with Salmonella Typhimurium 
and Salmonella Enteritidis being the most represented 
(32 % and 16 % of Salmonella spp. respectively). For 
comparison, Salmonella Typhimurium and Salmonella 
Enteritidis were also the serotypes most represented 
in 2008 and 2009 and all other Salmonella serotypes 
that were discussed in 2010 were different compared to 
2009. 
UIs on Salmonella spp. were followed by UIs on 
Cryptosporidium spp. and Listeria monocytogenes, rep-
resenting 10 % and 7 % of the total of UIs, respectively. 
The detailed breakdown of pathogens associated with 
UIs is shown in Table 3.6.
Nine pathogen groups were included in the UIs in 2010, 
which are four groups more than in 2009. New pathogen 
iii A country is considered as active when it has posted or replied to at 
least one urgent inquiry in 2010.
groups discussed in 2010 were norovirus, staphylococ-
cus, Vibrio cholerae and marine biotoxin. 
Table 3.6. Distribution of pathogens associated with 
urgent inquiries and suspected and confirmed vehicles, 
2010
Pathogen
Number 
of urgent 
inquiries
Suspected or confirmed 
vehicle of infection
Salmonella spp. 19 (61.3 %)
S. Typhimurium 6 Meat and meat products (beef, pork, other), eggs 
S. Enteritidis 3 Pork meat
S. Bareilly 1 Bean sprout
S. Java 1 Salad and herbs
S. Kottbus 1 -
S. Mbandaka 1 Eggs
S. Montevideo 1 Dietary supplement
S. Napoli and S. Poona 1 -
S. Newport 1 Salad and herbs
S. Panama 1 Pork meat
S. Senftenberg 1 Seeds and nuts
S. Urbana 1 -
Cryptosporidium spp. 3 (9.7 %) Drinking water, salad and herbs
Listeria monocytogenes 2 (6.5 %) Fish
VTEC/STEC 2 (6.5 %) -
Hepatitis A virus 1 (3.2 %) Semi-dried tomatoes
Norovirus 1 (3.2 %) Frozen raspberries
Staphylococcus 1 (3.2 %) Pastry
Vibrio cholerae 1 (3.2 %) Drinking water
Marine biotoxin 1 (3.2 %) Mussels
Figure 3.8. EPIS-FWD active members in the EU/EEA countries, 2010
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For 74 % of the UIs, a vehicle of infection was suspected 
or confirmed. This is a slight increase compared to 2009 
(69 %). 
In 2010, no UI was related to exposure to pet reptiles and 
domestic animals and a decrease in UI related to travel 
has been observed (from four in 2009 to one in 2010). 
Countries reported new suspected vehicles of infection 
such as fish and seafood products, eggs and drinking 
water (see Tables 3.6 and 3.7).
Table 3.7. Distribution of urgent inquiries by vehicle/
origin of infection, 2010
Suspected or confirmed 
vehicle of infection Number of urgent inquiries
Fruits and vegetables 6 (19 %)
Meat and meat products 6 (19 %)
Fish and seafood 3 (10 %)
Eggs 2 (6 %)
Drinking water 2 (6 %)
Travel associated 1 (3 %)
Other 3 (10 %)
No vehicle identified 8 (26 %)
Aﬀ ected countries
In 2010, 22 UIs (71 %) involved a single country compared 
to 17 (61 %) in 2009. Twenty-seven (87 %) were limited to 
EU and EEA/EFTA countries and 4 (13 %) involved non-EU 
or EEA/EFTA country. Compared to 2009, the number of 
UI involving only EU and EEA/EFTA countries increased 
to 27 in 2010 compared to 19 in 2009. 
In 2010, UIs involving at least one non-EU or EEA/EFTA 
country were related to infection with hepatitis A virus, 
Salmonella Typhimurium DT8, VTEC and Vibrio cholerae. 
Almost one third (9 out of 31) of UIs launched in 2010 
were considered multinational, affecting more than one 
country. For the following analysis of the multistate UIs, 
we excluded the UI on Vibrio cholerae posted by the 
United States as this UI was not related to the posting 
country and none of the affected countries are FWD net-
work members. 
EWRS and Rapid Alert System for Food and 
Feed (RASFF) 
For eight of the 31 UIs launched in 2010, a notification 
was issued through the European Rapid Alert System 
for Food and Feed (RASFF). For four of these events, the 
RASFF notifications were issued before the launch of the 
UI in EPIS-FWD. Twice the RASFF notifications and the 
UIs were issued at the same time and twice the UIs were 
launched first. 
Five (16 %) of the UIs launched in 2010 were also 
reported through the EWRS. Of these five, the UI was 
launched once prior to the EWRS, twice UIs and EWRS 
were launched on the same day and twice the EWRS 
alerts were launched first.
For the hepatitis A outbreak related to semi-dried 
tomatoes from a country outside the EU, the World 
Health Organization sent an international alert through 
the International Food Safety Authorities Network 
(INFOSAN) and a notification through the International 
Health Regulation (IHR) mechanism.
Legionellosis threats
On 1 April 2010, the European Legionnaires’ Disease 
Surveillance Network (ELDSNet) was transferred to 
ECDC. In 2009 and up to April 2010, all notified travel-
associated Legionnaires’ disease (TALD) clusters were 
monitored as an open threat in the Threat Tracking Tool 
(TTT). After the transition, only rapidly evolving TALD 
clusters or clusters with a particular international dimen-
sion, e.g. the ones fulfilling the EWRS criteria, led to the 
opening of a threat in the TTT. 
In 2010, 863 travel-associated cases of Legionnaires’ 
disease (TALD) were reported compared to 824 in 2009. 
This increase is of the same magnitude as the whole 
tourist industry experienced in 2010. Legionella pneu-
mophilia serogroup 1 was found in a majority of the 
cases. The peak month for onset of disease was August, 
when more than 150 cases fell ill and the ratio males 
versus females was 2.6:1, which is in line with previ-
ous years. The case fatality rate was 4.7 % (males 5.4 %, 
females 2.8 %). 
France, the United Kingdom, the Netherlands and Italy 
reported 74 % of all TALD in 2010. A total of 1 272 accom-
modation sites were reported in 2010. Italy, with 279 
sites, was the country with most accommodation sites 
associated with a TALD, followed by France with 236 
sites and Spain with 135 sites. Accommodations sites in 
these three countries account for more than 50 % of all 
reported sites. 
One hundred clusters were reported in 2010 which is 
an increase from the 88 reported in 2009. However, the 
number of clusters inside Europe (75 clusters) remained 
the same as in the previous year, while the number of 
clusters outside Europe (25 clusters) almost doubled 
compared with 2009. The size of TALD clusters was 2.4 
cases on average. The largest cluster, with 14 TALD, was 
associated with a cruise ship, affecting citizens of seven 
different countries. Six rapid evolving clusters were 
reported. The added value of a European surveillance 
is noted since 44 % of the clusters were detected only 
through the network.
Emergence of New-Delhi 
metallo-beta-lactamase (NDM-1) 
in Enterobacteriaceae
Enterobacteriaceae are a part of the normal gut flora 
but frequently cause community-acquired and health-
care-associated infections, such as urinary tract, 
bloodstream and intra-abdominal infections. These 
bacteria can acquire mobile genetic elements that 
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encode beta-lactamases. Dependent on the type, these 
enzymes make them resistant to various classes of 
beta-lactam antibiotics (e.g. penicillins, cephalosporins, 
carbapenems) used as the main treatment for these 
infections. New Delhi metallo-beta-lactamase (NDM-1) 
is a carbapenemase enzyme which was first detected in 
2008 in Klebsiella pneumoniae and E. coli isolates from 
a patient repatriated to Sweden after being treated in 
a hospital in New Delhi, India3. The majority of NDM-1-
producing bacteria described to date are extensively 
antibiotic-resistant and only susceptible to two antibi-
otics: colistin and, less consistently, tigecycline3,4. This 
severely limits the therapeutic options for serious infec-
tions caused by NDM-1-producing bacteria. Other types 
of carbapenemase-producing K. pneumoniae, carrying 
enzymes such as VIM (Verona integron-encoded met-
allo-beta-lactamase ) and KPC (Klebsiella pneumoniae 
carbapenemase), have caused outbreaks in healthcare 
settings and later spread to the community5. Although 
rarely occurring in the majority of European countries, 
carbapenem-resistant strains cause a high proportion of 
invasive K. pneumoniae infections in Greece (44 %) and 
Cyprus (17 %)6.
On 11 August 2010, The Lancet Infectious Diseases 
published an article describing the spread of 
Enterobacteriaceae carrying NDM-1 between India, 
Pakistan and United Kingdom, which attracted signifi-
cant media attention worldwide. On 17 August 2010, 
ECDC published a epidemiological update on its web-
site and on 27 August 2010, an ECDC risk assessment 
was posted on the EWRS. ECDC requested information 
about the situation in EU and EEA/EFTA Member States 
and the results were published in Eurosurveillance on 16 
November 2010. 
Thirteen EU and EEA/EFTA Member States reported 77 
NDM-1 cases including seven fatal cases since 2008 of 
which 39 were diagnosed in 2010: United Kingdom (51), 
France (4), Belgium (3), Austria (3), Germany (3), Italy 
(2), Netherlands (2), Norway (2), Slovenia (2), Sweden 
(2), Denmark (1), Finland (1), and Spain (1). Forty per cent 
of the pathogens carrying the NDM-1 were K. pneumo-
niae (31) and 21 % E. coli (16). Thirty-one (56 %) of the 55 
case patients with available travel history had received 
healthcare or travelled to India or Pakistan while five 
had received healthcare in the Balkans. In 13 cases, 
secondary nosocomial transmission in Europe was pre-
sumed. National guidelines for detection of carbapen-
emases, including NDM-1, were available in 14 EU and 
EEA/EFTA Member States and guidelines for their control 
were available in 11 Member States.
It was concluded that NDM-1 carrying Enterobacteriaceae 
pose a significant public health risk due to the limited 
therapeutic options, genetic mobility and international 
dissemination. There is need for further research on 
molecular epidemiology, reservoirs, mode of transmis-
sion, clinical relevance and case fatality. Preparedness 
and enhanced surveillance at national level should be 
implemented, and monitoring and exchange of informa-
tion at EU level is necessary. Risk factors for infection 
and disease, accuracy of detection methods and effec-
tiveness of control interventions need to be further 
assessed. In addition, this event underlined the need for 
an EU system of rapid exchange of information on the 
emergence and cross-border spread of extensively drug-
resistant pathogens.
Inﬂ uenza
The end of the 2009 pandemic
The ECDC crisis response to the 2009 influenza pandemic 
was de-escalated on 18 January, as by then transmis-
sion was minimal in Europe. Public health event opera-
tions were stopped and the response was handled by 
the disease-specific programme with support from epi-
demic intelligence activities7. Cases and deaths from EU 
Member States continued to be reported or announced 
during the following months but active surveillance of 
national websites ceased at the end of March. After indi-
cators of community transmission and severe illness in 
the EU suggested no more continued transmission, the 
ECDC focus moved to the Southern Hemisphere coun-
tries to assess the future development of the pandemic 
and the next seasonal wave to be expected in Europe. 
This monitoring and information was used to inform the 
ECDC Forward Look Risk Assessment published in March 
and updated in October.
On 10 August 2010, following advice from the 
International Health Regulation Emergency Committee, 
the WHO Director-General declared that the 2009 (H1N1) 
pandemic had entered the post-pandemic phase. This 
advice was based on a review of the current epidemio-
logical situation indicating that influenza activity world-
wide had returned to levels that are normally seen for 
seasonal influenza. 
Adverse events following immunisation with a 
pandemic vaccine
On 17 August 2010, the Swedish regulatory agency for 
medicinal products issued a statement upon receiv-
ing six reports of narcolepsy as a suspected adverse 
reaction following vaccination with one pandemic vac-
cine, Pandemrix®8. The following day, ECDC was made 
aware of similar cases reported from Finland. Following 
these reports, national studies to investigate a possible 
causal link between pandemic vaccine and narcolepsy 
were initiated. On August 24, Finland suspended the 
use of Pandemrix® as a precautionary measure9. The 
European Medicines Agency (EMA) evaluated the data 
available and rapidly issued an opinion on the use of the 
vaccine stating that ‘although the cases of narcolepsy 
have been reported in temporal association with the use 
of Pandemrix, it is at present not known if the vaccine 
caused the disorder’10. ECDC assessed the available evi-
dence from a public health perspective and produced a 
threat assessment on 25 August 2010 concluding that 
further studies are needed. 
To supplement the national studies, a multicountry study 
was subsequently initiated within the ECDC Vaccine 
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Adverse Event Surveillance & Communication (VAESCO) 
project. The interim report of the Finnish retrospective 
study was published on 1 February 2011 indicating a 9.2 
fold relative risk of developing narcolepsy among the 
Pandemrix® vaccinated children between 4–15 years of 
age in comparison to those not vaccinated in the same 
age group though the absolute risk of developing nar-
colepsy in an immunised child is likely to be low. These 
results were thoroughly examined by EMA, which on 18 
February 2011 concluded that ‘the new evidence added 
to the concern arising from case reports in Finland 
and Sweden, but that the data were still insufficient to 
establish a causal relationship between Pandemrix® and 
narcolepsy’11. 
On 24 February 2011, ECDC issued an update of the 
rapid risk assessment stating that ‘caution should be 
exercised when considering the use of Pandemrix® 
until more data from pharmacoepidemiological studies 
become available. Its use in situations when trivalent 
seasonal vaccines are not available or are likely to be 
ineffective (e.g. in immunodeficient patients) should 
be based on careful benefit–risk assessments at indi-
vidual or population level’. In addition, ECDC published 
a public health development on the website conclud-
ing that ‘immunisation against seasonal influenza is 
important and prevents many severe influenza cases 
and fatalities. When it comes to the choice of vaccines, 
seasonal vaccines are what should be used to pre-
vent seasonal influenza as they will cover the different 
viruses involved. Assuring the highest standards of vac-
cine safety requires constant monitoring and systematic 
epidemiological assessments. This is an essential com-
ponent of safe and effective vaccination programmes. It 
is also important in retaining the confidence of the pub-
lic and professionals in the safety and effectiveness of 
vaccines’9.
These were preliminary results until mid-June 2011, the 
final results of all of these studies are expected by the 
end of 2011. The impact of investigations on the pos-
sible association between pandemic vaccines and nar-
colepsy caused significant media and political attention 
in some countries. The impact of this, and controversies 
over the need for the pandemic vaccine in some coun-
tries, on vaccination programmes in some EU Member 
States is as yet unknown and will be assessed in the 
annual Vaccine Europe New Integrated Collaboration 
Effort (VENICE) surveys of influenza immunisation and 
national evaluations of childhood vaccination.
Severe clinical cases in Europe during the start 
of the 2010–2011 season
Following the start of the 2010–11 influenza season in 
Western Europe, ECDC was informed on 13 December 
2010 of reports of severe illness among patients infected 
with the 2009 influenza A(H1N1) strain requiring inten-
sive care. ECDC produced a threat assessment on the 
situation on 13 December 2010, concluding that patterns 
of illness appeared to be similar to the pandemic waves 
seen during the previous year, but that an increase in the 
number of severe cases could not be ruled out at that 
stage. Subsequently, critical care services in the United 
Kingdom and Ireland were under heavy pressure dur-
ing their peak weeks of the season with more intensive 
treatment unit bed occupancy (> 1.0 cases per 100 000 
population) than during the pandemic. This resulted in 
some local disruption of services. ECDC subsequently 
published a risk assessment and the same pattern was 
repeated in some other Member States though at lower 
population rates apart from in Greece.
Inﬂ uenza A(H5N1)
During 2010, WHO acknowledged 48 national reports 
of cases of influenza A(H5N1) in humans, 24 of which 
had fatal outcomes. These are the second lowest fig-
ures reported since 2005. The majority of cases were 
reported from Egypt (29), Indonesia (9) and Vietnam 
(7), while few cases were detected in China (2) and 
Cambodia (1). None were reported to be parts of clus-
ters. All these are countries where A(H5N1) is considered 
entrenched in the domestic poultry population. Almost 
all of the cases were reported to have had contact with 
sick or dying poultry before disease onset. Monitoring 
of individual cases of influenza A(H5N1) remains impor-
tant for ECDC because of the high case–fatality rate and 
the pandemic potential of this influenza, but individual 
cases like these seem inevitable. A higher priority is 
to monitor for human cases in other countries which 
might indicate extension of infection and clusters and 
outbreaks which could indicate more human-to-human 
transmission than has been observed so far12.
Mosquito-borne diseases
West Nile virus in Europe in 2010
On 23 July July 2010, Portugal reported the existence of a 
suspected case of neuro-invasive illness following West 
Nile virus (WNV) infection in an adult woman in the Vale 
do Tejo region, close to Lisbon, through the EWRS. Even 
though this case could not be confirmed, this EWRS 
message signalled the start of the European WNV sea-
son in 2010. 
On 7 August 2010, the Greek authorities reported 11 prob-
able cases of WNV human infection, two of which were 
confirmed following the EU West Nile virus infection case 
definition, in the northern region of Central Macedonia. 
Between 5 August and 18 November 2010, a total of 262 
human cases were diagnosed of which 191 (73 %) had 
central nervous system (CNS) involvement (meningitis/
encephalitis) and 71 (27 %) had mild symptoms, includ-
ing febrile illness. More than half of the human cases 
with CNS involvement resided in urban areas of Central 
Macedonia. The median age was 72 years and 5 % were 
under 30 years of age. Culex pipiens was most likely the 
predominant vector of this outbreak13. A high prevalence 
of seropositive horses and donkeys were confirmed in 
the prefecture of Thessaloniki, and for the first time 
encephalitis due to WNV was identified in horses in 
Greece. A series of preventive and control measures, 
including enhanced human and animal surveillance, 
were implemented by the Greek authorities. Four other 
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EU Member States (Hungary, Romania, Italy and Spain) 
reported confirmed WNV infection cases up to the end 
of December 2010. 
This was the first report of human confirmed cases of 
WNV infection with clinical neuro-invasive disease in 
Spain since 200414. In total, 340 cases were reported in 
EU and EEA/EFTA Member States, the majority of which 
were neuro-invasive clinical presentation of this viral 
infection (Figure 3.8) with a total of 41 deaths (35 in 
Greece, five in Romania and one in Hungary). The inci-
dence of new human cases of WNV infection in Greece 
was highest among all reporting EU Member States in 
2010 and is the largest human outbreak of WNV infec-
tion reported at the EU level since 199615. 
Analysis of viral isolates from mosquito pools, infected 
horses and humans throughout the EU showed that 
WNV strains from different lineages circulated. The 
genetic sequence of the Greek lineage 2 WNV was simi-
lar to virus isolated from wild birds in previous years in 
Hungary and Austria13,16,17 and to antibodies found in cor-
vids six to eight months prior to the human epidemic in 
Greece. Comparatively, the Romanian lineage 2 WNV was 
genetically similar to viruses isolated in outbreaks in the 
Volgograd region of Russia in 2007 and 201018. In 2010, 
in both Italy and Spain the circulating WNV was found to 
belong to lineage 1 and was similar to strains identified 
in the Mediterranean region in previous years19,20.
The increased reports of WNV circulation among humans 
between June and December 2010 in the EU were in the 
context of similar increased circulation being reported 
in donkeys and horses in Bulgaria, horses in Morocco, 
humans in Israel (where WNV is considered endemic 
with annual outbreaks), Russia (Volgograd region) and 
Turkey, all of which were detected through ECDC epi-
demic intelligence activities.
ECDC’s concern during the summer of 2010 in relation 
to WNV was focused on determining what caused the 
different patterns of WNV epidemiology in EU Member 
States and to ensure that preparedness for the disease 
was strengthened in countries reporting human cases 
of WNV infection or countries at risk of such outbreaks.
Dengue in Croatia and France
On 13 September 2010, the French Ministry of Health 
reported the first indigenous case of dengue fever in 
metropolitan France. The case was detected through 
the routine enhanced surveillance system in place from 
May to October in areas infested by Aedes albopictus in 
south-eastern France13. The information was made avail-
able on the public website of the Ministry of Health and 
through EWRS on the same day. 
Figure 3.9. Probable and confirmed human cases of West Nile virus infection detected through ECDC epidemic 
intelligence activities, 2010
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The cases displayed for Greece and Italy are only West Nile virus neuroinvasive infections (either probable or conﬁ rmed) and for Hungary, Romania and Spain all 
conﬁ rmed cases are displayed (neuroinvasive and non-neuroinvasive).
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The case, residing in Nice (département of Alpes-
Maritimes) developed symptoms on 23 August 2010 
and fully recovered after hospitalisation. Laboratory 
tests performed in early September 2010 confirmed the 
infection. The case had no history of recent international 
travel and no blood transfusion. 
A second case from the same neighbourhood, present-
ing onset of symptoms at the beginning of September, 
was laboratory confirmed on 17 September 2010. These 
two indigenous cases of dengue fever were clustered in 
space and time and suggested ongoing local transmis-
sion of dengue. In response to this event, the French 
authorities have strengthened entomological surveil-
lance in the infested regions and vector control activities 
in the areas where the cases were reported. Active case 
finding in the neighbourhood where cases were residing 
were implemented; communication campaigns for the 
general public and health professionals took place14. 
On 30 September 2010, the German health authorities 
notified through EWRS a laboratory-confirmed case of 
dengue fever in a German citizen returning from Croatia. 
The patient spent two weeks in the beginning of August 
in Podobuce/Orebić on the Pelješac peninsula, 60 km 
northwest from Dubrovnik, in the southern part of the 
country. Considering the onset of symptoms and the 
incubation period of the disease, the patient was most 
likely infected during his stay in Croatia15. The national 
health authorities of Croatia took adequate control 
measures, including awareness raising among health 
professionals, strengthening of human and vector sur-
veillance, enhancing of vector surveillance, implementa-
tion of control measures and communication of personal 
protective measures to the public. On 22 October 
2010, one more case with febrile illness was identified 
through active case finding in the same village where 
the infected tourist resided. In addition, nine of 14 blood 
samples of healthy individuals living in close vicinity 
suggested recent infection with dengue virus16. Further 
evidence of indigenous transmission was suggested 
following a seroprevalence survey using a random sam-
ple of the population living in the area. Five per cent of 
tested individuals presented laboratory indication of 
recent infection17.
On 15 September 2010, ECDC shared a threat assessment 
for the EU conducted in collaboration with national and 
disease-specific experts with EU Member States through 
the EWRS. It was concluded that the detection of two 
indigenous cases of dengue fever in France and the first 
indigenous case in Croatia were significant public health 
events, but not unexpected. The described events have 
been the first locally acquired dengue cases reported in 
continental Europe since 1927–1928, when large dengue 
outbreaks occurred in Greece. All cases in 2010 occurred 
in areas known to be infested by Aedes albopictus mos-
quitoes. Previous events, including the chikungunya 
fever outbreak in Italy, the occurrence of vector-borne 
diseases around airports and other ports of entry and a 
previous risk assessment on dengue introduction in the 
EU18 indicate that indigenous transmission of dengue in 
continental Europe is possible, as confirmed by these 
events. At the end of the period of mosquito activity, 
usually in October–November, the risk of establishment 
of sustained transmission of dengue in south-eastern 
France and in southern Croatia and further spread in 
Europe during 2010 appeared very limited. These two 
events highlighted the need to further strengthen vector 
monitoring, active surveillance for imported and indig-
enous human cases, awareness of healthcare provid-
ers, and laboratory capacities in countries where Aedes 
albopictus is present, and rapid exchange of information 
among countries.
Chikungunya fever in France
On 24 September 2010, the French Ministry of Health 
reported the first indigenous case of chikungunya fever 
in metropolitan France and on 27 September the French 
authorities confirmed a second case21. Both cases were 
detected through enhanced surveillance, which is imple-
mented from May to November in south-eastern France 
where Aedes albopictus mosquito populations have 
established progressively since 200422.
The cases, two 12-year-old girls, resident in Fréjus 
(département of Var), developed symptoms on 18 
September 2010, including fever, arthralgia, myalgia, 
rash and headache. The two girls were living in the same 
neighbourhood and frequenting the same local school. 
Both cases had no recent history of travel in an endemic/
epidemic area or blood transfusion23.
The possible index case was a 7-year-old child, with a 
travel history to India, who was residing in the same 
street as the second indigenous case. This imported 
case had onset on 29 August 2010 and was notified 
in the surveillance system on 6 September. Measures 
of vector control (mosquito control) had taken place 
around his home and school.
ECDC published a threat assessment on 28 September 
2010 and concluded that together with the earlier 
reported cases of dengue in the region, and also taking 
into account the Italian chikungunya fever outbreak of 
2007, the possibility of indigenous transmission of tropi-
cal mosquito-transmitted viruses in continental Europe 
was again confirmed. These events stress the need to 
strengthen preparedness plans in EU Member States 
where the Aedes albopictus vector is established, in 
terms of enhanced human and vector surveillance, as 
well as with regards to the timely response once cases 
have been identified, to limit further spread. In addition, 
in Member States or regions where the vector is not (yet) 
established (Figure 3.10), vigilance and adequate meas-
ures to avoid and monitor the vector’s establishment are 
important.
Malaria in Spain
A laboratory-confirmed case of Plasmodium vivax 
malaria was reported in October 2010 by the Spanish 
health authorities of Aragon in a woman with no travel 
history to endemic or epidemic areas and no contact 
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Recently present
Absent
No data
with persons visiting or residing in such areas. This 
resulted to be the first indigenous case of malaria in 
the country since 1961. Malaria was officially eradicated 
from Spain in 196424.
The case was confirmed by the national health authori-
ties and additional information was shared with ECDC 
and EU Member States through EWRS. Anopheles 
atroparvus, a potential vector for malaria, had been 
described in the area where the case was identified; 
local control measures were immediately implemented. 
ECDC produced a threat assessment in collaboration 
with the national and disease-specific experts. Based on 
this evaluation, it was considered that there was a neg-
ligible risk for further local transmission in the involved 
area, although the identification of sporadic cases in the 
future could not be excluded.
In January 2011, the Spanish health authorities shared 
through EWRS more details on the investigation done at 
local level reinforcing the hypothesis of an indigenous 
transmission. The risk assessment from ECDC and the 
country remained the same. 
During the expert consultation on mosquito-borne dis-
ease transmission in Paris in November 2010, it was con-
cluded that sporadic indigenous malaria cases in Europe 
can occur in places where the presence of the Anopheles 
vector coincides with imported malaria cases. To ensure 
early detection and prompt treatment, increased aware-
ness of clinicians is needed. Risk area mapping and spe-
cial attention to the situation of specific groups such as 
migrants, which may be asymptomatic carriers, would 
be of value25.
Vaccine-preventable disease 
outbreaks
Measles outbreak in Bulgaria with spread to 
other countries
The likely index case of the large measles outbreak 
in Bulgaria was a 24-year-old Bulgarian citizen who 
returned from Hamburg, Germany, in March 2009. He 
transmitted measles to his 1-year-old daughter and 
at least 13 other friends and relatives with whom he 
had contact during his infectious period. The outbreak 
rapidly spread among the Roma population, which 
accounted for more than 90 % of all cases related to 
this outbreak; the majority of them were unvaccinated 
individuals. Between March 2009 and December 2010, 
24 254 cases, including 24 deaths, were reported in 
Bulgaria and the previously case-based reporting had to 
be switched to aggregate reporting due to the high work-
load. A joint international expert team from ECDC and 
WHO Regional Office for Europe supported the national 
authorities in the investigation of the outbreak.
This outbreak was not limited to Bulgaria; clusters with 
epidemiological links were reported from several other 
EU and EEA/EFTA Member States: Greece reported 126 
measles cases between January and July 201026 and 149 
until the end of 201027. Of these, 38 % were Roma with 
Greek citizenship, 35 % Greek non-Roma citizens, 26 % 
Figure 3.10. Distribution of Aedes albopictus mosquitoes in Europe, June 2010
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Bulgarian citizens and 2 % from other countries. Eight 
per cent of them were children under one year of age, and 
thus not eligible for vaccination, and 33 % were 15 years 
and older. Interestingly, 83 % of cases with Bulgarian 
citizenship and Greek Roma were under 15 years of age 
whereas among the Greek non-Roma cases 79 % were 15 
years and older28.
Between June and August 2010, 48 measles cases, 
including one case suffering from encephalitis, were 
reported around Munich, Germany. The likely index case 
was a 39-year-old Bulgarian citizen belonging to the 
Roma ethnic group. The outbreak spread to the general 
population and 18 cases were reported in non-Roma citi-
zens (38 %). Nearly half of the cases (48 %) were aged 
age 18 years or older (range nine months to 36 years of 
age), suggesting high susceptibility levels in adults29.
Ireland reported 320 measles cases between August 
2009 and March 201030 and a total of 406 cases in 
201027, two thirds of them were unvaccinated individu-
als. In the early stages of the Irish outbreak some cases 
were reported among the Roma community and other 
citizens from Eastern Europe, as well as a substantial 
number of cases linked to the Irish Traveller commu-
nity30. In March 2010, Slovenia, after 10 years being 
measles free, reported a nosocomial cluster involving 
three cases where the index case was an Irish travel-
ler. He reported that his brother was hospitalised one 
week prior in Rome, Italy. No information on secondary 
cases is available. Spain reported 46 cases from January 
to May 2010. The likely index case was a 1-month-old 
Bulgarian Roma baby. 
Vulnerable populations have limited access to health-
care, which partly explains the high number of unvac-
cinated individuals and the high number of deaths 
(1:1 000) despite the often high vaccine coverage among 
the general population in the affected countries.
Polio in Tajikistan
On 10 April 2010, the World Health Organization Country 
Office in Tajikistan was informed about a multidistrict 
increase in the number of acute flaccid paralysis (AFP) 
cases in the country. Sixty-three cases of AFP were 
reported in a four-month period with the first date of 
onset on 26 December 2009, compared to an annual 
average of 35 AFP cases, usually peaking in July and 
October. On 23 April 2010, WHO announced the confir-
mation of wild poliovirus serotype 1 (WPV1) in seven AFP 
cases31. The virus was most likely imported from Uttar 
Pradesh, India. The outbreak resulted in 476 confirmed 
cases from five countries: Tajikistan (458), Russia (14), 
Turkmenistan (3; in one of which wild poliovirus type 
3 was found), Kyrgyzstan (1) and Kazakhstan (1). Also 
bordering Uzbekistan reported a high number (130) of 
AFP cases: although samples from 15 patients were sent 
to the WHO Regional Reference laboratory in Moscow, 
poliovirus was not confirmed in any of them. 
The number of AFP cases was much higher in all of the 
affected countries than the number of confirmed polio 
cases: until 16 December 2010, Tajikistan reported 709 
AFP cases, of which 40 were negative and two with 
pending results. Fifteen AFP cases were reported since 
the onset of symptoms of the last confirmed case in 
Tajikistan on 28 June; Russia reported 379 AFP cases and 
the onset of paralysis of the last confirmed polio case of 
this outbreak was on 25 September, Turkmenistan 46, 
Kazakhstan 94, and Kyrgyzstan 56 AFP cases (49 nega-
tive and six with pending results).  
As response to this multicountry outbreak, at least two 
rounds of supplementary immunisation activities were 
conducted in all six countries. Monovalent oral poliovac-
cine type 1 was predominantly used and the reported 
achieved coverage was 95 % or higher in the target 
groups in all six countries32. This was the first outbreak 
of polio in the WHO European Region since it has been 
certified polio free in 2002. It did not result in indige-
nous transmission as this is defined by WHO as uninter-
rupted transmission occurring for more than 12 months.
Anthrax in injecting drug users, 
follow-up
In December 2009, two fatal cases of anthrax in inject-
ing drug users (IDU) were reported from Glasgow, 
Scotland, who had developed symptoms in the first 
week of December. The initial cluster of five cases in 
Scotland increased to 47 cases with 16 fatalities until 
the outbreak was declared over.
In January 2010, one fatal case of anthrax in an IDU was 
reported from Germany. Even though the strains identi-
fied in Germany and Scotland were indistinguishable, no 
link to Scotland could be established. Two further cases 
were subsequently identified in Germany. On 5 February 
2010, cases started to be reported also in England, 
the first case coming from the London area. Since the 
beginning of the outbreak in December 2009, 55 cases 
of anthrax in injecting drug users have been reported 
(Scotland 47, England 5, Germany 3), 21 of them fatal 
(Scotland 16, England 4, Germany 1), resulting in a case 
fatality of 38 %. The last case was reported from Kent, 
United Kingdom, on 3 November 2010. On 23 December 
2010, the outbreak was officially declared over. 
In Scotland and England, information was sent out to hos-
pitals, general practitioners, emergency departments, 
microbiologists and drug services to raise awareness 
and to request that cases of severe soft tissue infection 
or sepsis affecting an IDU were reported to their local 
public health authority. Samples of heroin were tested 
in Scotland in order to identify a possible contaminated 
batch, but did not yield any positive results. Considering 
the complex international distribution chain of heroin 
and the laboratory-confirmed link between strains of 
Bacillus anthracis in Scotland and Germany, the expo-
sure to a contaminated batch of heroin distributed in 
several EU Member States seemed probable. However, 
the source could not be identified and additional cases 
occurred over the course of the year from the three ini-
tially affected areas. Even though skin and soft tissue 
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infections in IDUs are common, anthrax as the cause of 
such infection, especially when fatal, is rare, and very 
few cases have been described so far33,34.
Immediately after the first notifications through EWRS, 
ECDC and the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) issued a joint threat assess-
ment and alerted their networks to gather additional 
information and to strengthen surveillance to detect 
possible additional cases in Europe. The threat assess-
ment was updated after the reports about additional 
cases from England, which suggested a potentially wider 
spread of the possible source. Europol, the European 
law enforcement agency, had been informed and sup-
ported EU Member States in attempts to identify a pos-
sible source of contamination. 
Cholera in Haiti
On 21 October 2010, the Haitian National Public Health 
Laboratory confirmed the first outbreak of cholera in 
the country in at least a century35. The first cases were 
identified in the Artibonite department. The Vibrio chol-
erae strain responsible for the outbreak in the coun-
try is similar to recent South Asian strains. The way of 
introduction has been strongly debated but still needs 
confirmation36.  
More than two months into the epidemic, on 31 December 
2010, the Haitian Ministry of Health reported 145 405 
cases of cholera seen in the country, out of which 83 189 
had been hospitalised and 3 352 had died (case fatality 
of 2.3 %)37. Cases were reported country-wide, from all 10 
departments. The worst affected departments were the 
Nord-Ouest and Artibonite, with an attack rate of 3.8 % 
and 3.2 % respectively. In absolute numbers, Artibonite 
(52 257 cases) and Port-au-Prince (28 776 cases) carried 
the heaviest case load. Mortality rates per department, 
reaching 13.5 % in the Sud-Est and 11.0 % in Nippes, 
illustrated the great challenges ahead at the end of the 
year.
A large international response was mobilised, establish-
ing cholera treatment centres (CTC) and units (CTU) all 
over the country. However, considering the remoteness 
and limited accessibility of some villages, both pre-
vention and the rapid treatment of new cases through 
oral rehydration distribution points in the communities 
proved to be difficult. Access to clean water and latrines, 
and coordination among all actors were identified as 
priority38. 
ECDC supported the international response through 
close collaboration with the Pan American Health 
Organization/World Health Organization, through the 
mobilisation of three EU Member State experts and 
four EPIET fellows. In addition, three ECDC experts 
were deployed to support the European Commission’s 
Humanitarian Aid and Civil Protection (ECHO) office in 
Port-au-Prince. This support through the mobilisation of 
expertise continued in 2011. 
Non-infectious disease threats
Mass gathering events during 2010
In 2010, ECDC supported several mass gathering 
events with different levels of involvement. Fellows of 
the European Field Epidemiology Training Programme 
(EPIET) were sent to support the local authorities dur-
ing two mass gathering events, which both took place in 
August: the ‘50th Guča trumpet festival’ in Serbia with 
500 000 Serbian and 10 000 visitors from EU and EEA/
EFTA countries, and the ‘Boom’ festival, a psychedelic 
music festival, in Indanha-a-Nova, Portugal, with 30 000 
participants, half of them from abroad. A small outbreak 
of gastroenteritis involving 20 persons was reported 
during the event in Serbia and one measles case in an 
English citizen who developed symptoms during the 
event in Portugal. No secondary measles cases were 
reported. Most patients who sought healthcare during 
these events were related to traumatic events.
The Winter Olympics and Paralympic Games, held on 
12–26 February and 12–21 March 2010 in Vancouver 
and Whistler, Canada, resulted in no major public health 
problems. A measles outbreak began in Vancouver 
coincident in time with the games but no known cases 
occurred among participating athletes39.
Between 11 June and 11 July 2010, the FIFA Football World 
Cup took place in nine cities in South Africa and 350 000 
foreign spectators attended the event. An outbreak of 
measles, which started in 2009 and peaked prior to 
the games, affected all provinces with 12 089 reported 
cases in 2010. Despite mass vaccination campaigns, 
it resulted in several cases due to genotype B3 among 
attendees40. A Rift Valley fever (RVF) outbreak with 238 
cases including 26 deaths in 2010 also peaked before 
the games. The majority of RVF cases (93 %) reported 
contact with infected ruminants41 and the risk for tourist 
was considered to be low in a risk assessment prepared 
by ECDC prior to the games. One alert of a possible case 
of RVF in a returning passenger from an EU Member State 
was identified to be African tick-bite fever, which is also 
endemic in South Africa. The games took place during 
the beginning of the influenza season in the Southern 
Hemisphere, but the season started later and was milder 
than usual. Influenza A(H3N2) and B predominated dur-
ing the season and there was little pandemic influenza 
A(H1N1) activity40. Five food-borne outbreaks were 
reported, which mainly affected volunteers. No major 
outbreak was reported among foreign visitors. 
Natural disasters
A volcano under Iceland’s Eyjafjallajökull glacier erupted 
on 14 April 2010 for the second time in a month, spew-
ing clouds up to 10 000 metres into the air, which had 
a significant impact on air travel in Europe. ECDC pre-
pared a threat assessment upon request of the European 
Commission42. The main conclusions were that popu-
lations in the close vicinity of the volcanic eruption 
directly exposed to the ashes might have been at risk 
due to noxious gas and the high concentration of ashes 
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in the atmosphere. In the rest of Europe, the population 
was considered to be exposed only to very low concen-
trations of ashes. The public health impact of such low 
exposure was considered negligible. Some Member 
States advised risk groups, such as asthmatics, to carry 
inhalers with them and avoid excessive outdoor activity 
in case of exacerbated symptoms. Several EU and EEA/
EFTA Member States implemented syndromic surveil-
lance but no reports of human disease related to this 
event were reported. 
During the 2010 summer, starting in June, Russia expe-
rienced a severe heatwave. A new temperature record 
was set in Yashkul, Kamlykia with 44°C and Moscow 
reported a night-time temperature of 36°C, the highest 
since 1947. During the month of July, a large portion of 
European Russia was more than 7°C warmer than nor-
mal. This heat wave triggered several hundred wild fires 
across the country; some of them were reported close to 
nuclear power plants. The carbon monoxide (CO) levels 
in Moscow exceeded 6.6 times the permissible limits in 
August and the suspended particulate levels, 2.2 times. 
An increase of gastrointestinal diseases was reported 
from 52 of 83 regions of Russia. The Moscow city health 
officials quoted a daily mortality rate of 700 deaths per 
day, which was double the seasonal average. The media 
widely discussed the health effects of the heatwave, air 
pollution and re-suspension of Chernobyl-related radio 
nuclides.
Upon request from the European Commission, a threat 
assessment was conducted by ECDC to assess the risk 
of the wild fires to human health. It was concluded that 
there was a significant increased risk for respiratory dis-
eases such as asthma, chronic obstructive pulmonary 
disease and acute bronchitis, especially for infants, 
those aged 65 years and older and persons with under-
lying chronic respiratory and cardiovascular disease in 
the affected areas due to poor air quality and increased 
temperature. The effect of newly released Chernobyl 
fallout radioactivity was considered negligible43 and, 
therefore, unlikely to result in any acute or long-term 
health effects44. Higher mortality was observed in previ-
ous heatwaves45,46 and other health effects such as eye 
irritation, anxiety and depression were expected to be 
observed. The decrease of the water quality and the mal-
functioning of the cold chain for food were considered to 
result in a further increase of gastrointestinal diseases 
lasting for some time. Nevertheless, the risk for EU coun-
tries related to the Russian wild fires was considered to 
be very limited.  
Cold waves also account for significant excess mortal-
ity during winter months and countries not used to cold 
weather are considered to be more at risk47,48. In 2010, 
deaths due to cold weather were reported by media from 
the following countries: Czech Republic (6), Romania 
(22), Poland (202), and the Ukraine (250). Most deaths 
affected poor and homeless populations. Data from 
health authorities were available only for few countries 
such as Poland, reporting 176 deaths since November 
200949. Media in the United Kingdom reported an esti-
mated 40 000 excessive winter deaths.
On 12 January 2010, Haiti was hit by an earthquake 
magnitude of 7.3 on the Richter scale, which resulted 
in estimated 222 570 deaths and 300 000 persons with 
injuries50. Ten months later, on 21 October 2010, a chol-
era outbreak was confirmed by the Haitian National 
Public Health Laboratory and by 19 November the out-
break had reached every department of the country (see 
‘Cholera in Haiti’)50.
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The key sources of epidemic intelligence remain 
restricted networks like the European Legionnaires’ 
Disease Surveillance Network (ELDSNet) and the confi-
dential communication platform of EWRS. These sources 
reported three quarters of the monitored threats, indi-
cating the value of the networks.
The decreasing trend of the monitored threats in 2010 
compared to the previous year is mainly due to the inte-
gration of the travel-associated legionellosis network 
into regular ECDC activities. This change introduced in 
April 2010 led to a remarkable decrease of threats moni-
tored in the Threat Tracking Tool (TTT). Nevertheless, 
in ELDSNet, a total of 103 new travel-associated clus-
ters and 38 cluster updates were reported during 2010, 
which is slightly more compared to previous years and 
will explain the reduced number of threats monitored 
during 2010.
The EWRS system usage in 2010 was similar to previ-
ous years excluding 2009, when it was extensively used 
during the pandemic. The different levels attributed to 
messages is neither reflecting the need for timeliness 
of information exchange nor the need for action and its 
necessity has been discussed among the stakeholders 
of the system during 2010. The fact that most of the orig-
inal message threads are constantly posted on Fridays 
may suggest that Member States are ensuring timely 
distribution of information rather than postponing it to 
after weekends. 
During 2010, the epidemic intelligence information sys-
tem (EPIS), a restricted platform for exchange of techni-
cal information related to food- and waterborne diseases 
(FWD) was fully implemented in April 2010. The transfer 
of the urgent inquiries to the EPIS-FWD platform has 
allowed smooth and transparent information sharing of 
potential food- and waterborne related outbreaks affect-
ing more than one country. There was no reduction in 
the number of urgent inquiries compared to 2009, which 
demonstrates a good level of acceptance of the EPIS-
FWD tool by the FWD network. The fact that the scope of 
the pathogens to be reported through the FWD network 
3.4 Discussion
is broader than in 2009 might suggest that the expertise 
within the FWD network is growing and that EPIS-FWD is 
seen as a useful tool to identify potential multicountry 
outbreaks of rare FWD pathogens and not just the ‘usual 
suspects’ such as Salmonella spp.
The single threat related to antimicrobial resistance 
that was monitored in 2010 highlights the need for con-
certed European action to ensure patient safety. The EU 
Member States collaborated effectively to assess the 
situation related to this emerging drug resistance. The 
worldwide dissemination of highly resistant bacterial 
strains producing carbapenemases and the difficulty of 
coordinating control measures in the global healthcare 
marketplace underline the need for close monitoring of 
this threat.
The ambitious goal of measles elimination in 2010 in 
the WHO European Region was not achieved in the EU. 
In contrast, the year 2010 has the highest ever reported 
incidence of the disease in EU and EEA/EFTA countries 
since measles surveillance was implemented in a sys-
tematic way in Europe through the EUVAC.NET51–59. The 
preliminary number of reported measles cases in EU and 
EEA/EFTA countries for 2010 was 30 259 as of 9 March 
201160. This was mainly due to the huge measles outbreak 
in Bulgaria (22 005 cases in 2010) which also resulted in 
clusters in several other EU countries. But it was not only 
the Bulgarian outbreak alone that accounted for the high 
incidence, several other EU countries are far from hav-
ing eliminated measles (one country reported more than 
5 000 cases, two countries reported between 500 and 
1 000 cases and five countries reported between 100 
and 500 cases). In 2010, less than one third (8/29) EU 
and EEA/EFTA Member States (excluding Liechtenstein) 
did not report any case. Between 2005 and 2010 the 
number of EU and EEA/EFTA countries reporting zero 
cases varied between six in 2008 and nine in 2007. 
The deadline to reach the elimination status has been 
postponed by five more years by the WHO Regional 
Committee for Europe but to reach the goal additional 
ambitious efforts are necessary. Political commitment 
220
SURVEILLANCE REPORTAnnual epidemiological report 2011
is of utmost importance to ensure that all the necessary 
resources are provided. Nevertheless, the main strategy 
for elimination of measles and rubella remains to reach 
and maintain high vaccination coverage with two doses 
of measles- and rubella-containing vaccine in all sub-
populations (e.g. vulnerable populations, hard-to-reach 
groups, healthcare workers, etc.) and all districts. 
The large polio outbreak in Tajikistan reminded us that 
the risk for outbreaks following importation of this 
devastating disease is still present in Europe. In 1996, 
Albania reported 138 laboratory-confirmed cases of 
WPV1 including 16 deaths and 24 cases were recorded 
from the bordering United Nations Administered Province 
of Kosovo, following the migration resulting from open-
ing of Albania’s borders in 199261. The last outbreak in 
the EU, with 71 confirmed cases including two deaths 
due to WPV3, affected the Netherlands in 1992 and 1993 
in a community objecting vaccination62. 
Furthermore, the huge measles outbreak in Bulgaria 
may lead to the conclusion that the susceptibility for 
measles is a proxy for susceptibility to polio. If so, out-
breaks may occur in hard-to-reach populations following 
seeding events through importation and rapidly spread. 
Detection may be late, especially as only one in a hun-
dred infected polio cases is symptomatic. The fact that 
several EU and EEA/EFTA Member States have other 
effective surveillance strategies rather than AFP surveil-
lance in place, such as enterovirus surveillance and/or 
environmental surveillance63, might contribute to late 
detection. 
These arguments underline the need for reliable vac-
cine coverage data by age group, subpopulation and 
district. In addition, measuring susceptibility to polio-
virus through sero-surveys of subpopulations, such as 
hard-to-reach populations, explicitly but not exclusively 
Roma, and groups objecting vaccinations for whatever 
reason, might be indicated.
The indigenous transmission of dengue fever and 
chikungunya fever in continental Europe was not totally 
unexpected. In recent years, large outbreaks of dengue 
and chikungunya were reported from endemic areas, 
including areas of EU touristic interest and EU overseas 
territories. Aedes albopictus, a known Asian vector for 
these viruses, is currently established in several areas 
in Europe64. The described events clearly indicated that 
indigenous transmission of dengue and chikungunya in 
continental Europe is possible in areas where competent 
vectors are well established. The risk of establishment of 
sustained transmission in the affected areas can be con-
sidered still limited but there is a clear need to further 
strengthen vector monitoring, surveillance of imported 
and locally acquired cases and increased awareness of 
health professionals in all the EU countries where the 
vectors are described or might be present. 
The outbreak of West Nile virus (WNV) infection in 
Europe was unusual but also not unexpected. However, 
the transmission cycle for WNV is extremely complex 
(between birds, mosquitoes and humans and equidae) 
in addition to a variety of other factors, of which the 
influence on WNV circulation, in the European context, 
is not yet well understood (including meteorological fac-
tors, bird migration routes, viral strains, etc.). Therefore, 
no clear theory for increased viral circulation and trans-
mission to humans in 2010 has been determined. 
VBORNET, a network of medical entomologists and 
public health experts, provide regularly updated maps 
of distribution of Aedes albopictus mosquitoes in the 
EU on ECDC’s website. In addition, following an ECDC-
sponsored expert consultation on WNV (in collaboration 
with the Greek Centre for Disease Control and Prevention 
and the WHO Regional Office for Europe) upcoming oper-
ational tools are being prepared and will be made availa-
ble to Member States to facilitate preparedness planning 
for WNV throughout the EU.
The number of threat assessments increased by 30 %, 
from 25 in 2009 to 33 in 2010. Similar to the monitored 
threats, the highest request for rapid risk assessments 
was in the late summer and early autumn period. All 
rapid risk assessments were distributed through the 
restricted EWRS system to all EU Member States.
For the first time since its establishment, ECDC was 
requested to closely collaborate with other EU bodies 
like the EU Humanitarian Aid department (ECHO) and the 
EU Centre for Information Monitoring (MIC) in humanitar-
ian assistance during the cholera outbreak. This support 
was continued for several months focussing both on 
coordination and direct field support. Deployed experts 
were from Member States, fellows of the European 
Programme for Intervention Epidemiology Training 
(EPIET) and ECDC experts.
The close collaboration with local health authorities dur-
ing mass gathering events is not only limited to activi-
ties during the event but also during the preparatory 
phase as, for example, for the EURO 2012 which will be 
held in Poland and the Ukraine.
ECDC’s focus for non-infectious disease threats related 
to natural disasters remains on possible consequences 
related to infectious diseases (e.g. cholera in Haiti).
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ECDC has now gained five years of experience in epi-
demic intelligence and threat assessment and has con-
tinuously enhanced its tools. In 2010, ECDC organised 
an expert meeting where common guiding principles for 
epidemic intelligence were discussed with experts from 
EU Member States, international organisations and third 
countries. These principles together with epidemic intel-
ligence tools such as MediSys, which has been strength-
ened in collaboration with the Commission’s Joint 
Research Centre (JRC), were made available for Member 
States’ use. 
The EPIS tool for food- and waterborne diseases has 
been successfully implemented in 2010 and the number 
of posted urgent inquiries increased, suggesting that 
the implementation has been smooth. In 2011, EPIS is 
planned to be implemented for sexually transmitted 
infections, antimicrobial resistance and vaccine-pre-
ventable diseases. The experience gained through the 
transition process of food- and waterborne diseases will 
hopefully ease the transition of the other disease-spe-
cific networks to ECDC. 
In 2011, EUVAC.NET, the network for surveillance and 
outbreak monitoring of vaccine-preventable diseases 
targeted for elimination (measles and rubella), but also 
covering other vaccine-preventable diseases (e.g. per-
tussis, mumps, varicella), will be transferred to ECDC. 
Maintaining the currently well-working network will be a 
challenge but also an opportunity to enhance communi-
cation on clusters and outbreaks and implemented con-
trol measures to the European network. 
ECDC, in collaboration with experts in the Member 
States, is developing a series of practical tools that 
aim to facilitate the coordination in the investigation of 
outbreaks. In order to support European-level outbreak 
investigations, a ‘toolkit’ is being developed for events 
that involve at least two EU Member States, for both 
food- and waterborne diseases and for Legionnaire’s dis-
ease. In addition, evidence-based operational European 
guidelines for assessing the risk of transmission of com-
municable diseases in aircrafts (RAGIDA) addressing 
3.5  Conclusions
measles and rubella as well as viral haemorrhagic fevers 
were published in 201065. 
Even though none of the monitored mass gathering 
events in 2010 has been associated with large commu-
nicable disease outbreaks, the risk of such outbreaks 
remains. In today’s globalised world, the possibility of 
communicable disease outbreaks following mass gath-
ering events always has to be taken into consideration 
and preparedness for such events is crucial. ECDC con-
tinues to further develop tools and to support Member 
States in its preparedness activities. 
The added value of ECDC in the detection and control of 
communicable disease threats in 2010 has not only been 
proven by the number of threat assessments requested, 
the involvement in support missions for outbreaks and 
the number of expert meetings organised but also by 
the rapid distribution of relevant information through 
weekly bulletins and postings on its website.
In 2011, ECDC will continue on this path, providing even 
more sophisticated tools for the rapid detection and 
control of communicable diseases for the European 
Union community.
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Annex   List of communicable diseases for 
EU surveillance
Annex I of Commission Decision 2000/96/EC of 22 
December 1999 on the communicable diseases to be 
progressively covered by the Community network under 
Decision No 2119/98/EC of the European Parliament and 
of the Council, as amended by Decisions 2003/534/
EC, 2003/542/EC, 2007/875/EC, 2009/312/EC and 
2009/539/EC.
1 Communicable diseases and special health 
issues to be progressively covered by the 
community network as referred to in Article 1 
[of Decision 2000/96/EC]
1.1 For the communicable diseases and special health 
issues listed in this Annex, epidemiological surveillance 
within the Community network is to be performed by the 
standardised collection and analysis of data in a way 
that is to be determined for each communicable disease 
and special health issue when specific surveillance net-
works are put in place.
2 Diseases
2.1 Diseases preventable by vaccination
Diphtheria 
Infections with haemophilus influenza group B 
Influenza – including influenza A(H1N1)
Measles 
Mumps 
Pertussis 
Poliomyelitis 
Rubella 
Smallpox 
Tetanus
2.2 Sexually transmitted diseases
Chlamydia infections
Gonococcal infections
HIV infection
Syphilis
2.3 Viral hepatitis
Hepatitis A
Hepatitis B
Hepatitis C
2.4 Food- and waterborne diseases and diseases of 
environmental origin
Anthrax 
Botulism
Campylobacteriosis
Cryptosporidiosis
Giardiasis
Infection with Enterohaemorrhagic E.coli
Leptospirosis
Listeriosis
Salmonellosis
Shigellosis
Toxoplasmosis
Trichinosis
Yersinosis
2.5 Other diseases
2.5.1 Diseases transmitted by non-conventional agents
Transmissible spongiform encephalopathies, variant 
Creutzfeldt–Jakob’s disease
2.5.2 Airborne diseases
Legionellosis
Meningococcal disease
Pneumococcal infections
Tuberculosis
Severe Acute Respiratory Syndrome (SARS)
2.5.3 Zoonoses (other than those listed in 2.4)
Brucellosis
Echinococcosis
Rabies
Q Fever
Tularaemia 
Avian influenza in humans
West Nile virus infection 
2.5.4 Serious imported diseases
Cholera
Malaria
Plague
Viral haemorrhagic fevers
3 Special health issues
3.1 Nosocomial infections
3.2 Antimicrobial resistance
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